

THE BRAIN TUMOUR CHARITY

England & Wales · Charity number 1150054

Details

Other names	TBTF
Status	Registered
Legal form	Charitable company
Company number	08266522
Registered	2012-12-05
Register	View on the Charity Commission register

Contact

Address	The Brain Tumour Charity Fleet 27 Rye Close Fleet Hampshire GU51 2UH
Phone	01252749990
Email	enquiries@thebraintumourcharity.org
Website	www.thebraintumourcharity.org

Activities

Objects: 4.1 The objects of the Charity (the “Objects”) are for the public benefit:-4.1.1 to relieve sickness and to promote and protect good health by supporting research into the nature, causes, diagnosis and treatment and social consequences of tumours of the brain and central nervous system and to publish the useful results of such research;4.1.2 the relief of suffering of people with tumours of the brain and central nervous system and their families and carers, through the provision of information and support to them; and4.1.3 to advance the education of the public in all areas relating to tumours of the brain and central nervous system.

Activities: The Brain Tumour Charity is at the forefront of the fight to defeat brain tumours, making a difference every day to the lives of people with a brain tumour and their families. We are committed to having the biggest possible impact for everyone affected by a brain tumour, to defending the most amazing part of the human body, so that the diagnosis of a brain tumour is no longer a death sentence.

Classification

- **How:** Makes Grants To Organisations, Provides Services, Provides Advocacy/advice/information, Sponsors Or Undertakes Research
- **What:** Education/training, The Advancement Of Health Or Saving Of Lives, Disability
- **Who:** Children/young People, Elderly/old People, People With Disabilities, Other Defined Groups, The General Public/mankind

Geography

- Northern Ireland
- Scotland
- Throughout England And Wales

Finances

Period end	Income	Expenditure	Assets	Employees
2025-03-31	£15,330,000	£15,334,000	£8,788,000	118
2024-03-31	£14,195,000	£14,659,000	£8,531,000	116
2023-03-31	£12,715,000	£11,235,000	£8,231,000	100
2022-03-31	£11,475,000	£10,625,000	£7,610,000	86
2021-03-31	£8,298,000	£11,332,000	£6,857,000	108

Trustees

Name	Role	Appointed
Fraser Alexander Longden	Chair	2025-12-11
Anna Rhian Jarvis		2022-06-16
Caroline Steel		2022-06-16
Dr Elena Bechberger		2020-09-17
Dr Kieran Richard Palmer		2022-06-16
Dr Rachel Suzanne Edgar		2025-03-21
Hayley Ann Conroy		2022-06-16
Julia Clare Osgerby		2025-09-18
Matimba Charity Swana		2022-06-16
Sukhdip Sandhu		2022-06-16

THE BRAIN TUMOUR CHARITY

England & Wales - Charity number 1150054

Accounts

ANNUAL REPORT AND ACCOUNTS

2024-2025



**THE
BRAIN
TUMOUR
CHARITY**



CONTENTS

Chair's report	4
CEO's report	5
Strategic report	6-33
Thanks	34-35
Trustees and governance	36-39
Independent auditor's report	40-43
Statement of financial activities	44
Balance sheet	45
Consolidated Statement of cash flows	46
Notes to the accounts	47-61

OUR VISION, GOALS AND VALUES

OUR VISION

Our vision is for everybody diagnosed with a brain tumour to live longer, better lives.

OUR GOALS

We'll achieve our vision by:

TRANSFORMING THE RESEARCH LANDSCAPE

We're committed to funding the world-class research that moves us further, faster towards cures for all brain tumours. However, we also need to invest in transforming the research landscape so that breakthroughs in the lab become new treatments that are available to the community.

RAISING VOICES TO CAMPAIGN FOR CHANGE

We're more powerful when we join forces to call for change. That's why we're dedicated to bringing together people who share our goals and helping them become voices for change - whether that's persuading policymakers to go further, faster in defeating brain tumours or raising vital funds to power our work.

IMPROVING QUALITY OF LIFE AND PROVIDING SUPPORT AND BEST CARE FOR EVERYONE

We're committed to making sure that everybody in the brain tumour community - no matter who they are or where they're being treated - has access to the care and support they need.

OUR VALUES

Our values underpin everything we do. They define what we believe and guide our actions every day.

The way we work is always:

COMMUNITY FIRST

We put the community's needs first, ensuring our work is informed by those with lived experience and that they are the driving force behind our decisions. We include everyone, amplifying their voices and uniting in our shared purpose to create change

COLLABORATIVE

We know that we're stronger together, so we choose to lean on each other, share openly and utilise expertise and knowledge wherever it exists. We seek out and support diverse perspectives, operate without ego and are part of a connected eco-system that everyone can join.

BOLD

We're unapologetically ambitious and true to ourselves. We'll be confident and relentless in challenging the status quo, even when that means making difficult decisions. We're determined, focused and unstoppable.

INNOVATIVE

We're creative and adopt a growth mindset, always using our experience and imaginations to find smarter and more effective ways to propel progress. We're not afraid to think differently, find new ways to solve problems and be agile in 'testing and learning', so we can move at pace in pursuit of our vision.



CHAIR'S REPORT

If you were to ask me for a single word that described 2024/25 for The Brain Tumour Charity, it would have to be “transformative”.

Across the entire organisation, teams have been undergoing programmes of work that have laid the foundations for us to deliver on our ambitious strategy that runs until 2030.

Underpinning all of this is the work of our fundraising team. Not only has it been a record-breaking year for fundraising – achieving an incredible income of £15.3m – but we’ve also developed a new dedicated fundraising strategy. This piece of work will prove to be vital in helping us grow our income to match our ambitious goals and empower us to move further, faster for people affected by brain tumours.

Of course, I can’t talk about fundraising without mentioning the monumental impact of our partnership with Wickes. Our two-year partnership is now over, but the team at Wickes will forever be part of the DNA of The Charity. Not only have they raised a transformative amount of money – more than £2m over the two years – but they’ve also raised our profile significantly by showcasing our work at more than 230 stores across the UK. A special thank you to them.

As I reflect on my seven years as a Trustee and Chair of The Brain Tumour Charity, I gain a greater perspective and appreciation about the challenges we’ve faced. In overcoming these challenges, we’ve become a stronger, more resilient organisation and this has enabled us to greatly increase our impact without losing our ethos of being led by the brain tumour community.

This is in no small part thanks to the efforts of Neil Dickson, who retired from the Board and as Vice Chair, in September 2024 but continues to support The Charity, along with his wife Angela, as Emeritus Founder Trustees. After the loss of their dear daughter Samantha to a brain tumour, Neil and Angela founded the Samantha Dickson Brain Tumour Trust which would go on to become The Brain Tumour Charity as we know it today – the largest dedicated funder of research into brain tumours globally which continues to go from strength to strength. Thank you so much, Neil and Angela, for what you started.

I’d also like to thank our other retiring Trustees – Sean Hird, Justine McIlroy, Dr Alan Palmer and Beth Worrall – for their incredible support and contribution in taking The Charity forward. And indeed, our serving Trustees who give their time, experience and skills so generously.

And thank you to everybody else who’s stood alongside us. Whether you’re a fundraiser, a donor, a volunteer, campaigner or a member of our team, the achievements that we share in this Annual Report are only possible thanks to your hard work and determination.

Jack Morris CBE
Chair of Trustees



CEO'S REPORT

Achieving meaningful, transformational impact takes more than ambition and moving at pace towards our goals. To make the biggest difference for people affected by brain tumours, we need to actively listen to them and consciously place their lived experience at the heart of everything we do.

I believe this year's Annual Report highlights our ongoing commitment to doing this and showcases the deep connection we share with the brain tumour community.

Nowhere is this more clearly reflected than in our decision to launch two new, innovative grant rounds, which were shaped by the community, who shared their most urgent unmet needs with us.

Our Quality-of-Life Award was introduced in response to a clear need for an evidence-based approach to improving the lives of people diagnosed with a brain tumour. To make sure we funded projects with the greatest potential for achieving meaningful change, we brought together three vitally important groups of people – researchers, healthcare professionals and people personally affected by the disease – to develop these promising ideas into impactful programmes of work (see page 9).

The community was even clearer about the need for new treatments to be developed and become available faster. That's why we also launched our Translational Award that aims to speed up the pace by which important scientific findings in the laboratory are developed into new treatments for patients. I'm confident this new funding will be a catalyst to change for those who have waited far too long for new treatments to emerge (see page 7).

Deciding to fund new programmes of work inevitably means we sometimes have to choose to bring existing projects to an end. After careful evaluation, we decommissioned our BRIAN app in August 2024, so we could invest in the projects we believe will have the greatest

impact on our ability to achieve our mission.

It's this type of difficult decision-making that enabled us to spend £6.2m on innovative research grants during 2024/25. That means, since the launch of our new strategy just two years ago, we've funded more than £11m on world class research into brain tumours and are on course to achieve our goal of awarding more than £50m to researchers by 2030.

But we aren't just looking to the future. We're also helping more people right now through our Support and Information services. This year saw a 6% growth in the number of people we supported with our free counselling service growing by 74%.

This year, we've also been busy working to make sure the unmet needs of the brain tumour community are addressed by the new government. We were proud to support Dr Scott Arthur MP in drafting the Rare Cancers Bill and working collaboratively with charity colleagues to mobilise our communities to achieve the required parliamentary support for its successful passage through early readings.

Perhaps the most significant news from the year was the landmark approval of the combination of dabrafenib and trametinib for treating children diagnosed with BRAF-mutated gliomas. This marks the first positive change in brain tumour treatment in a generation and I'm proud of the role we played – both in our campaigning work today and the research we funded in the past (see page 7).

But none of this would be possible without your support. Only with your help are we able to blend science and compassion year after year, and for that I can only offer my deepest thanks.



Dr Michele Afif
CEO



STRATEGIC REPORT

TRANSFORMING THE RESEARCH LANDSCAPE

We believe that funding the best research globally will propel the most powerful change for everyone diagnosed with a brain tumour – now and in the future.

But we don't just need to fund research projects. We must transform the research landscape to build research capacity, deliver clinical trials and drive translational research to make sure that the discoveries made in labs are turned into real-world benefits for people affected by brain tumours.



DESIGN, DELIVER AND SUPPORT INNOVATION AND IMPACTFUL RESEARCH AWARDS AND GRANTS

By 2030, we aim to invest at least £50m in the best and most pioneering research. We're committed to funding all types of research, from creating new knowledge and speeding up diagnosis to accelerating new treatments through translational research.

Goals for 2024/25

Deliver our first-ever Translational Award grant round and award four Translational grants.

Deliver one Quest for Cures grant round and award two Quest for Cures grants.

Deliver two Expanding Theories grant rounds and award four Expanding Theories grants.

Deliver one Future Leaders Post-Doctoral grant round and award six Future Leaders Post-Doctoral grants.

Provide funding for an early detection symposium.

Outcomes

Delivered our first-ever Translational Award grant round and awarded two Translational grants with one additional grant subject to final agreement.

Delivered one Quest for Cures grant round and awarded two Quest for Cures grants.

Delivered two Expanding Theories grant rounds and awarded four Expanding Theories grants.

Delivered one Future Leaders Post-Doctoral grant round and awarded five Future Leaders Post-Doctoral grants.

Awarded a grant to support an early detection symposium in Manchester.

We also: Co-funded two new grants with Worldwide Cancer Research.

HIGHLIGHTS OF 2024/25

Funding new and pioneering research projects

2024/25 was a landmark year for The Charity as we funded £6.2m of research grants. As well as funding new Future Leaders, Expanding Theories and Quest for Cures grants, we also designed and delivered some pioneering new awards.

For the first-time ever, we opened and awarded our new Translational Award that's specifically designed to move breakthroughs out of labs and make them available to the community. Unfortunately, the nature of these projects means we haven't been able to share information about them at the time of writing, but we're extremely excited about their potential impact.

Towards the end of the year, we were delighted to announce our latest funding collaboration with Worldwide Cancer Research. We'll be co-funding two new projects that are aimed at developing our understanding of Diffuse Midline Glioma – one of the deadliest forms of childhood brain tumour.

A treatment nearly 20 years in the making!

In May 2024, NICE published their final guidance for use of dabrafenib and trametinib for treatment of high and low grade gliomas in children – meaning the treatment would be available through the NHS in England. This was later followed by approval in Northern Ireland, Scotland and Wales.

This approval marked the first new treatment for children with brain tumours in decades to be approved for use in the NHS. Some of the underlying research behind the clinical trials that led to the approval was first discovered thanks to Professor David Jones' research that we funded nearly 20 years ago.

We also played a vital role in the approval process by providing evidence during the NICE appraisal and making sure the voice of the community was represented. Our Trustee Suki Sandhu also attended the appraisal and shared how her family was affected when her son, Raj, was diagnosed with a high grade glioma.

Our research reveals potential new drug to target rare childhood brain tumour

Professor Chris Jones and his team had research published in the Cancer Cell journal that revealed a potential new drug to target Diffuse Hemispheric Glioma (DHG) – a rare and deadly form of brain tumour.

As part of one of our Quest for Cures grants, the team aimed to uncover clues about how DHG cells behave and found a key weakness in the cells that could be targeted by ribociclib.

Ribociclib is a drug already used to treat certain types of breast cancer and after pre-clinical testing, the research moved to trialling ribociclib in a child diagnosed with a DHG after other treatments had failed.

These are very early results as the drug has only been tested in one child for this purpose. However, the results were remarkable.

Treatment with ribociclib resulted in stable disease for a further 17 months after first- and second-line treatment had failed. The child's tumour has since grown back and they are receiving further treatment, more than four years since their diagnosis.

DHGs typically have a prognosis of 18-22 months and the tumour typically starts growing back 3.5 months after treatment – so, no recurrence for 17 months following ribociclib treatment is extremely promising.

To determine how effective ribociclib truly is, it needs to be tested as part of a clinical trial. However, these results are a great starting point to build a clinical trial upon.

New insights may improve treatment for meningiomas

Research funded by The Charity and published in Nature Medicine last year suggests that we may be able to use molecular testing to predict how somebody diagnosed with a meningioma will respond to certain treatments.

Dr Gelareh Zadeh and her team in Toronto built upon their own prior research that found four distinct molecular sub-types of meningioma. This new research advances the knowledge further by accurately predicting how a tumour may respond to treatment, which could help tailor surgical and radiotherapy approaches.

This is a hugely promising discovery as meningiomas are the most common type of adult brain tumour, but they're currently very difficult to predict.

One of our Junior Fellow's research is featured in Cancer Cell

Dr Spencer Watson – one of our Junior Fellows – had his research published in Cancer Cell in 2024/25. His research focuses on understanding why glioblastomas grow back and he'd previously discovered tumours often regrow next to scarred regions in the brain inadvertently caused by treatment.

His newest research used cutting-edge technology his team had previously developed to understand the environment around the tumour in unprecedented detail. This helped them to see exactly how the scars form and how they protect the tumour cells from the immune system.

With this knowledge, the team were able to combine immunotherapy drugs with drugs that prevent scarring. This significantly reduced scar formation in preclinical models, not only decreasing tumour recurrence, but also improving overall survival.



DESIGN AND DELIVER QUALITY-OF-LIFE AWARD

Through our Quality-of-Life Award, we're determined to invest in research that helps us build an evidence-based understanding of how we can improve quality of life for the brain tumour community. Then we can work towards making sure it's embedded into standard practice.

Goals for 2024/25

Design and deliver our first-ever Quality-of-Life Award and award up to £400,000 in Quality-of-Life grants.



Outcomes

Designed and delivered our first-ever Quality-of-Life Award and awarded four Quality-of-Life grants totalling £380,000.

We also: Held our first Quality-of-Life sandpit event on 11 and 12 November 2024.

HIGHLIGHTS OF 2024/25

Bringing together experts to collaborate for a cure

In November 2024, we held our first-ever Quality-of-Life sandpit event. The aim was to bring together a wide variety of experts working in care and research – including researchers, doctors, nurses, psychologists and physiotherapists – to discuss the challenges they face when it comes to improving quality of life for children and young people following treatment for a brain tumour.

These discussions were supported by some of our incredible community members who helped to make sure the lived experiences of people affected by a brain tumour were central and highlight how the disease can impact quality of life.

This is collaboration at its best. Harnessing the connections between different people from across disciplines and experiences to achieve a shared goal.

During the sandpit, project groups were established to develop potential research ideas and brought together different areas of expertise to address some of the challenges that had been identified.

The project groups then met online to develop their ideas further, as well as get feedback on their potential projects from the wider group and expert mentors – helping them create stronger applications for our Quality of Life grant round.

Announcing our new Quality of Life grants

In March 2025, we announced which projects developed during our sandpit event we'd be funding.

In total we awarded

£380,000

across four projects designed to improve quality of life for children and young people living with the effects of a brain tumour.

The four pioneering projects each have a very different focus:

- developing a national approach to making sure children are well supported as they return to education after being diagnosed with a brain tumour
- helping families better understand and manage their child's fatigue
- creating a roadmap for better, evidence-based support for children living with a brain tumour
- understanding how genetics might affect the long-term impact of a brain tumour diagnosis.

ENGAGE THE RESEARCH COMMUNITY

Although we're an organisation that's always punched above its weight, we need to increase the size of our reach and influence among the research community to help us achieve our goals.

Our aim is to truly be within the research community, helping researchers to build important networks and make connections that will drive more and better research into brain tumours.

Goals for 2024/25

Hold two online training events for our Future Leaders with external speakers.

Agree a date in 2025/26 to hold our first-ever in-person Future Leaders event.

Increase awareness of The Charity among researchers by sponsoring, exhibiting and attending research conferences.

Send a quarterly e-newsletter for our research community and grow the size of our mailing list.

Hold four engagement events for the research community.

Outcomes

We held three online training events for our Future Leaders with external speakers.

Our in-person Future Leaders event took place on 12-13 June 2025.

We sponsored the International Symposium on Paediatric Neuro-Oncology (ISPNO), exhibited at the Society of Neuro-Oncology (SNO) Annual Meeting and the European Association of Neuro-Oncology (EANO) Annual Meeting, as well as attending the Cancer Research UK Brain Tumour Conference and the British Neuro-Oncology Society Annual Conference.

Sent a quarterly e-newsletter for our research community and grew the size of our mailing list by more than 7%.

We supported three lab tours.

HIGHLIGHTS OF 2024/25

Investing further in our Future Leaders

We've been delighted to watch our Future Leaders programme go from strength to strength. We now have ten Future Leaders across two cohorts, as well as our two Junior Fellows (the second stage of the programme).

The success of the programme shows that making this funding available for early-career researchers encourages them to establish themselves as leaders in the field. This is further evidenced by the fact that in 2024/25, two of our researchers – Dr Tyler Miller and Dr Ángel Álvarez-Prado – have been able to set up their own labs and are now leading teams of their own. You can find out more on page 11.

It's been incredible to bring the brightest early-career researchers together and see them support each other with their research. The mentorship that's provided as part of this programme is also proving invaluable to our Future Leaders.

Connecting researchers with the community

Whether it's at lab tours, fundraising events or special occasions like our Quality of Life sandpit, we're committed to keeping our researchers connected to the brain tumour community.

We do this because it makes sure the lived experiences of people affected by a brain tumour are central to the research we fund.

SUPPORT WORKFORCE INFRASTRUCTURE

Research into brain tumours is chronically underfunded. Together, we've been working hard to change this, but this historic lack of investment has meant fewer opportunities for researchers in the field – which has affected the number of researchers working towards finding cures for brain tumours.

We want to change this by supporting early-career researchers and making sure the most talented researchers are attracted to the field of neuro-oncology – as well as retaining that talent. We're also dedicated to improving research infrastructure so that more clinical trials can happen.

“Working at The Brain Tumour Charity taught me the importance of funding in advancing research and gave me first-hand insight into how science and compassion come together to fuel progress.”

Raz Methuen, Former Research Intern

Goals for 2024/25

Identify the biggest gaps in the research workforce.



Outcomes

We're in the process of reviewing the current challenges facing the research workforce and the initiatives already in place to support this – helping us better understand how we can have the biggest impact.

HIGHLIGHTS OF 2024/25

Two of our Future Leaders set up their own labs

We were delighted to see two members of our Future Leaders programme establish their own labs in 2024/25.

In June 2024, it was announced that Dr Tyler Miller was setting up his own research lab at Case Western Reserve University School of Medicine in the US. Dr Miller is one of our Junior Fellows, which is the second stage of our Future Leaders programme.

The team at his new lab will be focused on developing immunotherapies to treat brain tumours.

In March 2025, we learned that Dr Ángel Álvarez-Prado – part of our 2022 cohort of Future Leaders – would be leading his own research group at the Luxembourg Institute of Health. His research group will be studying how changes in DNA affect the immune system's fight against cancer and how this impacts the success of treatments.

“The brightest people in the world have options and the choices they make depend upon the opportunities that are presented to them. The Brain Tumour Charity gives them the opportunity to lead the world in brain tumour research.”

Professor Richard Gilbertson, Li Ka Shing Chair of Oncology and Senior Group Leader at the Cancer Research UK Cambridge Institute.


RAISING OUR VOICES TO CAMPAIGN FOR CHANGE

To build powerful momentum and push policymakers to go further, faster in defeating brain tumours, we're committed to bringing more people together who share our goals and helping them become champions for the brain tumour community.

Together, we'll increase our impact as we raise awareness of brain tumours and strive to improve experiences for everybody affected by a brain tumour at every step of their pathway.



Dr Scott Arthur MP with one of
our Involvement Champions



DEVELOP AND IMPLEMENT A NATIONAL BRAIN TUMOUR STRATEGY

To make a bigger impact, we need to turn up the volume of our calls for change and we can only do this by increasing the number of people who get behind our campaigning activity. We know that we also need to engage the right stakeholders at the right time to make a difference on pertinent policy issues.

Improving awareness of brain tumour signs and symptoms is also a priority. Through campaigns and incentives like our Better Safe Than Tumour campaign, we aim to increase the number of people who can name at least two symptoms of a brain tumour.

Goals for 2024/25

40,000 people to sign open letter calling for a National Brain Tumour Strategy between the launch in March 2024 and closing it in April 2024.

300 people to take 'Write to MP' action, asking them to support a National Brain Tumour Strategy.

Hold parliamentary engagement events in all four devolved nations.

10 Parliamentary Questions related to the awareness and treatments of brain tumours.

Outcomes

52,000 people signed our open letter between the launch in March 2024 and closing it in April 2024.

3,400 people took our 'Write to MP' action.

We held parliamentary engagement events in three nations and attended events in all four nations across the UK.

43 government responses to our Parliamentary Questions across all four nations.

HIGHLIGHTS OF 2024/25

We continue to push for progress through a National Brain Tumour Strategy

In April, we handed in our open letter at each of the parliaments across the UK that called on the government to implement a dedicated National Brain Tumour Strategy. This was supported by four groups of cross-party politicians who wrote to each of their respective devolved nations' Health Ministers to echo our calls for a National Brain Tumour Strategy.

But we haven't stopped there. In October, we launched a campaign encouraging people to write to their MP and invite them to discuss a National Brain Tumour Strategy with us. In total, more than 3,400 took part, resulting in us reaching MPs in over 94% of constituencies and has led to direct contact with more than 120 MPs.

Strengthening partnerships and platforms

Throughout 2024/25, we've continued to strengthen our partnerships with coalitions including One Cancer Voice, Cancer52 and the Less Survivable Cancers Taskforce. Working together, we've advocated for more joined-up action on rare and less common cancers, as well as pushing for equitable access to diagnosis and treatment.

We've extended our reach across the devolved nations, too. Throughout the year, we held multiple events to engage a wide variety of stakeholders – from parliamentarians and GPs to NHS clinical leads and innovation partners – in England, Scotland and Wales. We also attended events in Northern Ireland.

Supporting The Rare Cancers Bill

We're incredibly proud to have supported Dr Scott Arthur MP in his fight to get the Rare Cancers Private Members Bill through the House of Commons and to have helped shape the Bill. After his father-in-law died just six months after being diagnosed with a glioblastoma, Scott experienced the all too familiar story of loss and confusion around why there were so few treatment options and so little progress to improve cure rates in this devastating disease.

The aim of the Rare Cancers Bill is to incentivise research and investment into the treatment of rare cancers, like glioblastoma

and many other types of brain tumours. The Bill passed its second reading after an emotional debate in which MPs shared personal stories and made it clear that we can – and must – do better for people affected by rare cancers.

There's still lots of work to be done before The Rare Cancers Bill becomes an Act of Parliament and we'll continue to be one of the driving forces behind the change that's so urgently needed.



Foysoil Choudhury,
Scottish Labour MSP
with our supporters

DEVELOP EVIDENCE LED POLICY AND INFLUENCE POLICY DEVELOPMENT

We're committed to developing robust policy positions that cover research, diagnosis, care and treatment that are grounded in trustworthy data and the lived experience of people affected by brain tumours.

As well as gaining the support of the community, these need to have a real-world impact in convincing policymakers to act on our behalf.

Goals for 2024/25

Publish two 'bitesize' pieces of the National Brain Tumour Strategy that focus on research participation and faster diagnosis.



Outcomes

We completed research to help us better understand the detailed issues surrounding GP direct access to imaging and patient participation in research. We published these findings in Summer 2025.

HIGHLIGHTS OF 2024/25

The 10-Year Health Plan: making sure the brain tumour community is recognised in national healthcare policy

In December 2024, we worked with the community to respond to the Government's call for evidence for the 10-Year Health Plan.

The plan aims to modernise the NHS through three "big shifts": moving care into communities, improving health technology, and detecting illnesses earlier. While improvements in these areas offer promise in the way that brain tumour care is delivered, we still need a National Brain Tumour Strategy to comprehensively address the unmet need in diagnosis, care, treatment and research.

We focused on these key areas in our response to ensure the needs of those facing this devastating disease are listened to. New incentives developed must consider the unique nature of brain tumours to ensure the community's care does not continue to fall further behind.

Turning insight into influence

To help strengthen our campaign for a National Brain Tumour Strategy, we developed two bitesize pieces that add to the evidence of unmet need in key areas - including faster, better diagnosis, and access to new, better treatments to improve outcomes for brain tumour patients.

Our Exploring GP Access to Imaging reports shed light on the barriers GPs in England and Scotland face in accessing MRI brain scans. Based on evidence from patients, GPs and clinical experts, the report found that clinicians are committed but constrained, with urgent reform needed if we are to reduce diagnostic delays.

Research access remains a core priority, too. Our Barriers to Participation in Research report reveals the challenges that still prevent many people affected by brain tumours from taking part in trials or donating tissue. Developed in collaboration with patients, carers, clinicians and researchers, this report reveals the systemic, cultural and geographic obstacles that prevent too many people from participating in research.

Conducting research at this level, where the insights are expected to have far-reaching impact, takes time. We're looking forward to working with NHS leaders and policy makers to develop practical recommendations that help to combat these challenges.



IMPROVING QUALITY OF LIFE AND PROVIDING SUPPORT AND BEST CARE

We're committed to making sure that everybody in the brain tumour community - no matter who they are or where they're being treated - has access to the care and support they need.

This goes beyond what's delivered in the hospital or the community and needs to be tailored to the individual needs and choices of people affected by brain tumours.

Ultimately, our goal is for everybody affected by a brain tumour to be able to live better and cope with the impact of a diagnosis while having access to the best wraparound care from all UK treatment centres.



Involvement Champions
23-25 cohort

INDIVIDUAL FRONTLINE SUPPORT

From the moment people are diagnosed with a brain tumour, we want to make sure they have access to the information and support they need.

Across our wide range of Support and Information services, we want to have a notable impact at the right moment for anybody who contacts us. To make sure we're meeting the needs of the brain tumour community, we strive to work with people who use our service to better understand our impact.

Goals for 2024/25

Outcomes

Improve access to our Support and Information services across all channels



- 95% of calls to our Support and Information line answered first time.
- 46% visibility in online search results for Support and Information website pages.
- Counselling waiting list no longer than four weeks.
- Two-day response time for emails.
- Two-day response time on requests to join Online Brain Tumour Support Groups.

- 75% of calls answered first time.
- 57% visibility in online search results for Support and Information website pages.
- Counselling waiting list was two weeks or less.
- Two-day or less response time for emails.
- Two-day or less response time on requests to join Online Brain Tumour Support Groups.

Increase the positive impact of our Support and Information services



- Score higher than 85% on all reported outcomes.

Out of 387 people who responded to surveys on the impact of our Support and Information services:

- 88% of people who contacted our Support and Information Line said it helped.
- 79% of people who used our free counselling service said it made a difference to their emotional well-being.
- 100% of children who attended a Family Day felt more confident and 100% of adults who attended felt better connected.

Grow our capacity across our Support and Information services



- Maintain current capacity for all other Support and Information services.

- The number of people we helped through individual support grew 6% to 12,958 people.
- The number of times we helped somebody through individual support grew 19% to helping people 18,109 times.

Grow our free counselling service to 800+ users per year.



Our free counselling service grew 74% year-on-year with 739 users.

HIGHLIGHTS OF 2024/25

Providing high quality services and meeting the needs of the community

2024/25 was a year in which we aimed to continue to meet the increased post-pandemic demand for our Support and Information services. A key goal for the year was maintaining the high quality we strive for and continuing to have a meaningful impact on the community.

Individual support continues to grow year-on-year, with the team helping 12,958 people (an increase of 6% year-on-year) on 18,109 occasions (an increase of 19% year-on-year).

One area that we did actively work to grow was our free counselling service. In 2023/24, we had 425 people enter the service and wanted to increase this to more than 800 people.

We knew that aiming to almost double the number of people entering this service in a single year was a very ambitious target. While we didn't quite achieve this goal, we were still able to grow the service by 74% and provide free counselling for 739 people.


Launching our new Benefits Checker tool

The financial impact of a brain tumour diagnosis can't be overstated. In 2016, we launched our Benefits and Money Clinic in partnership with Citizens Advice Rushmoor to help people affected by a brain tumour navigate the benefits system.

While our Benefits and Money Clinic remains one of our most popular services, we know that some people would prefer to use a digital tool to check what benefits they may be eligible for.

That's why we made the decision to launch our new Benefits Checker tool on the website. This enables people to answer a few questions and then receive information about the financial support they may be entitled to.

Since launching this in September 2024, it's been used by 331 people.



“ Without The Charity's support, I think I would have given up. It can often feel like you're fighting a constant battle with the benefits system - as well as coping with the impact of your diagnosis - so it's brilliant to have someone on your side. **”**

Micheal, who got in touch with the Benefits and Money Clinic



12,958

people helped through
individual support
(+6% YoY)



18,109

interactions between
our Support and
Information team and
individuals seeking
support (+19% YoY)



4,250

cases opened through
our Support and
Information line
(+4% YoY)



513

people supported
through our Benefits
and Money Clinic
(-7% YoY)



More than

£1m

claimed in new benefits
through our Benefits
and Money Clinic
(-6% YoY)



739

people entered our free
counselling service
(+74% YoY)



165

Brainy Bags sent out to
children affected by a
brain tumour



709

Paediatric Brain Tumour
Information Packs
sent out to parents
and carers of a child
recently diagnosed with
a brain tumour



4,602

Information Packs sent
to people affected by a
brain tumour



36,396

total members of our
Online Brain Tumour
Support Groups
(+14% YoY)



255

people took part in our
Family Days



Over

1.1m

active users of online
support information
across our websites



HEALTHCARE PROFESSIONAL ENGAGEMENT AND COMMUNITY INVOLVEMENT

We're committed to working with healthcare professionals across the entire care spectrum to improve the experiences of people affected by a brain tumour – whether that's helping optical professionals spot symptoms or making sure neuro-oncology teams know we're here to support their patients.

Community first is one of our core values and we live this every day by championing the voice of the community and the power of lived experience in all areas of our work.

Goals for 2024/25

Appoint research team responsible for validating our Improving Brain Tumour Care surveys and have the project underway.



Outcomes

The project to validate our Improving Brain Tumour Care surveys is currently on hold until 2025/26.

We also:

- Involved members of our Involvement Network in 123 projects across The Charity.
- Trained almost 3,500 optical professionals to recognise the symptoms of a brain tumour.
- Presented to 922 healthcare professionals over 19 events thanks to our Healthcare Engagement team.

HIGHLIGHTS OF 2024/25

Championing community involvement across The Charity

2024/25 was another strong year for community involvement with our Involvement Network participating in 123 projects that spanned various teams across The Charity including marketing, policy, support, events, fundraising and research.

49% of the involvement projects were focused on research, showcasing our commitment for centring the voice of people affected by brain tumours in discussions about how to accelerate new cures for brain tumours.

Our commitment to listening to the lived experience of the brain tumour community and using their insights to shape critically important work, was never more evident than at our Quality of Life Sandpit event (read more on page 9).

49%



of the involvement projects were focused on research

SUPPORT BEST PRACTICE AND EQUITY OF ACCESS AND CARE FOR ALL

Overarching goals until 2030

We want to discover what best-practice looks like across the entire care pathway - from diagnosis and first-line treatment to rehabilitation and palliative care. Once we have an evidence-based view of this, we want other organisations to aspire to meet that standard and for it to become central to care improvement policy work and programmes across the sector.

Where we find gaps in the care that's available, we'll strive to fill them by collaborating across the UK with partners that can help us meet unmet needs.

Goals for 2024/25

Launch of our Faster, Better Diagnosis GP Programme pilot.



Outcomes

Our Faster, Better Diagnosis GP Programme pilot is currently still being developed and is due to launch in 2025.

HIGHLIGHTS OF 2024/25

Faster, Better Diagnosis GP Programme pilot

This year we managed to do the bulk of the work on a new project designed to help GPs recognise the common signs and symptoms of a brain tumour and feel more confident in referring suspected brain tumour cases to achieve a faster, better diagnosis.

Throughout 2024/25, we've worked with a steering group of GPs, radiologists, neurologists and other healthcare professionals to develop the new campaign and training resources. We're now hoping to test the campaign across a number of pilot sites in 2025/26.

Our Improving Brain Tumour Care surveys have repeatedly highlighted that people are regularly experiencing delays in getting a diagnosis through primary care settings, so we're excited to begin seeing the impact of this programme and to empower more GPs and primary care staff to recognise and refer suspected brain tumour cases faster.

Tessa Jowell Centres of Excellence for Children announced

As a member of The Tessa Jowell Brain Cancer Mission, we're delighted to see the first six Tessa Jowell Centres of Excellence for Children announced in April 2024.



Tessa Jowell
Centre of Excellence

These awards follow rigorous assessments by healthcare professionals and patient representatives, including information provided by our Paediatric Improving Brain Tumour Care surveys.

Six centres gained this accreditation and all 15 centres that applied will now be part of the Tessa Jowell Network. This is positive as it means they'll be working collaboratively to raise the bar for the treatment, care and research for children with brain tumours across the UK.

RAISING FUNDS TO GO FURTHER, FASTER

None of the vital work that we do is possible without the generosity of our supporters. We owe a huge thank you to each and every person who donated or raised funds for The Charity throughout 2024/25.

Our organisational strategy is extremely ambitious and to be successful we know that we need to develop a sustainable approach to increasing our income year-on-year through effective stewardship of existing supporters and a bold plan for acquiring new supporters.



HIGHLIGHTS OF 2024/25

A record-breaking year for fundraising

We're delighted that we've been able to increase our income to match our rapidly growing ambitions as an organisation.

In total, our amazing community helped us to raise a staggering £15.3m in 2024/25. That's an 8% increase on the previous year and meant we exceeded our income target by £300,000.

£15.3M

raised in 2024/25!

Wickes partnership raised £2m over two years

Since our partnership with Wickes began in 2023, colleagues across over 230 stores and in the Support and Distribution centres have rallied together to fundraise through events, personal challenges and customer 50p asks in their stores.

The partnership raised an incredible £2m to help power our work across research, support and campaigning. But it hasn't just raised vital funds, it's also spread awareness with an estimated three million people each month hearing our adverts in-store.



We are delighted to win the
**BEST SHORT-TERM
PARTNERSHIP AWARD**
in 2025 for our partnership
with Wickes.

Our fundraisers go further for a cure

2024/25 was a monumental year for our fundraisers, whether they were taking part in events organised by The Charity and our partners or organising their own fundraising activity.

Our flagship event – The Twilight Walk – returned once again during Brain Tumour Awareness Month and raised an incredible £524,000. 1,215 people joined us for The Twilight Walk London, with a further 1,300 people walking it their own way at The Twilight Walk Own Walks up and down the country.

Our TCS London Marathon team had a record-breaking year with 135 people pounding the pavement and collectively raising an astounding £820,000. High up in the Alps, our fearless fundraisers took on another gruelling Everest in the Alps challenge and raised nearly £450,000 to help fund our future research.

A huge thank you to everyone who took part in an event to help raise funds for The Brain Tumour Charity in 2024/25 – from runs, bike rides and hikes to bake sales, quizzes and skydives.

£820,000

raised by our TCS London
Marathon team

Generous gifts

We're incredibly grateful to everybody who donated to The Charity in 2024/25, including the philanthropists, trusts and family-led partners who supported us. We were humbled to also receive several unexpected large gifts from long-standing supporters throughout the year.

Spectacular Supporter Groups

Year-on-year, our Supporter Groups continue to make a huge impact by helping to spread awareness and raise funds across the country. We never take for granted that so many in the community have chosen to make The Charity part of their or their loved one's legacy.

We're delighted that six new Supporter Groups joined us this year and have already raised £70,000 - with lots of exciting fundraising plans for the near future.

We want to wish a warm welcome to The Bobby Spencer Fund, The Adam Stimpson Fund, The Angus James Gibson Fund, Maynards, Matt Bayfield Legacy Fund and Guernsey "Jim" James Robillard Fund.

Last year was also notable as we saw our first Supporter Group achieve the milestone of raising a total of £1m. The Silas Pullen Fund was helped to reach this achievement thanks to a donation from the family of Rory St John, who sadly passed away earlier in the year following a brain tumour diagnosis.

6 new Supporter Groups joined us this year.

Testing the water with new fundraising initiatives

To grow income sustainably and engage new supporters, we explored new ways of raising funds in 2024/25.

We piloted a door-to-door fundraising campaign that brought in almost 600 new donors, as well as raising awareness of brain tumours with a whole host of new potential supporters.

600 NEW DONORS
joined us through a door-to-door fundraising campaign.

We're stronger together with our corporate partners

Throughout 2024/25, our corporate partners have helped us raise funds and spread awareness of brain tumours.

We were thrilled to be named as one of three founding charity partners of the newly created Majestic Wine Charitable Foundation. The Foundation focuses on creating long-term impact through sustained charitable giving and has already activated customer-facing fundraising initiatives in over 200 Majestic Wine stores that have the power to benefit The Charity.

We partnered with the iconic cinema brand Pearl and Dean to raise awareness of the common brain tumour signs and symptoms on the silver screen. Our Better Safe Than Tumour advert was screened to an estimated 1.6m cinemagoers.

1.6M

cinemagoers estimated to have seen our Better Safe Than Tumour advert.

Developing a dedicated fundraising strategy

Over the past year, we've been developing a new dedicated fundraising strategy to help us reach our ambitious aim of growing our annual income to £25m by 2030.

The comprehensive process has helped us better understand how to capitalise on new opportunities that we've identified and how to overcome some of the barriers that are currently holding us back.

We're ready to get started on some exciting programmes of work to set us up for short and long-term growth.

Wickes

THE
BRAIN
TUMOUR
CHARITY

CHARITY PARTNER FOR
2023 - 2025

TOGETHER AGAINST BRAIN TUMOURS



Brain tumours are the biggest cause of cancer deaths in children and adults

EQUALITY, DIVERSITY AND INCLUSION

This year, The Charity has made meaningful progress in laying the foundations for a long-term, strategic approach to Equity, Diversity and Inclusion (EDI). We're proud of the steps we've taken to build a more inclusive organisation and to make sure EDI plans are underpinned within The Charity's strategy.

We've defined clear EDI goals aligned to our 2023-2030 strategic pillars - transform the research landscape, raise our voices to campaign for change and improve quality of life, provide support and make sure everyone has access to the best care. These goals focus on building robust baseline data, increasing access and inclusion across all areas of our work and ensuring strong governance and accountability.

However, we know there's always more we can do. Building a fully inclusive organisation requires sustained effort, transparency and partnership. We're committed to moving further, faster on that journey thanks to the continued support of the EDI Subcommittee of the board, EDI Champions, our fantastic charity team, volunteers and our community.

COLLECTING BASELINE DATA AND GATHERING INSIGHTS

We're collecting EDI data across our workforce and volunteers, as well as launching a brand development and audience insight project that has EDI as a central focus.

This will provide crucial information on how to reach and better support unmet needs.

BUILDING INCLUSIVE RESEARCH PRACTICES

Our Research team has progressed work to drive greater diversity in the research landscape, addressing barriers to diversity in grant applications and highlighting the importance of inclusive research design.

IMPROVING ACCESS TO SUPPORT AND SERVICES

We've advanced inclusive service delivery through pilot initiatives such as increasing meaningful community involvement and a renewed collaboration with Brainstrust to improve early access to support.

FUNDRAISING WITH INCLUSION AT ITS HEART

During the development of our new fundraising strategy, we made sure that EDI was a core element from the outset, focusing on inclusive team culture and growing supporter networks among currently underserved communities.

CREATING A CULTURE OF BELONGING AT WORK

We have a highly engaged team at The Charity. During 2024/25, we've introduced new policies including Disability Leave, a Menopause at Work policy and enhanced Sickness Pay.

Awareness-raising initiatives, inclusive recruitment and our vibrant EDI Champions Group are supporting us to create a strong sense of belonging across The Charity.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

A social ethos is intrinsic in The Charity since its purpose of existence is to serve the brain tumour community and drive change, and our values reflect this. We have comprehensive policies on matters such as anti-modern slavery and, through our Governance and Ethics committee, keep under constant review our partnerships to ensure the highest ethical standards in all our relationships.

REDUCING ENVIRONMENTAL IMPACT

Every team in The Charity considers what changes, big or small, they can make to reduce the environmental impact of what we do. Our Sustainability Champions group also meets regularly to review the actions being taken, make suggestions for improvements and keep environmental considerations at the forefront of people's work and personal life. This year, we added to our Cycle to Work scheme by offering staff the option of leasing Electric Vehicles which several members of staff have taken advantage of, replacing their combustion engine vehicles. We also continue to implement sustainable practices and strive to protect the environment by, for example:

- not using balloons
- avoiding lamination, coating and binding, as these reduce recyclability
- making a conscious effort to use local suppliers, and printers who are ISO 14001 certified and who report on their environmental impacts

- encouraging Twilight Walk participants to reuse t-shirts from previous years
- recycling and refurbishing old fundraising stock
- discontinuing plastic bag use.

We are a member of ECO Hub, a 700-charity-strong social media forum dedicated to reducing the environmental impact of charities across the globe. We share ideas and information and engage in constructive discussion to find alternative solutions, to make a positive impact.



FINANCE REVIEW

Income grew 8% in the year to March 2025 to a record £15.3m for The Charity, exceeding our budgeted expectation of £15m. The income is vital to funding the essential work The Charity does improving the lives and outcomes of those affected by brain tumours.

Expenditure on charitable activities increased by 7% year-on-year, driven by expenditure on awards into world-class scientific research. In the year to March 2025, research related expenditure was £7.7m, representing 50% of income. Within this research expenditure, our direct research grants grew from £5.4m to £6.2m but didn't achieve our ambitious aim of £7.5m, with some unavoidable delays in making some awards.


INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year, income was up year-on-year and £0.3m ahead of our budget for the 2024/25 with no income streams substantively under-performing.

Our Corporate income was £1.7m, in line with our expectations, and was bolstered from the second year of our partnership with Wickes.

Events and celebrity foundations income was 14% up compared to 2023/24 and 15% up on our budgeted expectation. Our TCS London Marathon team of a record 135 runners and the fearless fundraisers who undertook the gruelling Everest in the Alps event added to the many other participants raising money in the year.

Our Community Fundraising and Supporter Groups, having grown in 2023/24, didn't achieve the ambitious 11% growth we had budgeted for 2024/25 but still achieved an impressive £3m of income in 2024/25 through the hard efforts and generosity of our many community supporters.



EXPENDITURE

Expenditure in the year increased by £0.7m to £15.3m which was below our budgeted expenditure of £17.1m.

One of The Charity's primary objectives is to fund quality research and we aim to spend half of our income in this area as it's vital to us achieving our ambitious objectives. Expenditure on research, which comprises of both the current year's instalments of grant awards to institutions performing the research and The Charity's costs of running and managing this process, increased by £0.7m year-on-year to £7.7m. Of this £7.7m, £6.2m was on research grants, up on the £5.4m spent in 2023/24 but did fall short of the ambitious £7.5m we were aiming to spend with only two of the planned four new translational awards being ready to award before the end of the financial year.

Expenditure on support for those affected by the disease increased by 6% over 2023/24, in line with plans. Campaigning and awareness expenditure decreased by 8% year-on-year following an above usual spend in 2023/24 and in line with budget. These areas form the other main strands of The Charity's primary objectives, to support those affected by brain tumours, to campaign for improved healthcare, research and treatments and to raise awareness of the disease.


In 2024/25, spending on The Charity's charitable objectives represented 80p of every pound we spent.

In 2022/23, The Charity formed trading subsidiaries to commercialise the intellectual property developed by The Charity in creating its BRIAN app and database, with the intention they become a source of income for The Charity in the future by donating any profits to The Charity.

In May 2024, as stated in the Annual Report 2023/24 Finance Review, it became apparent that this endeavour was taking longer than anticipated to grow to a point of reaching a positive contribution and the decision was taken to terminate the operational activities of this venture and cease any further expenditure, beyond the minimum to meet statutory requirements. The loans from The Charity to the subsidiaries have been fully provided for and the Trustees have made appropriate filings to the Charity Commission.

In August 2024, The Charity made the difficult decision to terminate its BRIAN application and database to focus resources on other activities. Despite a loyal following for the application and a great deal of effort over many years to build a database that could make a real difference, it was decided that resources could be better utilised in other areas.

The Charity also has a trading subsidiary, TBTC Trading Limited. This subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a trading profit of £9,000 which will be donated to The Charity.



INVESTMENTS AND CASH

World stock markets were highly volatile over the financial year, driven in large part by announcements by the US Government. At the end of the financial year, The Charity's investments were valued at £12.9m, down from March 2024 after £2m was converted from investments into cash in December 2024 to fund The Charity's work and maintain working capital. Realised and unrealised gains on investments in the year were £0.3m. All investments are held in highly liquid assets and the high level of cash held by The Charity facilitate being selective on when investments are liquidated to avoid losses due to short-term volatility. Current forecasts don't expect the investments to need to be liquidated in the next 12 months. Cash held as at 31 March 2025 was £5.2m.

RESERVES POLICY

The Charity's Reserves Policy is intended to ensure the long-term sustainability of The Charity, its ability to fund committed research expenditure and maintain its core services and Charitable Objectives by ensuring an adequate level of reserves are maintained to manage through a crisis.

Each year the Trustees review forecasts of income, expenditure, cash flows and reserves, to ensure The Charity maintains the level of reserves sufficient to manage a reduction of income that cannot be offset by a reduction in expenditure. In deciding on the level of reserves, the Trustees consider the risk and impact of potential unforeseen events and the ability of The Charity to react to such events.

In addition to considering income and expenditure, the Trustees ensure The Charity maintains a high level of liquid assets to meet foreseen and unforeseen circumstances and to meet our research commitments.

At 31 March 2025, the target level of unrestricted general reserves was £1m. This has been calculated as being the higher of:

- £1m or,
- the sum of 25% loss of income from forecast for 2025/26 levels equating to £3.9m, being offset by 25% savings of non-committed operating expenditure calculated as £2.0m and delaying budgeted new research awards of £1.6m, giving a value of £0.3m. This calculation quantifies the potential loss of income and ability to react.

The £1m minimum unrestricted reserve target is on the basis that the Trustees consider it appropriate to always maintain a minimal reserve to fund closure of The Charity in an extreme event.

The level of total Funds at 31 March 2025 was £8.8m, consisting of unrestricted General reserves of £1.9m, unrestricted Designated of £5.6m and Restricted of £1.3m. Free reserves, defined as general reserves of £1.9m less functional fixed assets of £0.2m, were £1.7m. Total unrestricted reserves are £7.5m, the unrestricted general reserves were £1.9m, £0.9m above the target level of £1m.

Designated funds are set aside by Trustees for specific purposes. Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group, amounting to £0.6m. The Trustees have also designated £5m, to be used to fund future programmes that are planned, including £3m on research, £1m on support services and £1m on fundraising to support the strategic and sustainable growth of The Charity. Designated reserves are expected to be spent in the next two years.

At 31 March 2025, we had unaccrued but committed research expenditure totalling £13m which was subject to satisfying our ongoing monitoring requirements. The investments and cash at 31 March 2025 (which are all liquid) were £18.1m.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's Investment Policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Two investment managers, Albert E Sharp and Evelyn, have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £12.9m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. The portfolio generated income of £581,000 and a valuation gain of £261,000.

In addition to managed investment funds, in 2022/23 The Charity formed subsidiaries to commercialise the intellectual property and technology it had developed in creating BRIAN, The Charity's database tool. As stated in the Expenditure section above, these activities ceased in May 2024 with provisions made in prior years for loans made to subsidiaries that may not be repaid.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy and also champions equality, diversification and inclusion. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.


The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have active volunteers across the UK who support in different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting a variety of projects.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Governance and Ethics Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

- **That we fail to secure adequate income.** We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain adequate reserves. We have no overreliance on any one income. The investment in CRM systems helps optimise stewardship plans.
- **That we are the victim of cyber-crime or that our IT infrastructure is not adequate to support our activities.** We have invested in growing our in-house IT capacity and capability, growing the size and skills of our team. We have reviewed and updated our systems and policies, investing in reputable and leading software solutions as well as utilising outsourced capability where necessary. We ensure that we have leading-edge malware protection and cyber security.
- We utilise multi-factor authentication and encryption and conduct appropriate staff training on cyber security. Online banking arrangements include double authorisation of all transactions and security devices. All websites use SSL technology. In addition, we have a cyber insurance policy.
- **That we become affected by damage to our reputation, or by negative sentiment in the charity sector.** We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups. We undertake careful recruitment of staff and volunteers and associated training, having strong policies and process to adhere to laws and regulations. We're cautious with who we work with and partnerships we engage in and conduct due diligence checks on significant partners. We have strong safeguarding procedures with an experienced safeguarding team.
- **That we aren't able to commission enough high-quality research projects.** We're developing our engagement with the research community into brain tumours and working to build capacity in the sector. We've developed our Future Leader programme to encourage and support world-class talent to enter and stay within the brain tumour research field. We fund globally and put significant emphasis on building relationships with key researchers.



OBJECTIVES FOR 2025-26

The Charity's objectives remain aligned to its core values and our priority objectives for the year are:

- Transforming the research landscape.
- Raising voices to campaign for change.
- Improving quality of life and providing support and the best care for everyone.

In addition to achieving The Charity's core objectives, The Charity will undertake numerous projects to:

- Accelerate income growth.
- Strengthen the organisation including investing in the right systems to protect The Charity and everyone we interact with and maintaining our culture.

PLANS FOR THE FUTURE

Our vision remains unchanged: for everyone diagnosed with a brain tumour to live longer, better lives.

We're investing time and effort on expanding our fundraising to grow and provide income for years to come, money

that will be used to fund our ambitious year-on-year investment in the best global research.

Our current strategy will guide us to 2030 and will set our direction and the shape we need to become in future years.



THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research as well as raising awareness and supporting thousands of people affected by a brain tumour.

The work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we can't thank you enough for continuing to help us to strive to defeat brain tumours.

In addition to the donors named below, we'd like to thank all of our anonymous donors.

TRUSTS AND FOUNDATIONS

The AOK Trust
Maurice Hatter Foundation
The Netherdale Trust
The Colin Oliphant Charitable Trust
The Reed Foundation
The Syncona Foundation
The James Tudor Foundation
Garfield Weston Foundation

FAMILY-LED CHARITY PARTNERS

Angel Child
Iggy's Fund
James Clifford Campling Trust
Joss Searchlight
Shay's Smiles
Team Syren
The Albie Sugden Foundation
The Emily Morris Fund
The Jake McCarthy Foundation
The Oli Hilsdon Foundation
The William Low Trust

CORPORATE PARTNERS

Allports Group
Bank of England
BPL Global
British Council for Offices
British Horseracing Authority
Citi Belfast
CMS
DLA Piper
Ekco (formerly Bluecube Technology Solutions)
Gallagher
Gowlings Solicitors
Hollis
Knight Protection
Liberty Specialty Markets
The Majestic Charitable Foundation
The Puppet Company
Wickes Group PLC
Winckworth Sherwood

CO-FUNDING PARTNERS

Brain Tumour Research
Cancer Research Horizons
Cancer Research UK
Worldwide Cancer Research

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Nicki Chapman
Hal Cruttenden
Tom Daley
Dawn French
Sherrie Hewson
Miles Jupp
Sophie Kinsella
Dominic Matteo
Holly Matthews
John Maynard
Vicki Michelle
Lewis Moody
Amy Nuttall
Sian Reese-Williams
Marc Silk
Lord Spencer
Phil Spencer
The Wanted

SCIENTIFIC ADVISORY BOARD (SAB)

Chair

Prof. Steve Clifford

Vice Chair

Dr Susan Chang

SAB members

Dr Omer Bayraktar
Dr Adrienne Boire
Prof. Benjamin Deneen
Dr Phedias Diamandis
Dr Mariella Filbin
Dr Catherine Flores
Dr Mark Gilbert
Prof. Cynthia Hawkins
Prof. Marcel Kool
Dr Stephen Mack
Dr Tyler Miller
Prof. Simona Parrinello
Dr Lucy Stead
Dr Gerry Thompson
Dr Spencer Watson
Prof. Colin Watts

TRANSLATIONAL ADVISORY BOARD (TAB)

Chair

Prof. Petra Hamerlik

Vice Chair

Prof. Neil Carragher

SAB members

Prof. John Greenman
Dr Chris Ireson
Prof. Ruman Rahman
Dr Jann Sarkaria
Dr Karin Straathof
Dr Martin Swarbrick
Dr Cathy Tralau-Stewart

LAY ADVISORY BOARD (LAB)

Helen Brain
Shona Brooks
Kate D'Aubney
Viv Davies
John Graham
Karen Hong
Donald Innes
Neil Munn
Dean Richardson
Rick Taylor

QUALITY-OF-LIFE REVIEW PANNEL

Director

Prof. Jon Emery

Facilitator

Tim Morley

Quality-of-Life review panel members

Prof. Anne-Sophie Darlington
Dr Cheney Drew
Dr Jurgen Lemiere
Dr Antony Michalski

TRUSTEES AND GOVERNANCE

TRUSTEES

Dr Elena Bechberger
Hayley Conroy
Neil Dickson OBE (resigned 30/09/2024)
Dr Rachel Edgar (resigned 13/06/2024
and reappointed 21/03/2025)
Dr Russell Hagan
Sean Hird (resigned 31/12/2024)
Anna Jarvis
Justine McIlroy (resigned 30/09/2024)
Jack Morris CBE
Dr Alan Palmer (resigned 30/09/2024)
Dr Kieran Palmer
Sukhdip Sandhu
Caroline Steel
Matimba Swana
Beth Worrall (resigned 13/06/2024)

The directors and trustees had liability insurance during the financial year.

GOVERNANCE

CHIEF EXECUTIVE OFFICER

Dr Michele Afif

COMPANY SECRETARY

Liam Heffernan

CHARITY REGISTRATION

CHARITY NUMBERS

England and Wales 1150054
Scotland SC045081

COMPANY NUMBER

08266522

PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,
GU51 2UH

AUDITORS

Menzies LLP, Magna House, 18-32 London
Road, Staines-upon-Thames, TW18 4BP

BANKERS

Lloyds Bank Plc, 147 High Street, Guildford,
GU1 3AG

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon

Evelyn Partners, 25 Moorgate, London

THE CHARITY'S OBJECTS

The objects of the Charity are for the
public benefit:

- 1) to relieve sickness and to promote and protect good health by supporting research into the nature, causes, diagnosis and treatment and social consequences of tumours of the brain and central nervous system and to publish the useful results of such research;
- 2) the relief of suffering of people with tumours of the brain and central nervous system and their families and carers, through the provision of information and support to them; and
- 3) to advance the education of the public in all areas relating to tumours of the brain and central nervous system.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion
- Remuneration

The Charity has formed Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. The Advisory Boards are supported by expert and lay advisors who kindly donate their time to support our work.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and help the whole community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward on all areas of EDI within The Charity.



GRANT-MAKING POLICY

The Charity has established its Grant-making Policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our research strategy 'Accelerating a Cure' launched in 2021/2022. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and more than 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research team, supported by our Scientific Advisory Board. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We used the services of professional third-party fundraisers, Ethicall and Family First Professionals during the year, in a limited capacity to contact potential new donors and supporters. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received three complaints this year relating to fundraising.

There have been no breaches of the Code of Practice during the year.

WORKING WITH PARTNERS

We're committed to working with all partners including those in the pharmaceutical and biotech industry in order to meet our objectives. We remain vigilant that our independence is not compromised and we act in the best interests of our community at all times.

STATEMENT OF TRUSTEE'S RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.
- The Trustees are responsible for

keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They're also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we're aware:

- There're no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 19 September 2025 and signed on their behalf by:



Jack Morris CBE

Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2025 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2025 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSION RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

. Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit.

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.

- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.

We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:

- Posting of fraudulent journal entries
- Posting of fraudulent payments and receipts in the accounting software
- Authorisation, processing, and payment of fraudulent expenses
- Fictitious employees
- Timing of revenue recognition

Audit procedures performed by the engagement team included:


- Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
- Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
- Challenging assumptions and judgments made by management in its significant accounting estimates; and
- Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
- Carrying out checks to establish the validity of employees, and
- Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: [www.frc.org.uk/ auditor's responsibilities](http://www.frc.org.uk/auditor's-responsibilities). This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Janice Matthews
FCA (Senior statutory auditor)
for and on behalf of

Menzies LLP
Chartered Accountants
Statutory Auditor
Magna House,
18-32 London Road,
Staines-upon-Thames,
TW18 4BP

Date: 19 September 2025

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2025

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2025 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000
<u>Income and expenditure</u>							
Income from:							
Donations and legacies	3	11,567	2,571	14,138	10,926	1,704	12,630
Other trading	3	510	101	611	925	77	1,002
Investments		581	-	581	563	-	563
Total income		12,658	2,672	15,330	12,414	1,781	14,195
Expenditure on:							
Raising funds		3,060	1	3,061	3,130	33	3,163
Charitable activities							
Research		5,390	2,330	7,720	4,766	2,241	7,007
Patient support		2,776	365	3,141	2,389	569	2,958
Campaigning & raising awareness		1,371	41	1,412	1,369	162	1,531
Total expenditure on charitable activities		9,537	2,736	12,273	8,524	2,972	11,496
Total expenditure	4	12,597	2,737	15,334	11,654	3,005	14,659
Net (expenditure)/income before gains and losses on investment assets		61	(65)	(4)	760	(1,224)	(464)
Realised and unrealised gains on investment assets		261	-	261	764	-	764
Net movement in funds for the year		322	(65)	257	1,524	(1,224)	300
Reconciliation of funds							
Balances at 1 April		7,202	1,329	8,531	5,678	2,553	8,231
Balances at 31 March		7,524	1,264	8,788	7,202	1,329	8,531

The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities. The notes on pages 47-61 form part of these financial statements

CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2025

Company number: 08266522

		Consolidated		Company	
	Notes	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Fixed assets					
Intangible assets	10	-	1	-	1
Tangible assets	11	200	221	200	221
Investment in subsidiaries	12	-	-	-	-
Investments	12	12,947	14,636	12,947	14,636
Current assets					
Stock		44	50	-	-
Debtors	13	1,044	1,478	1,148	1,498
Cash at bank		5,176	3,487	5,151	3,401
		6,264	5,015	6,299	4,899
Creditors					
Amounts falling due within one year	14	(10,523)	(11,242)	(10,562)	(11,222)
Net current (liabilities)		(4,259)	(6,227)	(4,263)	(6,323)
Provision for liabilities					
	15	(100)	(100)	(100)	(100)
Net assets		8,788	8,531	8,784	8,435
Funds					
General reserve		1,897	6,194	1,893	6,098
Designated funds		5,627	1,008	5,627	1,008
Unrestricted funds		7,524	7,202	7,520	7,106
Restricted funds		1,264	1,329	1,264	1,329
	19	8,788	8,531	8,784	8,435

The financial statements were approved by the trustees on 19 September 2025 and signed on their behalf by:



Jack Morris CBE
Chair of Trustees



Hayley Conroy
Chair of Finance Committee

The notes on pages 47-61 form part of these financial statements.

CONSOLIDATED STATEMENT OF CASH FLOWS FOR THE YEAR ENDED 31 MARCH 2025

	2025 £'000	2024 £'000
Net (expenditure) / income for the year (as per the statement of financial activities)		
Net income for the year	257	300
Adjustments for:		
Depreciation	22	29
(Losses) on investments	(261)	(764)
Income from investments	(581)	(563)
Decrease/(Increase) in stocks	5	(17)
Decrease in debtors	434	215
Decrease in creditors	(719)	(809)
Net cash (used in) provided by operating activities	(843)	(1,609)
Statement of cash flows		
Cash flows from operating activities		
Net cash (used in) provided by operating activities	(843)	(1,609)
Cash flows from investing activities:		
Dividends, interest and rents from investments	581	563
Purchase of computer software	-	-
Purchase of property plant & equipment	-	-
Sale/(purchase) of investments	1,951	(33)
Net cash provided by investing activities	2,532	530
Change in cash and cash equivalents in the year	1,689	(1,079)
Balances at 1 April	3,487	4,566
Balances at 31 March	5,176	3,487
Analysis of cash and cash equivalents		
Cash in hand	5,025	1,161
Notice deposits (less than 3 months)	151	2,326
Total cash and cash equivalents	5,176	3,487

Analysis of changes in net debt				
	At 1 April 2024	Cash from purchase of investments	Other Cash flows	At 31 March 2025
Cash	1,161	1,951	1,913	5,025
Cash equivalents	2,326	-	(2,175)	151
Net debt	3,487	1,951	(262)	5,176

NOTES TO THE FINANCIAL STATEMENTS

1. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 36. The principal activity of the company and the nature of its operations are set out in the trustees' report starting on page 6.

2. ACCOUNTING POLICIES

(a) basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity ("The Charity") constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity's subsidiary undertakings, TBTC Trading Ltd, Acquist Data Holdings Ltd, Acquist Data Ltd, Medli Health Holding Ltd and Medli Health Ltd have been consolidated on a line by line basis. All Group companies prepare their accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £349,000 (2024: £346,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) Company status

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 36. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) Income

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Legacy income is recognised when the charity has sufficient evidence that a gift has been left to it (through knowledge of the existence of a valid will and the death of the benefactor); receipt is probable (there has been grant of probate and conditions attached to the legacy are within the control of the charity), and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the charity, can be reliably measured.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such as grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Employee Termination Benefits are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

(e) Stocks

Stock is measured at the lower of cost and net realisable value.

(f) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Designated funds are unrestricted funds that are set aside by Trustees for specific purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) Fixed assets

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) Estimated useful lives

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) Investments

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) Donated assets and services

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at the estimated price we would pay in the open market.

(k) Operating lease

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) Pensions

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) Going concern

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. INCOME

a. Donations and Legacies

	Unrestricted £'000	Restricted £'000	Total 2025 £'000	Unrestricted £'000	Restricted £'000	Total 2024 £'000
Ordinary activities:						
Regular giving	439	74	513	381	75	456
Donations, appeals and fundraising	9,087	2,329	11,416	8,799	1,443	10,242
Gift aid	1,084	143	1,227	874	45	919
Legacies	957	25	982	789	141	930
Government grants	-	-	-	83	-	83
	11,567	2,571	14,138	10,926	1,704	12,630

Government grants consist of amounts received under the COVID Medical Research Charity Support Fund.

b. Other trading

Other trading income comprises income from fundraising events such as The Twilight Walk and community events £530,000 (2024: £900,000), product sales £78,000 (2024: £82,000) and services sales £3,000 (2024: £20,000).

4. ANALYSIS OF RESOURCES EXPENDED

	Direct Costs £'000	Grants £'000	Support Costs £'000	2025 Total £'000
Raising funds	2,773	-	288	3,061
Charitable activities:				
Research	1,426	6,206	88	7,720
Patient support	2,981	-	160	3,141
Campaigning and raising awareness	1,272	-	140	1,412
Total expenditure on charitable activities	5,679	6,206	388	12,273
Total expenditure	8,452	6,206	676	15,334

	Direct Costs £'000	Grants £'000	Support Costs £'000	2024 Total £'000
Raising funds	2,891	-	272	3,163
Charitable activities:				
Research	1,507	5,415	85	7,007
Patient support	2,806	-	152	2,958
Campaigning and raising awareness	1,399	-	132	1,531
Total expenditure on charitable activities	5,712	5,415	369	11,496
Total expenditure	8,603	5,415	641	14,659

5. RESEARCH GRANT COST ANALYSIS

	2025 £'000	2024 £'000
Research programmes	2,942	3,938
Research projects	2,311	758
Clinical trials	803	719
Fellowships	139	-
Conferences	11	-
	6,206	5,415

A breakdown of research costs by individual award is provided in note 21.

6. SUPPORT COSTS BY ACTIVITY

2025	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	52	167	69	288
Charitable activities:				
Research	16	51	21	88
Patient support	29	92	39	160
Campaigning and raising awareness	25	81	34	140
Total	122	391	163	676

2024	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	75	138	59	272
Charitable activities:				
Research	23	44	18	85
Patient support	42	77	33	152
Campaigning and raising awareness	36	67	29	132
Total	176	326	139	641

Governance costs of £97,000 (2024: £82,000) are included in central management & governance.

7. GOVERNANCE COSTS

	2025 £'000	2024 £'000
Auditor's remuneration	28	32
Trustee meetings	-	1
Legal and professional fees	19	1
Staff	50	48
	97	82

In addition to Auditor's remuneration for audit shown above, a further £3,840 was paid for accounting and tax advice (2024: £840). Trustees received no remuneration (2024: £nil). Trustees received no reimbursement for travel expenses in the year totalling £nil (2024: £127). The premium in respect of professional liability insurance covering trustee indemnity was £5,484 (2024: £5,179).

8. STAFF COSTS

	Consolidated		Company	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Wages and salaries	4,617	4,304	4,617	4,223
Social security costs	456	416	456	405
Payments to defined contribution pension plans	359	310	359	310
	5,432	5,030	5,432	4,938

During the year redundancy payments were made totalling £6,000 (2024: £nil).

The average number of employees during the year was 118 (2024: 116).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2025	2024
£60,001 - £70,000	6	2
£70,001 - £80,000	2	2
£80,001 - £90,000	2	3
£90,001 - £100,000	1	-
£100,001 - £110,000	-	-
£110,001 - £120,000	-	-
£120,001 - £130,000	1	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £776,000 (2024: £708,000).

9. TAXATION

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. INTANGIBLE FIXED ASSETS

Consolidated and Company	Computer Software £'000
Cost	
At 1 April 2024 and 31 March 2025	161
Depreciation	
At 1 April 2024	160
Charge for the year	1
At 31 March 2025	161
Net book value	
At 31 March 2025	-
At 31 March 2024	1

11. TANGIBLE FIXED ASSETS

Consolidated and Company	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2024	292	174	466
Disposals	-	(128)	(128)
At 31 March 2025	292	46	338
Depreciation			
At 1 April 2024	72	173	245
Charge for the year	20	1	21
Disposals	-	(128)	(128)
At 31 March 2025	92	46	138
Net book value			
At 31 March 2025	200	-	200
At 31 March 2024	220	1	221

12. INVESTMENTS

(a) Subsidiary Investment

Equity investment in group undertakings

Cost	£
At 1 April 2024 and 31 March 2025	201

The Charity owns 100% of the £1 ordinary share capital of Medli Health Holding Limited, a company incorporated in England and Wales, company number 14368728. Medli Health Holding Limited owns 100% of Medli Health Limited, a company incorporated in England and Wales, company number 14371364.

The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holdings Limited, a company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Limited owns 100% of Acquist Data Limited, a company incorporated in England and Wales, company number 13951572.

The purpose of the above companies were to commercialise the intellectual property created in developing the BRIAN database, to generate income to be donated to The Charity.

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2025 £'000	2024 £'000
Turnover	77	74
Cost of sales	(53)	(45)
Gross profit	24	29
Other operating expenses	(15)	(7)
Profit before donation	9	22
Donation	(23)	(12)
Retained profit/ (loss)	(14)	10

At 31 March 2025 the aggregate assets of TBTC Trading Ltd were £51,000 (2024: £53,000), aggregate liabilities £42,000 (2024: £30,000) and shareholder's funds £9,000 (2024: £23,000).

The net trading loss of Medli Health Ltd consolidated is as set out below.

	2025 £'000	2024 £'000
Turnover	3	20
Expenditure	(81)	(402)
Retained (loss)	(78)	(382)

At 31 March 2025 the aggregate assets of Medli Health Ltd were £123,000 (2024: £142,000), aggregate liabilities £1,350,000 (2024: £1,291,000) and shareholder's deficit £1,227,000 (2024: £1,149,000).

Medli Health Holding Ltd, Acquist Data Holdings Ltd and Acquist Data Ltd did not trade during the year.

(b) General investments

Equity investment in group undertakings

	2025	2024
Consolidated and Company	£'000	£'000
At 1 April	14,636	13,838
Additions at cost	502	471
Disposals	(1,301)	(387)
Net unrealised profit/(loss) on revaluation	(890)	714
At 31 March	12,947	14,636
Historical cost	11,635	12,469

	2025	2024
	£'000	£'000
Investments at market value comprised:		
UK equities	2,859	3,191
Overseas equities	3,622	4,377
Property	297	239
Multi asset funds	782	887
Alternative investments	97	93
Fixed income securities	5,232	5,819
Cash held within the investment portfolios	58	29
Accrued income	-	1
At 31 March	12,947	14,636

Financial instruments

During the year income from listed investments was £492,000 (2024: £472,000) and interest on deposits £89,000 (2024: £91,000).

Financial assets measured at fair value through income and expenditure amounted to £12,947,000 (2024: £14,636,000) comprise fixed asset investments. The value of investments is calculated with reference to the market value of the shareholding.

13. DEBTORS

	Consolidated		Company	
	2025	2024	2025	2024
	£'000	£'000	£'000	£'000
Trade debtors	182	171	182	169
Accrued income and prepayments	805	1,161	805	1,161
Other debtors	57	146	3	40
Amounts owed by Group companies	-	-	158	128
	1,044	1,478	1,148	1,498

14. CREDITORS

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2025: £535,000 (2024: £357,000) of income was deferred and £357,000 (2024: £310,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Grants payable	9,464	10,424	9,464	10,424
Accruals and deferred income	624	459	618	446
Trade creditors	269	192	265	185
Other creditors	50	51	50	51
Social security and other taxes	116	116	165	116
	10,523	11,242	10,562	11,222

15. PROVISION FOR LIABILITIES

	Consolidated		Company	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
At 1 April and 31 March	100	100	100	100

The provision relates to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. RESEARCH COMMITMENTS

At 31 March 2025 The Charity had authorised commitments that were subject to outstanding conditions amounting to £12,969,000 (2024: £13,082,000), these are expected to fall due as follows:

	2025 £'000	2024 £'000
Within one year	5,276	5,237
Between one and two years	4,418	3,717
Between two and three years	2,149	2,858
Between three and four years	1,126	1,270
	12,969	13,082

The above commitments will be funded from reserves and future income.

17. OPERATING LEASE COMMITMENTS

The total of future minimum lease payments on operating leases are as follows:

	On Property		On Equipment	
	2025 £'000	2024 £'000	2025 £'000	2024 £'000
Consolidated and Company				
Within one year	218	218	42	10
Between one and five years	195	467	69	28
	413	685	111	38
Operating lease charges in the year	218	216	27	10

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Consolidated			Company		
	Unrestricted Funds £'000	Restricted Funds £'000	Total 2025 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2025 £'000
2025						
Intangible fixed assets	-	-	-	-	-	-
Tangible fixed assets	200	-	200	200	-	200
Investments	12,947	-	12,947	12,947	-	12,947
Other current assets	3,062	3,202	6,264	3,097	3,202	6,299
Current liabilities	(8,685)	(1,938)	(10,623)	(8,724)	(1,938)	(10,662)
	7,524	1,264	8,788	7,520	1,264	8,784

	Consolidated			Company		
	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000
2024						
Intangible fixed assets	1	-	1	1	-	1
Tangible fixed assets	221	-	221	221	-	221
Investments	14,636	-	14,636	14,636	-	14,636
Other current assets	1,540	3,475	5,015	1,424	3,475	4,899
Current liabilities	(9,196)	(2,146)	(11,342)	(9,176)	(2,146)	(11,322)
	7,202	1,329	8,531	7,106	1,329	8,435

19. FUNDS

Consolidated 2025	At 1 April 2024 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2025 £'000
Restricted funds:					-	
Research funds	999	2,205	(2,120)	-	-	1,084
Everest fund	-	3	(3)	-	-	-
Awareness funds	-	41	(41)	-	-	-
Support funds	330	423	(573)	-	-	180
	1,329	2,672	(2,737)	-	-	1,264
Unrestricted funds:						
General reserve	6,194	11,923	(11,481)	(5,000)	261	1,897
Designated funds	1,008	735	(1,116)	5,000	-	5,627
	7,202	12,658	(12,597)	-	261	7,524
	8,531	15,330	(15,334)	-	261	8,788

Company 2025	At 1 April 2024 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2025 £'000
Restricted funds:						
Research funds	999	2,205	(2,120)	-	-	1,084
Everest fund	-	3	(3)	-	-	-
Awareness funds	-	41	(41)	-	-	-
Support funds	330	423	(573)	-	-	180
	1,329	2,672	(2,737)	-	-	1,264
Unrestricted funds:						
General reserve	6,098	11,866	(11,332)	(5,000)	261	1,893
Designated funds	1,008	735	(1,116)	5,000	-	5,627
	7,106	12,601	(12,448)	-	261	7,520
	8,435	15,273	(15,185)	-	261	8,784

Consolidated 2024	At 1 April 2023 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2024 £'000
Restricted funds:						
Research funds	1,169	1,141	(1,311)	-	-	999
Everest fund	745	184	(929)	-	-	-
Awareness funds	159	4	(163)	-	-	-
Support funds	480	452	(602)	-	-	330
	2,553	1,781	(3,005)	-	-	1,329
Unrestricted funds:						
General reserve	3,985	11,395	(9,950)	-	764	6,194
Designated funds	1,693	1,019	(1,704)	-	-	1,008
	5,678	12,414	(11,654)	-	764	7,202
	8,231	14,195	(14,659)	-	764	8,531

Company 2024	At 1 April 2023 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2024 £'000
Restricted funds:						
Research funds	1,169	1,141	(1,311)	-	-	999
Everest fund	745	184	(929)	-	-	-
Awareness funds	159	4	(163)	-	-	-
Support funds	480	452	(602)	-	-	330
	2,553	1,781	(3,005)	-	-	1,329
Unrestricted funds:				-		
General reserve	3,843	11,313	(9,822)	-	764	6,098
Designated funds	1,693	1,019	(1,704)	-	-	1,008
	5,536	12,332	(11,526)	-	764	7,106
	8,089	14,113	(14,531)	-	764	8,435

PURPOSE OF RESTRICTED FUNDS

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 21.
Everest fund	The Everest Centre is a specified programme for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is Better Safe Than Tumour.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated funds represent unrestricted funds set aside by Trustees for specific purposes. In addition to funds set aside by Trustees for research, fundraising and support services, they include accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. The Trustees have also, approved funding of a Chair position at a UK university and have designated other funds for Research and Support services.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or move to general reserves to designated funds.

20. RELATED PARTIES

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2025 The Charity was owed from TBTC Trading Ltd £36,726 (2024: £24,458).

The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited.

The Charity owns 1 of the issued £1 ordinary shares of Medli Health Holding Limited, a company with the same registered address as The Charity. Medli Health Holding Limited wholly owns the share capital of Medli Health Limited.

Acquist Data Limited and Medli Health Limited were formed to commercialise the intellectual property developed by The Charity in creating its BRIAN database and app.

At 31 March 2025 The Charity:

- Was owed £400,000 (2024: £400,000) from Acquist Data Ltd in the form of an intercompany loan.
- Was owed £31,702 (2024: £31,702) from Acquist Data Ltd on an intercompany balance.
- Was owed £860,000 (2024: £860,000) from Medli

Health Ltd in the form of intercompany loans.

- Was owed £89,185 (2024: £71,443) from Medli Health Ltd on an intercompany balance.
- The Charity has fully provided as a bad debt provision for the loans owed to it from Medli Health Ltd totalling £860,000 (2024: £860,000) and Acquist Data Ltd totalling £400,000 (2024: £400,000).
- Was owed £82 from Acquist Data Holdings Ltd (2024: £300).
- Was owed £158 from Medli Health Holding Ltd (2024: £199).

Acquist Data Ltd was owed £395,239 (2024: £345,958) from Medli Health Ltd and has provided £345,958 as a potential bad debt.

Trustees, their close family members and entities they control, made donations to The Charity totalling £319,610 (2024: £216,739) during the year. They also paid contributions totalling £nil (2024: £713) for purchases.

21. RESEARCH AWARDS

	2025 £'000	2024 £'000
Research and Innovation Centre for Paediatric Low Grade Brain Tumours (Everest) - Dr. David Jones	1,004	988
Quality of Life - Prof. Colin Kennedy	35	61
Quest for Cures - Dr. Paul Northcott	-	184
Quest for Cures - Dr. Todd Hankinson	-	20
Quest for Cures - Prof. Simona Parrinello	-	218
Quest for Cures - Prof. Richard Gilbertson	-	304
Quest for Cures - Prof. Neil Carragher	-	525
Quest for Cures - Prof. Louis Chesler	239	266
Quest for Cures - Dr. Rameen Beroukhim	282	315
Quest for Cures - Prof. Marcel Kool	317	259
Quest for Cures - Dr. Jun Ishihara	340	349
Quest for Cures - Prof. Juan Pedro Martinez-Barbera	332	273
CONNECT TarGeT - Prof. Darren Hargrave	-	176
Quest for Cures - Prof. Barry Pizer	288	-
Quest for Cures - Dr. Pau Creixell	105	-
Total Programmes	2,942	3,938

Clinical Biomarkers – Dr. Gelareh Zadeh	41	58
Future Leaders – Dr. Mara De Martino	75	-
Future Leaders – Dr. Jessica Taylor	71	-
Future Leaders – Dr. Christopher Mount	75	-
Future Leaders – Mr. Ola Rominiyi	75	-
Future Leaders – Dr. Ángel Álvarez-Prado	75	-
Future Leaders – Dr. Claire Vinel	75	-
Brain Tumour Data Accelerator – Dr. Matthew Williams	-	46
Future Leaders Junior Fellowship – Dr. Spencer Watson	150	150
Future Leaders Junior Fellowship – Dr. Tyler Miller	150	150
LMIC award – Prof. Alan Davidson	-	26
Expanding Theories – Prof. Michael Brown	-	59
Expanding Theories – Dr. Manish Aghi	-	69
ICR Centre of Excellence – Prof. Chris Jones	-	200
Expanding Theories – Dr. Lucy Stead	67	-
Expanding Theories – Prof. Khuloud Al-Jamal	56	-
Future Leaders – Dr. Bo Sun	62	-
Future Leaders – Dr. Antonio Carlos Fuentes Fayos	100	-
Future Leaders – Dr. Charlotte Eaton	75	-
Future Leaders – Dr. Mathew Clement	47	-
Future Leaders – Dr. Emily Bates	74	-
Expanding Theories – Dr. Elizabeth Cooper	72	-
Expanding Theories – Dr. Youri Hoogstrate	73	-
Cancer Tech Accelerator – Mr. Richard Mair	70	-
Centre for Genomic Regulation – Prof. Luciano Di Croce	28	-
Institute of Biomedical Research – Dr. Maria Alieva	24	-
The Translational Award – Prof. John Anderson	246	-
The Translational Award – Prof. Maya Thanou	275	-
Quality of Life – Dr. Faye Didymus	67	-
Quality of Life – Ms. Vicky King	43	-
Quality of Life – Dr. Sarita Depani	72	-
Quality of Life – Dr. Debbie Hicks	73	-
Total Projects	2,311	758
PNET5 – Prof. Pamela Kearns	-	22
High Risk Medulloblastoma – Prof. Simon Bailey	85	84
BRAIN MATRIX – Prof. Colin Watts	611	613
ARISTOCRAT – Prof. Susan Short	107	-
Total Clinical Trials	803	719
Chair of Translational Neuro-oncology – Prof. Petra Hamerlik	139	-
Conferences, workshops and other	11	-
Total Research Award Expenditure	6,206	5,415



thebraintumourcharity.org

Registered office: Fleet 27, Rye Close,
Fleet, Hampshire, GU51 2UH
© The Brain Tumour Charity 2025.
Registered Charity in England and
Wales (1150054) and Scotland (SC045081).

**THE
BRAIN
TUMOUR
CHARITY**

Accounts

ANNUAL REPORT AND ACCOUNTS

2023-2024



**THE
BRAIN
TUMOUR
CHARITY**



CONTENTS

Chair's report	3
CEO's report	4
Report of the Trustees	5-37
Strategic report	6-30
Independent auditor's report	38
Statement of financial activities	42
Balance sheet	43
Cash flow statement	44
Notes to the accounts	45-59



CHAIR'S REPORT

This has been a very active year for The Charity. Among other achievements, we spent nearly £5.5m on cutting-edge research grants, launched a hugely successful policy campaign, and supported more than 12,000 people. This was all enabled by our most successful fundraising year to date, with our community raising an astonishing £14m towards our mission of helping everyone with a brain tumour live a longer, better life.

Notably, our income from community fundraising events, such as walks, runs, dinners and birthdays, achieved an incredible £2.4m. We fielded our biggest London Marathon team so far, our wonderful high-profile partner Wickes raised over £1m, and there were countless other milestones and highlights to celebrate – such as Team Syren tackling Everest in the Alps, a gruelling challenge inspired by our former trustee Rob Ritchie, to raise money for The Everest Centre for Research into Paediatric Low Grade Brain Tumours.

As we head into 2024-25, this strong fundraising outcome allows us to continue delivering excellence in research across a three-pronged strategy of creating new knowledge, accelerating new treatments and enhancing quality of life. It will also allow us to continue providing specialist support to adults, young people, children and families, and, as we build awareness and raise our voices for change, strengthen ties with policymakers to drive change – which will improve treatment and care for even more people affected by this awful disease.

It's crucial that new treatments reach patients sooner, and we were delighted to see a positive outcome of our efforts throughout the year in this area when, in April 2024, the National Institute for Health and Care Excellence (NICE) made dabrafenib and trametinib available through NHS prescribing – the first new treatment in decades for children with certain types of glioma. Research we funded laid the early groundwork for this breakthrough, and we ensured the voices of our community were heard during the NICE appraisal process.

But we must ensure that progress like this continues into the future. It's vital that we attract the brightest minds to neuro-oncology and encourage them to remain in the field through investment in talented early-career researchers, like our two Junior Fellows, Dr Spencer Watson and Dr Tyler Miller, whom we recently awarded £600,000 each to fund their research for a further four years, marking the second step in our Future Leaders programme.

I want to thank our CEO, Dr Michele Afif, for expertly steering us through her first year whilst implementing our community-created strategy, Living Longer and Better, a unique and special collaboration that will serve as our guiding light through to 2030. I'd also like to thank our Senior Leadership Team and wider staff for their incredible passion and skill in taking The Charity's work forward. And finally, of course, my deepest thanks to our dedicated Trustees, wonderful donors and partners for coming together and achieving what they do. Thank you so much.

I greatly look forward to working alongside you all, and seeing our hard work bear fruit in the years to come.

Thank you,

Jack Morris CBE
Chair of Trustees



CEO'S REPORT

It has been my privilege to take the helm of a charity which is already delivering impactful change for the community it serves and, as I join this amazing team, I am delighted to see that this year has been no different.

Brain tumours are relentless – harming people young and old almost beyond measure. In response, our charity is equally relentless in its determination to make the goal of *Living Longer and Better* a reality, and 2023/24 is marked out by numerous achievements which reflect our commitment to that guiding principle.

Nowhere is this more apparent than in the depth and breadth of our research programme. Delivering Accelerating a Cure is so much more than building a set of individual awards – it's our way of truly finding and then funding the very best work and brightest minds from across the world in our drive to transform the whole research landscape. Just some of those leaps forward this year include investing £4.5m into three new Quest for Cures grants, and the continued progress of The Everest Centre's transformative work developing pioneering new treatments for children with low grade gliomas, following our further £5m commitment (2022-2027).

This level of ambition takes long-term financial investment. It's a commitment that can only be met through the generosity of our donors and the tirelessness of a fundraising team that doesn't just think in terms of amounts raised but how to build that fund in solidarity with our community.

I believe this year's flagship event, The Twilight Walk, perfectly captures that sense of connectedness that underpins and motivates our work, bringing our whole community together in ways that moved, supported and inspired. It was also wonderful to see our supporters share their stories, raise awareness and even win awards. Showing that age is no barrier, nine-year-old Ravi Adelekan has raised

over £100,000 so far for us and our friends at Braintrust, and the incredible Harry Smith, 13, who lost his sister to a brain tumour, won JustGiving's 2023 Young Fundraiser of the Year Award.

Our desire to really listen to our community about how they experience the impact of a brain tumour diagnosis is at the very heart of all we do. This year, our Support team helped 12,189 people, with 425 people entering our specialist counselling service and, through our Money and Benefits clinic, 550 people finding more than £1.3 million in new benefits. Membership of our peer support groups is up to 32,200 and we had at least 1.1 million active users of support on our main website and Better Safe Than Tumour.

This year is particularly special. During March 2024 our Policy team took those insights – and so many more – and amplified them into a hugely powerful and successful call for a National Brain Tumour Strategy. Supported by more than 52,000 people, I believe this creates a mandate to work even more collaboratively with others to influence for change at the very highest levels.

And as ever, our guiding light is our freshly launched, community-created strategy *Living Longer and Better: 2023-30*. This is a living document, drawn from real experience, which gives us not only our direction but provides a blueprint on how to work so we are as effective and successful as possible. It is both exhilarating and humbling to join a team which is unashamedly collaborative, ambitious, bold and innovative – actively harnessing those values to bring our strategy to life. This year, as we move into full implementation, I know without doubt that the *Living Longer and Better* principles will serve as a constant reminder of the need to keep seeking maximal impact if we are to have any chance of defeating this devastating group of diseases.

Thank you,

Dr Michele Afif
CEO

OUR GOALS AND VALUES

OUR GOALS

Our vision is for people diagnosed with a brain tumour to live longer and better lives, and our goals are our blueprint for getting there. Simply put, if something doesn't help us achieve one of these goals, we know that it's not the right direction for us.

We've set ourselves goals that are unashamedly ambitious as this is the only way we'll see a real and lasting difference. We want to:

- double survival in the UK
- halve the harm that brain tumours have on quality of life in the UK

OUR VALUES

Our values underpin everything that we do, they define what we believe and guide our actions every day.

The way we work is always:

COMMUNITY FIRST

We put the community's needs first, ensuring our work is informed by those with experience and that they are the driving force behind our decisions. We include everyone, amplifying their voices and uniting in our shared purpose to create change.

COLLABORATIVE

We know that we're stronger together, so we choose to lean on each other, share openly and utilise expertise and knowledge wherever it exists. We seek out and support diverse perspectives, operate without ego and are part of a connected eco-system that everyone can join.

BOLD

We are unapologetically ambitious and true to ourselves. We'll be brave and think bigger – as there's just no time to waste. We'll be confident and relentless in challenging the status quo, even when that means making difficult decisions. We're determined, focused and unstoppable.

INNOVATIVE

We are creative and adopt a growth mindset, always using our experience and imaginations to find smarter and more effective ways to propel progress. We're not afraid to think differently, find new ways to solve problems and be agile in 'testing and learning', so we can move at pace in pursuit of our vision.

STRATEGIC REPORT

WE WILL ACCELERATE CURES FOR ALL BRAIN TUMOURS

We fund the highest-quality research around the world to:

- create new knowledge and understanding
- accelerate new treatments and translate breakthroughs into benefits for patients
- enhance quality of life.

EMBODYING EXCELLENCE IN RESEARCH

Brain tumours remain the biggest cancer killer of the under-40s, reducing life expectancy by 27 years on average – the highest of any cancer. But even survivors or those with low grade disease often face harms to long-term function, mental health and quality of life. Our research strategy, Accelerating a Cure, underpins our determination to address this, with a core commitment to spend 50% of our annual income on research awards every single year.

We've pledged to commit at least £50m by 2030, creating a platform for much-needed investment into the best, most pioneering research.

But we don't just want to fund research projects – we need to transform the research landscape to build research capacity, deliver clinical trials and drive translational research which pushes innovation from concept to clinic.

To build capacity, our innovative Future Leaders programme ensures the brightest minds are attracted to the sector and stay working within it. It not only supports excellent researchers just beginning their careers to establish themselves as leading experts, but also inspires more researchers to join our movement, encourages them to remain working within the field and will exponentially create and grow enthusiasm for neuro-oncology. We've funded 10 Future Leaders so far, with more to be announced in the coming financial year.

We're proud that our research funding is driving both global and UK research excellence and capacity, as collaboration is key to delivering community benefit. With your continued support, we'll go further, faster until everyone with a brain tumour lives a longer, better life.





COMMITTING CRUCIAL FUNDS

We were delighted to commit the funding we'd anticipated in the discovery research space this year, including £4.5m going towards three new Quest for Cures grants, £600,000 going to each of our two Junior Fellows (the second stage in our Future Leaders programme), and commitments of £150,000 each to two new Expanding Theories grants.

Our record fundraising total this year provides an exciting springboard for major investment into truly excellent research going into 2024-25. This year, we have focused on setting ourselves up for future investment, empowering our team to build on our research progress to date so we can continue to improve our knowledge of brain tumours and, most importantly, ensure this knowledge is translated into new treatments.

In January, we welcomed our new Chief Scientific Officer, Dr Simon Newman. With his background in cancer drug discovery, he is well placed to propel our research strategy, including our pioneering new Translational Awards (see below), and has been laying the groundwork for significant investment next year.

To overcome the challenge of translating promising research into actual clinical benefit we developed our new Translational Awards. These awards will fund key laboratory studies required to build data packages to help secure the subsequent significant funding for clinical trials. This is an exciting opportunity to develop a translational mindset within the research landscape to ensure the best ideas move from bench to bedside as efficiently as possible.

Our commitment to tackle key quality-of-life challenges is also taking shape, with a collaborative, idea-generating 'sandpit' planned, from which will emerge funding for novel solutions and interventions to combat the unmet needs of children and young adults living with a brain tumour diagnosis and its long-term effects.

ACCELERATING NEW TREATMENTS

Advancing knowledge of childhood brain tumours

Progress continues following our further £5m commitment (2022-2027) to researchers at The Everest Centre for Research into Paediatric Low-Grade Gliomas. Established in the UK and Germany in 2017 with an initial £5m funding from us, The Centre is a landmark consortium, undertaking foundational work to further understanding of, and discover new treatments for, paediatric low grade gliomas.

At The Charity, we believe no tumour is benign. The side-effects of low grade gliomas and the current standard of care, which includes chemotherapy, radiotherapy and high-risk surgery, can cause lifelong and permanent harm. Improvements are sorely needed.

The first five years of funding led to fundamental changes in the World Health Organisation (WHO)'s classification of these tumours, seeing them gain their own category for the first time, as well as several new subtypes. Research also resulted in the discovery of novel drugs that may offer new treatment options for children.

Under the leadership of Dr David Jones, the team are now advancing their work into the epidemiology, genetics and molecular biology of paediatric low grade brain tumours, and the clinical trial that we helped set up, LOGGIC/FIREFLY-2, is well underway. This next round of funding will help advance knowledge of low grade brain tumours, how they behave in the body, how to better treat them and how to improve quality of life for children affected.

“ This pioneering research will allow scientists to accelerate progress towards finding more effective treatments for the disease and could be revolutionary in improving the lives of children living with low grade tumours. ”

Rob Ritchie, former Trustee, founder of Everest in the Alps, and father to Toby, who was diagnosed with an inoperable brain tumour at the age of five.

Driving the quest for cures

In August, we announced the latest recipients of our Quest for Cures grants. Designed to foster collaboration, which is essential to accelerating cures, these grants award funding of up to £1.5m over five years and invest in teams with transformational research ideas, whose projects have game-changing potential to push breakthroughs from bench to bedside.

Professor Martinez-Barbera at UCL will study senescent (non-dividing) cells in order to identify and develop new treatments for paediatric diffuse high-grade gliomas (PDHGGs), while Professor Marcel Kool at Princess Máxima Center, Utrecht, aims to advance our understanding of different types of medulloblastoma, one of the most common aggressive childhood brain tumours, in order to help develop more effective treatments.

Finally, Dr Jun Ishihara aims to engineer a cutting-edge immunotherapy drug that could prevent recurrent glioblastoma. So far, experimental models have been highly promising. His team will build upon this work, with the potential to take the treatment through to phase 1 clinical trials in humans.

Using teardrops to detect brain cancer early

One significant step-change award has been the £1.35m grant to fund the first ever The Brain Tumour Charity Chair of Translational Neuro-Oncology at The University of Manchester's Cancer Research Centre (MCR). Professor Petra Hamerlik has previously worked in industry so brings a translational mindset to all the projects she is working on, whether they be potential new treatments or innovative diagnostic technologies. One exciting piece of work emerging from her studies to date is the potential for using biomarkers in teardrops to detect brain tumours. Compared to the collection of blood or cerebrospinal fluid, successful tear collection could potentially be a risk-free way of detecting brain tumours and is non-invasive. The team have made promising progress so far and going forward, are focusing on validating and refining their technique.

Funding this inaugural appointment demonstrates our long-term commitment to developing new and innovative ways to improve survival and ensure a better quality of life for those affected by a brain tumour.

Establishing a platform for new drug discovery

Our continued funding of the revolutionary Tessa Jowell BRAIN MATRIX platform, led by Professor Colin Watts, has resulted in more than 400 adults with gliomas being recruited, with 10 sites now open across England and Scotland. It aims to establish a new pathway for standard of care, using innovative technologies such as DNA sequencing and enabling enrolment into biomarker-driven trials.

Recruiting patients to trials is always a challenge, and BRAIN MATRIX has been no exception, with a slower start than we'd hoped. But these issues are now improving, and the challenges have pointed us towards further work we need to do to break down barriers to recruitment.

We're so excited to be supporting this first-of-its-kind platform, which is paving the way for future drug treatments to be tested faster.

400 

adults with gliomas recruited to the BRAIN MATRIX platform.


Trialling cannabinoids as a glioblastoma treatment

When the community told us they were interested in the potential of cannabinoids to not only relieve symptoms but also have a positive impact on survival, we listened!

This resulted in our pioneering ARISTOCRAT study, which opened in February 2023, to investigate whether combining nabiximols (Sativex) with chemotherapy can help extend the lives of people with recurrent glioblastoma.

As with all clinical trials, there have been challenges, with the opening of centres and consequently patient recruitment being slower than we had hoped, as well as the fact that, by the nature of the disease, patients recruited are often very unwell. However, we know there is huge interest from patients, with only very few who are eligible choosing not to participate in the trial. We're really excited that this world-first trial could help extend survival for those diagnosed with this devastating disease, and we're so grateful to everyone who has helped fund such an important study.

The challenges faced in setting up these trials again shows how urgently we need to improve and transform the research landscape in order to set crucial trials up for success. This work is informing our ongoing policy work as we push for the national changes brain tumour patients need (see page 12).



ENHANCING QUALITY OF LIFE

2023 saw the completion of two of our funded quality-of-life projects, both of which have the potential to improve patients' lives:

- Dr Sophie Thomas's investigation into Acceptance and Commitment Therapy (ACT), a psychological intervention incorporating CBT and mindfulness, produced positive results, with data showing that young people had better-rated quality of life, wellbeing, psychological flexibility and satisfaction with relationships.
- Professor Linda Sharp's development of a self-management programme for adults with low grade brain tumours – a real unmet need – has resulted in the publication of a number of papers, from how to make self-management more effective for patients and the healthcare system, to a systematic review of the literature on quality of life among people with low and intermediate grade gliomas.

PROPELLING TRANSLATIONAL RESEARCH

Translational research aims to bridge the lab and the clinic, translating discoveries into treatments available to patients. Sadly, there's a funding gap in this type of research for brain tumours due to the difficulties of treating a complex and rare disease, including the challenge of bypassing the blood-brain barrier. Our co-created strategy clearly identified the need to plug this gap, so we're committed to funding translational research to accelerate the development of crucial new treatments.

Our 2019 award to Professor Neil Carragher and his team in Edinburgh showcases our commitment to translation. The £2.96m fund over five years made in collaboration with Cancer Research UK for a total of £6.2m overall, has enabled an ambitious and long-term programme of work, which has so far screened more than 3,000 compounds for their potential efficacy against glioblastoma cells – all in hope of finding better ways to treat this terrible disease.

A number have shown potential and will be taken on to the next stages of the research. Alongside this, the team have identified two enzymes involved in cancer cells' survival and are investigating different drug combinations that target these enzymes. They've also identified a number of different genes that could be involved in treatment resistance and will investigate these further to find which ones are most important and how we could combat them. Finally, the team aim to develop a chemical 'courier' to deliver the drug combinations, to try to overcome the blood-brain barrier.

This work has been made possible as a result of funds raised by The Emily Morris Fund.



3,000 

compounds screened for their potential efficacy against glioblastoma cells.

BUILDING FOUNDATIONS FOR FUTURE RESEARCH

Attracting and retaining the brightest minds

We are committed to enabling not only world-class excellence in the brain tumour research space, but also long-term inspiration to join the field, through investment in talented early-career researchers. This year marked the next step in our Future Leaders programme, with further awards of £600,000 over four years, each, for two of our most promising candidates.

£600,000 ↗

investment over four years for our Junior Fellows.

In April, having been so inspired and impressed by their passion and dedication, we were thrilled to award Dr Tyler Miller and Dr Spencer Watson our Junior Fellows grants to support their research for four more years!

Dr Miller is investigating why certain cells within gliomas become immunosuppressive and will seek ways to target this immunosuppression. He aims to make gliomas more sensitive to immunotherapy and potentially extend survival for those diagnosed.

Dr Watson is studying how cells interact with each other in glioblastoma tumours and their microenvironments. He aims to develop new and better treatments to fight tumour recurrence and extend survival.



Collaborating for cures

As a Charity, we strive to connect with people and other organisations, as well as with each other, to foster the growth of good ideas:

- We attend international conferences and support our researchers in presenting their work – for example in November 2023, Dr Veronica Rendo, who was funded by our Future Leaders programme in 2020, presented her findings at the Society for Neuro-Oncology Annual Meeting.
- We have Scientific Advisory Boards made up of internationally renowned scientific experts working in different areas of cancer research, ranging through basic, clinical, translational and quality-of-life research, as well as lay members personally affected by a brain tumour – ensuring our community's interests remain at the forefront of our grant award process.
- We co-fund research. Just some examples are our joint funding with Cancer Research UK of Professor Neil Carragher's translational research (above), and our recent collaboration with Brain Tumour Research, seeing money raised by our valued Supporter Group, Emily Oliver's Fighting Fund, going towards a dedicated research project into diffuse midline gliomas.

RAISING OUR GLOBAL VOICES

We'll raise our global voices, connecting and collaborating in the UK to amplify awareness of brain tumours, be activists for progress and generate the resources and income we need to power change!

HIGHLIGHTS OF 2023/24

ADVOCATING FOR CHANGE

Coming together to call for a National Brain Tumour Strategy

On 29 February 2024, 34 people from the brain tumour community – including some of our High Profile Supporters, researchers, volunteers, trustees and representatives from family-led charities and Supporter Groups – stood outside Westminster to launch our most high-profile policy campaign yet, *It's a No Brainer*.

They let the world know about the desperate need for a National Brain Tumour Strategy and reminded people of the human lives behind the statistic that 34 people are diagnosed with a brain tumour every day in the UK.

The campaign urged people to sign our open letter to the Government calling for a National Brain Tumour Strategy.

Thanks to the support of the community, we hit more than 52,000 signatures in just six weeks!





52,000 

signatures in six weeks to our open letter calling for a National Brain Tumour Strategy.

This rallying cry clearly resonated, with politicians and parliamentarians across the devolved nations as well as colleagues in the brain tumour charity space supporting our call and demanding change.

With the community firmly behind us, we sent a message loud and clear to government now and in future, that we can no longer wait to deliver solutions to the challenges faced by people affected by brain tumours.

Our next steps will be to engage with the new government and develop a National Brain Tumour Strategy, with the support of the community, that improves outcomes and works for everyone affected, no matter where they are or the grade of their tumour.

“ We all stood strong in the rain! Congratulations to you and the team for putting the event together on such an impactful date, and for making us all feel valued. As a community, we were seen and we will be heard. **”**

Mark, one of our Involvement Champions, who lost his partner Cecilia to a brain tumour

Collaborating for change in partnership with NICE

We're proud of our involvement in the April 2024 landmark decision by the National Institute for Health and Care Excellence (NICE) to make dabrafenib and trametinib available through NHS prescribing.

This will be the first new treatment in decades for children with certain types of glioma and marks a real step change for families who have often had to rely on compassionate prescribing, travel abroad or costly private funding to access new, effective treatments.

Twenty years ago, we funded research which laid the early groundwork for the drugs' targeting of the BRAF V600E mutation. We worked with NICE and invited our community to share their stories right into the room, and used data from our paediatric brain tumour surveys to highlight the community's unmet needs during the NICE appraisal process.

A huge thank you to all the families and trustees who shared their experiences as part of this process, and whose compelling stories were crucial to this positive outcome.



Engaging a wide range of stakeholders

We know that we can't succeed on our own. That's why we've been more purposeful in working with a wide range of stakeholders. As well as working closely with partners in the pharmaceutical industry to help them better understand the true unmet needs of the brain tumour community, we've worked with charity partners and clinicians to address specific challenges in whole genome sequencing and access to clinic trials.

We've also been able to work collaboratively with other charities and the Office of Life Sciences to offer guidance and feedback on the delivery of the Government's Cancer Mission.

BUILDING OUR COMMUNITY

Growing our community

We were thrilled to grow our community by 80,000 new people this year, with 4,696 coming via our Better Safe Than Tumour campaign. We also achieved a total of 4,487 pieces of media coverage – helping us reach new audiences.

Boosting relationships with High Profile Supporters

AMY NUTTALL



Our new celebrity partner Amy Nuttall, who lost her mum to a glioblastoma, released a charity single with proceeds coming to us, supported our call for a National Brain Tumour Strategy and took part in The Twilight Walk.

"I know that [my mum] would have absolutely wanted me to use my platform in any way that I can to do good and help raise awareness for this awful disease."

Amy Nuttall

VICKI MICHELLE



Much-loved stage and screen actress Vicki Michelle also came on board, having lost her sister, Suzie, to a glioblastoma.

"The advice and guidance [The Charity] gave was invaluable in helping us make the most of the time we were able to share together."

Vicki Michelle

DRIVING AWARENESS OF SIGNS AND SYMPTOMS OF BRAIN TUMOURS

Helping the public spot the signs and symptoms

Listening to our community, we know there's a real lack of awareness out there. This has to change if people are going to feel more confident approaching their GP. This year, we grew our Better Safe Than Tumour campaign, with 49% of people able to name one brain tumour symptom by the end of 2023/24 – an increase of 21 percentage points on before the campaign!

27M



people reached with our signs and symptoms campaign through TV, radio, podcasts and more.

In total, over 100,000 people have checked their symptoms using our checker, and we've reached more than 27m people through TV, radio, podcasts and more.



RAISING FUNDS TO GO FURTHER FASTER

We rely on voluntary income to be able to do all our work, and in an increasingly challenging external environment, we continue to be amazed and humbled by the extraordinary ways in which our supporters raise money, raise awareness and donate to ensure we can continue with our mission. To each and every person, **thank you**. Without you, our work wouldn't be possible.

Increasing our income

We're delighted that we've been able to increase our income to match our rapidly growing ambitions as an organisation. In total, our amazing community helped us raise a whopping £14,195,000 in 2023/24. That's an incredible 11.6% increase on the previous year and achieved our budgeted target of £14.2m.

£14M+ (£)

raised in 2023/24.





A bold new event

We began the financial year with one of the boldest events in The Charity's history – our Time art exhibition. For 10 days we took over the Business Design Centre in London to exhibit over 200 pieces of art made or donated by people from the brain tumour community. We had almost 1,000 visitors and used the gift of the space donated to us for our Celebrating You Awards 2023 and the launch of our *Living Longer and Better* strategy.

Record fundraising attempts

The Twilight Walk returned once again in Brain Tumour Awareness Month in March, with a record 1,200 people coming together in London and 1,300 people walking it their own way up and down the country. In total, a whopping £495,000 was raised!

£495,000 £

raised during The Twilight Walk.

We also had our most successful TCS London Marathon ever. 132 people ran to accelerate cures, raising an astounding £454,000. And thanks to everyone who took part in an event, from running to cycling and trekking, they have raised £3.1m, including The Lewis Moody Foundation. Our wonderful corporate partners and major donors helped make our Summer and Winter Appeals huge successes by building generous pledge pots for our matched-funding appeals – raising £150,000 and £230,000 respectively.

£454,000 £

raised at TCS London Marathon.

Another huge achievement was increasing Community Fundraising income from DIY activities – for example, challenges, walks, runs, cycles, dinners and birthdays. This income grew to £2,428,000.

Spectacular Supporter Groups

Year on year, our invaluable Supporter Groups continue to have a huge impact by raising funds and awareness across the UK. Overall, our Supporter Group community raised an awe-inspiring £843,000 in 2023/24. We were also thrilled to welcome nine new Supporter Groups to The Charity.

Partnering with Wickes

2023/24 saw us kick off our partnership with DIY retailer Wickes. In May 2024, we celebrated the one-year anniversary of the partnership beginning and crossing the £1m fundraising mark!

On top of this incredible amount raised, the partnership is about much more than money. It's a great opportunity to raise awareness of The Charity, most notably through in-store radio adverts, which reach an estimated audience of three million people each month.

Leaving a lasting legacy

We're very grateful to have received almost £1m of legacies this year. We're so thankful to everyone who chooses to support us in this way – these gifts will ensure that you have lasting impact.

DRIVING THE BEST LIFELONG CARE

We're committed to making sure that everybody in the brain tumour community – no matter who they are or where they're being treated – has access to the care and support they need. This goes beyond what's delivered in hospital or the community and needs to be tailored to the individual needs and choices of people affected by brain tumours.

And, where there are gaps, we do our best to provide that support ourselves or partner with organisations who can.

WRAP SUPPORT AROUND EVERYONE

Our aim for 2023/24 was to grow all our support services by 10%, while still achieving the high standard of more than 85% of people reporting that we helped them significantly.

We're delighted to report that we managed to increase one-to-one support by 33%. In total, we helped 12,189 people in 2023/24, compared with 9,153 the previous year.





SUPPORT AND INFORMATION LINE

3,129

people helped via Support and Information Line

82% positively responded to getting what they were looking for

79% positively responded to "has it helped"



EVENTS

219 76

people helped via events

at the Young Adult Ball

128

at Family Days



RESOURCES

4,238

helped via resources including Information Packs, Brainy Bags and Young Adult Well-being Packs

3,916

Adult Information Packs

Launched new Paediatric Information Packs through the website and paediatric neuroscience centres

12,189

people helped in individual support*



ONLINE

1.1M

active users of support in the main website and the Better Safe Than Tumour website

32,212

memberships of our online brain tumour support groups

91% of those surveyed would recommend our groups to others

85% felt better connected to others who understand



BENEFITS CLINIC

550

people helped via Benefits Clinic

£1.31M

in new benefits accessed



COUNSELLING SERVICE

425

people entered Counselling Service

2,785

counselling sessions delivered

81% of people reported the counselling has made a difference to their emotional well-being and ability to cope, with wellbeing scores (Core-10) improving by 34%

87% of people said they were likely or extremely likely to take action or do something different as a result of the counselling

100% of people rated their experience of counselling as very good or good

100% of people would recommend the service to others



HELPING SET THE STANDARD FOR EXCELLENT CARE

In 2023/24 we continued to help neuroscience centres and healthcare professionals across the UK level up their care, while also giving power to the voices of everybody affected by a brain tumour.

Partnering with the Tessa Jowell Brain Cancer Mission

Our Improving Brain Tumour Care (IBTC) surveys play an integral role as the patient voice in the accreditation process for Tessa Jowell Centres of Excellence (TJCoE) – a programme run by the Tessa Jowell Brain Cancer Mission (TJBCM).

TJCoE accreditation recognises centres that provide excellent treatment, care and research opportunities for patients with brain tumours. The accreditation process includes an extensive application form, patient feedback – collected through our IBTC surveys – and a virtual site visit from the TJCoE team.

Since the launch of the programme in 2020, each of the neuroscience centres in the UK have been invited to apply to become a TJCoE. So far, 17 adult centres have been awarded TJCoE accreditation and other centres that've applied have been provided feedback on how to improve so they can hopefully achieve accreditation in the future.

In 2023/24, we used 1,544 responses to our IBTC surveys to produce reports about 17 neuroscience centres.

These reports help highlight areas of best practice and identify where improvements can be made. They play a valuable role in spreading best practice across the entire network of neuroscience centres in the UK.

In June 2023, we launched our Paediatric Improving Brain Tumour Care (PIBTC) surveys that were designed to capture the treatment and care experiences of children diagnosed with a brain tumour and their carers.

This coincided with the opening of a new programme by TJBCM that recognises paediatric neuro-oncology centres that provide excellent treatment, care and research activities for patients with brain tumours and their families – the Tessa Jowell Centres of Excellence for Children (TJCoEfC).

All 17 paediatric neuro-oncology centres in the UK were invited to apply. 15 of the centres applied and we used 251 responses to our PIBTC surveys to create reports on 11 of those centres to support their application.

In every centre, TJBCM found remarkable examples of NHS staff working well beyond what was asked for to deliver excellent care for their patients. Six centres were given TJCoEfC accreditation, with the wider network of 15 centres working together and with TJBCM to spread best practice so that all 15 centres can achieve TJCoEfC accreditation.

Championing the community voice in everything we do

We understand that the lived experience of people affected by brain tumours adds huge amounts of value to our work. That's why we champion the community voice in everything we do through our Involvement Network. In September 2023, we recruited 21 new Involvement Champions to replace the existing cohort.

121 

involvement projects.

In 2023/24, there were 121 involvement projects that spanned various teams across The Charity including marketing, policy, support, data, events, fundraising and research.

72 (60%) of the involvement projects were helping research teams – not just those funded by us – and making sure the community voice is present in discussions focused on how we accelerate new cures for brain tumours.

As part of Brain Tumour Awareness Month, four Involvement Champions attended parliamentary drop ins and six Champions also took part in the activation event in London for the launch of our National Brain Tumour Strategy campaign. The Involvement Network was also heavily involved in campaign development.

In 2023/24, we also recruited our fifth cohort of Young Ambassadors. Our Young Ambassadors help accelerate a cure in a wide range of ways – from supporting our events and championing our work, to sharing their stories and campaigning for change.

They play an important role in our work by helping us support other teenagers and young adults affected by a brain tumour diagnosis. Their ideas and input have been vital in shaping our Young Adult Service and in developing our resources.



Image right:
Young Ambassador group



“ I didn’t know anyone else who had been through this at my age – but the support from the Young Adults Service has been incredible. From the online meet ups, to messages in the groups, nothing has ever been too much of an ask for the staff and they always go above and beyond.

When I joined my first online meet up, I was feeling quite low, to be honest with you. I couldn’t see the light at the end of the tunnel.

A brain tumour diagnosis is scary and isolating. But talking to the other young people makes you realise you’re not alone! At a scary time in your life, it’s humbling to know there’s others there who are experiencing the same thing.

”

Mel Kelly (Young Ambassador)

“ Since doing counselling my ability to cope has dramatically improved. My counsellor has given me so many helpful tools to use now and in the future. ”

Counselling service client

FILL THE GAPS

Where possible, we fill the gaps in diagnosis, treatment and care that the brain tumour community have told us need to be filled. We work in partnership with a wide range of healthcare professionals and other organisations to do this.

Growing our free counselling service

In 2023/24, we focused on increasing the scope of our free counselling service so that more people were able to access counselling.

We now have 11 paid counsellors, 10 qualified volunteers and 7 student volunteers providing counselling, with 9 volunteers helping assess people who apply for the service.

This helped us deliver 151% more sessions in 2023/24 than in the previous year.

151% 

more counselling sessions than last year.

Training professionals to help diagnose brain tumours

In 2023/24, our Optical Engagement Manager directly trained 4,737 optical professionals to recognise the optical signs of a brain tumour – a 13% increase year on year.

In a new collaboration with the Association of Optometrists, we're now delivering a short series of presentations on diagnosing brain tumours with 584 people attending the first of these on papilloedema.

This will allow us to reach more people at a lower cost.

4,737 

trained to recognise optical signs of a brain tumour.

We're also progressing the scoping work on faster diagnosis with professionals, starting with GPs and the GP pathway, recruiting GPs to a working group to help shape this work.

EQUALITY, DIVERSITY AND INCLUSION

We take seriously our responsibility to meet the diverse needs of the brain tumour community and our wider stakeholders – both internally and externally. That’s why we’ve continued to undertake significant work to further our Equality, Diversity and Inclusion (EDI) agenda – though we know there is much more to be done.

ACCELERATING CURES FOR ALL BRAIN TUMOURS

By building a diverse research community that brings together the widest possible range of talents, backgrounds, perspectives and experiences, we know that we can increase the innovation and creativity of the research we fund.

A number of external factors – for example, access to education and university places – can affect diversity in research. The Charity is contributing towards the creation of a truly diverse research environment in the following areas.

- Our Future Leaders programme – aimed at preventing brilliant early-career researchers from leaving the field of research into brain tumours due to difficulty securing funding – has gone from strength-to-strength. As well as opening applications for our next round of Future Leaders, we announced our first-ever Future Leader Junior Fellows – which is the second stage of the programme.
- Two of our Trustees – Matimba Swann and Rachel Edgar – gave presentations to The Charity about the importance of International Day of Women and Girls in Science.
- Wherever possible we try to maintain diversity on our Scientific Advisory Board and at each meeting we actively guard against unconscious bias.

DRIVING THE BEST LIFELONG CARE

We’re dedicated to identifying and eliminating inequalities and unmet needs in healthcare treatment and support.

This year we’ve:

- Expanded our Policy and Campaigns work across the devolved nations of the UK, so that we’re always advocating for what’s best for the brain tumour community no matter where they live in the UK. This has included drop-in events at Westminster, Holyrood and the Senedd, as well as meetings with the Minister of State for Health and Secondary Care, the Minister for Public Health in Scotland and the Minister for Health in Wales as part of the Wales Cancer Alliance,
- Run round four of the Adult Improving Brain Tumour Care surveys that aims to identify gaps in care and unmet needs – as well as launching our Paediatric Improving Brain Tumour Care surveys.
- Increased the availability of our free counselling service, which aims to reduce inequalities in who can access emotional support after a brain tumour diagnosis.
- Co-sponsored the Scottish Brain Tumour Early Detection Roundtable that brought together charity partners, politicians and industry experts with the aim of understanding the current barriers to a brain tumour diagnosis in Scotland and to identify how the diagnosis pathway can be improved.

RAISING OUR GLOBAL VOICES

EDI is a core component of everything we do in Fundraising, Marketing and Community Experience, ensuring that our events, fundraising, website and all outward facing channels and teams are accessible and inclusive.

This year we’ve:

- Continued to grow community involvement in our work, including growing our Involvement Network, welcoming our newest cohort of Young Ambassadors and appointing new Involvement Champions.
- We work to ensure that our brand and campaigns are diverse and inclusive.
- We have audited and started to fill gaps in our story, image and video libraries.

- We work with our community to ensure community fundraising and events are accessible.
- Accessibility remains at the heart of our website – and recent developments have improved it further.
- We continue to monitor, track and evolve our vulnerable person, complaints and fundraising guidance policies, to ensure we're giving the very best experience to all in our community.

EDI AND OUR TEAM

We believe it's important that our team is representative of the community we serve, so we strive to be as diverse and inclusive as possible. We also want everyone who works with us to feel that they belong, have a voice in the things that matter most to them and, ultimately, have a positive experience of their time with The Charity – whether they're in a paid role or volunteer with us.

Among other projects and initiatives, we've:

- been certified as a Disability Confident Committed Employer as part of the government's Disability Confident Scheme. By being part of this scheme, The Charity highlight how passionate we are about creating an inclusive environment for all, and how committed we are to increasing people's understanding of disabilities and challenging attitudes that people may have about disabilities.
- created a new sensory room at our Head Office in Fleet for people who are neurodivergent
- strengthened our EDI Champion group and EDI Trustee Committee
- celebrated multiple cultural and religious events
- continued to create an accessible and inclusive working environment
- improved our recruiting processes with a particular focus on improving diversity and inclusion, including:
 - blinding applications
 - structure interviews
 - diverse interview panels
 - constructive feedback to unsuccessful applicants
 - improved collection of diversity data
 - advertising job openings on websites that target a wide spectrum of individuals.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG) SOCIAL AND GOVERNANCE

A social ethos is intrinsic in The Charity since its purpose of existence is to serve the brain tumour community and drive change, and our values reflect this. We have comprehensive policies on matters such as anti-modern slavery and, through our Governance and Ethics committee, keep under constant review our partnerships to ensure the highest ethical standards in all our relationships.

REDUCING ENVIRONMENTAL IMPACT

Every team in The Charity considers what changes, big or small, they can make to reduce the environmental impact of what we do. Our Sustainability Champions group also meets regularly to review the actions being taken, make suggestions for improvements and keep environmental considerations at the forefront of people's work and personal life.

This year, we introduced a Cycle to Work scheme for staff. We also continue to implement sustainable practices and strive to protect the environment by, for example:

- not using balloons
- avoiding lamination, coating and binding, as these reduce recyclability
- making a conscious effort to use local suppliers, and printers who are ISO 14001 certified and who report on their environmental impacts
- encouraging Twilight Walk participants to reuse t-shirts from previous years
- recycling and refurbishing old fundraising stock
- discontinuing plastic bag use.

We are a member of ECO Hub, a 700-charity-strong social media forum dedicated to reducing the environmental impact of charities across the globe. We share ideas and information and engage in constructive discussion to find alternative solutions, to make a positive impact.

FINANCE REVIEW

Income grew 11.6% in the year to March 2024 to a record £14.2m for The Charity, meeting our budgeted expectation. The income is vital to funding the essential work The Charity does improving the life and outcomes of those affected by brain tumours.

Expenditure on charitable activities increased by 38% year-on-year, driven by expenditure on awards into world-class scientific research. In the year to March 2024 research related expenditure was £7m, just short of our target of 50% of income.

INCOME


Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year, income was up year-on-year in most areas.

We saw year-on-year growth of between 15% and 22%, beating our expectations, in our wider-community participation income, including Events, Community Fundraising, Supporter Groups and Donations. These areas represent roughly half our income and the growth reflects the generosity of the community and the growth of our donor base.

Our Corporate and Trusts income also increased from £1.9m in 2022/23 to £2.6m in 2023/24, due to our Charity partnership with Wickes which brought in over £1m.

Investment income grew by 47%, driven in part by Central banks increasing interest rates.

The Charity received funding from the Medical Research Council which stems from the UK Government Covid Medical Research Charity Support Fund, setup to assist charities funding medical research impacted by the Covid pandemic. In the year to March 2024 we received £83k, a fall from the £540k received in 2022-23.




EXPENDITURE

Expenditure in the year increased by £3.4m to £14.7m at the Group level.

The Charity’s primary objective is to fund quality research and we aim to spend half of our income in this area as it is vital to us achieving our ambitious objectives. Expenditure on Research, which comprises of both the current year’s instalments of grant awards to institutions performing the research and The Charity’s costs of running and managing this process, increased by £2.2m year-on-year to £7.0m which is 49% of income.

Patient Support and Campaigning and Awareness expenditure both increased by 27% year-on-year. These areas form the other main strands of The Charity’s primary objectives, to support those affected by brain tumours, to campaign for improved healthcare, research and treatments and to raise awareness of the disease.

The Charity, excluding subsidiaries formed to commercialise BRIAN app technology, met its goal in the year to March 2024 to spend 80p in every pound spent on its charitable objectives.



INVESTMENTS AND CASH

World stock markets made a strong recovery in the year and income from interest bearing investments increased as interest rates went up in the UK. At the end of the financial year The Charity’s investments were valued at £14.6m, with realised and unrealised gains of £0.8m.

In 2022-23 The Charity formed trading subsidiaries to commercialise the intellectual property developed in creating the BRIAN app and database. The intention was these subsidiaries, after a period of investment, would make profits that they would donate to The Charity. In the year to March 2024 The Charity loaned Medli Health Ltd £360k to fund the company to build a customer base and establish itself. This was in addition to loans made in the year to March 2023 totalling £0.9m. However Medli failed to grow income as planned and produced a financial deficit. In May 2024, the decision was taken to terminate the operational activities of the Medli business as it became apparent it was taking longer than anticipated to grow to a point of profit. The Charity is in negotiations for a sale of the Intellectual Property and has fully provided for the intercompany loans as potential bad debts. Charity Commission guidelines require charities to notify them of any potential loss of income or assets of more than £25,000 and accordingly appropriate filings have been and will be made. To date The Commission has made no further enquiries or taken any action in relation to this matter.

The Charity also has a trading subsidiary, TBTC Trading Limited. This subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a trading profit of £22k which will be donated to The Charity.

All investments are held in highly liquid assets. Current forecasts do not expect the investments to need to be liquidated in the next 12 months hence short-term volatility in values is not considered a significant risk. Cash held as at 31 March 2024 was £3.5m.

RESERVES POLICY

The Charity's Reserves Policy is intended to ensure the long-term sustainability of The Charity, its ability to fund committed research expenditure and maintain its core services and Charitable Objectives by ensuring an adequate level of reserves are maintained to manage through a crisis.

Each year the Trustees review forecasts of income, expenditure, cash flows and reserves, to ensure The Charity maintains the level of reserves sufficient to manage a reduction of income that cannot be offset by a reduction in expenditure. In deciding on the level of reserves, the Trustees consider the risk and impact of potential unforeseen events and the ability of The Charity to react to such events.

In addition to considering income and expenditure, the Trustees ensure The Charity maintains a high level of liquid assets to meet foreseen and unforeseen circumstances and to meet our research commitments.

At 31 March 2024, the targeted level of unrestricted reserves is £1m. This is calculated as being the higher of £1m or the sum of 25% loss of income from forecast for 2024-25 levels equating to £3.8m, being offset by 25% savings of non-committed operating expenditure calculated as £1.7m and delaying budgeted new research awards of £2.1m. The £1m minimum unrestricted reserve target is on the basis that the Trustees consider it appropriate to always maintain a minimal reserve to fund closure of The Charity in an extreme event. It is expected in future years the calculation will require The Charity maintain higher unrestricted reserves as more money is committed to Research.

The level of total Funds at 31 March 2024 was £8.5m, consisting of unrestricted general reserves of £6.2m, designated of £1.0m and restricted of £1.3m. Free reserves, defined as general reserves of £6.2m less functional fixed assets of £0.2m, were £6.0m.

At 31 March 2024, we had unaccrued but committed research expenditure totalling £13.0m which was subject to satisfying our ongoing monitoring requirements. The investments and cash at 31 March 2024 (which are all liquid) were £18.1m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually

include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Evelyn have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £14.6m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. The portfolio generated income of £563k and a valuation gain of £764k.

In addition to managed investment funds, the Trustees decided in 2022/23 to invest in commercialising the intellectual

property and technology it had developed in creating BRIAN, The Charity's database tool. The Charity formed new subsidiaries for this commercial venture and evaluates any investments being made on its financial return against an equivalent asset class.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have over one thousand active volunteers across the UK who support in different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how

we endeavour to mitigate these, are:

- That we fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain adequate reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.
- That we are not able to commission enough high-quality research projects. We are developing our engagement with the brain tumour research community, and working to build capacity in the sector. We are also looking at alternative research models. In addition, we have extended funding globally and put significant emphasis on building relationships with key researchers.
- That we become affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective talent and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.
- That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.
- That we are the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres, and ensure that we have leading edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have cyber insurance policy.

GOING CONCERN

The Trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

OBJECTIVES FOR 2024-25

The Charity's objectives remain aligned to its core values and our priority objectives for the year are:

- We will **Accelerate Cures** for all brain tumours
- We will drive the **Best Lifelong Care** across the UK, driving up the quality of treatment centres in the UK and empowering our community to share their experiences.
- We will raise our **Global Voices**, sharing evidence and platforms so passion and experience is amplified to support those affected, to raise funds and drive progress.

In addition:

- Identify the best global research to be funded through a new round of Research Grant funding
- Plan and adapt The Charity so that we can deliver the goals of our new organisational strategy, *Living Longer and Better*, which was co-created as a community.

PLANS FOR THE FUTURE

Our vision remains unchanged: for everyone diagnosed with a brain tumour to live longer, better lives. We are investing time and effort on expanding our fundraising to grow and to provide income for years to come, money that will be used to fund our ambitious year-on-year investment in the best global research.

Our new strategy will guide us to 2030 and will set our direction and the shape we need to become in future years.

THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research as well as raising awareness and supporting thousands of people affected by a brain tumour.

This work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we cannot thank you enough for continuing to help us as we strive to defeat brain tumours!

In addition to the donors named below, we would like to thank all our anonymous donors.

TRUSTS

The AOK Trust
The Colin Oliphant Charitable Trust
The Syncona Foundation
The Reed Foundation

FAMILY-LED CHARITY PARTNERS

Angel Child
James Clifford Campling Trust
The Brian Cross Memorial Trust
The Emily Morris Fund
The Oli Hilsdon Foundation
Joss Searchlight
The Be More Laura Foundation
Tom's Trust
Shay's Smiles
The William Low Trust
Larsen's Pride
Iggy's Fund
Naseem's Manx Brain Tumour Charity
Jersey Brain Tumour Charity
The Jake McCarthy Foundation

CORPORATES

Allports Group
Atrato Capital Group
Bluecube BPL
Business Design Centre
Cross Country Trains
GlobalLogic
Gowling WLG
Hanne & Co Solicitors
JM Finn
K&L Gates
Knight Protection
Microsoft
NEX Group PLC
Quirk Solutions
Salesforce
Underbelly
Team Lewis
Wickes

CO-FUNDING PARTNERS

Brain Tumour Research
Children with Cancer UK
CRUK
GOSHCC

PATRON

Earl Spencer

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Alastair Stewart OBE
Amy Nuttall
Anthony Forder and Laura
Archie Goodburn
Charly Clive
Dawn French
Dominic Matteo
Ella and Matt Mills (Deliciously Ella)
Hal Cruttenden
Holly Matthews
Ian Chillcott
James Jordan
Jason Durr
John Maynard
Jonny Wilkinson CBE
Kelsey Parker
Lewis Moody OBE and Annie Moody
Marc Silk
Matt Allwright
Mel Giedroyc
Miles Jupp
Nick Baines (Peanut – Kaiser Chiefs)
Nicki Chapman
Olivia Colman CBE
Owain Arthur
Phil Spencer
Philippa Forrester
Russell Watson
Sandy Lyle MBE
Sherrie Hewson
Sian Reese-Williams
Sophie Kinsella
Steve Backshall
Tchéky Karyo
The Neales
The Wanted
Tim Burgess and The Charlatans
Tom Daley
Vicki Michelle

RESEARCHERS IN OUR NETWORK

As well as members of our Scientific Advisory Board (mentioned on page 33), these are just some of the researchers providing an ongoing contribution to our success.

Adel Samson
Alasdair Rooney
Anthony Byrne
Anthony Chalmers
Antoni Michalski
Chris Jones

Christopher Mount
Colin Kennedy
Colin Watts
Darren Hargrave
David Jones
Diane Puccetti
Duane Mitchell
Esther Becker
Gelareh Zadeh
Helen Hartley
Ingela Oberg
Jessica Taylor
Juan Pedro Martinez-Barbera
Jun Ishihara
Kirsty Maddock
Linda Dirvan
Linda Sharp
Louis Chesler
Lucy Stead
Manish Aghi
Mara De Matino
Marcel Kool
Marion Smits
Martin Taphoorn
Melanie Calvert
Michael Brown
Michael Hawkins
Michael Jenkinson
Monika Hegi
Neil Carragher
Ola Rominiyi
Pamela Kearns
Paul Brennan
Paul Northcott
Petra Hamerlik
Philipp Euskirchen
Pim French
Rameen Beroukhim
Richard Gilbertson
Rohitashwa Sinha
Sara Melhuish
Sebastian Brandner
Simon Bailey
Simona Parrinello
Sophie Thomas
Spencer Watson
Steve Clifford
Steve Pollard
Stuart Smith
Susan Short
Thomas Wurdinger
Todd Hankinson
Tyler Miller
Veronica Rendo
Vincenzo D'Angiolella

BIOMEDICAL SCIENTIFIC ADVISORY BOARD

NAME

Dr Adrienne Boire
Dr Benjamin Deneen
Dr Catherine Flores
Professor Colin Watts
Professor Cynthia Hawkins
Dr Gerry Thompson
Dr Lucy Stead
Dr Marcel Kool
Dr Mariella Filbin
Dr Mark Gilbert
Dr Omer Bayraktar
Dr Phedias Diamandis
Professor Simona Parrinello
Dr Spencer Watson
Dr Stephen Mack
Professor Steve Clifford
Dr Susan Chang
Dr Tyler Miller

INSTITUTION

Memorial Sloan Kettering Cancer Center, USA
Baylor College of Medicine, USA
University of Florida, USA
University of Birmingham, UK
The Hospital for Sick Children, Canada
University of Edinburgh, UK
University of Leeds, UK
German Cancer Research Centre, Germany
Harvard Medical School, USA
National Institutes of Health (NIH), USA
The Wellcome Trust Sanger Institute, UK
University of Toronto, Canada
University College London (UCL), UK
University of Lausanne, Switzerland
St Jude Children's Research Hospital, USA
The Institute of Child Health, Newcastle University, UK
University of California San Francisco, USA
Massachusetts General Hospital, USA

PAEDIATRIC CLINICAL TRIAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Arzu Onar-Thomas
Professor Jordan Hansford
Dr Jurgen Lemiere
Professor Martin van den Bent
Dr Matthias Karajannis
Professor Michael Weller

INSTITUTION

St Jude Children's Research Hospital, USA
University of Adelaide, Australia
KU Leuven, Belgium
Erasmus MC Cancer Center, Netherlands
Memorial Sloan Kettering Cancer Center, USA
University Hospital Zurich, Switzerland

LAY ADVISORS

Ms Christina Brincat
Mr Donald Innes
Mr John Graham
Ms Louise Webber-Edwards
Mr Neil Munn
Mrs Rachel Rathbone



TRUSTEES AND GOVERNANCE

TRUSTEES

Dr Alan Palmer
Anna Jarvis
Beth Worrall (resigned 02/05/23, reappointed 28/07/23 and resigned 13/06/24)
Caroline Steel
Dr Elena Bechberger
Hayley Conroy
Jack Morris CBE
Jessica Sass (resigned 21/09/23)
Justine McIlroy
Dr Kieran Palmer
Matimba Swana
Neil Dickson OBE
Dr Rachel Edgar
Dr Russell Hagan
Sean Hird
Simon Hay (resigned 21/09/23)
Sukhdip Sandhu

The directors and trustees had liability insurance during the financial year.

CHIEF EXECUTIVE OFFICER

Dr Michele Afif (appointed 17/07/2023)

COMPANY SECRETARY

Liam Heffernan

CHARITY REGISTRATION NUMBERS

England and Wales 1150054
Scotland SC045081

COMPANY NUMBER

08266522

PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,
GU51 2UH

AUDITORS

Menzies LLP, Magna House, 18-32 London
Road, Staines-upon-Thames, TW18 4BP

BANKERS

Lloyds Bank Plc, 147 High Street,
Guildford, GU1 3AG

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon
Evelyn Partners, 25 Moorgate, London

THE CHARITY'S OBJECTS

The objects of the Charity are for the public benefit:

- 1) to relieve sickness and to promote and protect good health by supporting research into the nature, causes, diagnosis and treatment and social consequences of tumours of the brain and central nervous system and to publish the useful results of such research;
- 2) the relief of suffering of people with tumours of the brain and central nervous system and their families and carers, through the provision of information and support to them; and
- 3) to advance the education of the public in all areas relating to tumours of the brain and central nervous system.

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review. Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion
- Remuneration

The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the (Cannabinoid Clinical Trial SAB) can be found on page 33.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and help the whole community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward on all areas of EDI within The Charity.

GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our research strategy 'Accelerating a Cure' launched in 2021-22. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and more than 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We used the services of a professional third party fundraiser, Ethicall, during the year in a limited capacity to contact potential new donors. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity. We monitored the work of Ethicall with regular calls and reviewing reports on issues and complaints to ensure standards were adhered to.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

WORKING WITH PARTNERS

We are committed to working with all partners including those in the pharmaceutical and biotech industry in order to meet our objectives. We remain vigilant that our independence is not compromised and we act in the best interests of our community at all times.

PUBLIC BENEFIT

The Trustees confirm that they have referred to the Charity Commission's guidance on public benefit when reviewing the Charity's aims and objectives and in planning future activities.

EXCEPTIONAL REAPPOINTMENT OF TRUSTEE

In September 2023 the Board extended the appointment of Neil Dickson OBE, a founder trustee, by one year to September 2024. This was to provide continuity and assistance to the Research Committee during a period of change following the resignation of the Chief Scientific Officer.

STATEMENT OF THE TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.


Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities. In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 27 September 2024 and signed on their behalf by:



Jack Morris CBE
Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2024 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2024 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.


- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.
- We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:
 - Posting of fraudulent journal entries
 - Posting of fraudulent payments and receipts in the accounting software
 - Authorisation, processing, and payment of fraudulent expenses
 - Fictitious employees
 - Timing of revenue recognition
- Audit procedures performed by the engagement team included:
 - Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
 - Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
 - Challenging assumptions and judgments made by management in its significant accounting estimates; and
 - Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
 - Carrying out checks to establish the validity of employees, and
 - Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Janice Matthews

FCA (Senior statutory auditor)
for and on behalf of

Menzies LLP

Chartered Accountants
Statutory Auditor
Magna House,
18-32 London Road,
Staines-upon-Thames,
TW18 4BP

Date: 27/09/2024

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2024

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2023 £'000
<u>Income and expenditure</u>							
Income from:							
Donations and legacies	3	10,926	1,704	12,630	9,456	2,513	11,969
Other trading	3	925	77	1,002	284	79	363
Investments		563	-	563	383	-	383
Total income		12,414	1,781	14,195	10,123	2,592	12,715
Expenditure on:							
Raising funds		3,130	33	3,163	2,892	31	2,923
Charitable activities							
Research		4,766	2,241	7,007	2,293	2,482	4,775
Patient support		2,389	569	2,958	1,879	448	2,327
Campaigning & raising awareness		1,369	162	1,531	876	334	1,210
Total expenditure on charitable activities		8,524	2,972	11,496	5,048	3,264	8,312
Total expenditure	4	11,654	3,005	14,659	7,940	3,295	11,235
Net (expenditure)/income before gains and losses on investment assets		760	(1,224)	(464)	2,183	(703)	1,480
Realised and unrealised gains/(loses) on investment assets		764	-	764	(859)	-	(859)
Net movement in funds for the year		1,524	(1,224)	300	1,324	(703)	621
Reconciliation of funds							
Balances at 1 April		5,678	2,553	8,231	4,354	3,256	7,610
Balances at 31 March		7,202	1,329	8,531	5,678	2,553	8,231


The Statement of Financial Activities includes all gains and losses recognised in the year.
All incoming resources and resources expended derive from continuing activities.
The notes on pages 45-59 form part of these financial statements

CONSOLIDATED BALANCE SHEET AS AT 31 MARCH 2024

Company number: 08266522

		Consolidated		Company	
	Notes	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Fixed assets					
Intangible assets	10	1	7	1	7
Tangible assets	11	221	244	221	244
Investment in subsidiaries	12	-	-	-	-
Investments	12	14,636	13,838	14,636	13,838
Current assets					
Stock		50	34	-	-
Debtors	13	1,478	1,693	1,498	1,572
Cash at bank		3,487	4,566	3,401	4,551
		5,015	6,293	4,899	6,123
Creditors					
Amounts falling due within one year	14	(11,242)	(12,051)	(11,222)	(12,023)
Net current (liabilities)/ assets		(6,227)	(5,758)	(6,323)	(5,900)
Provision for liabilities	15	(100)	(100)	(100)	(100)
Net assets		8,531	8,231	8,435	8,089
Funds					
General reserve		6,194	3,985	6,098	3,843
Designated funds		1,008	1,693	1,008	1,693
Unrestricted funds		7,202	5,678	7,106	5,536
Restricted funds		1,329	2,553	1,329	2,553
	19	8,531	8,231	8,435	8,089

The financial statements were approved by the trustees on 27 September 2024 and signed on their behalf by:


 Jack Morris CBE
 Chair of Trustees


 Hayley Conroy
 Chair of Finance Committee

The notes on pages 45-59 form part of these financial statements.

CONSOLIDATED CASH FLOW FOR THE YEAR ENDED 31 MARCH 2024

	2024 £'000	2023 £'000
Net (expenditure) / income for the year (as per the statement of financial activities)		
Net income for the year	300	621
Adjustments for:		
Depreciation	29	31
Losses/ (gains) on investments	(764)	859
Income from investments	(563)	(383)
(Increase)/ decrease in stocks	(17)	(27)
Decrease/ (increase) in debtors	215	(873)
Increase / (decrease) in creditors	(809)	(1,123)
Net cash (used in)/ provided by operating activities	(1,609)	(895)
Statement of cash flows		
Cash flows from operating activities		
Net cash (used in)/ provided by operating activities	(1,609)	(895)
Cash flows from investing activities:		
Dividends, interest and rents from investments	563	383
Purchase of computer software	-	-
Purchase of property plant & equipment	-	-
Sale/(purchase) of investments	(33)	(162)
Net cash provided by/ (used in) investing activities	530	221
Change in cash and cash equivalents in the year	(1,079)	(674)
Balances at 1 April	4,566	5,240
Balances at 31 March	3,487	4,566
Analysis of cash and cash equivalents		
Cash in hand	1,161	2,544
Notice deposits (less than 3 months)	2,326	2,022
Total cash and cash equivalents	3,487	4,566

Analysis of changes in net debt				
	At 1 April 2023	Cash from purchase of investments	Other Cash flows	At 31 March 2024
Cash	2,544	(33)	(1,350)	1,161
Cash equivalents	2,022	-	304	2,326
Net debt	4,566	(33)	(1,046)	3,487

NOTES TO THE FINANCIAL STATEMENTS

1. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 34. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 5.

2. ACCOUNTING POLICIES

(a) basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities. The Brain Tumour Charity ("The Charity") constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity. The results and balance sheet of The Charity's subsidiary undertakings, TBTC Trading Ltd, Acquist Data Holdings Ltd, Acquist Data Ltd, Medli Health Holding Ltd and Medli Health Ltd have been consolidated on a line by line basis. All Group companies prepare their accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £346,000 (2023: £520,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) Company status

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 34. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) Income

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Legacy income is recognised when the charity has sufficient evidence that a gift has been left to it (through knowledge of the existence of a valid will and the death of the benefactor); receipt is probable (there has been grant of probate and conditions attached to the legacy are within the control of the charity), and the fair value of the amount receivable, which will generally be the expected cash amount to be distributed to the charity, can be reliably measured.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such as grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Employee Termination Benefits are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

(e) Stocks

Stock is measured at the lower of cost and net realisable value.

(f) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) Fixed assets

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) Estimated useful lives

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) Investments

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) Donated assets and services

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) Operating lease

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) Pensions

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) Going concern

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. INCOME

a. Donations and Legacies

	Unrestricted £'000	Restricted £'000	Total 2024 £'000	Unrestricted £'000	Restricted £'000	Total 2023 £'000
Ordinary activities:						
Regular giving	381	75	456	336	76	412
Donations, appeals and fundraising	8,799	1,443	10,242	7,201	1,780	8,981
Gift aid	874	45	919	970	47	1,017
Legacies	789	141	930	949	70	1,019
Government grants	83	-	83	-	540	540
	10,926	1,704	12,630	9,456	2,513	11,969

Government grants consist of amounts received under the COVID Medical Research Charity Support Fund.

b. Other trading

Other trading income comprises income from fundraising events such as The Twilight Walk and community events £900,000 (2023: £300,000), product sales £82,000 (2023: £54,000) and services sales £20,000 (2023: £9,000).

4. ANALYSIS OF RESOURCES EXPENDED

	Direct Costs £'000	Grants £'000	Support Costs £'000	2024 Total £'000
Raising funds	2,891	-	272	3,163
Charitable activities:				
Research	1,507	5,415	85	7,007
Patient support	2,806	-	152	2,958
Campaigning and raising awareness	1,399	-	132	1,531
Total expenditure on charitable activities	5,712	5,415	369	11,496
Total expenditure	8,603	5,415	641	14,659

	Direct Costs £'000	Grants £'000	Support Costs £'000	2023 Total £'000
Raising funds	2,678	-	245	2,923
Charitable activities:				
Research	818	3,885	72	4,775
Patient support	2,204	-	123	2,327
Campaigning and raising awareness	1,104	-	106	1,210
Total expenditure on charitable activities	4,126	3,885	301	8,312
Total expenditure	6,804	3,885	546	11,235

5. RESEARCH GRANT COST ANALYSIS

	2024 £'000	2023 £'000
Research programmes	3,938	2,002
Research projects	758	961
Clinical trials	719	909
Conferences	-	13
	5,415	3,885

A breakdown of research costs by individual award is provided in note 21.

6. SUPPORT COSTS BY ACTIVITY

2024	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	75	138	59	272
Charitable activities:				
Research	23	44	18	85
Patient support	42	77	33	152
Campaigning and raising awareness	36	67	29	132
2024 Total	176	326	139	641

2023	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	66	124	55	245
Charitable activities:				
Research	20	36	16	72
Patient support	33	63	28	124
Campaigning and raising awareness	29	53	23	105
2023 Total	148	276	122	546

Governance costs of £82,000 (2023: £84,000) are included in central management & governance.

7. GOVERNANCE COSTS

	2024 £'000	2023 £'000
Auditor's remuneration	32	27
Trustee meetings	1	3
Legal and professional fees	1	1
Staff	48	53
	82	84

In addition to Auditor's remuneration for audit shown above, a further £840 was paid for accounting and tax advice (2023: £1,210). Trustees received no remuneration (2023: £nil). Trustees received £127 reimbursement for expenses in the year (2023: £nil). The premium in respect of professional liability insurance covering trustee indemnity was £5,179 (2023: £4,511).

8. STAFF COSTS

	Group		Company	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Wages and salaries	4,304	3,496	4,223	3,391
Social security costs	416	335	405	321
Payments to defined contribution pension plans	310	272	310	272
	5,030	4,103	4,938	3,984

During the year redundancy payments were made totalling £nil (2023: £3,000). At 31 March 2024 there was £nil provided (2023 £nil).

The average number of employees in the Group during the year was 116 (2023: 100) and in Company was 115 (2023: 99).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2024	2023
£60,001 - £70,000	2	-
£70,001 - £80,000	2	2
£80,001 - £90,000	3	2
£90,001 - £100,000	-	-
£100,001 - £110,000	-	1

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £708,000 (2023: £661,000).

9. TAXATION

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. Subsidiaries in the Group donate any net trading profit to The Brain Tumour Charity and accordingly have no taxable income. No charge to taxation therefore arises.

10. INTANGIBLE FIXED ASSETS

	Computer Software £'000
Cost	
At 1 April 2023 and 31 March 2024	161
Depreciation	
At 1 April 2023	154
Charge for the year	6
At 31 March 2024	160
Net book value	
At 31 March 2024	1
At 31 March 2023	7

11. TANGIBLE FIXED ASSETS

	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2023 and 31 March 2024	292	174	466
Depreciation			
At 1 April 2023	53	169	222
Charge for the year	19	4	23
At 31 March 2024	72	173	245
Net book value			
At 31 March 2024	220	1	221
At 31 March 2023	239	5	244

12. INVESTMENTS

(a) Subsidiary Investment

Equity investment in group undertakings

Cost	£
At 1 April 2023 and 31 March 2024	201

The Charity owns 100% of the £1 ordinary share capital of Medli Health Holding Ltd, a company incorporated in England and Wales, company number 14368728. Medli Health Holding Ltd owns 100% of Medli Health Limited, a company incorporated in England and Wales, company number 14371364.

The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holdings Ltd, a company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Ltd owns 100% of the £1 ordinary share capital of Acquist Data Ltd, a company incorporated in England and Wales, company number 13951572.

The purpose of the above companies is to commercialise intellectual property created in developing the BRIAN database, to generate income to be donated to The Charity.

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing. The net trading profit of TBTC Trading Ltd consolidated in these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2024 £'000	2023 £'000
Turnover	74	54
Cost of sales	(45)	(39)
Gross profit	29	15
Other operating expenses	(7)	(3)
Profit before donation	22	12
Donation	(12)	(41)
Retained profit/ (loss)	10	29

Cost of sales represent cost of stock sold in the year and the cost of fulfilment of orders.

At 31 March 2024 the aggregate assets of TBTC Trading Ltd were £53,000 (2023: £41,000), aggregate liabilities £30,000 (2023: £29,000) and shareholder's funds £23,000 (2023: £12,000).

The net trading loss of Medli Health Ltd is as set out below.

	2024 £'000	2023 £'000
Turnover	20	9
Expenditure	(402)	(776)
Retained (loss)	(382)	(767)

At 31 March 2024 the aggregate assets of Medli Health Ltd were £142,000 (2023: £89,000) aggregate liabilities £1,291,000 (2023: £856,000) and shareholder's deficit £1,149,000 (2023: £767,000). Medli Health Holding Ltd, Acquist Data Ltd and Acquist Data Holdings Ltd did not trade during the year.

(b) General investments

Equity investment in group undertakings

	2024 £'000	2023 £'000
Group and Company		
At 1 April	13,838	14,536
Additions at cost	471	361
Disposals	(387)	(290)
Net unrealised profit/(loss) on revaluation	714	(769)
At 31 March	14,636	13,838
Historical cost	12,469	12,298

	2024 £'000	2023 £'000
Investments at market value comprised:		
UK equities	3,191	3,234
Overseas equities	4,377	3,537
Property	239	206
Multi asset funds	887	766
Alternative investments	93	144
Fixed income securities	5,819	5,834
Cash held within the investment portfolios	29	116
Accrued income	1	1
At 31 March	14,636	13,838

Financial instruments

During the year income from listed investments was £472,000 (2023: £356,000) and interest on deposits £91,000 (2023: £27,000). Financial assets measured at fair value through income and expenditure amounted to £14,636k (2023 £13,838k) comprise fixed asset investments. The value of investments is calculated with reference to the market value of the shareholding.

13. DEBTORS

	Consolidated		Company	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Trade debtors	171	715	169	715
Accrued income and prepayments	1,161	844	1,161	844
Other debtors	146	134	40	-
Amounts owed by Group companies	-	-	128	13
	1,478	1,693	1,498	1,572

14. CREDITORS

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2024 £357,000 (2023: £302,000) of income received in the year was deferred and £310,000 (2023: £260,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
Grants payable	10,424	11,410	10,424	11,410
Accruals and deferred income	459	372	446	366
Trade creditors	192	121	185	111
Other creditors	51	67	51	67
Social security and other taxes	116	81	116	69
Amounts owed to Group companies	-	-	-	-
	11,242	12,051	11,222	12,023

15. PROVISION FOR LIABILITIES

	Consolidated		Company	
	2024 £'000	2023 £'000	2024 £'000	2023 £'000
At 1 April and 31 March	100	100	100	100

The provision relates to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. RESEARCH COMMITMENTS

At 31 March The Charity had authorised commitments that were subject to outstanding conditions expected to fall due as follows:

	2024	2023
	£'000	£'000
Within one year	5,237	3,765
Between one and two years	3,717	3,101
Between two and three years	2,858	1,931
Between three and four years	1,270	1,846
Between four and five years	-	90
Five years and further	-	-
	13,082	10,733

The above commitments will be funded from reserves and future income.

17. OPERATING LEASE COMMITMENTS

The total of future minimum lease payments on operating leases are as follows:

	On Property		On Equipment	
Group and Company	2024	2023	2024	2023
	£'000	£'000	£'000	£'000
Within one year	218	216	10	10
Between one and five years	467	685	28	38
	685	901	38	48
Operating lease charges in the year	216	211	10	15

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted Funds £'000	Restricted Funds £'000	Total 2024 £'000
2024			
Intangible fixed assets	1	-	1
Tangible fixed assets	221	-	221
Investments	14,636	-	14,636
Other current assets	1,540	3,475	5,015
Liabilities	(9,196)	(2,146)	(11,342)
	7,202	1,329	8,531

	Unrestricted Funds £'000	Restricted Funds £'000	Total 2023 £'000
2023			
Intangible fixed assets	7	-	7
Tangible fixed assets	244	-	244
Investments	13,838	-	13,838
Other current assets	687	5,606	6,293
Liabilities	(9,098)	(3,053)	(12,151)
	5,678	2,553	8,231

19. FUNDS

Consolidated 2024	At 1 April 2023 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2024 £'000
Restricted funds:						
Research funds	1,169	1,141	(1,311)	-	-	999
Everest fund	745	184	(929)	-	-	-
Awareness funds	159	4	(163)	-	-	-
Support funds	480	452	(602)	-	-	330
	2,553	1,781	(3,005)	-	-	1,329
Unrestricted funds:						
General reserve	3,985	11,395	(9,950)	-	764	6,194
Designated funds	1,693	1,019	(1,704)	-	-	1,008
	5,678	12,414	(11,654)	-	764	7,202
	8,231	14,195	(14,659)	-	764	8,531

Company 2024	At 1 April 2023 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2024 £'000
Restricted funds:						
Research funds	1,169	1,141	(1,311)	-	-	999
Everest fund	745	184	(929)	-	-	-
Awareness funds	159	4	(163)	-	-	-
Support funds	480	452	(602)	-	-	330
	2,553	1,781	(3,005)	-	-	1,329
Unrestricted funds:						
General reserve	3,843	11,313	(9,822)	-	764	6,098
Designated funds	1,693	1,019	(1,704)	-	-	1,008
	5,536	12,332	(11,526)	-	764	7,106
	8,089	14,113	(14,531)	-	764	8,435

Consolidated 2023	At 1 April 2022 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2023 £'000
Restricted funds:						
Research funds	2,199	1,482	(2,683)	171	-	1,169
Everest fund	-	545	200	-	-	745
Awareness funds	382	114	(337)	-	-	159
Support funds	675	451	(475)	(171)	-	480
	3,256	2,592	(3,295)	-	-	2,553
Unrestricted funds:						
General reserve	2,662	9,302	(7,120)	-	(859)	3,985
Designated funds	1,692	821	(820)	-	-	1,693
	4,354	10,123	(7,940)	-	(859)	5,678
	7,610	12,715	(11,235)	-	(859)	8,231

Company 2023	At 1 April 2022 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2023 £'000
Restricted funds:						
Research funds	2,199	1,482	(2,683)	171	-	1,169
Everest fund	-	545	200	-	-	745
Awareness funds	382	114	(337)	-	-	159
Support funds	675	451	(475)	(171)	-	480
	3,256	2,592	(3,295)	-	-	2,553
Unrestricted funds:						
General reserve	2,621	9,280	(7,199)	-	(859)	3,843
Designated funds	1,692	821	(820)	-	-	1,693
	4,313	10,101	(8,019)	-	(859)	5,536
	7,569	12,693	(11,314)	-	(859)	8,089

PURPOSE OF RESTRICTED FUNDS

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 21.
Everest fund	The Everest Centre is a specific programme for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is Better Safe Than Tumour.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation.

20. RELATED PARTIES

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2024 The Charity was owed £24,000 from TBTC Trading Ltd (2023: £24,000).

The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited.

The Charity owns 1 of the issued £1 ordinary shares of Medli Health Holding Limited, a company with the same registered address as The Charity. Medli Health Holding Limited wholly owns the share capital of Medli Health Limited.

Acquist Data Limited was formed to commercialise the intellectual property developed by The Charity in creating its BRIAN app and database. At 31 March 2024 The Charity:

- Was owed £400,000 (2023: £400,000) from Acquist Data Ltd in the form of an intercompany loan bearing interest at 3% above Bank of England Base Rate.
- Was owed £31,702 (2023: £nil) from Acquist Data Ltd on an intercompany balance.
- Was owed £860,000 (2023: £500,000) from Medli Health Ltd in the form of intercompany loans bearing interest at 3% above Bank of England Base Rate.
- Was owed £71,443 (2023: £10,282) from Medli Health Ltd on an intercompany balance.
- The Charity has fully provided as a bad debt provision for the loans owed to it from Medli Health Ltd totalling £860,000 and from Acquist Data Ltd £400,000.
- Was owed £300 from Acquist Data Holdings Ltd (2023: £nil)
- Was owed £199 from Medli Health Holding Ltd (2023: £199)

Acquist Data Ltd is owed £345,958 from Medli Health Ltd and has fully provided for this as a potential bad debt.

Trustees, their close family members and entities they control made donations to The Charity totalling £216,739 (2023: £36,536) during the year, including a £150,000 Gifts in Kind. They also paid contributions totalling £713 (2023: £65) for purchases.

21. RESEARCH AWARDS

	2024 £'000	2023 £'000
Programme - Jones - DKFZ - Everest Centre	988	(200)
Programme - Kennedy - University Southampton - PNET5 QoL	61	46
Programme - Northcott - St Judes - MERIT	184	243
Programme - Hankinson - University Colorado - Adamantinomous craniopharyngioma	20	142
Programme - Parrinello - UCL - Mapping spatio-temporal heterogeneity	218	374
Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC	304	302
Programme - Carragher - University Edinburgh - Therapeutic combinations in GBM	525	479
Programme - Kool & Becker - Heidelberg - COMMAND	259	-
Programme - Ishihara - Imperial College - Elimination of recurrent Glioblastoma	349	-
Programme - Barbera - Neural Development Unit TANGENTIAL	273	-
Programme - Hargrave - UCL -CONNECT TarGeT	176	-
Programme - Quest for Cures 2019 - Chesler ICR	266	292
Programme - Quest for Cures 2019 - Beroukhim - Dana-Farber	315	324
Total Programmes	3,938	2,002
Project - Jones - ICR - Gene editing for DIPG - Billie Butterfly fund	-	(4)
Project - Thomas - Nottingham Childrens' Hospital - AC therapy in young people	-	83
Project - Clinical Biomarkers 2019/2 - Zadeh - UHN	58	99
Project - Clinical Biomarkers 2019/2 - Euskirchen - Charite Hospital	-	96
Project - Future Leaders 2019 - Croal - Nottingham	-	66
Project - Future Leaders 2019 - Watson - Lausanne	-	60
Project - Future Leaders 2019 - Miller - Massachusetts	-	60
Project - Future Leaders 2019 - Rendo - Dana-Farber	-	60
Project - Future Leaders 2022/3 - De Martino - New York	-	74
Project - Future Leaders 2022/3 - Taylor - Cambridge	-	67
Project - Future Leaders 2022/3 - Mount - Harvard Masschusetts - Enhancing CAR-T cell therapies for gliomas	-	75
Project - Future Leaders 2022/3 - Rominiyi - Sheffield	-	75
Project - Future Leaders 2022/3 - Alvarez-Prado - Lausanne	-	75
Project - Future Leaders 2022/3 - Vinel - London	-	75
Project - Watson - Lausanne	150	-
Project - Miller - Massachusetts	150	-
Project - Williams - IC London	46	-
Project - Davidson Uni of Cape Town	26	-
Project - Jones - ICR Centre of Excellence	200	-
Project - Brown - Royal Adelaide Hospital	59	-
Project - Aghi - University of California San Francisco	69	-
Total Projects	758	961
Clinical Trial - Watts - Birmingham - BRAIN-MATRIX	613	582
Clinical Trial - Kearns - University Birmingham - PNET5 CTU	22	44
Clinical Trial - HR-MB - Bailey - Newcastle	84	89
Clinical Trial - ARISTOCRAT - Short - Leeds	-	194
Total Clinclal Trials	719	909
Conferences, workshops and other	-	13
	5,415	3,885

thebraintumourcharity.org

Registered office: Fleet 27, Rye Close,
Fleet, Hampshire, GU51 2UH
© The Brain Tumour Charity 2024.
Registered Charity in England and
Wales (1150054) and Scotland (SC045081).

**THE
BRAIN
TUMOUR
CHARITY**

THE BRAIN TUMOUR CHARITY

England & Wales - Charity number 1150054

Accounts

ANNUAL REPORT AND ACCOUNTS

2022-2023



**THE
BRAIN
TUMOUR
CHARITY**



CHAIR'S REPORT

Looking back at 2022-3, as with most years at The Brain Tumour Charity, it is no mean feat to distill what has been achieved over the past twelve months into just a few paragraphs.

Most excitingly, The Charity returned to significant research grant rounds after sadly needing to reduce these during the pandemic. An impressive £6.3 million was committed to research in the financial year to 31 March 2023, including to our five new Future Leaders (see page 15), and we expect to exceed this level of grants in our next financial year.

We saw a record year of income at £12.7 million, which represents growth of 11% on 2021/22. I'd like to extend much gratitude to the marvellous team at The Charity who have ensured its vital work has continued to shine during this period, as well as to all those incredible people in our community who continue to support us and enable us to achieve what you will read about in the following pages – we truly couldn't do it without you!

I was thrilled to attend and speak at The Twilight Walk in March 2023, during Brain Tumour Awareness Month. We came together with the community for our first Charity-organised, in-person walk since the pandemic, taking strides past London's landmarks for the first time. At the same time, people affected by brain tumours held their own walks up and down the country. This was an incredibly inspiring month of awareness-raising and fundraising, and you can read more about it on page 23.

This year marks the end of our interim strategy, *Leaning In*, and the beginning of our new seven-year strategy for change, *Living Longer and Better: 2023-2030*, which you can find out more about over the next few pages. Co-created with our community and consisting of bold commitments to accelerate cures for all

brain tumours, drive the best lifelong care and raise our global voices, I'm confident that this strategy will propel powerful change for everyone diagnosed with a brain tumour and their loved ones.

I'd like to thank our amazing Trustees for all the dedicated and generous hard work they give in support of The Charity. I am fortunate indeed to have the help of people with a wide range of experience and skills which, working together, help make it such an outstanding and successful organisation. Particular thanks go to our former trustees Graham Norton and Graham Lindsay for so expertly steering The Charity in 2022-23 as our Interim CEO, and Interim Deputy CEO as we conducted our search for a new permanent CEO. Thanks also to Beth Worrall, for temporarily stepping down as a Trustee and so adeptly leading The Charity as Interim CEO from April to June 2023.

We've been looking for someone with very special, almost unique, qualities to lead The Charity into the future, and I'm pleased to say we believe we have now found that person. Dr Michele Afif's wide professional experience in the medical, legal and charity sectors is almost unparalleled and her empathetic style fits well with the caring and understanding culture we promote amongst our staff and within the brain tumour community we serve. We're delighted to have Michele join us and take The Charity onward and upward as we move forward with our new strategy. You'll hear from Michele on page 6.

We can only achieve everything we do by working together. So if you'd like to get involved, whether by raising awareness, raising funds, campaigning for change, volunteering, sharing your story or anything else, please do visit thebraintumourcharity.org/get-involved

Thank you,

Jack Morris CBE
Chair of Trustees


CONTENTS

Report of the Trustees	3
a. Strategic Report	12
b. Statement of the Trustees' responsibilities	36
Independent auditor's report	37
Statement of financial activities	40
Balance sheet	41
Cash flow statement	42

LIVING LONGER AND BETTER: OUR NEW CO-CREATED STRATEGY FOR 2023-2030

Brain tumours kill more children and adults under 40 than any other cancer. They reduce life expectancy by an average of 35 years globally and 27 years in the UK – far more than any other cancer or significant disease. And in the UK, just 13% of people survive brain cancer for more than five years.

OUR STRATEGY AT A GLANCE



This is not a small disease – it's a global community of over one million people, 88,000 of them living in the UK. These people, their families and carers deserve better than the prognoses they currently face. They urgently need cures and to live longer and better.

Until recently, survival rates and treatments had barely improved for a generation. But that's now changing, with research funding tripling in the last decade. It's crucial that, together, we not only sustain but accelerate this progress!

People affected by brain tumours told us they desperately need more effective treatments and prompter diagnoses. They need more hope and less fear. They need to be treated holistically, as people and not just patients, to feel connected and powerful, and to make choices about what matters to them.

Ultimately, they need cures, they need better lifelong care, and their voices must be heard globally.

That's why we came together with the community to co-create *Living Longer and Better: 2023-2030* – our new seven-year strategy for change. This is how we're going to not only build a better future but improve lives today. And we can't do it alone. We're asking you to join us as we accelerate cures and forge ahead towards a world where people diagnosed with a brain tumour live longer and better.

Living Longer and Better was created by and for the brain tumour community. It's a bold leap forward in ambition and collaboration, and that boldness comes from the strength and power in the community. It's their experiences that form the lynchpin of this strategy and their voices that are steering our future.

To co-create this strategy, we collaborated with 1,200 people from across the community, the output of which has resulted in a transformative step change in taking on brain tumours – a brave blueprint for a better future that's laser-focused to create the most impact.

It sets out our vision of a world where people affected by brain tumours live longer and better. It sets out our goals – to double survival and halve the harm brain tumours have on quality of life. And it sets out the commitments we must drive forward as a collaborative ecosystem, both in the UK and globally.

Built around three core commitments –

- accelerating cures for all brain tumours
- driving the best lifelong care, and
- raising our global voices

– we know this strategy gives us the best chance of reaching our shared vision. We recognise and embrace that we're part of a global ecosystem of people and organisations united by a common purpose. We haven't created this strategy alone and we're not going to deliver it alone – we must work together internationally and go further, faster to achieve our goals.

Now that we've experienced the power of co-creation, we're resolved to collaborate in everything we do. We commit and look forward to working alongside all of *you*, together striding forward towards cures for all brain tumours and a world where people diagnosed live longer and better.



CEO'S REPORT

It was my great privilege to take up the CEO role at The Brain Tumour Charity in July 2023 and join such a capable and dedicated team, relentless in their search for a cure and tireless in their support for all those who've experienced this most difficult of diagnoses.

A doctor by training and background, my experience working in paediatric haematology and oncology meant I saw first hand the cruelties associated with brain tumours. With so many advances elsewhere in cancer treatment, there's an urgent need to see similar improvements for the brain tumour community.

This year, the team and all our supporters have gone above and beyond to make amazing things happen. We are united in the pursuit of our shared goals, which continue to drive us towards a world where people with brain tumours live longer and better lives.

In addition to the resumption of our research grant programme, and alongside reaching a record income, incredible achievements this year include:

- growth in our **online support community memberships** to more than 28,000 memberships and supporting over 9,000 people one-on-one (7% more than the previous year)
- the launch of our new **counselling support service** which helped 261 people, the majority of whom reported a significant and positive impact on their wellbeing – the basis on which we will continue to expand this service

- publishing our **Brain Tumours: Fighting for Faster Diagnosis** report which details eight policy recommendations that we believe would enable faster diagnosis and, in turn, improve experiences and quality of care

- launching our **Better Safe Than Tumour Campaign** which has so far resulted in over 32,000 people using our interactive online signs and symptoms tracker. We have also had the opportunity to train over 4,000 healthcare professionals in recognising the signs and symptoms that may be indicative of a brain tumour.

Even as so much has been achieved, there is undoubtedly much more to do. Over the course of this year we collaborated with 1,200 people, bringing their voices together to create the community's mandate for change. This mandate forms the lynchpin of our new strategy, *Living Longer and Better: 2023-2030*, which will guide The Charity's activities over the next seven years.

I look forward to working alongside this amazing community to ensure The Brain Tumour Charity's hugely important work continues unabated in the drive to deliver its unashamedly ambitious goals. We are committed to doubling survival and halving the harm that brain tumours have on quality of life by 2030, and we know that with your continued support, together, we will achieve these goals.

Thank you,

Dr Michele Afif
CEO

OUR GOALS AND VALUES

OUR GOALS

Our vision is for a world where brain tumours are defeated and our goals are our blueprint for getting there. Simply put, if something doesn't help us achieve one of these goals, we know that it's not the right direction for us.

We've set ourselves goals that are unashamedly ambitious as this is the only way we'll see a real and lasting difference. We want to:

- **double survival in the UK**
- **halve the harm that brain tumours have on quality of life in the UK**

OUR VALUES

Our values underpin everything that we do, they define what we believe and guide our actions every day.

The way we work is always:

PIONEERING

We're relentless and courageous in the pursuit of our vision, seeking new ways to make a difference.

PASSIONATE

People are at the heart of everything we do. We're passionate about finding a cure and ensuring everyone affected by a brain tumour has the highest quality of life and chance of survival.

COLLABORATIVE

We'll only achieve our vision by building networks, partnerships and a strong community of people affected by a brain tumour. We collaborate and value everyone's contribution.

SMART

We're focused and intelligent in our approach to defeating brain tumours.

EQUALITY, DIVERSITY AND INCLUSION (EDI)

We continue to undertake significant work to further our Equality, Diversity and Inclusion (EDI) agenda to ensure we can meet diverse needs both internally and externally to the community and our stakeholders

ACCELERATING CURES FOR ALL BRAIN TUMOURS

Diversity in research suffers from a number of external factors, such as access to education and university places. The Charity is contributing towards the creation of a truly diverse research environment in the following areas.

- Our Future Leaders programme aims at supporting researchers early in their career, a period where difficulty securing support can lead to brilliant minds choosing different career paths.
- We've also reshaped our Expanding Theories award. In addition to allowing early career researchers to apply for their own funding, this award is now blinded during review, minimising any unconscious bias during the process.
- We aim to maintain diversity on our Scientific Advisory Board wherever possible and actively guard against unconscious bias at each meeting.

DRIVING THE BEST LIFELONG CARE

We're dedicated to identifying and eliminating inequalities and unmet needs in healthcare treatment and support.

- Next year we'll be evolving the Wraparound Care Standard and focusing on parts of the pathway where the greatest gaps exist.
- This year we've run Round 3 of the Adult Improving Brain Tumour Care surveys and developed our Faster Diagnosis policy paper and recommendations, which will help us drive equal access to the best care and prompt diagnoses.
- We've developed several services this year specifically to address large gaps and differences in care, including counselling (see page 19) and My Support Plan (see page 18). We're also currently working to improve access for underserved groups.

RAISING OUR GLOBAL VOICES EDI AND OUR TEAM

EDI is a core component of everything we do in Fundraising, Marketing and Customer Experience, ensuring that our events, fundraising, website and all outward facing channels and teams are accessible.

- We work to ensure that our brand and campaigns are diverse and inclusive.
- We have audited and started to fill gaps in our story, image and video libraries.
- We work with our community to ensure community fundraising and events are accessible.
- Accessibility remains at the heart of our website – and recent developments have improved it further.
- We continue to monitor, track and evolve our vulnerable person, complaints and fundraising guidance policies, to ensure we're giving the very best experience to all in our community.
- Our growing Involvement Network of people affected by a brain tumour increasingly shapes everything we do, including co-creating our new strategy.

We strive to be a diverse and inclusive Charity because we believe it's important that we represent the community that we serve, and want everyone who works with us to have a positive experience, feel that they belong and have a voice in the things that matter most to them.

Among other projects and initiatives, we've been:

- collecting and monitoring diversity data
- celebrating cultural and religious events
- educating and training the team around EDI topics
- strengthening our EDI Champion group and EDI Trustee Committee
- creating an accessible and inclusive working environment
- establishing new organisational values which help underpin a radically inclusive approach: Community first, Collaborative, Bold, and Innovative.

ENVIRONMENTAL, SOCIAL AND GOVERNANCE (ESG)

SOCIAL AND GOVERNANCE

A social ethos is intrinsic in The Charity since its purpose of existence is to serve the brain tumour community and drive change, and our values reflect this. We have comprehensive policies on matters such as anti-modern-slavery and through our Governance and Ethics committee keep under constant review our relationships and compliance to ensure the highest standards.

REDUCING ENVIRONMENTAL IMPACT

Every team in The Charity considers what changes, big or small, they can make to reduce the environmental impact of what we do.

Examples of the specific actions we have made in the year are:

- Eco-friendly collection boxes
- Wooden medals
- Website optimisation
- Moving investments to support greener energy

Our Sustainability Champions group also meets regularly to review the actions being taken, make suggestions for improvements and keep environmental considerations at the forefront of people's work and personal life.



OUR OBJECTIVES AND ACTIVITIES

The objectives of The Charity are to provide public benefit by:

- relieving sickness and protecting good health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain and central nervous system
- relieving the suffering of people with tumours of the brain and central nervous system, their families and carers, through the provision of information and support
- advancing the education of the public in all areas relating to tumours of the brain and central nervous system.

PUBLIC BENEFIT STATEMENT

The Trustees have considered the Charity Commission’s general guidance on public benefit and have taken it into account when reviewing The Charity’s aims and objectives and in planning its future activities. The Trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.



DEFEATING BRAIN TUMOURS: LEANING IN

COVID-19 had a major impact on those with brain tumours, on brain tumour care, on the pace of research and on our own resources. Our short-term strategy, *Defeating Brain Tumours: Leaning In*, was developed in order to support the community’s heightened needs through the pandemic and beyond.

In 2022-3, we were able to move on from the emergency response needed after March 2020 towards tackling some of the longer-term issues that had arisen or remained pressing – such as restarting our research funding, launching our adult early diagnosis campaign, generating and sharing the insights we needed to drive change, and providing tools for our team and the wider community to amplify our voices.

As well as retaining the four pillars (Power of Data, Best Care Everywhere, Voices for Change and Make it Count) from *Leaning In*, we added a fifth pillar, Accelerate a Cure, to reflect the restarting of our research funding.

Accelerate a Cure Funding research to create new knowledge and understanding, accelerating new treatments by translating breakthroughs into benefit for patients, and enhancing quality of life.

Power of Data Harnessing the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

Best Care Everywhere Driving the best care everywhere across the UK, empowering the community to access high levels of care no matter where they’re located and helping treatment centres reach the highest possible standards.

Voices for Change Empowering everybody affected by a brain tumour to become a voice for change, giving the community everything they need to drive progress – whether they’re fundraisers or change makers.

Make it Count Using our resources, skills and technology efficiently and effectively to make sure we maximise our impact with minimal resources.

BETTER SAFE THAN TUMOUR

We’re not slowing down in our mission to drive down diagnosis times for brain tumours! In July 2022, we launched our **Better Safe Than Tumour** campaign to raise crucial awareness of the signs and symptoms of a brain tumour.

6M

people saw the ad on TV!

The campaign was built on all the amazing groundwork done by our previous signs and symptoms awareness campaign, HeadSmart.

But while HeadSmart focused on spreading awareness of the common signs and symptoms of a brain tumour in childhood, **Better Safe Than Tumour** also aims to raise awareness of the signs and symptoms in adults.

We also gave the campaign a brand new, attention-grabbing look and feel that gives it a closer link to The Brain Tumour Charity.

And we’ve already had an incredible impact:

- 161,000 people accessed the campaign website
- Over 32,000 people completed the signs and symptoms tracker
- 5,000 people requested a pdf download of their symptoms to take with them when consulting a healthcare professional



STRATEGIC REPORT

ACCELERATE A CURE

We fund research to create new knowledge and understanding, accelerate new treatments by translating breakthroughs into benefit for patients, and enhance quality of life.

HIGHLIGHTS OF 2022/23

RESTARTING GROUNDBREAKING RESEARCH

This year, we restarted our research funding programme after pausing it during the COVID-19 pandemic. Much of the effort put in this year will bear fruit early in 2023-24, with applications opening this year resulting in awards being made during the next financial year.

In total during 2022-23, we were able to commit £6.3 million to new research, marking a real return from the hiatus seen due to the global downturn.

We have re-established our Expanding Theories awards – small project grants to take promising ideas and provide proof of concept data. We have also restarted our Quest for Cures awards – large programmatic awards supporting collaborative research bringing projects close to clinical testing.

£6.3M

committed to new research

Both these rounds attracted the highest number of applications we have ever seen, possibly due to the lack of funding from many sources during the pandemic, and possibly due to the success of our

pandemic webinar series, which saw us double the number of researchers who now hear about our awards.

We also had a call for a Paediatric Clinical Trial, looking to deliver on our strategic commitment to support complex innovative design trials. We asked the community to suggest ideas for a multi-arm platform study in paediatric high grade glioma, allowing all children, teenagers and young adults with high grade gliomas access to innovative treatments based on their molecular diagnosis. We hope to be making an award in this area in the next financial year.

FUNDING NEW FUTURE LEADERS

While the above grants are yet to be awarded, our priority this year was ensuring our Future Leaders programme continued, and we're delighted to report that our third Postdoctoral Fellowship round has awarded grants to five aspiring leaders in neuro-oncology.

The recipients are based in the UK, Europe and the USA, and are a mix of clinician scientists and discovery scientists, whose research will create the foundations of new knowledge in the field and form the basis of their careers as they establish independent laboratories. You can read more about them on page 15.

Excitingly, we also ran the first of our second stage applications in this programme and will be making awards to our Junior Fellowships early in the 2023-24 period.

RENEWING EVEREST CENTRE FUNDING

Finally, we were able to support a second five-year award for the Everest Centre. Established in 2017 between researchers at the German Cancer Research Centre (DKFZ) in Heidelberg and St Bart's and UCL in London, this world-leading programme has led to real progress in understanding and treating paediatric low grade glioma, including:

- the development of molecular classification of paediatric brain tumours, meaning more accurate diagnosis and changes to treatments
- understanding of the unique growth cycle of low grade glioma and how this helps the tumours resist treatment
- novel treatments that target this phenomenon which are ready for clinical trials
- the establishment of the LOGGIC trial, supporting the progression of a molecularly targeted treatment toward approval in paediatric low grade glioma.

The renewed funding of £5 million will allow the researchers to gain a more detailed understanding of the cells in low grade brain tumours and find ways to predict which patients will benefit most from different treatment options being tested in clinical trials.

They also plan to speed up the confirmation of a specific diagnosis by using new technologies and building on their previous work. By combining this with artificial intelligence they hope to be able to make world-leading diagnostic approaches available to all children, no matter where in the world they are.

Finally, this next-stage funding will support the establishment of clinical trials, enabling the translation of these key discoveries into real-world advances in patient outcomes.



THE POWER OF DATA

We harness the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

HIGHLIGHTS OF 2022/23

ESTABLISHING A DATA STRATEGY

This year we completed The Charity's data strategy and began to operationalise it. The strategy, which covers the period from 2023 to the end of 2024, outlines: (1) the data structure and technology we need, (2) plans for advancing our use of analytics, (3) a SWOT (strengths, weaknesses, opportunities and threats) analysis, (4) improvements to our data maturity and governance and (5) the data strategy roadmap.

As part of this work, we've introduced training to improve the wider Charity's skills and understanding of data, in order to build a more data-driven culture.

To support this work and to further our desire to be a data-led Charity, we've been producing a number of dashboards on a data visualisation tool called Power BI, allowing all users to easily see and utilise the data from across The Charity. We are also looking at ways that we can make some of these data available outside of the organisation, increasing the transparency of our work and providing the information for the community to support their own campaigns and messages.

IMPROVING OUR BRIAN APP

Registered users to BRIAN continue to increase. BRIAN is our app and databank designed to support people affected by a brain tumour and provide researchers with valuable data. We've had a 33% growth in users in the last year, bringing the total to 9,796 users. Work continues to re-design the app so that it is more intuitive to use.

As part of this, with the involvement of our community, in early 2023 we completed a rapid redesign process, taking forward novel ideas to enhance the app user experience and deepen engagement, and these are being taken forward now, with plans to complete this development for a launch in the winter.

We continue to increase the data sources that support BRIAN as well as work to improve the accessibility of these data. We've agreed to work with Dr Matthew Williams at Imperial College NHS Trust and other trusts to take in MRI images from at least 1,000 patients with a brain tumour – a project called the Brain Tumour Data Accelerator (BTDA). This has kicked off and received Research Ethics Committee approval.

We are not only directly accumulating key data for research use but have also engaged a provider called AIMES to produce a Trusted Research Environment (TRE) to house the data. This will enable researchers to access the data they need to drive advances in treatment and care.

This approach is becoming the industry standard, with the NHS moving to a similar set-up. It allows researchers appropriate access to the data, without the need to transfer the data to their servers, meaning increased security and less chance of data breaches.

Researchers are not allowed to extract the individual data but rather the insights they derive from it, meaning only a single copy of the data is maintained. Once data is available from the BTDA project, it will be taken in to the TRE and made available to researchers.

OUR NEW RESEARCH FUTURE LEADERS

These five talented scientists and clinicians have been awarded a combined total of over £1.1 million in funding for their innovative research projects, which aim to improve our understanding of brain tumours and develop new treatments.



Dr Mara De Martino is investigating the connection between lipid metabolism and immune escape in glioblastoma. Her goal is to identify molecules that promote treatment resistance and develop novel treatments targeting lipid pathways to enhance immunotherapy effectiveness against brain cancers.



Dr Ola Rominiyi is researching DNA repair in glioblastoma on a cellular level to identify treatment weaknesses. His work aims to create new treatment strategies with DNA repair inhibitor drugs that are more effective and have fewer side effects.



Dr Jessica Taylor is developing a novel strategy called ADCIPs (Antibody-Directed Cytotoxic and Imaging Probes) to identify and treat WNT-medulloblastoma, a highly curable brain tumour in children, without the need for surgery.



Dr Christopher Mount is developing a new approach to treat gliomas by engineering immune cells to specifically identify and destroy multiple types of cells within the tumour.



Dr Angel Alvarez-Prado is developing a novel therapeutic approach to treat glioblastoma by inhibiting a protein called ADAR1 in combination with TME-targeted immunotherapies, which target cancer cells and their supporting microenvironment.

BEST CARE EVERYWHERE

Our vision is for everyone affected by a brain tumour, no matter who and where they are, to have access to the same world-class, holistic treatment and support that's right for them. Currently there are gaps and inequalities. So we're growing our support to help more people in an ever-more significant way, we're finding the gaps where people need more support and we're working alongside the community to design and deliver solutions to fill those gaps.

HIGHLIGHTS OF 2022/23

MAKING MORE DIFFERENCE

Our services now include our:

- support lines for adults, young adults, children and families
- counselling service
- money and benefits clinic
- online support groups
- events
- podcasts
- printed resources
- website support
- BRIAN app.

86%

said we were able to help them significantly

We've made significant progress this year and here are just some of the highlights:

- Our online support groups grew by 16% to over 28,000 memberships.
- Our individual support grew by 7% to help 9,000 people 12,000 times. And 86% say we were able to help them significantly.

- We helped 339 people through our money and benefit service to find an extra £808k income, averaging £2,400 each.
- We relaunched and simplified our digital support which helps nearly 1 million support seekers with over 500 different pages of brain tumour specific information and support.
- We launched a free, in-house counselling service for all affected adults which helped over 260 people, with 78% reporting a significant improvement to their emotional wellbeing in spite of the ongoing impact of their tumour experience.
- We returned to face-to-face events with 143 guests joining us at family days.
- We have grown podcasts into a major channel with 41 episodes so far.
- People shared 825 more experiences of their diagnosis and treatment through our Improving Brain Tumour Care surveys, to help improve care for everyone.
- We trained over 4,300 more healthcare professionals to recognise the signs and symptoms of a brain tumour and play their part in faster diagnosis.

WORKING AS A COMMUNITY

Our community is integral to the strategy, design and delivery of our services. When we think about our support team, we don't just think about what we can do as a team of 17 staff, we think about our 43 volunteers, 28,169 online support group members giving and receiving support, 40 champions and over 1,000 others in our Involvement Network, as well as the healthcare professionals and other charities with whom we're partnered to help people. We all work together to discover our community's unmet needs and then fill the gaps, improve healthcare and deliver support.

28,000

memberships of our online support communities

Here are just some examples of how we're doing this:

- We have **community volunteers helping to deliver support** in nearly every role alongside our staff. Forty-three volunteers expand the team by 15%, and their commitment and skill means we can grow and innovate in ways we simply couldn't do without their help.
- We're enabling the **community to support each other**. In our large online support communities, people are giving and receiving support 24/7. We have 14 different groups catering to different needs and experiences, and membership grew by 16% to 28,000 this year, with memberships from over 100 countries.
- Our **podcasts**, which have grown into an important support channel, are developed and delivered by a team including three volunteers, all current or former Involvement Champions and Young Ambassadors. Our podcasts are listened to in 24 countries and are in the top 15% most shared and top 20% most followed!



FINDING AND FILLING THE GAPS

We enabled people to share their experiences of treatment and care through the Improving Brain Tumour Care surveys and this has resulted in the sharing of 825 diagnosis and treatment experiences from the last two years. The gaps we find feed into our work and the Tessa Jowell Centres of Excellence programme to eliminate healthcare inequalities.

Here are just some of the biggest gaps revealed:

- Diagnosis is slow, hard and poorly supported for too many people. Now 74% go through A&E en route to diagnosis and 46% are first told of their tumour by an A&E doctor not specialised in brain tumours.
- Communication needs to improve – 27% said their prognosis was not explained in a way they understood.
- People still don't have enough professional support and coordination of their care – 43% didn't have good access to a clinical nurse specialist and 70% didn't have a needs assessment and resulting support plan.
- The majority of people have one or more unmet needs, e.g. 58% need more help coping emotionally.
- Access to clinical research trials is too low: only 12% of those surveyed participated in a clinical trial.
- Half of people (55%) strongly recommend their treatment team but a quarter (25%) would not, scoring them 0–6 out of 10.

Engagement in our Improving Brain Tumour Care surveys has helped to grow our Involvement Network to over 1,000 people with diverse backgrounds and experiences. Our involvement programme is how we shape everything we do with the help of our community.

The network and our champion groups help us identify and understand the gaps, design services to fill those gaps and even help deliver the solutions themselves. This way of working permeates our work in research, fundraising, awareness raising, support, campaigning and influencing... everything!

This year, the involvement network has helped shape an 'A to Z' of initiatives from us and others: AI devices for brain activity EEGs (electroencephalograms), bereavement support, the BRIAN app design, counselling, events, our faster diagnosis policy paper, a feelings chart for children, holistic needs assessments, legacy giving campaigns, paediatric information packs, rehab pathways, and research projects on topics ranging from fatigue to glioblastoma outcomes, COVID shielding to immunotherapy, use of the drug dexamethasone to use of aspirin to alleviate cardiovascular risks after tumour diagnoses.

The culmination of this approach has been the co-creation of our charity strategy as a community during the last year. See pages 4–5 for more on this.

An example of filling the gaps...

Having a good holistic needs assessment and resulting personal support plan is critical to people having control of their care and recovering and optimizing their quality of life. Unfortunately we know that this doesn't happen for 70% people. So we decided to develop a brain tumour specific digital tool within our BRIAN app. It is called My Support Plan. It aims to facilitate a more effective and efficient guided conversation about support with your clinical team so you can partner with them and take an active ownership of your support. We have built the tool with the input of clinicians and the community, received great feedback in testing and are now entering pilots with neuroscience centres.

OUR COUNSELLING SERVICE



The community said there is a big gap around emotional support, with 58% of people needing more help. We found there was not enough counselling available quickly and accessible to all.

So, we launched a free counselling service this year which has significantly helped over 260 people with nearly 1,200 sessions, with 94% rating the service very good and outcomes improving by 32%.

We are doubling the service in each of the next two years.

“

I am really grateful for the service. It was something I could depend on when lots of things felt out of my control and gave me a chance to discuss issues important to me at the time.

”

Feedback from our pilot counselling service

VOICES FOR CHANGE

We're committed to empowering everybody affected by a brain tumour to become a voice for change, giving the community everything they need to drive progress – whether they're fundraisers or change makers.

HIGHLIGHTS OF 2022/23

RELENTLESSLY RAISING FUNDS

This year, in fundraising, we were thrilled to raise £12.7 million. Within this was an incredible £1 million+ in legacies, a record breaking amount for us. We launched a new Gifts in Wills proposition this year and have been receiving many enquiries as a result.

£12.7M
raised

We continued to build our prize-led fundraising stream, with 864 players and 400 winners in our Win Big Lottery so far, and launching our Win Big Raffle in March.

We were pleased to raise over £378,000 in our Spring and Winter Appeals, and also to launch acquisition mailings this year. These have recruited brand new supporters to The Charity, attracting over 200 new financial supporters and raising awareness in 88,000 households with the Better Safe than Tumour campaign leaflets we included in our mailing.

Acquisition of new donors is a key driver of future income and we will be investing in this as we continue to grow The Charity.

Within Community Fundraising, a real highlight was the flourishing of our Supporter Groups, who raised a record-breaking £1 million+ for the first time. We welcomed eight new Supporter Groups, and two existing ones hit major milestones: Lizzie's Fund reaching £500,000 and The Silas Pullen Fund exceeding £800,000.

COMING TOGETHER WITH THE COMMUNITY

As in-person events resume, our flagship campaign The Twilight Walk was a huge success and we were delighted to return to holding our in-person, Charity-led Twilight Walk event, which this year took place in London. We were also thrilled to see so many people holding their own walks up and down the UK to raise awareness and drive change. See more on page 23.

Another amazing event this year was Everest in the Alps. This gruelling challenge – climbing the height of Everest over four consecutive days in the Alps – was inspired by our former trustee Rob Ritchie, whose five-year-old son Toby was diagnosed with a low-grade tumour and who has vowed to help speed up the search for a cure. Rob and his team raised nearly £400,000, an astonishing amount!

RAISING VITAL AWARENESS

This year marked the launch of our vitally important Better Safe Than Tumour awareness campaign, intended to raise awareness of the signs and symptoms of a brain tumour in adults and children. We've now reached over 15 million people with the campaign, 146,500 of them going on to access the campaign website and 5,200 completing the symptom checker. On 1 March, for two weeks, our first Better Safe Than Tumour TV advert went live across Sky, Sky VOD, 4OD and ITV Hub to coincide with Brain Tumour Awareness Month, driving over 20,000 people to the website in that time period alone.

7%

growth in our social media accounts

Alongside this, we created and printed our new community walking campaign pack, allowing the community to distribute signs and symptoms cards in their communities. So far we've had over 500 requests for packs and this number increases daily.

We were excited to gain 2,234 followers on social media during Brain Tumour Awareness Month this year compared to 1,107 followers last year, and our brand ads generated over 8.5 million impressions, reaching more than 2.5 million accounts. We also secured over 1,100 pieces of coverage, up +64% vs the prior year.

5,324

pieces of media coverage



DRIVING POLICY CHANGE

Our policy work continues to raise awareness, share our Better Safe Than Tumour campaign and push for change among policymakers. We developed and published our *Brain Tumours: Fighting For Faster Diagnosis* report, for which we interviewed GPs, clinicians, nurses, royal colleges, optometrists and researchers, as well as three lived experience focus groups. This year, 30 MPs and parliamentarians across the UK publicly supported the campaign – including a Member of the Senedd who translated the campaign into Welsh.

337%

increase in the number of people in our campaigner network

We also responded to the government's 10-Year Cancer Plan for England, helped members of the community submit their own responses, and made a video appeal to the new Secretary of State highlighting the One Cancer Voice coalition petition. This petition encouraged the government to recognise the importance of cancer in their new Major Conditions Strategy (which replaced the 10-Year Cancer Plan).



TAKING STRIDES TO CHANGE LIVES – THE TWILIGHT WALK 2023



We were thrilled to see so many people unite to take strides for The Twilight Walk throughout Brain Tumour Awareness Month in March 2023, as well as hold their own walks in October 2022.

In March, for the first time, we took on The Twilight Walk London, with over 850 members of the community forming a sea of red walkers, passing iconic landmarks such as Big Ben, Buckingham Palace and Hyde Park.

And over 860 people affected by brain tumours took part in 265 Own Walks up and down the country in March 2023 and October 2022, all determined to raise awareness and make a difference for everyone affected by this disease. In total, their efforts raised more than £416,000! This awe-inspiring amount is enough to fund over three and a half years of world-class research into brain tumours.

MAKE IT COUNT

We're committed to creating and adapting The Charity to best support the delivery of our goals, building a first-class team to utilise our resources, skills and technology in order to maximise our impact as efficiently as possible.

HIGHLIGHTS OF 2022/23

GROWING ONCE AGAIN

This was the first full year with the pandemic truly behind us, although its shadow continues to be felt, whether through NHS backlogs for treatment, people living with long Covid symptoms or workplaces adapting to hybrid working. Layered on to this has been the economic story of higher inflation and higher prices driving pressure on the cost of living.

In acknowledging that impact, we find our resolve strengthened and our ambitions for the future brighter than ever. With the co-creation of our new strategy, this year has been about growing back stronger to meet the needs of the community and deliver on our goals. This growth has included our team and volunteers.

Our team has continued to grow from an average of 86 in 2021-22 to 100 in 2022-23. Finding the right people in a competitive recruitment landscape can be difficult but we are delighted that the fantastic culture and rewarding nature of the work has allowed us to do just that. The growth in our team is enabling us to do more, as you will have read in the other sections of this report.

We continued to invest in our people, with the launch of our Management Development programme, to enhance the core skills of our people managers. We are most grateful to Barclays Bank with whom ten members of our team have been matched with external mentors via their Charity

Mentoring Scheme. We have developed and undertaken workshops to embed our new Charity Values, held learning lunches on a wide range of topics and continued our champions groups on culture, sustainability, well-being and equality, diversification and inclusion.

Working in a hybrid way continues to present both opportunities and challenges, opportunities to better engage those working remotely from our office such as our wonderful community fundraisers and the community as well as sometimes saving time and money on travel. The challenges are to ensure we retain our strong culture and to stay effective.

CELEBRATING OUR VOLUNTEERS

Our volunteers were pivotal to our achievements in 2022-23. We have over 1,000 volunteers across the UK, who so generously lend their time, experience and expertise to support us to achieve our goals.

Our team of volunteers help with everything from fundraising and spreading awareness of the signs and symptoms of a brain tumour in their local communities, to providing professional sports coaching to our London Marathon runners and quality-checking the accuracy of our medical and scientific information.

Most notable this year were our Involvement Champions, who helped co-create our new strategy alongside many others in the community. They worked tirelessly to shape this remarkable blueprint, which we're certain will have an amazing impact in the coming years.

We recruited a further five qualified counsellors and three student placement counsellors to join our support service, reducing the waiting times for this growing and highly valued service. Twelve Charity Ambassadors were appointed in the first phase of our community fundraising team and six search engine optimisation volunteers joined us to optimise our support pages. These are just a few examples of how we have expanded the scope and range of our volunteer programme aided by our Volunteer Coordinator Forums to help us share ideas and co-ordination across The Charity to fully leverage the power of volunteers.

POWERED BY TECHNOLOGY

The Charity strives to be a digital-first organisation, using the power of technology to reach and help more people and be more effective.

We've invested in updating much of our technology, including rolling out improved back-up systems, enhanced multi-factor authentication, updated hardware and moving to more software-as-a-service.

In addition, we have increased automation, streamlining the transformation and loading of data. These changes help ensure we meet our responsibilities to the community to keep their information safe.

We have also invested in new systems such as Marketing Cloud and deSelect to enhance our communication with our supporters. These tools allow us to tailor our messages to those most relevant and of interest to our supporters.

A new volunteer management system is being rolled and we are currently testing new HR systems.

It is these behind-the-scenes improvements that facilitate the growth in our front-line services and it is why our IT team has grown from two to five people and will grow further. The groundwork we have been laying in investing in technology will allow this growth to continue.



FINANCE REVIEW

The year to March 2023 was another strong one for The Charity's finances. Despite the mounting pressures on households and business due to the cost of living and inflationary increases, income grew over 10% from last year to hit a new record of £12.7m, exceeding our target of £12.3m. The generosity of the community continues to galvanise us and demonstrates the demand to improve the life and outcomes of those affected by brain tumours.

Expenditure on charitable activities fell year-on-year as a result of a significant multi-year research programme, known as Everest, into paediatric low grade tumours. This world-class programme, which The Charity continues to fund and this year announced a further £5m of funding over five years, has been slower to get fully up to speed and as a result under-spent against the amounts The Charity has previously awarded it. This resulted in The Charity's expenditure on research funding in the year to March 2023 being £1.1m lower than we had planned at the start of the year.

INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year income was up year-on-year in almost all areas.


In most areas such as Events, Community Fundraising, Supporter Groups and general donations, which represents roughly half our income, income was up between 10% and 20% over 2021-22. This reflects the generosity of the community and the general growth in The Charity as we did more and expanded the number of donors.

We were particularly delighted with the response and participation in our Twilight Walk. Held in London in March it was the first time we have been able to come together in person since the pandemic.

Income from gifts left in legacies, an area The Charity has been working hard to expand, almost doubled from 2021-22 to exceed £1m.

The main area where income was down year-on-year was from Major gifts. This was not a surprise since 2021-22 was an exceptional year having benefitted from £450k to fund a first-of-its-kind clinical trial.

The Charity once again received funding from the Medical Research Council, receiving £540k. The UK Government Covid Medical Research Charity Support Fund was to assist Charities funding medical research impacted by the COVID pandemic.



EXPENDITURE


Expenditure in the year increased to £11.2m at the Group level.

The Charity's primary objective is to fund quality research and we aim to spend half of our expenditure in this area as it is vital to us achieving our ambitious objectives. Expenditure on Research declined £1.4m, as described in the introduction to the Financial Review, £1.1m of this reduction was due to one research programme running behind schedule and not fully utilising awards made in previous periods.

Patient Support and Campaigning and Awareness expenditure increased by £1.0m year-on-year. £0.4m of the increase was due to a major awareness campaign, Better Safe than Tumour that was launched in the year. The goal of the campaign is to raise public awareness of the signs and symptoms of a brain tumour.

The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. For The Charity (excluding subsidiaries) we spent 80p in the pound in the year to March 2023 on its charitable objectives.

The largest increase in expenditure, at the Group level, was in Fundraising. Within Fundraising expenditure, £0.8m was in new, wholly owned, trading subsidiaries Acquist Data Holdings Limited, Acquist Data Limited, Medli Health Holding Ltd and Medli Health Ltd.



INVESTMENTS AND CASH

World stock markets continued to be volatile as they adjusted to the effects of the Russian invasion of Ukraine in February 2022 and to higher lending rates and inflation. At the end of the financial year The Charity's investments were valued

In 2022 The Charity embarked on a new investment with the primary objective to create a significant new income stream through the commercialisation of the Intellectual Property created within our BRIAN application.

New subsidiary entities were formed to appropriately manage this investment and the related new application development. The Charity funded the investment by way of intercompany loans in line with Charity Commission guidance.

In early 2023 development of the new application and platform, known as Medli, was completed and we were delighted to onboard its first client, Pancreatic Cancer UK.

As a result of slower than anticipated additional client onboarding, Management and the Board of Trustees have taken the decision to minimise any further investment into the Medli application and the related subsidiaries for the foreseeable future. In light of the uncertainty regarding future income opportunities from Medli, and in the interests of prudence, the intercompany loans between The Charity and its subsidiaries have been provided for as a potential bad debt as at 31 March 2023.

The Charity also has a trading subsidiary, TBTC Trading Limited. This subsidiary, which is wholly owned by the Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a profit of £12k which will be donated to The Charity.

at £13.9m a fall of £0.6m over the previous year, where we had budgeted for a £0.1m growth. All investments are held in highly liquid assets. Current forecasts do not expect the investments to need to be liquidated in the next twelve months as such short-term volatility in values is not considered a significant risk. Cash held as at 31 March 2023 was £4.6m.

RESERVES POLICY

The level of total Funds at 31 March 2023 was £8.2m, consisting of unrestricted general reserves of £3.9m, designated of £1.7m and restricted of £2.6m. Free reserves, defined as general reserves of £3.9m less functional fixed assets of £0.2m, were £3.7m.

The Charity's interim reserves policy, implemented due to the Covid pandemic, ended in March 2023 and so we have reverted back to the previous policy of maintaining unrestricted reserves in excess of six months' operational costs. As at 31 March 2023, unrestricted reserves, which comprise of General Reserve and Designated Funds totalled £5.7m and annual operational costs were estimated at £9.0 making the actual cover was 7.6 months. The purpose of this policy is to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments.

At 31 March 2023, we had unaccrued but committed research expenditure totalling £10.7m which was subject to the satisfying of our ongoing monitoring requirements and expected to fall due over the next five years. The investments and cash at 31 March 2023 (which are all liquid) were £18.4m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Evelyn Partners have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £13.8m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. The portfolio generated income of £383k and a valuation loss of £859k.

In addition to managed investment funds, the Trustees decided in the year to invest in commercialising the intellectual property and technology it had developed in creating BRIAN, The Charity's database tool. The Charity has formed new subsidiaries for this commercial venture and evaluates any investments being made on its financial return against an equivalent asset class.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have over one thousand active volunteers across the UK who support in different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

1. That we fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at least six months of reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.

2. That we are not able to commission enough high-quality research projects. We are developing our engagement with the brain tumour research community, and working to build capacity in the sector. We are also looking at alternative research models. In addition, we have extended funding globally and put significant emphasis on building relationships with key researchers.

3. That we are adversely affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective talent and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.

4. That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.

5. That we are the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres, and ensure that we have leading edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have cyber insurance policy.

GOING CONCERN

The Trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

OBJECTIVES FOR 2023-24

The Charity objectives remain aligned to its core values and our priority objectives for the year are:

- We will **accelerate cures for all brain tumours**.
- We will **drive the best lifelong care** across the UK, driving up the quality of treatment centres in the UK and empowering our community to share their experiences.
- We will **raise our global voices**, sharing evidence and platforms so passion and experience is amplified to support those affected, raise funds and drive progress.

In addition:

- Identifying the best global research to be funded through a new round of Research Grant funding.
- Plan and adapt The Charity so that we can deliver the goals of our new organisational strategy, Living Longer and Better, co-created as a community.

PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat brain tumours. We are investing time and effort on expanding our fundraising to grow and to provide income for years to come, money that will be used to fund our ambitious year-on-year investment in the best global research.

Our new strategy will guide us from 2023 to 2030 and will set our direction and the shape we need to become in future years.

THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research and began funding new projects again, as well as raising awareness and supporting thousands of people affected by a brain tumour.

This work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we cannot thank you enough for continuing to help us as we strive to defeat brain tumours!

In addition to the donors named below, we would like to thank all our anonymous donors.

TRUSTS

BBC Children in Need
St James's Place Charitable Foundation
The AOK Trust
The Colin Oliphant Charitable Trust
The Lewis Moody Foundation
The Syncona Foundation
The Reed Foundation
The Bert, Aase, Kevin and Jane Trust

FAMILY-LED CHARITY PARTNERS

Angel Child
James Clifford Campling Trust
Joss Searchlight
Nick's Fund
OSCAR'S Paediatric Brain Tumour Charity
The Brian Cross Memorial Trust
The Emily Morris Fund
The Oli Hilsdon Foundation

CORPORATES

Allports Group
Atrato Capital Limited
BECG Group
Bluecube
BPL Global
Business Design Centre
GlobalLogic
Gowling WLG
Hanne & Co Solicitors
JM Finn
K&L Gates
Knight Protection
Microsoft
Oddballs Apparel Ltd
Quirk Solutions
Salesforce
Underbelly
Team Lewis
Wickes

CO-FUNDING PARTNERS

Children with Cancer UK
CRUK
GOSHCC
Leeds Hospital Charity

PATRON

Earl Spencer

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Alastair Stewart OBE
Charly Clive
Dawn French
Dee Anderson
Dominic Matteo
Ella and Matt Mills (Deliciously Ella)
Guy Opperman MP
Hal Cruttenden
Holly Matthews
Ian Chillcott
James Jordan
Jason Durr
Jess Mills
Jonny Wilkinson CBE
Lewis Moody OBE and Annie Moody
Liam Conlon
Lorraine Kelly OBE
Marc Silk
Matt Allwright
Mel Giedroyc
The Neales
Nick Baines (Peanut – Kaiser Chiefs)
Nicki Chapman
Olivia Colman CBE
Owain Arthur
Philippa Forrester
Phil Spencer
Russell Watson
Sandy Lyle MBE
Sherrie Hewson
Sian Reese-Williams
Steve Backshall
Tchéky Karyo
Tim Burgess and The Charlatans
Tom Daley
The Wanted
Vicki Michelle

TRUSTEES AND GOVERNANCE

TRUSTEES

Jack Morris CBE
Anna Jarvis
Matimba Swana
Sukhdip Sandhu
Jessica Sass (resigned 21/09/23)
Dr Kieran Palmer
Hayley Conroy
Dr Russell Hagan
Caroline Steel
Dr Rachel Edgar
Sean Hird
Dr Elena Bechberger
Neil Dickson MBE
Justine McIlroy
Dr Alan Palmer
Simon Hay (resigned 21/09/23)
Beth Worrall (resigned 02/05/23
and reappointed 28/07/23)
Graham Norton (resigned 03/07/22)
Graham Lindsay (resigned 30/06/22)
Philippa Murray (resigned 15/09/22)
Berendina Norton MBE (resigned 15/09/22)

The directors and trustees had liability
insurance during the financial year.

CHIEF EXECUTIVE OFFICER

Alex Lochrane (appointed 24/01/2022,
resigned 01/07/2022)
Graham Norton (Interim CEO appointed
04/07/2022, resigned 02/05/2023)
Graham Lindsay (Deputy-Interim
CEO appointed 04/07/2022, resigned
02/05/2023)
Beth Worrall (Interim CEO appointed
02/05/2023, resigned 27/07/2023)
Dr. Michelle Afif (appointed 17/07/2023)

COMPANY SECRETARY

Liam Heffernan

CHARITY REGISTRATION NUMBERS

England and Wales 1150054
Scotland SC045081

COMPANY NUMBER

08266522

PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,
GU51 2UH

AUDITORS

Menzies LLP Magna House, 18-32 London
Road, Staines-Upon-Thames, TW18 4BP

BANKERS

Lloyds Bank Plc, 147 High Street,
Guildford, GU1 3AG

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon
Evelyn Partners, 25 Moorgate, London

RESEARCHERS IN OUR COMMUNITY

As well as members of our Scientific Advisory
Board (mentioned on page 34), these are
just some of the researchers providing an
ongoing contribution to our success.

Adel Samson
Alasdair Rooney
Anthony Byrne
Anthony Chalmers
Antoni Michalski
Chris Jones
Christopher Mount
Colin Kennedy
Colin Watts
Darren Hargrave
David Jones
Diane Puccetti
Gelareh Zadeh
Helen Hartley
Ingela Oberg
Jessica Taylor
Kirsty Maddock
Linda Dirvan
Linda Sharp
Louis Chesler
Lucy Stead
Mara De Martino
Marion Smits
Martin Taphoorn

Melanie Calvert
Michael Hawkins
Michael Jenkinson
Monika Hegi
Neil Carragher
Ola Rominiyi
Pamela Kearns
Paul Brennan
Paul Northcott
Petra Hamerlik
Philipp Euskirchen
Pim French
Rameen Beroukhim
Richard Gilbertson
Rohitashwa Sinha
Sara Melhuish
Sebastian Brandner
Simon Bailey
Simona Parrinello
Sophie Thomas
Spencer Watson
Steve Clifford
Steve Pollard
Stuart Smith
Susan Short
Thomas Wurdinger
Todd Hankinson
Tyler Miller
Veronica Rendo
Vincenzo D'Angiolella



BIOMEDICAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Richard Gilbertson
Professor Steve Clifford
Professor Colin Watts
Dr Susan Chang
Professor Simona Parrinello
Dr Paul Northcott
Professor Cynthia Hawkins
Dr Gerry Thompson
Dr Lucy Stead
Dr Marcel Kool
Dr Mark Gilbert
Dr Omer Bayraktar
Dr Phedias Diamandis
Dr Stephen Mack
Dr Adrienne Boire
Dr Duane Mitchell

INSTITUTION

The Cambridge Cancer Centre, UK
The Institute of Child Health, Newcastle University, UK
University of Birmingham, UK
University of California San Francisco, USA
University College London (UCL), UK
St Jude Children's Research Hospital, USA
The Hospital for Sick Children, Canada
University of Edinburgh, UK
University of Leeds, UK
German Cancer Research Centre, Germany
National Institutes of Health (NIH), USA
The Wellcome Trust Sanger Institute, UK
University of Toronto, Canada
St Jude Children's Research Hospital, USA
Memorial Sloan Kettering Cancer Center, USA
University of Florida, USA

PAEDIATRIC CLINICAL TRIAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Martin van den Bent
Dr Matthias Karajannis
Professor Arzu Onar-Thomas
Professor Michael Weller
Professor Jordan Hansford
Dr Jurgen Lemiere

INSTITUTION

Erasmus MC Cancer Center, Netherlands
Memorial Sloan Kettering Cancer Center, USA
St Jude Children's Research Hospital, USA
University Hospital Zurich, Switzerland
University of Adelaide, Australia
KU Leuven, Belgium

LAY ADVISORS

Ms Christina Brincat
Mrs Deborah Crossan
Mrs Rachel Rathbone
Ms Louise Webber-Edwards
Mr John Graham

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion
- Remuneration
- Technology Commercialisation
- Databank (BRIAN)

The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details are on the previous page.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and help the whole community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward on all areas of EDI within The Charity.

GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our new research strategy 'Accelerating a Cure' launched in 2021-22 as we aim to double survival and halve the harm caused by brain tumours. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical

Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We used the services of a professional third party fundraiser, Ethicall, during the year in a limited capacity to contact potential new donors. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

WORKING WITH PARTNERS

We are committed to working with all partners including those in the pharmaceutical and biotech industry in order to meet our objectives. We remain vigilant that our independence is not compromised and we act in the best interests of our community at all times.

STATEMENT OF THE TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including

FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland. Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 17 October 2023 and signed on their behalf by:



Jack Morris CBE
Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2023 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2023 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities section of our report. We are independent of the Group in accordance with the ethical requirements that are

relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.
- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.
- We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:
 - Posting of fraudulent journal entries
 - Posting of fraudulent payments and receipts in the accounting software
 - Authorisation, processing, and payment of fraudulent expenses
 - Fictitious employees
 - Timing of revenue recognition
- Audit procedures performed by the engagement team included:
 - Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
 - Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
 - Challenging assumptions and judgments made by management in its significant accounting estimates; and


- Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
- Carrying out checks to establish the validity of employees, and
- Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.



Janice Matthews
FCA (Senior statutory auditor)
for and on behalf of
Menzies LLP
Chartered Accountants
Statutory Auditor
Magna House
18-32 London Road
Staines-Upon-Thames
TW18 4BP

Date: 17/10/2023

CONSOLIDATED STATEMENT OF FINANCIAL
ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2023

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2023 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2022 £'000
Income and expenditure							
Income from:							
Donations and legacies	3	9,456	2,513	11,969	8,681	2,276	10,957
Other trading		284	79	363	161	32	193
Investments		383	-	383	325	-	325
Total income		10,123	2,592	12,715	9,167	2,308	11,475
Expenditure on:							
Raising funds		2,892	31	2,923	1,872	1	1,873
Charitable activities							
Research		2,293	2,482	4,775	4,038	2,172	6,210
Patient support		1,879	448	2,327	1,394	386	1,780
Campaigning & raising awareness		876	334	1,210	760	2	762
Total expenditure on charitable activities		5,048	3,264	8,312	6,192	2,560	8,752
Total expenditure	4	7,940	3,295	11,235	8,064	2,561	10,625
Net income before gains and losses on investment assets							
		2,183	(703)	1,480	1,103	(253)	850
Realised and unrealised gains on investment assets		(859)	-	(859)	(97)	-	(97)
Net movement in funds for the year		1,324	(703)	621	1,006	(253)	753
Reconciliation of funds							
Balances at 1 April		4,354	3,256	7,610	3,348	3,509	6,857
Balances at 31 March		5,678	2,553	8,231	4,354	3,256	7,610


The Statement of Financial Activities includes all gains and losses recognised in the year.
 All incoming resources and resources expended derive from continuing activities.
 The notes on pages 43–57 form part of these financial statements

CONSOLIDATED BALANCE SHEET
AS AT 31 MARCH 2023

Company number: 08266522

	Notes	Consolidated		Company	
		2023 £'000	2022 £'000	2023 £'000	2022 £'000
Fixed assets					
Intangible assets	10	7	15	7	15
Tangible assets	11	244	267	244	267
Investment in subsidiaries	12	-	-	-	-
Investments	12	13,838	14,536	13,838	14,536
Current assets					
Stock		34	6	-	-
Debtors	13	1,693	820	1,572	820
Cash at bank		4,566	5,240	4,551	5,239
		6,293	6,066	6,023	6,059
Creditors					
Amounts falling due within one year	14	(12,051)	(13,174)	(12,023)	(13,208)
Net current (liabilities)/ assets		(5,758)	(7,108)	(5,990)	(7,149)
Provision for liabilities					
	15	(100)	(100)	(100)	(100)
Net assets		8,231	7,610	8,089	7,569
Funds					
General reserve		3,985	2,662	3,843	2,621
Designated funds		1,693	1,692	1,693	1,692
Unrestricted funds		5,678	4,354	5,536	4,313
Restricted funds		2,553	3,256	2,553	3,256
	19	8,231	7,610	8,089	7,569

The financial statements were approved by the trustees on 17 October 2023 and signed on their behalf by:



Jack Morris CBE
 Chair of Trustees



Neil Dickson MBE
 Vice-Chair of Trustees

The notes on pages 43–57 form part of these financial statements.

CONSOLIDATED CASH FLOW FOR
THE YEAR ENDED 31 MARCH 2023

	2023 £'000	2022 £'000		
Net (expenditure) / income for the year (as per the statement of financial activities)				
Net income for the year	621	753		
Adjustments for:				
Depreciation	31	42		
Losses/ (gains) on investments	859	97		
Income from investments	(383)	(325)		
(Increase)/ decrease in stocks	(27)	2		
Decrease/ (increase) in debtors	(873)	(367)		
Increase / (decrease) in creditors	(1,123)	274		
Net cash (used in)/ provided by operating activities	(895)	(72)		
Statement of cash flows				
Cash flows from operating activities				
Net cash (used in)/ provided by operating activities	(895)	(72)		
Cash flows from investing activities:				
Dividends, interest and rents from investments	383	325		
Purchase of property plant & equipment	-	(10)		
Sale/(purchase) of investments	(162)	19		
Net cash provided by/ (used in) investing activities	221	334		
Change in cash and cash equivalents in the year				
	(674)	262		
Balances at 1 April	5,240	4,978		
Balances at 31 March	4,566	5,240		
Analysis of cash and cash equivalents				
Cash in hand	2,544	5,240		
Notice deposits (less than 3 months)	2,022	-		
Total cash and cash equivalents	4,566	5,240		
Analysis of changes in net debt				
	At 1 April 2022	Cash from purchase of investments	Other Cash flows	At 31 March 2023
Cash	5,240	(162)	(2,534)	2,544
Cash equivalents	-	-	2,022	2,022
Net debt	5,240	(162)	(512)	4,566

NOTES TO THE FINANCIAL STATEMENTS

1. STATEMENT OF COMPLIANCE

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 33. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. ACCOUNTING POLICIES

(a) basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertakings, TBTC Trading Ltd, Acquist Data Holdings Ltd, Acquist Data Ltd, Medli Health Holding Ltd and Medli Health Ltd have been consolidated on a line by line basis.

All Group companies prepare their accounts to 31 March. The results for Acquist Data Holdings Ltd (incorporated 3 March 2022), Acquist Data Ltd (incorporated 3 March 2022), Medli Health Holding Ltd (incorporated 21 September 2022) and Medli Health Ltd (incorporated 22 September 2022) are from their dates of incorporation to 31 March 2023.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £521,000 (2022: outgoing £733,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) Company status

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 32. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) Income

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) Expenditure

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

(e) Stocks

Stock is measured at the lower of cost and net realisable value.

(f) Fund accounting

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) Fixed assets

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) Estimated useful lives

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) Investments

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) Donated assets and services

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) Operating lease

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) Pensions

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) Financial instruments

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) Going concern

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. DONATIONS AND LEGACIES

	Unrestricted £'000	Restricted £'000	Total 2023 £'000	Unrestricted £'000	Restricted £'000	Total 2022 £'000
Ordinary activities:						
Regular giving	336	76	412	308	39	347
Donations, appeals and fundraising	7,201	1,780	8,981	6,756	1,949	8,705
Gift aid	970	47	1,017	815	45	860
Legacies	949	70	1,019	273	243	516
Government grants	-	540	540	529	-	529
	9,456	2,513	11,969	8,681	2,276	10,957

Government grants consist of amounts received under the Government Coronavirus Job Retention Scheme and the COVID Medical Research Charity Support Fund.

4. ANALYSIS OF RESOURCES EXPENDED

	Direct Costs £'000	Grants £'000	Support Costs £'000	2023 Total £'000
Raising funds	2,678	-	245	2,923
Charitable activities:				
Research	818	3,885	72	4,775
Patient support	2,204	-	123	2,327
Campaigning and raising awareness	1,104	-	106	1,210
Total expenditure on charitable activities	4,126	3,885	301	8,312
Total expenditure	6,804	3,885	546	11,235

	Direct Costs £'000	Grants £'000	Support Costs £'000	2022 Total £'000
Raising funds	1,721	-	152	1,873
Charitable activities:				
Research	1,086	5,079	46	6,210
Patient support	1,706	-	74	1,780
Campaigning and raising awareness	675	-	87	762
Total expenditure on charitable activities	3,466	5,079	207	8,752
Total expenditure	5,188	5,079	359	10,625

5. RESEARCH GRANT COST ANALYSIS

	2023 £'000	2022 £'000
Research programmes	2,002	3,640
Research projects	961	1,145
Clinical trials	909	299
Conferences	13	(5)
	3,885	5,079

A breakdown of research costs by individual award is provided in note 21.

6. SUPPORT COSTS BY ACTIVITY

2023	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	66	124	55	245
Charitable activities:				
Research	20	36	16	72
Patient support	33	63	28	124
Campaigning and raising awareness	29	53	23	105
2023 Total	148	276	122	546

2022	Finance and human resources £'000	Central facilities & information technology £'000	Central management & governance £'000	Total £'000
Raising funds	44	69	39	152
Charitable activities:				
Research	13	21	12	46
Patient support	21	34	19	74
Campaigning and raising awareness	25	39	23	87
2022 Total	103	163	93	359

Governance costs of £84,000 (2022: £65,000) are included in central management & governance.

7. GOVERNANCE COSTS

	2023 £'000	2022 £'000
Auditor's remuneration	27	15
Trustee meetings	3	-
Legal and professional fees	1	-
Staff	53	50
	84	65

In addition to Auditor’s remuneration for audit shown above, a further £1,210 was paid for accounting and tax advice. Trustees received no remuneration (2022: £nil). Trustees received no reimbursement for expenses in the year (2022: £nil). The premium in respect of professional liability insurance covering trustee indemnity was £4,511 (2022: £3,759).

8. STAFF COSTS

	Group		Company	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
Wages and salaries	3,496	2,776	3,391	2,776
Social security costs	335	223	321	223
Payments to defined contribution pension plans	272	223	272	223
	4,103	3,222	3,984	3,222

During the year redundancy payments were made totalling £3,000 (2022: £nil). At 31 March 2023 there was £nil provided (2022 £nil).

The average number of employees in the Group during the year was 100 (2022: 86).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2023	2022
£60,001 - £70,000	-	2
£70,001 - £80,000	2	1
£80,001 - £90,000	2	1
£90,001 - £100,000	-	-
£100,001 - £110,000	2	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £661,000 (2022: £453,000).

9. TAXATION

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. Subsidiaries in the Group donate any net trading profit to The Brain Tumour Charity and accordingly have no taxable income. No charge to taxation therefore arises.

10. INTANGIBLE FIXED ASSETS

	Computer Software £'000
Cost	
At 1 April 2022 and 31 March 2023	161
Depreciation	
At 1 April 2022	146
Charge for the year	8
At 31 March 2023	154
Net book value	
At 31 March 2023	7
At 31 March 2022	15

11. TANGIBLE FIXED ASSETS

	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2022 and 31 March 2023	292	174	466
Depreciation			
At 1 April 2022	34	165	199
Charge for the year	19	4	23
At 31 March 2023	53	169	222
Net book value			
At 31 March 2023	239	5	244
At 31 March 2022	258	9	267

12. INVESTMENTS

(a) Subsidiary Investment

Equity investment in group undertakings

Cost	£
At 1 April 2022	200
Additions	1
At 31 March 2023	201

The Charity formed two subsidiaries, Medli Health Holding Ltd and Medli Health Ltd on 21 and 22 September 2022 respectively, during the year. The Charity owns 100% of the £1 ordinary share capital of Medli Health Holding Ltd, a company incorporated in England and Wales, company number 14368728. Medli Health Holding Ltd owns 100% of Medli Health Limited, a company incorporated in England and Wales, company number 14371364.

The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holdings Ltd, a company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Ltd owns 100% of the £1 ordinary share capital of Acquist Data Ltd, a company incorporated in England and Wales, company number 13951572.

The purpose of the above companies is to commercialise intellectual property created in developing the BRIAN database, to generate income to be donated to The Charity.

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

The net trading profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2023 £'000	2022 £'000
Turnover	54	59
Cost of sales	(39)	(15)
Gross profit	15	44
Other operating expenses	(3)	(3)
Profit before donation	12	41
Donation	(41)	(21)
Retained profit/ (loss)	(29)	20

Cost of sales represent cost of stock sold in the year and the cost of fulfilment of orders.

At 31 March 2023 the aggregate assets of TBTC Trading Ltd were £41,000 (2022: £45,000), aggregate liabilities £29,000 (2022: £4,000) and shareholder’s funds £12,000 (2022: £41,000).

The net trading loss of Medli Health Ltd is as set out below.

	2023 £'000
Turnover	9
Expenditure	(776)
Retained (loss)	(767)

At 31 March 2023 the aggregate assets of Medli Health Ltd were £89,000, aggregate liabilities £856,000 and shareholder’s deficit £767,000.

(b) General investments

Equity investment in group undertakings

	2023 £'000	2022 £'000
At 1 April	14,536	14,652
Additions at cost	361	635
Disposals	(290)	(533)
Net unrealised (loss) on revaluation	(769)	(218)
At 31 March	13,838	14,536
Historical cost	12,298	12,306

	2023 £'000	2022 £'000
Investments at market value comprised:		
UK equities	3,234	3,236
Overseas equities	3,537	3,679
Absolute return funds	-	418
Property	206	124
Multi asset funds	766	509
Alternative investments	144	287
Fixed income securities	5,834	3,421
Cash held within the investment portfolios	116	2,862
Accrued income	1	-
At 31 March	13,838	14,536

During the year income from listed investments was £356,000 (2022: £324,000) and interest on deposits £27,000 (2022: £1,000).

13. DEBTORS

	Consolidated		Company	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
Trade debtors	715	373	715	373
Accrued income and prepayments	844	446	844	446
Other debtors	134	1	-	1
Amounts owed by Group companies	-	-	13	-
	1,693	820	1,572	820

14. CREDITORS

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2023 £302,000 (2022: £191,000) of income received in the year was deferred and £260,000 (2022: £357,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
Grants payable	11,410	12,650	11,410	12,650
Accruals and deferred income	372	381	366	378
Trade creditors	121	38	111	38
Other creditors	67	28	67	28
Social security and other taxes	81	77	69	76
Amounts owed to Group companies	-	-	-	38
	12,051	13,174	12,023	13,208

15. PROVISION FOR LIABILITIES

	Consolidated		Company	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
At 1 April and 31 March	100	100	100	100

The provision relates to the future cost of obligations under the terms of a property operating lease at Fleet27.

16. RESEARCH COMMITMENTS

At 31 March The Charity had authorised commitments that were subject to outstanding conditions expected to fall due as follows:

	2023 £'000	2022 £'000
Within one year	3,765	3,712
Between one and two years	3,101	2,768
Between two and three years	1,931	1,361
Between three and four years	1,846	134
Between four and five years	90	134
Five years and further	-	145
	10,733	8,254

The above commitments will be funded from reserves and future income.

17. OPERATING LEASE COMMITMENTS

The total of future minimum lease payments on operating leases are as follows:

Group and Company	On Property		On Equipment	
	2023 £'000	2022 £'000	2023 £'000	2022 £'000
Within one year	216	301	10	18
Between one and five years	685	1,182	38	21
	901	1,483	48	39
Operating lease charges in the year	211	57	15	19

18. ANALYSIS OF NET ASSETS BETWEEN FUNDS

	Unrestricted Funds £'000	Restricted Funds £'000	Total 2023 £'000
2023			
Intangible fixed assets	7	-	7
Tangible fixed assets	244	-	244
Investments	13,838	-	13,838
Other current assets	687	5,606	6,293
Liabilities	(9,098)	(3,053)	(12,151)
	5,678	2,553	8,231

	Unrestricted Funds £'000	Restricted Funds £'000	Total 2022 £'000
2022			
Intangible fixed assets	15	-	15
Tangible fixed assets	267	-	267
Investments	14,536	-	14,536
Other current assets	(887)	6,953	6,066
Liabilities	(9,577)	(3,697)	(13,274)
	4,354	3,256	7,610

19. FUNDS

	At 1 April 2022 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2023 £'000
Consolidated 2023						
Restricted funds:						
Research funds	2,198	1,482	(2,682)	171	-	1,169
Everest fund	-	545	200	-	-	745
Awareness funds	382	114	(337)	-	-	159
Support funds	675	451	(475)	(171)	-	480
	3,256	2,592	(3,295)	-	-	2,553
Unrestricted funds:						
General reserve	2,662	9,302	(7,120)	-	(859)	3,985
Designated funds	1,692	821	(820)	-	-	1,693
	4,354	10,123	(8,019)	-	(859)	5,678
	7,610	12,715	(11,235)	-	(859)	8,231

Company 2023	At 1 April 2022 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2023 £'000
Restricted funds:						
Research funds	2,198	1,482	(2,682)		-	1,169
Everest fund	-	545	200	171	-	745
Awareness funds	382	114	(337)	-	-	159
Support funds	675	451	(475)	(171)	-	480
	3,256	2,592	(3,295)	-	-	2,553
Unrestricted funds:				-		
General reserve	2,621	9,280	(7,198)	-	(859)	3,843
Designated funds	1,692	821	(820)	-	-	1,693
	4,313	10,101	(8,019)	-	(859)	5,536
	7,569	12,692	(11,313)	-	(859)	8,089

Consolidated 2022	At 1 April 2021 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2022 £'000
Restricted funds:					-	
Research funds	2,056	1,637	(1,495)	-	-	2,198
Everest fund	486	191	(677)	-	-	-
Awareness funds	383	2	(3)	-	-	382
Support funds	584	478	(387)	-	-	675
	3,509	2,309	(2,562)	-	-	3,256
Unrestricted funds:						
General reserve	1,752	8,112	(7,105)	-	(97)	2,662
Designated funds	1,596	1,054	(958)	-	-	1,692
	3,348	9,166	(8,063)	-	(97)	4,354
	6,857	11,475	(10,625)	-	(97)	7,610

Company 2022	At 1 April 2021 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2022 £'000
Restricted funds:						
Research funds	2,056	1,637	(1,495)	-	-	2,198
Everest fund	486	191	(677)	-	-	-
Awareness funds	383	2	(3)	-	-	382
Support funds	584	478	(387)	-	-	675
	3,509	2,308	(2,561)	-	-	3,256
Unrestricted funds:						
General reserve	1,731	8,053	(7,087)	21	(97)	2,621
Designated funds	1,596	1,054	(958)	-	-	1,692
	3,327	9,107	(8,046)	21	(97)	4,313
	6,836	11,416	(10,607)	21	(97)	7,569

PURPOSE OF RESTRICTED FUNDS

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 21.
Everest fund	During 2015/16 we received exceptional income of £2,890,000 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is Better Safe Than Tumour.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated funds represent accumulated net income raised by our supporters where they have expressed a preference over how the funds they raise should be spent. Preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. RELATED PARTIES

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2023 The Charity was owed £24,000 from TBTC Trading Ltd (2022: £38,000 owed to TBTC Trading Ltd).	• Was owed £nil from Acquist Data Holdings Ltd (2022: owed £100) • Was owed £199 (2022: £nil) from Medli Health Holding Ltd • Was owed £400,000 from Acquist Data Ltd in the form of an intercompany loan bearing interest at 3% above Bank of England base rate. • Was owed £500,000 from Medli Health Ltd in the form of an intercompany loan bearing interest at 3% above Bank of England base rate and owed Medli Health Ltd £10,282 on an intercompany balance
The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited.	
The Charity owns 1 of the issued £1 ordinary shares of Medli Health Holding Limited, a company with the same registered address as The Charity. Medli Health Holding Limited wholly owns the share capital of Medli Health Limited.	The Charity has created a bad dept provision in full for the intercompany loans payable by Acquist Data Ltd and Medli Health Ltd.
Acquist Data Limited was formed to commercialise the intellectual property developed by The Charity in creating its BRIAN app and database. During the year The Charity formed a new company, Medli Health Ltd to replace Acquist Data Ltd as a trading entity and Acquist transferred to Medli Health Ltd the costs it had incurred. At 31 March 2023 The Charity:	At 31 March 2023 Medli Health Ltd owed Acquist Data Ltd £345,958.
	Trustees, their close family members and entities they control, made donations to The Charity totalling £36,536 during the year (2022: £41,336) and paid contributions totalling £65 (2022: £381) during a number of our fundraising events.

21. RESEARCH AWARDS

	2023 £'000	2022 £'000
Programme - Chesler - ICR - Medullo super enhancers	-	308
Programme - Jones - DKFZ - Everest Centre	(200)	914
Programme - Kennedy - University Southampton - PNET5 QoL	46	45
Programme - Zadeh - University Health Network - Clinically aggressive meningiomas	-	130
Programme - Northcott - St Judes - MERIT	243	131
Programme - Hankinson - University Colorado - Adamantinomous craniopharyngioma	142	267
Programme - Parrinello - UCL - Mapping spatio-temporal heterogenity	374	357
Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC	302	299
Programme - Carragher - University Edinburgh - Therapeutic combinations in GBM	479	564
Programme - Quest for Cures 2019 - Chesler ICR	292	296
Programme - Quest for Cures 2019 - Beroukhim - Dana-Farber	324	329
Total Programmes	2,002	3,640
Project - Jones - ICR - Gene editing for DIPG - Billie Butterfly fund	(4)	-
Project - Sharp - Newcastle University - Self-supporting management for survivors	-	111
Project - Northcott - St Judes - Refining medullo in USA clinical trials	-	100
Project - Hawkins - Uni Birmingham - Combining child and young adult data for better monitoring	-	18
Project - Thomas - Nottingham Childrens' Hospital - AC therapy in young people	83	82
Project - Hegi - Lausanne - MGMT methylation	-	42
Project - Rominiyi - Sheffield - Ex-vivo 3D models	-	60
Project - Clinical Biomarkers 2019/2 - Zadeh - UHN	99	207
Project - Clinical Biomarkers 2019/2 - Euskirchen - Charite Hospital	96	96
Project - Expanding Theories 2019/2 - French - Erasmus	-	60
Project - Expanding Theories 2019/2 - Brandner - UCL	-	58
Project - Future Leaders 2019 - Croal - Nottingham	66	66
Project - Future Leaders 2019 - Watson - Lausanne	60	60
Project - Future Leaders 2019 - Miller - Massachusetts	60	60
Project - Future Leaders 2019 - Rendo - Dana-Farber	60	60
Project - Future Leaders 2022/3 - De Martino - New York	74	-
Project - Future Leaders 2022/3 - Taylor - Cambridge	67	-
Project - Future Leaders 2022/3 - Mount - Harvard Masschusetts - Enhancing CAR-T cell therapies for gliomas	75	-
Project - Future Leaders 2022/3 - Rominiyi - Sheffield	75	-
Project - Future Leaders 2022/3 - Alvarez-Prado - Lausanne	75	-
Project - Future Leaders 2022/3 - Vinel - London	75	-
Project - Quality of Life 2019 - Byrne - Cardiff	-	65
Total Projects	961	1,145
Clinical Trial - Watts - Birmingham - BRAIN-MATRIX	582	-
Clinical Trial - Kearns - University Birmingham - PNET5 CTU	44	44
Clinical Trial - HR-MB - Bailey - Newcastle	89	109
Clinical Trial - ARISTOCRAT - Short - Leeds	194	146
Total Clinical Trials	909	299
Conferences, workshops and other	13	(5)
	3,885	5,079

thebraintumourcharity.org

Registered office: Fleet 27, Rye Close,
Fleet, Hampshire, GU51 2UH
© The Brain Tumour Charity 2023.
Registered Charity in England and
Wales (1150054) and Scotland (SC045081).

The logo for The Brain Tumour Charity is displayed on a white, rounded rectangular background. It features the words "THE BRAIN TUMOUR CHARITY" in a bold, black, sans-serif font. The word "THE" is positioned above "BRAIN". The word "TUMOUR" is on the same line as "BRAIN", with a red exclamation mark replacing the letter "I". The word "CHARITY" is positioned below "TUMOUR".

**THE
BRAIN
TUMOUR
CHARITY**

THE BRAIN TUMOUR CHARITY

England & Wales - Charity number 1150054

Accounts

ANNUAL REPORT AND ACCOUNTS

2021-2022



**THE
BRAIN
TUMOUR
CHARITY**



CHAIR'S REPORT

First of all, may I start with a heartfelt thank you for standing with us over the past year.

This year has been one requiring resilience from us all – a year where the needs of families affected by a brain tumour have only been heightened. NHS and community resources are at full stretch, people are waiting longer to receive urgently needed care and valuable emotional support is in high demand.

Our response has been to turn to The Charity's greatest resource – you!

By joining together as a stronger, collective voice we've been able to create meaningful change, despite the challenging environment. Our voice is made of many remarkable people making individual differences. Some of you are highlighted in this Report – our inspiring new cohort of Young Ambassadors, our relentless founding Trustees and our indefatigable Head of Strategy – but standing with them are countless others similarly passionate about improving the outlook for families affected by brain tumours.

Despite the lasting effects of the pandemic and now the emerging cost of living crisis, the overwhelming generosity and incredible drive of the community means we've been able to meet the increased demand for our support services, continue to push for the best care everywhere and also begin funding new research projects again and start rebuilding our team.

This progress has not been easy. On behalf of my fellow Trustees, I would like to thank The Charity's leadership team – with particular thanks to our Interim CEO and Chief Scientific Officer, Dr David Jenkinson – for navigating us through this critical and challenging period. As David returns to his research role and we resume the search for a permanent CEO, I'm delighted and most grateful that two of our long-standing and highly experienced Trustees,

Graham Norton and Graham Lindsay, have stood down from the Board and stepped forward to give the leadership team their support as Interim CEO and Interim Deputy CEO, respectively.

We were saddened to hear of the death of The Charity's President Professor Sir Colin Blakemore in late June 2022. In 2011, Colin agreed to join Brain Tumour UK, one of the charities that merged to form The Brain Tumour Charity, and continued his work with The Charity after the merger. He always gave all his energy to the projects he was involved in and was particularly impactful in the early days of BRIAN, serving as the Chair of the Patient Mandate Group, steering the development of the app and access to data. Our thoughts are with his family and those who knew him.

Above all though, I want to thank you for standing alongside us through these difficult times, whether you're a fundraiser, a donor, a change maker or helping us defeat brain tumours in the lab or clinic.

Our goals remain ambitious – to double survival and halve the harm that brain tumours have on quality of life. Our growing union with you, our community, takes us closer towards these goals and enriches everything we do and I'm excited we're using this as a springboard to a better future by creating our next strategy together – *Beyond Brain Tumours*. It's not too late to join in and I look forward to continuing this work with you.

In the meantime, on behalf of all those affected, thank you again for the vital role you have played in helping us meet the challenges past, present and future.

I wish you a peaceful and hopeful year.

Jack Morris CBE
Chair of Trustees

CONTENTS

Report of the Trustees	3
a. Strategic Report	12
b. Statement of the Trustees' responsibilities	38
Independent auditor's report	39
Statement of financial activities	42
Balance sheet	43
Cash flow statement	44

YOUNG AMBASSADORS

In 2021, we were delighted to welcome our fourth cohort of Young Ambassadors to The Charity.

Our Young Ambassadors are an integral part of The Brain Tumour Charity, working tirelessly to raise awareness and create a better future for everyone affected by a brain tumour.

By sharing their deeply personal experiences of a brain tumour, they help us to better connect with those who come to us for support, especially other young adults, and help us encourage new supporters and Government officials to join our voices for change.

Our Young Ambassadors have also contributed their time and expertise by getting involved as we develop our new organisational strategy – *Beyond Brain Tumours*.

We consider ourselves fortunate to have their enthusiasm and deep commitment. We're always in awe of how they've reacted to the hardest life experiences by wanting to give their time and put other people first. We're eternally grateful for their involvement.



“

Losing my Mum to a brain tumour, at such a young age, has been the hardest thing I have ever had to face. I want to be a Young Ambassador to help provide support to others who have been through or are going through something similar. I want to not only help raise awareness of brain tumours, but also help to raise awareness of the effects that it has on the loved ones. I felt that I lost my Mum long before she passed, as her tumour changed her in many ways. I wish I had opened up more on how this affected me, so I would love to be a support to others going through this struggle.

Amy

“

My Dad unfortunately lost his 18-month battle with a grade 4 Glioblastoma last July. I witnessed first-hand just how debilitating this illness was for Dad, but in many ways, it was just as debilitating for my Mum, sisters and me too. Whilst it would be far too easy for me to dwell in bitterness, frustration and disappointment, I know that my Dad would not want this for me. Being a Young Ambassador means that I'm able to direct my energy into something positive whilst keeping the memory of the greatest man I've ever known alive.

Kajal

“

I wanted to become a Young Ambassador because I would like to become more confident in myself and also become more confident talking about my tumour and how it affects me. I would like to help The Charity as it has helped me so much. I would also like to campaign for better and faster treatment for people with low grade tumours like mine.

Kate

“

Being diagnosed with a brain tumour can be terrifying. However, having experienced the support The Brain Tumour Charity have to offer, I want to help them make a difference to others' lives in my role as a Young Ambassador.

Jazz

“

I became a Young Ambassador to be there for people and their loved ones who have been impacted by a brain tumour, as well as to help raise awareness for brain tumours (especially in the UK) because I know it is a problem, through personal experience. I believe my story has the potential to make an impact and I would like to get involved in campaigns that involve speaking to policy makers and the media about how to tackle brain tumour awareness and diagnosis.

Rhudi

“

I'm excited to become a Young Ambassador to support other young people who are affected by brain tumours. The research and support available now, compared to when I had my treatment ten years ago, is phenomenal, and I'm really looking forward to engaging with other young people going through similar experiences. I'm excited to get involved in lots of fundraising and awareness events and help raise the profile of research into brain tumours.

Rebecca

 [Meet our Young Ambassadors](#)



CEO'S REPORT

I would like to second Jack's thanks for your unwavering support during another challenging year.

We're all here for one simple reason – to improve the lives of the estimated 88,000¹ people living with a brain tumour in the UK. Over 12,000 more people face a brain tumour diagnosis each year and, despite momentum gathering from the threefold increase in research funding over the past decade², just 12% of those people survive more than five years (compared with an average across all cancers of 54%).³

It's important to remember that these aren't just numbers. The recent death of Tom Parker, less than 18 months after his diagnosis of a glioblastoma, shone a harsh light on the brutal reality behind these statistics. We know Tom's death hit the community hard as his story is reflective of so many of your experiences – demonstrating how far we still have left to go.

Highlights have included

- achieving record annual income of £11.5m (a growth of 38% from 2020/21) and reaching the incredible milestone of raising a total of £100m since The Charity was founded 25 years ago
- making significant improvements to our BRIAN app for its 7,000+ users, including making it easier for researchers to use BRIAN's data to accelerate a cure
- embedding our Improving Brain Tumour Care surveys in many neuroscience centres in the UK, helping to hold treatment centres accountable for gaps in care

- airing our first ever TV advert across the UK
- returning to holding in-person events, much to the relief of the community and our Events team.

Perhaps most exciting of all, we launched our forward-thinking new research strategy, *Accelerating a Cure*. It's impossible not to read this and be excited about our direction of travel.

And we still have so much ahead of us to look forward to! As I write, we're launching our long-awaited *Better Safe Than Tumour* campaign to raise awareness of common brain tumour signs and symptoms, building on the success of our *Headsmart* campaign.

We're also deep into the process of engaging our UK and wider community in co-creating our next organisational strategy, *Beyond Brain Tumours*. This is a natural evolution of our focus on individuals, their needs and how we can move further, faster when we join together – but it feels more like a revolution! We've already brought together over 1,000 people from across the brain tumour community and there's still time for you to join us.

It's been a busy year for The Charity, regrouping after the pandemic and rebuilding our foundations stronger than ever. With you at our side, we're ready to face whatever the future holds, resolute in our aim to double survival and halve the harm that brain tumours have on quality of life.

Thank you for making a difference and please continue to add your voice for change.

Graham Norton
Interim CEO

OUR GOALS AND VALUES

OUR GOALS

Our vision is for a world where brain tumours are defeated and our goals are our blueprint for getting there. Simply put, if something doesn't help us achieve one of these goals, we know that it's not the right direction for us.

We've set ourselves goals that are unashamedly ambitious as this is the only way we'll see a real and last difference. We want to:

- double survival in the UK
- halve the harm that brain tumours have on quality of life in the UK

OUR VALUES

Our values underpin everything that we do, they define what we believe and guide our actions every day.

The way we work is always:

PIONEERING

We're relentless and courageous in the pursuit of our vision, seeking new ways to make a difference.

PASSIONATE

People are at the heart of everything we do. We're passionate about finding a cure and ensuring everyone affected by a brain tumour has the highest quality of life and chance of survival.

COLLABORATIVE

We'll only achieve our vision by building networks, partnerships and a strong community of people affected by a brain tumour. We collaborate and value everyone's contribution.

SMART

We're focused and intelligent in our approach to defeating brain tumours.

for every £1 we spent in 2021/22,

82p

was spent on charitable activities

for every £1 we spent in 2021/22 more than,

50%+

was spent on research

¹ TBTC estimate 2019, based on published survival rates and incidence from cancer registry data for England, Northern Ireland, Wales and Scotland.

² NCRI tables plus TBTC research spend (from our Annual reports). NCRI data: Cancer Research Spend Data Package 2019 Final [Internet]. Accessed 2020. Available from: <http://www.ncri.org.uk/what-we-do/research-database/>

³ Cancer Research UK, <https://www.cancerresearchuk.org/health-professional/cancer-statistics/statistics-by-cancer-type/brain-other-cns-and-intracranial-tumours/incidence>, Accessed April 2022

CLARE NORMAND, OUR HEAD OF STRATEGY, HONoured WITH OBE

Clare has been at the heart of The Charity since she joined the team in 2012 and runs a supporter group, The Alec Normand Fund, in memory of her son.



Clare's amazing work was recognised in the 2021 New Year's Honours list when she was awarded an OBE for her services to brain tumour charities. She's been at the heart of The Charity leadership team since 2012, leading on our strategy and making sure we hold ourselves accountable for progress and impact.

Clare began supporting The Samantha Dickson Brain Tumour Trust (now The Brain Tumour Charity) in 2007, after her nine-year-old son, Alec, was diagnosed with an inoperable brain tumour.

Alec tragically passed away just ten months after his diagnosis.

Since then, Clare, her husband Christopher, and their two other children – Oliver and Ursie – have been responsible for raising almost £700,000 for The Alec Normand Fund.

Clare was the driving force behind the ambitious *Defeating Brain Tumours* strategy that saw The Charity invest £38m towards research into brain tumours between 2015 and 2020 – nearly double our target of investing £20m during that period.

Always mindful that our greatest resource is the passionate brain tumour community, Clare masterminded our transitional *Leaning In* strategy that allowed The Charity to respond to the COVID-19 crisis by drawing on our strengths and leaning into the community to maximise the impact we can have together.

Now, Clare is making sure our next strategy, *Beyond Brain Tumours*, is truly led by the needs of the community through a process called co-creation – something that very few charities have attempted at this scale. Over 1,000 people have already contributed their insight, time and work to the new strategy. This diverse mix of people includes those personally affected by the disease, brain tumour researchers, healthcare professionals and other charities that are committed to defeating brain tumours.

Clare said, "Singling me out for an OBE must be put in context: my whole family has shared the loss of Alec and has given me the space over the last few years to pursue the promise he asked of us to stop this happening to others; there are countless families that have been devastated by the effects of a brain tumour; and there are hundreds of other people working tirelessly to find a cure for brain tumours.

"In accepting this honour, I consider myself to be a representative of all of them, and I hope this public recognition of our combined efforts will inspire further support."

In response to the news, our CEO said: "Clare has been instrumental in developing our strategy, shaping us into the world-leading charity that we are today.

"Her exceptional talent, drive and compassion, going above and beyond in everything she does, has played a key part in the growth in income and impact of The Brain Tumour Charity over the years. She continues to be a beacon of support and inspiration to so many in our community affected by a brain tumour diagnosis.

"I have worked with Clare for almost six years and I see her as the beating heart of The Charity. She is the very embodiment of our values, being supremely passionate, pioneering, smart and collaborative in everything she does. She brings a real inventiveness to our work combined with high levels of intellectual rigour, all delivered with her overwhelming generosity of spirit and personality."

David Jenkinson
Chief Scientific Officer,
past Interim CEO
(Jan 2021 – Jan 2022).

“

Her exceptional talent, drive and compassion, going above and beyond in everything she does, has played a key part in the growth in income and impact of The Brain Tumour Charity over the years.


OUR OBJECTIVES AND ACTIVITIES

The objectives of The Charity are to provide public benefit by:

- relieving sickness and protecting good health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain and central nervous system
- relieving the suffering of people with tumours of the brain and central nervous system, their families and carers, through the provision of information and support
- advancing the education of the public in all areas relating to tumours of the brain and central nervous system

PUBLIC BENEFIT STATEMENT

The Trustees have considered the Charity Commission’s general guidance on public benefit and have taken it into account when reviewing The Charity’s aims and objectives and in planning its future activities. The Trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.



DEFEATING BRAIN TUMOURS: LEANING IN

COVID-19 had a major impact on those with brain tumours, on brain tumour care, on the pace of research and on our own resources.

In order to support the community’s heightened needs through the pandemic and beyond, we developed a short-term strategy for 2021/22 that empowered us to do more with fewer resources available by leaning into our strengths, becoming a more flexible organisation and involving the community at every opportunity.

To do this, as well as make sure we’re in the best possible position to accelerate a cure in a much-changed post-pandemic world, this strategy was built around four pillars of work:

Power of Data

We’ll harness the power of data to accelerate research, tackle inequality, inform change, empower our community and maximise our impact.

Best Care Everywhere

We’ll drive the best care everywhere across the UK, empowering the community to access high levels of care no matter where they’re located and helping treatment centres reach the highest possible standards.

Voices for Change

We’ll empower everybody affected by a brain tumour to become a voice for change, giving the community everything they need to drive progress – whether they’re fundraisers or change makers.

Make it Count

We’ll use our resources, skills and technology efficiently and effectively to make sure we maximise our impact with minimal resources.

THE GIFT OF TIME

Watch the video here

In December 2021, The Charity launched our first ever TV advert based on the powerful and emotive short film created by our partner Runningman Two for our Winter Appeal.

The film was based on the idea that the best gift that families affected by a brain tumour could possibly receive is the gift of more time together.

Tom Buckley, a producer at Runningman Two, drew on his own experiences of a loved one being diagnosed with a brain tumour to bring the idea to life in a way that deeply resonated with the community.

The Winter Appeal was a huge success and as well as increasing the reach of the brand by appearing on TV screens across the UK over the festive period, we managed to raise over £225,000!

“ Being someone who is part of a family that has been directly affected by a brain tumour diagnosis at Christmas time; this campaign was close to me on a personal level.

I hate the idea of anyone else having to go through what we have in the Buckley family – I wanted to raise as much money as possible for this amazing cause.

Tom Buckley
Producer at Runningman Two



STRATEGIC REPORT

THE POWER OF DATA

We'll harness the power of data to conquer our goals of doubling survival and halving the harm caused by brain tumours.

Remaining evidence-led, we'll gather and analyse data and knowledge from reputable sources, including our pioneering BRIAN app and databank; experts by experience and those personally affected; government sources; research publications and other reliable sources.

We'll use these insights to tackle inequality, inform change and help those affected by a brain tumour make the right choices.

HIGHLIGHTS OF 2021/22

TAKING BRIAN TO THE NEXT LEVEL

Our BRIAN (the Brain tumouR Information and Analysis Network) project continues to go from strength to strength. We smashed our target of having 5,000 registered BRIAN users by the end of 2021/22, nearly doubling the number of BRIAN users from 3,800 to 7,200 users.

We're determined that the development of our BRIAN app will always be led by those who use it, so we regularly meet with BRIAN users and Young Ambassadors to get their thoughts – as well as running feedback surveys so every user can have a voice.

This led to an overhaul of the mobile app's interface in 2022, resulting in a new and improved user experience. We also built, tested and released two new features, the Seizure Tracker and Clinical Trial Link, that help better support the community and make it easier for researchers to collect the data they need for studies.

The Seizure Tracker allows users to record the type, time and duration of their seizures, which can then be shared with their clinicians.

7,200

registered BRIAN users

The Clinical Trial Link allows researchers to collect data from consenting clinical trial participants through BRIAN. This makes it easier for researchers to securely collect data, which is ring-fenced from the general data analysis in BRIAN until the trial has been completed and the results have been reported.

As part of the project, we received a refresh of data from both NHS Digital and Public Health England. In combination with our access to data from Scotland, Wales and Northern Ireland, this has allowed us to increase the number of insights available from 8 to 35. This is particularly significant as it now empowers the community in the devolved nations to understand their own treatment and care in relation to others in their home country.

IMPROVING SAFE AND SECURE ACCESS TO DATA

Making it easier for researchers to safely and securely access the data collected by BRIAN is key to our strategy for defeating brain tumours.

To help speed up the process of data access and make it easier for researchers to find the data they need we've been working with Health Data Research UK (HDRUK) to register BRIAN on their Innovation Gateway. As part of this process, we compiled the metadata in BRIAN to allow researchers to quickly understand what data is available and this was given the gold standard by HDRUK. We've also begun to explore moving access requests to the HDRUK platform, which will allow us to link into the national data usage register it curates and help ensure transparency around how the data is used.

To further enhance this process, we've explored the use of a Trusted Research Environment (TRE). A TRE makes it possible to give researchers access to the parts of the data they need to conduct their analyses without sharing the entire BRIAN dataset with them. This will significantly enhance the security of the data and

should reduce delays in granting access to researchers. After a rigorous selection process, we're now working to integrate our chosen TRE with BRIAN and transfer the data to it.

Ensuring the security of both the app and the data stored within BRIAN is a top priority for The Charity and in the past year the app was reviewed by ORCHA – the global leader in providing access to trusted digital health.

After being given a massive 92% rating, BRIAN is now in the top six apps in ORCHA's app library and is its top-rated cancer app.

92%

ORCHA rating for BRIAN

NHS Digital also performed its annual audit of our processes and data security. BRIAN was once again rated in the top category as being a low risk to the security of the NHS data or improper usage.



FUNDING NEW RESEARCH

The huge financial impact of the pandemic hit The Charity hard and we had to make the difficult decision to pause funding new research to make sure we were able to protect the projects we'd already pledged to support.

This year, once it became clear that income was recovering, we were excited to be able to return to new grant funding for research.

We progressed three grant calls during the year, with our Future Leaders programme opening for the third cohort of applicants. We look forward to selecting the successful applicants later in 2022.

We also began undertaking a review of our funding to the Everest Centre for Paediatric Low Grade Glioma as it nears its five-year anniversary. The work from the centre was integral to the new classification of brain tumours, released by the World Health Organisation in December 2021.

This classification includes the use of methylation, small marks on the DNA of cells telling them which genes to use and which to switch off, to assist pathologists. The Everest team pioneered this technology and made major contributions to the new system, along with several of our other funded researchers.

LAUNCHING OUR NEW RESEARCH STRATEGY

In late 2021, to help facilitate our return to traditional grant funding, we published our new research strategy - *Accelerating a Cure*.

Like everything we do, the development of *Accelerating a Cure* was led by the community. We consulted with people personally affected by brain tumours, leading researchers in the field and innovators from beyond the sector.

While groundwork for the strategy had mostly been completed pre-pandemic, we were able to take everything we've learned from operating through the COVID-19 crisis and use that knowledge to ensure *Accelerating a Cure* would be successful in the much-changed post-pandemic research landscape.

Accelerating a Cure builds on the incredible progress we made during our previous research strategy, *A Cure Can't Wait*, while identifying areas that need extra work to improve. **Key to this will be kick-starting translational research to ensure our world-class discovery research is used to develop new treatments for those living with a brain tumour.**

The community's voice will play a central role in our new approach to research that aims to enhance quality of life. We plan on working closely with the Tessa Jowell Brain Cancer Mission to validate areas of best practice around the neuroscience centres in the UK and provide evidence to ensure those practices are adopted widely.

 You can read more about [*Accelerating a Cure*](#) here.

“

Thank you, on behalf of all of us touched by this brutal disease. We're proud of having shaped the ambition and direction of *Accelerating a Cure* as a springboard for improving the future for those with brain tumours. Please get involved and help us go further, faster!

The Involvement Network

CELEBRATING OUR FOUNDERS

In November 2021, we welcomed our Founders, Neil and Angela Dickson MBE, to our new offices to celebrate everything that's been achieved in the 25 years since they founded The Samantha Dickson Research Trust.

Neil and Angela founded The Trust, which would later become known as The Brain Tumour Charity, in memory of their daughter Samantha, who passed away from a rare form of glioma when she was just 16.

"For everything that Neil and Angela have done over the 25 years, for everything they've done for the charity, our sincere and heartfelt thanks. They've helped us to make an impact to change the way people are being treated, being supported and an impact to change the future for everyone affected by a brain tumour diagnosis."

Dr David Jenkinson
Chief Scientific Officer, past Interim CEO
(Jan 2021 – Jan 2022)

"When we first set up The Charity, initially in our daughter's name, we never thought we would have achieved so much, and part of this is the fact that so little was being done for this disease. Brain tumours reduce average life expectancy by 27 years – by far the highest burden of any cancer or major disease.

"We have helped extend average life expectancy by 15 months (5%) for those with brain cancer, amongst the highest increase of any major disease or cancer since 2010."

Angela Dickson MBE
Founder



BEST CARE EVERYWHERE

We'll continue to drive the best care across all treatment centres in the UK to achieve our goal of everybody receiving consistently excellent care – no matter where they live or what kind of tumour they're diagnosed with.

By empowering the community to share their experiences of receiving treatment and care, we ensure the patient voice plays a key role in levelling up care. By working directly with healthcare professionals and the Tessa Jowell Brain Cancer Mission, we provide treatment centres with the tools they need to improve standards.

And, where there are gaps in care that can't currently be filled, we'll strive to provide services that ensure the community have their needs met.

HIGHLIGHTS OF 2021/22

CONTINUING TO MEET THE GROWING DEMAND FOR OUR SUPPORT SERVICES

Throughout 2021/22, we saw a continued increase in demand for our support services. Our Support and Information Line delivered 27% more support than the previous year and we supported 11,300 people on a one-to-one basis – up 9% on the previous year. We also had around 1.3m support seekers visiting our website for help this year.

1.3M

support seekers visiting our website for help

Our Online Brain Tumour Support Groups grew 21% this year to over 24,000 members. These groups are invaluable because they're a safe space to ask questions and receive advice at all hours of the day – as well as empowering people to support each other. They also help create a much-needed sense of community, connecting people affected by a brain tumour with others who share their experiences at a time when they can often feel most isolated and alone.

11,300

people supported one-to-one

It's only thanks to the incredible support we receive from our volunteer community that we've been able to manage this increased demand for our services. Well-trained and fully supported volunteers now triage every call to our Support and Information Line, help moderate our thriving Online Brain Tumour Support Groups and work collaboratively with us to create resources for the community.

24,000

24,000+ members of our Online Brain Tumour Support Groups

AMPLIFYING THE COMMUNITY'S VOICE TO MAKE MEANINGFUL CHANGES IN CARE

We've continued to empower the community to have their voices heard through our Improving Brain Tumour Care surveys and in September 2021, we began the latest round of analysis on just under 1,500 completed surveys.

Thanks to the community sharing where they were receiving best care and where there were gaps, we were able to send patient feedback reports to 25 of the 30 adult neuroscience centres in the UK to help those centres improve treatment and care.

25/30

neuroscience centres received feedback reports on their standard of care

These surveys are also the patient voice in the assessment of neuroscience centres for Tessa Jowell Centres of Excellence accreditation and 17 of the 30 adult neuroscience centres in the UK are now recognised as Centres of Excellence.

This is making a tangible difference to care, with many centres adding Clinical Nurse Specialist and Allied Health Professional posts in response to gaps identified in the Improving Brain Tumour Care surveys. Some centres have also been able to make successful business cases for other improvements using the evidence of what other centres have in place and what the community says is a shortfall.

17/30

neuroscience centres recognised as Centres of Excellence

Before COVID, we were funding CNS low grade posts to improve provision, but this patient and clinical-led assessment of excellence is proving to be a far more effective, scalable and sustainable way of bringing new investment and making change.

The Improving Brain Tumour Care surveys have also identified huge differences in people's experiences depending on where they received treatment from and whether they have a high grade or low grade tumour, as well as gaps in care across the UK.

This is unacceptable and we're working to close those gaps by sharing best practice across the Tessa Jowell Centres of Excellence, as well as with the neuroscience centres who haven't yet achieved that accreditation – as well as developing solutions to fix problems that continue to persist.

We submitted patient-led evidence to eight policy consultations across the UK, ensuring that better access to a CNS or key worker was recognised by the National Institute for Health and Care Excellence (NICE) as a priority area for improvement in its new Quality Standard on brain tumours in England.

We also presented key evidence from our Improving Brain Tumour Care surveys in Parliament to the All-Party Parliamentary Group on Brain Tumours. This ensured the findings from the survey were included in the Health and Social Care Select Committee's Report on progress towards the Government's cancer ambitions.

SUPPORTING HEALTHCARE PROFESSIONALS

As well as highlighting the gaps in care, we're also helping to close them with practical solutions.

In 2021/22 we trained 6,141 optical professionals to spot the signs and symptoms of a brain tumour more effectively. As we launch our *Better Safe than Tumour* campaign to drive earlier diagnosis, we'll be actively growing our healthcare engagement work to support this aim of reducing diagnosis times for adults and children.

6,141

optical professionals trained

Our BRIAN app is helping healthcare professionals offer more proactive care to patients and is now embedded in the pathway of four neuroscience centres. We've already heard stories of Clinical Nurse Specialist teams who prevented an unplanned admission because they contacted a patient when they saw their well-being scores dropping.

We were also made aware of a case where an individual was using BRIAN to record his seizures following treatment for a glioblastoma, after being introduced to the app by his Clinical Nurse Specialist. It was only via the app that this individual was identifying "brain fog" lasting for a few minutes and after showing his neurologist, his anti-epileptic medication was increased and no further episodes were recorded.

A new BRIAN feature aimed towards closing gaps in care has been in development this year, after consultation with our community of healthcare professionals. The My Support Plan feature is a Holistic Needs Assessment (HNA) and support planning tool, which directly answers the lack of HNA provision identified through the Improving Brain Tumour Care surveys as a gap in care that exists across the UK.



AN AWARD-WINNING PARTNERSHIP



We were delighted to accept Marketing Partnership of the Year at the Third Sector Business Charity Awards for an innovative project built with the help of 650 hours of time donated by the team at Salesforce Marketing Cloud for Nonprofits.

Marketing Cloud led a project to redefine our supporter experience, transforming how we understand and talk to our supporters. The project included data analysis, collaborative workshops and training sessions - ultimately delivering a new audience segmentation model and pilot campaign - featuring Young Ambassador Jeremy Daubeney and his Tour de Full English cycle challenge around Britain!

The campaign was a great success, but this is just the start! The true value of the partnership will be many times greater as we use the new approach to better communicate with all our supporters - improving their experiences, bringing them into the community and deepening their long term relationship with The Charity.

"The Team at Salesforce.org have been absolutely awesome; they kept us focused and helped us maximise the benefits of Marketing Cloud.

"We wanted to build a test-and-learn culture with a common language and they gave us that with a blueprint for future activity.

"We wanted to create and launch a new campaign and with their help, guidance and encouragement, we did.

"The team were with us every step of the way with practical advice, brilliant workshops, focused team training and advice on how to optimise our model.

"I never believed we could build something so creative and so practical in such a short space of time - we cannot thank them enough!"

Gina Almond
Director of Fundraising and Marketing

VOICES FOR CHANGE

We'll galvanise those who have the motivation, but not necessarily the means, to become a voice for change by giving the community the resources, knowledge, platforms and tools, they need to engage and help tackle the inequalities faced by those affected by brain tumours.

HIGHLIGHTS OF 2021/22

ACHIEVING RECORD-BREAKING INCOME

2021/22 was wildly successful from a fundraising perspective, as we managed to bring in an incredible £11.5m. This was The Charity's highest ever yearly income and an increase of 38% on the previous year. Without the financial support of our generous and dedicated community we couldn't continue our vital work. We'd especially like to shout out our major donors, who contributed a remarkable £2m to our record-breaking income.

£11.5M

raised in 2021/22

Unsurprisingly, our income from events suffered hugely during the pandemic, but in 2021/22 we returned to running in-person events, as well as utilising hybrid events to huge success. COVID restrictions meant we couldn't run a full calendar of events but our amazing supporters helped us bounce back and many events performed better than previous years.

A real highlight was the Virgin Money London Marathon in October 2021 – our most successful yet! 100 of our supporters laced

up their running shoes and took to the streets to support The Charity, raising an astonishing £435,169 and covering a whopping 2,620 miles.

We also celebrated two major milestones that were achieved this year by organisations who've been long-term supporters of The Charity and have played key roles in our success.

For 10 years, our corporate partner Bluecube Technology Solutions have been making sure our team stays connected to each other and the community. This year, the technical expertise they provide, combined with tremendous support for our matched-funding appeals, has surpassed a whopping £1m.

We can't possibly overemphasise how important their support has been. By making sure we have access to high-quality, reliable, efficient and safe IT systems and services, they've empowered The Charity to grow and increase the scale of our work. This was especially important during the pandemic, allowing us to seamlessly transition to working from home and continue to support the community.

Since 2014, ex-England Rugby Captain Lewis Moody has gone to some extreme lengths to tackle brain tumours – including cycling through rainforests and trekking to both the North and South Poles. In 2021/22, the World Cup winner achieved yet another historic milestone as The Lewis Moody Foundation celebrated raising a total of £2 million to help defeat brain tumours!

Lewis and his wife, Annie, were inspired to launch The Lewis Moody Foundation after they met the incredible Joss Rowley Stark in 2012. Sadly, Joss passed away in 2013 after a battle with a rare form of cancer and The Foundation was created in 2014 in his memory.

We're so proud of what Lewis, Annie and their amazing supporters have been able to achieve in raising funds for pioneering research and vital support services facilitated by The Charity.

FORGING AN AWARD-WINNING PARTNERSHIP

For several months and 650 hours of gifted time, The Charity worked with Salesforce Marketing Cloud for Nonprofits to create an audience segmentation model and automated journeys for our supporters to ensure they have the best possible experience.

The rich and moving content was built with one of our Young Ambassadors, Jeremy Daubeney, and resulted in an increase in donations, an increase in engagement with our content and a doubling in the average gift.

This is a major shift in digital delivery for The Charity as we move from product-led campaigns to audience led-campaigns. This amazing project also resulted in an award for Marketing Partnership of the Year at the *Third Sector Business Charity Awards*.

LIVING UP TO OUR VALUES AS PIONEERS

With the help and support of the community, we were also able to try some exciting new things this year.

In December 2021, we launched our first ever TV advert in support of our Christmas appeal. The advert was based on the powerful and emotive *The Gift of Time* animation that was gifted to us by our partner Runningman Two. It appeared across a wide range of TV channels during the holidays and was extremely well received.

As well as giving us the opportunity to dip our toes into the exciting waters of advertising on TV for the first time, it also enabled us to enhance our ability to receive donations via SMS.

After consultation with our Supporter Groups and family-led charities, we also launched our CREATE design platform that empowers the community to produce their own fundraising and awareness materials using our design assets.

Throughout 2021/22 we also developed two new campaigns that will launch in the summer of 2022, our Win Big Weekly Lottery and our long-awaited signs and symptoms campaign – *Better Safe Than Tumour*.

Better Safe than Tumour will build on our successful Headsmart campaign and expand upon it to cover adult signs and symptoms too. We look forward to the community seeing this new campaign and helping us spread it far and wide across all channels.



CELEBRATING OUR CELEBRITY SUPPORTERS

We owe our celebrity supporters a great deal of thanks for helping us raise funds and spread awareness of the cause.

We'd especially like to express our gratitude to Peter Kay for coming out of retirement to do a show in support of our very own Young Ambassador, Laura Nuttall. We'd also like to thank Tom Daley for his continued support and TikTok knitting antics.

We'd also like to thank Nicki Chapman for her continued support and championing of our work in the media, and for being a much-loved inspiration to so many other people affected by brain a tumour.

We, along with the entire community, were deeply saddened by the passing of Tom Parker in March 2022. We're so grateful for everything he and his loved ones did, and are continuing to do, to help improve the world for those affected by a brain tumour.

REACHING AND MOBILISING MORE VOICES FOR CHANGE

This year, we were delighted to significantly raise The Charity's profile by securing over 50% more media coverage compared to 2019/20. This has provided a boost in public awareness of the research we fund, the support services we provide, how we're campaigning for change and the ways we're raising money to help defeat brain tumours sooner.

We were so grateful to see over 400 people take action this year to become voices for change – including those personally affected by brain tumours, parliamentarians and celebrity supporters. Thanks to the amazing support take action to be voices for change on brain tumours.

Thanks to the incredible support we've received from our campaigners and Young Ambassadors, we were also able to host our first parliamentary drop-in event since the pandemic began. We shared key issues affecting the community with over 50 parliamentarians and were able to publically get their support.

A huge thank you to Tom, his wife Kelsey and his band members in The Wanted, for their generosity in gifting us £1 from every ticket sale to their Most Wanted UK tour – as well as to Jay, Max, Nathan, Siva,

everyone at The Wanted and Island Records and the song's writers and producers for generously donating all net proceeds for the first 12 months from sales of the single they released in Tom's memory – 'Forever Gold (for Tom)'.

And finally, our Head of Strategy, the indefatigable Clare Normand was honoured with an OBE this year for her work on behalf of The Alec Normand Fund and The Brain Tumour Charity.

MAKING SURE THE COMMUNITY'S VOICE IS PRESENT IN EVERYTHING WE DO

We now have over 1,300 people in our Involvement Network and through this group we're able to ensure the community's voice is present in everything we do. Led by 20 Involvement Champions, the Involvement Network have a say in helping us develop new services, resources, products and campaigns.

The absolute proof that everything we do is now driven by the community is that we've begun co-creating our entire new organisational strategy, *Beyond Brain Tumours*, as a community.

And we aren't just paying lip service to getting the community involved in developing the new strategy.

In fact, over 1,000 people have contributed so far, with a volunteer and staff team working group being guided by a steering group that includes those personally affected by a brain tumour, researchers, healthcare professionals and other brain tumour charities, including international charities.

"This idea for developing the strategy, an approach called 'Co-Creation', is a new and highly ambitious way to designing the path forward for The Charity.

It will be both challenging and, hopefully, extremely rewarding and successful. The Brain Tumour Charity has never tried this before – indeed, few organisations have – but it has the potential to be a very powerful process creating a strategy which the whole brain tumour community has contributed to, is aligned with and invested in."

Neil Munn

Involvement Champion and Co-Creator of *Beyond Brain Tumours*

BRINGING OUR TEAM BACK TOGETHER

In September 2021 we were able to hold our first full in-person Team Day for 18 months, which served as a fantastic opportunity to reconnect after so much time apart.

The aim of the day was to focus on the challenges facing the community, get the entire team involved with the development of our new strategy and get us all thinking about the role we're going to play in driving future change.

We were delighted to be joined by a diverse mix of speakers from the community, including those living with a brain tumour, carers and healthcare professionals.

Feedback from the event has been overwhelmingly positive, with over 95% of the team reporting feeling motivated and inspired as a result of attending.

“

It was so good to come together as a team, cement why we do what we do and celebrate our achievements.



MAKE IT COUNT

Due to the impact of the pandemic, we need to work even more efficiently, as a smaller and more adaptable charity.

We'll sustain our team culture and keep our commitment to defeating brain tumours by reallocating our time and resources – including streamlining the processes and technology we use.

HIGHLIGHTS OF 2021/22

ADAPTING TO A NEW NORMAL

Keeping our team connected to each other and the community during the pandemic was vital as we refused to slow down and compromise our mission of moving further, faster towards a world where brain tumours are defeated.

We take a huge amount of pride in our culture and connection with those we support, so it's fair to say there was a steep learning curve as we attempted to navigate the ever-changing lockdown restrictions.

By the end of 2021/22, we'd been able to settle into a new normal that embraced the hybrid nature of the post-pandemic workplace.

Our offices have been buzzing with creativity as a result of being able to collaborate in person again, but our time apart significantly improved our ability to work together remotely – setting us up for a bright future of teaming with international partners and making alliances with external organisations.

Our increased flexibility in offering more opportunities for staff to work remotely also means our team enjoys the best of both worlds and has allowed us to attract a wider range of talented individuals who may have previously shied away from commuting to our HQ five days a week.

In September 2021, we held our first annual Team Day event for 18 months, which was a great opportunity to spend time together after so much time apart and reflect on our progress to date. We dedicated a lot of time to hear from the community, learning about the experiences of those affected by brain tumours and understanding what's important to them.

It was a stark reminder of why we must continue to push for kinder treatments and, ultimately, a cure.

COMMERCIALISING BRIAN

Having invested in the technology and know-how that brings our BRIAN project to life, it became apparent this model would be valuable to other disease areas too. This provides a unique opportunity for The Charity to make a financial return on our investment, while also helping other communities affected by long-term illnesses.

Throughout 2021/22, The Charity has embarked in commercialising the technology underlying BRIAN (it's important to note that this does not include the data held within BRIAN) and has created new commercial trading subsidiary companies to do this. It's anticipated this new commercial venture will make a financial return and be a new income stream for The Charity within the next two years.

CELEBRATING OUR VOLUNTEERS

One of the things we're proudest of is the way we've grown involvement and volunteering during the pandemic.

In 2021, we were delighted to welcome our fourth cohort of Young Ambassadors to The Charity. They come from all over the UK and truly represent a diverse mix of experiences. Our Young Ambassadors embody our ethos of being a community-led charity. They're hopeful and determined and, like all our previous Young Ambassadors, will lead us forward and represent The Charity across campaigning, influencing, fundraising, support and research.

1,000+

volunteers lending their time, experience and expertise

Our team of volunteers help with everything from fundraising and spreading awareness of the signs and symptoms of a brain tumour in their local communities, to providing professional sports coaching for our London Marathon runners and quality checking the accuracy of our medical and scientific information – and so much more.

We simply couldn't have made the progress we have without them!



EMBRACING A NEW WAY OF FUNDING RESEARCH

Sadly, the COVID-19 pandemic meant that to be able to guarantee we could continue to fulfil our financial commitments to existing research projects, we were forced to pause our plans to fund new research through traditional grants funding.

This meant we needed to embrace a new way of funding if we were going to support pioneering new projects.

In August 2021, we launched an urgent fundraising appeal, calling upon everyone in the community to help us raise £450,000 to fund a first-of-its-kind clinical trial in the UK to investigate cannabinoids as a treatment for people with recurrent glioblastoma (GBM).

£450,000

raised in our cannabinoids appeal

Supported by generous major donors through The Big Give's matched-funding platform, and boosted by major national and international press coverage of our social media campaign (which featured over 50 members of our community), we were able to raise an incredible £139,311 in just one week!

We were then able to raise the additional funds required thanks to the support of the public and global research community, including a generous donation of £45,000 from Leeds Hospitals Charity.

Thanks to this new way of raising funds for research, the trial has been approved and will begin recruiting over 230 patients at 15 NHS hospitals across all UK nations in summer 2022.

"We are delighted to announce that, thanks to the support and generosity of so many in the community, the ARISTOCRAT trial will begin recruitment of patients in summer 2022.

"We know there has been significant interest among patients and researchers alike for some time about the potential activity of cannabinoids in treating glioblastomas. We're really excited that

this world-first trial here in the UK could help accelerate these answers and are so grateful to everyone who has donated to help us make this study possible – thank you.

"We'd also particularly like to thank Leeds Hospitals Charity for their significant contribution, which will enable up to 25 patients to access the trial at Leeds Teaching Hospitals.

"The recent early-stage findings were really promising and we now look forward to understanding whether adding Sativex to chemotherapy could help offer life-extension and improved quality of life, which would be a major step forward in our ability to treat this devastating disease."

Dr David Jenkinson, Chief Scientific Officer
Past Interim CEO (Jan 2021 – Jan 2022).

LEANING IN TO OUR RESPONSIBILITY FOR EQUALITY, DIVERSITY AND INCLUSION

We recognise that we have an important role in creating a fairer society and acknowledge that we, like many other charities, still have much work to do to ensure we're inclusive and representative of the communities we serve.

To help address this, we've begun to critically evaluate how inclusive and diverse we are as an organisation and developed an action plan that demonstrates our commitment to equality, inclusion and rooting out discrimination in all its forms.

To support this we established an Equality, Diversity and Inclusion working group, comprised of team members from across The Charity and with two team members acting as the Leads for driving forward our action plan. To keep us accountable for our progress we've also established a new Trustee Committee for Equality, Diversity and Inclusion.

EXCEPTIONAL RE-APPOINTMENT OF TRUSTEES

The pandemic has created a unique set of pressures for individuals and organisations throughout the world and The Charity is no exception. It also coincided with the departure of the CEO after ten years of dedicated service and a number of trustees reaching the end of their terms in office. After careful consideration by The Charity's Board, following a rigorous appraisal and in accordance with The Charity's constitution, in September 2021 The Board decided to extend the term by one year of two trustees, Berrie Norton and Graham Lindsay. Graham Lindsay subsequently resigned 30/06/2022 to assist the Interim CEO and leadership team.

Berrie Norton has had a long term involvement in the Support and Information Committee and a role in the recruitment of a new CEO. Graham Lindsay sat on the Remuneration and Governance and Ethics Committees. He also was a Co-Vice Chair and his reappointment provided valuable stability. The Board believed the continuity provided by extending their terms by one year beneficial to supporting The Charity.



FINANCE REVIEW

The global pandemic, which had a severe impact on The Charity's finances and activities throughout 2020-21, began to ease in the year to March 2022, allowing The Charity to return to growth.

The speed of growth combined with the remarkable generosity of the community resulted in income growing 38% to £11.5m, the highest income ever achieved by The Charity.

Total expenditure fell in the financial year compared to the previous year. This was due to the time it takes to recruit and scale back up operations following the pandemic.


INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments. In the year income was up year-on-year in most areas but there were a few notable items.

The ending of social distancing and restrictions on mass gatherings has permitted face-to-face events to happen once more. Accordingly, income from events such as marathons, cake sales and corporate fundraisers more than doubled year-on-year - rising by £1.2m.

Income from Major Gifts and Appeals were also substantially up, with the most notable item being £450k raised to fund a first-of-its-kind clinical trial in the UK to investigate cannabinoids as a treatment for people with recurrent glioblastoma (GBM).

The Charity also applied for and was successful in receiving £471k from a £20m fund from the Medical Research Council. The UK Government Covid Medical Research Charity Support Fund was established to assist charities funding medical research impacted by the COVID-19 pandemic.



EXPENDITURE

Expenditure in the year reduced by £0.7m to £10.6m. The reduction was in all areas of Charitable Activities and was due to the lasting effects of the pandemic.

The Charity's primary objective is to fund quality research and over half our expenditure is in this area as it is vital to achieving our ambitious objectives. Expenditure on research declined £0.4m due to research projects running behind schedule during the pandemic which has required rebudgeting of the timing of grants.


Patient support and campaigning and awareness expenditure also declined year-on-year. This was primarily due to lower salary costs after the size of the team significantly decreased in 2021/22 in response to financial impact of the pandemic and the time it takes to recruit and grow the team again. In 2021/22 the average number of employees in The Charity was 86 compared to 108 in 2020/21.

Fundraising expenditure increased £0.1m (7%) over the prior year. The primary driver of the increase is the cost of physical events taking place once again and reflects the 38% increase in income. This has off-set lower salary costs year-on-year as the average number of people in our Fundraising team also declined year-on-year in response to the pandemic.

The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. In the year to 31 March 2022 we managed to spend 82p as we continued our investment in quality research.

The Charity has a trading subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a profit of £41k which is to be donated to The Charity.

The Charity also formed two new subsidiaries, Acquist Data Holdings Limited and Acquist Data Limited in March 2022 which were dormant.



INVESTMENTS AND CASH

The COVID-19 pandemic caused considerable volatility in world-wide stock markets and this was compounded by the Russian invasion of Ukraine in February 2022. At the end of the financial year The Charity's investments were valued at £14.5m, a fall of £0.1m over the previous year.

All investments are held in highly liquid assets. Current forecasts do not expect the investments to need to be liquidated in the next twelve months as short-term volatility in values is not considered a significant risk.

Cash held as at 31 March 2022 was £5.2m.

RESERVES POLICY

The Charity's funds have recovered to their pre-pandemic levels, ending the financial year to 31 March 2022 at £7.6m.

The Charity maintained Unrestricted Funds of at least six months' operational costs to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments. The annual operational cost is about £6.7m. The level of Total Funds at 31 March 2022 was £7.6m, consisting of Unrestricted General Reserves of £2.7m, Designated of £1.7m and Restricted of £3.3m. After deducting the value of functional fixed assets £282k, Free Reserves available are £2.4m.

The Restricted and Designated Reserves are earmarked for use in the next two financial years. As a result of COVID-19, The Charity's Reserves Policy until 31 March 2023 is to have Total Reserves in excess of six months' operational costs. As at 31 March 2022, the actual cover was 13.6 months.

At 31 March 2022, we had unaccrued but committed research expenditure totalling £8.3m which was subject to satisfying of our ongoing monitoring requirements and expected to fall due over the next five years. The investments and cash at 31 March 2022 (which are all liquid) were £19.8m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who have appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Smith & Williamson have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £14.5m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash.

In a volatile year for investments due mostly to COVID-19 and the Russian invasion of Ukraine, the portfolio generated income of £325k and a valuation loss of £97k. In addition to managed investment funds, the Trustees decided in the year to invest in commercialising the intellectual property and technology it had developed in creating BRIAN, The Charity's database tool. The Charity has formed new subsidiaries for this commercial venture and evaluates any investments being made on its financial return against an equivalent asset class.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience,

pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across The Charity is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have over 1,000 active volunteers across the UK who support a wide range of different roles across The Charity. Voluntary activities include supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

1. That we fail to secure adequate income. We have developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We have invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at least six months of reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.

2. That we are not able to commission enough high-quality research projects. We are developing our engagement with the brain tumour research community and working to build capacity in the sector. We are also looking at alternative research models. In addition, we have extended funding globally and put significant emphasis on building relationships with key researchers.

3. That we become affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective talent and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.

4. That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.

5. That we are the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres and ensure that we have leading-edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have a cyber insurance policy.

6. That we are impacted by a global pandemic, just like COVID-19. We have an incident management plan and this was implemented in March 2020, with the priority of helping those most vulnerable in the community to deal with the anxiety and practicalities caused by the pandemic. We have set up The Charity so that everyone can work from home, we have introduced virtual fundraising activities and have been able to furlough staff members if necessary. By having a six months' reserve policy we should be able to ride out any significant adverse financial impact on The Charity.

GOING CONCERN

The Trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The COVID-19 pandemic impacted The Charity's community, finances and activities but as the restrictions associated with the pandemic have reduced or ended The Charity has adapted and returned to growth. Income has recovered more swiftly than expected although the financial outlook remains uncertain given the cost-of-living pressures in the global economy.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments. The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

OBJECTIVES FOR 2022-23

The Charity objectives remain aligned to its core values and our priority objectives for the year are:

- We will drive the **Best Care Everywhere** across the UK, driving up the quality of treatment centres in the UK and empowering our community to share their experiences.
- We will mobilise **Voices for Change**, sharing evidence and platforms so passion and experience is amplified to support those affected, raise funds and drive progress.
- We will harness the **Power of Data** to accelerate research, tackle inequality, empower choices, inform change and maximise our impact.

In addition:

- We will continue identifying the best global research to be funded through a new round of research grant funding
- We will complete and adopt our entirely new organisational strategy, *Beyond Brain Tumours* that we're co-creating as a community.
- We will start to see a financial return from the commercialisation of the intellectual property and technology underlying BRIAN (Brain tumouR Information and Analysis Network) – this does not include the data held in BRIAN.

PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat brain tumours. We are investing time and effort on expanding our fundraising to grow and to provide income for years to come, money that will be used to fund our ambitious year-on-year investment in the best global research.

Our new strategy that we are forming as a community in 2022-23 will guide our direction and the charity we need to become in future years.

THANKS

Last year, The Charity continued to fund our existing commitments to the highest quality research and began funding new projects again, as well as raising awareness and supporting thousands of people affected by a brain tumour.

This work is only possible due to the unprecedented support from the community and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us.

To everyone involved, we cannot thank you enough for continuing to help us as we strive to defeat brain tumours!

In addition to the donors named below, we would like to thank all our anonymous donors.

TRUSTS

BBC Children in Need
St James's Place Charitable Foundation
The AOK Trust
The Colin Oliphant Charitable Trust
The Julia and Hans Rausing Trust
The Syncona Foundation
The William Brake Foundation

FAMILY-LED CHARITY PARTNERS

Evie's Gift
James Clifford Campling Trust
Naseem's Manx Brain Tumour Charity
Nick's Fund
The Billie Butterfly Fund
The Brian Cross Memorial Trust
The Jake McCarthy Foundation
The Oli Hilsdon Foundation
Stay Strong Stu

CORPORATES

Allports Group
Atrato Capital Limited
BECG Group
Benesys
Bluecube Technology Solutions
Childs Farm
Clicky Media
CMC Markets
Federated Hermes
IHS Markit
JM Finn
John R. Adam & Sons
Knight Security Group
K&L Gates
Majestic Wine
Microsoft
Runningman Two
Salesforce
Thunderhead
Underbelly

CO-FUNDING PARTNERS

Action Medical Research
Cancer Research UK
Children with Cancer UK
Great Ormond Street Hospital
Children's Charity

HIGH PROFILE SUPPORTERS AND FRIENDS OF THE CHARITY

Alastair Stewart OBE
Charly Clive
Dominic Matteo
Earl Spencer
Ella and Matt Mills (Deliciously Ella)
Guy Opperman MP
Hal Cruttenden
Holly Matthews
Ian Chillcott
James Jordan
Jason Durr
Jess Mills
Jonny Wilkinson CBE
Lewis Moody OBE and Annie Moody
Liam Conlon
Lorraine Kelly OBE
Marc Silk
Matt Allwright
Mel Giedroyc
The Neales
Nick Baines (Peanut – Kaiser Chiefs)
Nicki Chapman
Olivia Colman CBE
Owain Arthur
Philippa Forrester
Phil Spencer
Russell Watson
Sandy Lyle MBE
Sherrie Hewson
Sian Reese-Williams
Steve Backshall
Tchéky Karyo
Tim Burgess and The Charlatans
Tom Daley
The Wanted

We'd also like to thank the actress and writer Dawn French, one of The Charity's first patrons and friend of Angela and Neil Dickson. Dawn has supported The Charity for over 20 years and continues to offer auction prizes and practical support wherever possible.

TRUSTEES AND GOVERNANCE

TRUSTEES

Jack Morris CBE (Chair)
Neil Dickson MBE (Vice Chair)
Graham Lindsay (resigned 30/06/2022)
Dr. Elena Bechberger
Dr. Rachel Edgar
Simon Hay
Sean Hird
Justine McIlroy
Philippa Murray
Berendina Norton
Graham Norton (resigned 03/07/2022)
Professor Alan Palmer
Beth Worrall
Anna Jarvis (appointed 16/06/2022)
Caroline Steel (appointed 16/06/2022)
Hayley Conroy (appointed 16/06/2022)
Jessica Sass (appointed 16/06/2022)
Dr Kieran Palmer (appointed 16/06/2022)
Matimba Swana (appointed 16/06/2022)
Dr Russell Hagan (appointed 16/06/2022)
Sukhdip Sandhu (appointed 16/06/2022)

The directors and trustees had liability insurance during the financial year.

PRESIDENT

Professor Sir Colin Blakemore
(passed away 27/06/2022)

CHIEF EXECUTIVE OFFICER

David Jenkinson (Interim CEO appointed 01/04/2021, resigned 24/01/2022)
Alex Lochrane (appointed 24/01/2022, resigned 01/07/2022)
Graham Norton (Interim CEO appointed 04/07/2022)
Graham Lindsay (Deputy-Interim CEO appointed 04/07/2022)

COMPANY SECRETARY

Liam Heffernan

CHARITY REGISTRATION NUMBERS

England and Wales 1150054
Scotland SC045081

COMPANY NUMBER

08266522

PRINCIPAL AND REGISTERED OFFICE

Fleet 27, Rye Close, Fleet, Hampshire,
GU51 2UH

AUDITORS

Menzies LLP Centrum House, 36 Station
Road, Egham, Surrey TW20 9LF

BANKERS

Lloyds Bank Plc, 147 High Street,
Guildford, GU1 3AG

INVESTMENT MANAGERS

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon
Smith and Williamson, 25 Moorgate, London

RESEARCHERS IN OUR COMMUNITY

As well as members of our Scientific Advisory Board (mentioned on page 36), these are just some of the researchers providing an ongoing contribution to our success.

Adam Waldman
Adel Samson
Alex Bullock
Andrew Peet
Anthony Byrne
Anthony Chalmers
Antony Michalski
Barry Pizer
Catherine McBain
Chris Jones
Colin Kennedy
Colin Watts
Conor Mallucci
Darren Hargrave
David Jones
David Walker
Denise Sheer
Diane Puccetti
Eric Aboagye
Federico Roncaroli
Filomena Maggino
Gelareh Zadeh
Gregor Hutter
Ian Waddell

Jan Schuemann
Michael Taylor
Michael Vogelbaum
Monika Hegi
Neil Carragher
Ola Rominiyi
Olivier Ayrault
Pamela Kearns
Paul Brennan
Paul Northcott
Paula Croal
Petra Hamerlick
Phedias Diamandis
Philipp Euskirchen
Pim French
Rameen Beroukhim
Richard Gilbertson
Roel Verhaak
Roger Packer
Russ Hagen
Sebastian Brandner
Sébastien Serres
Siddhartha Mitra
Simon Bailey
Simona Parrinello
Sophie Thomas
Spencer Watson
Stefan Pfister
Steve Pollard
Steven Clifford
Stuart Allan
Stuart Smith
Susan Short
Terri Armstrong
Thomas Würdinger
Todd Hankinson
Tyler Miller
Verónica Rendo
Victor Levin
Vincenzo D'Angiolella



BIOMEDICAL SCIENTIFIC ADVISORY BOARD

NAME

Professor Richard Gilbertson
Professor Steve Clifford
Dr Mark Gilbert
Dr David Adams
Dr Susan Chang
Dr Cynthia Hawkins
Dr Paul Northcott
Professor Simona Parrinello
Professor Colin Watts
Dr Duane Mitchell
Professor Rick Livesey
Dr Marcel Kool
Dr Lucy Stead
Dr Gerry Thompson

INSTITUTION

The Cambridge Cancer Centre, UK
The Institute of Child Health, Newcastle University, UK
National Institutes of Health (NIH), USA
The Wellcome Trust Sanger Institute, UK
University of California San Francisco, USA
The Hospital for Sick Children, Canada
St Jude Children's Research Hospital, USA
University College London (UCL), UK
University of Birmingham, UK
University of Florida, USA
German Cancer Research Centre, Germany
University of Leeds, UK
University of Edinburgh, UK

PAEDIATRIC LOW GRADE CENTRE SAB

NAME

Dr Nick Foreman
Dr Paola Scaffidi
Dr Anat Stemmer-Rachamimov
Professor Martin van den Bent
Dr Christian Dillon
Professor David Ashley
Dr Floris Barthel

INSTITUTION

Children's Hospital Colorado, Denver, USA
Francis Crick Institute, London, UK
Massachusetts General Hospital
Erasmus MC Cancer Center, The Netherlands
PhoreMost Ltd, Cambridge, UK
Duke Cancer Institute, USA
Translational Genomics Institute, Phoenix, USA

LAY ADVISORS

Ms Christina Brincat
Mrs Deborah Crossan
Mrs Rachel Rathbone
Ms Louise Webber-Edwards
Mr John Graham

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees who are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed on page 34.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance.

All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 8 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from committees which have been established to advise on key areas of activity, which are:

- Finance
- Research
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion

- Remuneration
- Technology Commercialisation
- Databank (BRIAN)

The Charity has formed two Scientific Advisory Boards (SABs) to ensure we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the Paediatric Low Grade Centre Scientific Advisory Board (Paediatric Low Grade Centre SAB) can be found on page 36.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and support the diverse community we serve.

The EDI committee comprising of at least two members of the Executive team and two Trustees along with other members as required has the purpose of making The Charity more proactive in reducing disparities, enhancing consistency of effort and raising awareness, as well as evidencing and reporting on progress. This is aided by a Champions Team made up from Charity staff who meet regularly to consider and drive forward all areas of EDI within The Charity.

GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our new research strategy 'Accelerating a Cure' launched in 2021-22 as we aim to double survival and halve the harm caused by brain tumours. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers.



We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research & Databank Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all our fundraising activity. We did not engage with any third-party fundraisers during the year. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

STATEMENT OF THE TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard

applicable in the UK and Republic of Ireland. Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:

- Select suitable accounting policies and then apply them consistently.
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 15 September 2022 and signed on their behalf by:


Jack Morris CBE
Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2022 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2022 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with

the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon.

Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or

- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of noncompliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud.

The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:

- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.
- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.
- We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. We considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:
 - Posting of fraudulent journal entries
 - Posting of fraudulent payments and receipts in the accounting software
 - Authorisation, processing, and payment of fraudulent expenses
 - Fictitious employees
 - Timing of revenue recognition
- Audit procedures performed by the engagement team included:
 - Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
 - Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
 - Challenging assumptions and judgments made by management in its significant accounting estimates; and

- Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations
- Carrying out checks to establish the validity of employees, and
- Reviewing and verifying the basis on which income is recognised in the accounts.

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

Janice Matthews

Janice Matthews
FCA (Senior statutory auditor)
for and on behalf of
Menzies LLP
Chartered Accountants
Statutory Auditor
Centrum House
36 Station Road
Egham
Surrey
TW20 9LF

Date: 15-09-2022

CONSOLIDATED STATEMENT OF FINANCIAL ACTIVITIES FOR THE YEAR ENDED 31 MARCH 2022

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2022 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2021 £'000
Income and expenditure							
Income from:							
Donations and legacies	3	8,681	2,276	10,957	6,577	1,180	7,757
Other trading		161	32	193	171	15	186
Investments		325	-	325	355	-	355
Total income		9,167	2,308	11,475	7,103	1,195	8,298
Expenditure on:							
Raising funds		1,872	1	1,873	1,742	2	1,744
Charitable activities							
Research		4,038	2,172	6,210	5,405	1,239	6,644
Patient support		1,394	386	1,780	1,724	371	2,095
Campaigning & raising awareness		760	2	762	829	20	849
Total expenditure on charitable activities		6,192	2,560	8,752	7,958	1,630	9,588
Total expenditure	4	8,064	2,561	10,625	9,700	1,632	11,332
Net income before gains and losses on investment assets		1,103	(253)	850	(2,597)	(437)	(3,034)
Realised and unrealised gains on investment assets		(97)	-	(97)	2,656	-	2,656
Net income/(expenditure)		1,006	(253)	753	59	(437)	(378)
Transfers		-	-	-	(955)	955	-
Net movement in funds for the year		1,006	(253)	753	(896)	518	(378)
Reconciliation of funds							
Balances at 1 April 2021		3,348	3,509	6,857	4,244	2,991	7,235
Balances at 31 March 2022		4,354	3,256	7,610	3,348	3,509	6,857

The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities.


The notes on pages 45-59 form part of these financial statements.

CONSOLIDATED BALANCE SHEET AT 31 MARCH 2022

Company number: 08266522

	Notes	Consolidated 2022 £'000	Consolidated 2021 £'000	Company 2022 £'000	Company 2021 £'000
Fixed assets					
Intangible assets	10	15	34	15	34
Tangible assets	11	267	281	267	281
Investment in subsidiaries	12	-	-	-	-
Investments	12	14,536	14,652	14,536	14,652
Current assets					
Stock		6	9	-	-
Debtors	13	820	452	820	453
Cash at bank		5,240	4,978	5,239	4,972
		6,066	5,439	6,059	5,425
Creditors					
Amounts falling due within one year	14	(13,174)	(13,449)	(13,208)	(13,456)
Provision for liabilities	15	(100)	(100)	(100)	(100)
Net current (liabilities)/ assets		(7,208)	(8,110)	(7,249)	(8,131)
Total assets less current liabilities		7,610	6,857	7,569	6,836
Funds					
General reserve		2,662	1,752	2,621	1,731
Designated funds		1,692	1,596	1,692	1,596
Unrestricted funds		4,354	3,348	4,313	3,327
Restricted funds		3,256	3,509	3,256	3,509
	19	7,610	6,857	7,569	6,836

The financial statements were approved by the trustees on 15 September 2022 and signed on their behalf by:


 Jack Morris CBE
 Chair of Trustees


 Beth Worrall
 Chair of Finance Committee

The notes on pages 45-59 form part of these financial statements.

CONSOLIDATED CASH FLOW FOR THE YEAR ENDED 31 MARCH 2022

	2022 £'000	2021 £'000		
<u>Reconciliation of net income to net cash flow from operating activities</u>				
Net income for the year	753	(378)		
Adjustments for:				
Depreciation	42	50		
Losses/ (gains) on investments	97	(2,619)		
Income from investments	(325)	(355)		
Provision for liabilities	-	100		
Loss/ (profit) on sale of fixed assets	-	2		
(Increase)/ decrease in stocks	2	2		
Decrease/ (increase) in debtors	(367)	268		
Increase / (decrease) in creditors	(274)	541		
Net cash (used in)/ provided by operating activities	(72)	(2,388)		
	2022 £'000	2021 £'000		
<u>Statement of cash flows</u>				
Cash flows from operating activities				
Net cash (used in)/ provided by operating activities	(72)	(2,388)		
Cash flows from investing activities:				
Dividends, interest and rents from investments	325	355		
Purchase of computer software	-	-		
Purchase of property plant & equipment	(10)	(296)		
Sale/(purchase) of investments	19	-		
Net cash provided by/ (used in) investing activities	334	59		
	2022 £'000	2021 £'000		
Change in cash and cash equivalents in the year	262	(2,328)		
Balances at 1 April 2021	4,978	7,306		
Balances at 31 March 2022	5,240	4,978		
	2022 £'000	2021 £'000		
<u>Analysis of cash and cash equivalents</u>				
Cash in hand	5,240	2,944		
Notice deposits (less than 3 months)	-	2,034		
Total cash and cash equivalents	5,240	4,978		
	At 1 April 2021	Cash from sale of investments	Other Cash flows	At 31 March 2022
<u>Analysis of changes in net debt</u>				
Cash	2,944	19	2,277	5,240
Cash equivalents	2,034	-	(2,034)	-
Net debt	4,978	19	243	5,240

NOTES TO THE FINANCIAL STATEMENTS

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2019) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 35. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. Accounting policies

(a) Basis of preparation of financial statements

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity (“The Charity”) constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity’s subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net incoming resources for The Charity in the year were £733,000 (2021: outgoing £394,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity’s accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) **Company status**

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 34. In the event of the company being wound up, the liability in respect of the guarantee is limited to £10 per member of the company.

(c) **Income**

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when The Charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) **Expenditure**

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attached are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

(e) **Stocks**

Stock is measured at the lower of cost and net realisable value.

(f) **Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) **Fixed assets**

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) **Estimated useful lives**

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) **Investments**

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) **Donated assets and services**

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) **Operating lease**

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) **Pensions**

The Charity operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independently of The Charity's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) **Financial instruments**

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) **Going concern**

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The COVID-19 pandemic began to impact in March 2020 and continued to affect this financial year but with diminishing impact as the year went on and restrictions in the UK eased. The Charity’s income through fundraising from mass participation events or the holding of physical fundraising events started to return as the year went on. Similarly, daily activities of The Charity with employees working remotely shifted to a hybrid working model. Financial investments continued to be volatile as financial markets reacted to global events. The Charity demonstrated it can adapt to these changes and has returned to growth. This growth is expected to continue in the next twelve months and beyond.

The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. Donations and legacies

	Unrestricted	Restricted	2022	Unrestricted	Restricted	2021
	£'000	£'000	Total £'000	£'000	£'000	Total £'000
Ordinary activities:						
Regular giving	308	39	347	258	41	299
Donations, appeals and fundraising	6,756	1,949	8,705	5,352	1,120	6,472
Gift aid	815	45	860	483	19	502
Legacies	273	243	516	155	-	155
Government grants	529	-	529	329	-	329
	8,681	2,276	10,957	6,577	1,180	7,757

Government grants consist of amounts received under the Government Coronavirus Job Retention Scheme and the COVID Medical Research Charity Support Fund.

4. Analysis of resources expended

	Direct Costs £'000	Grants £'000	Support Costs £'000	2022 Total £'000
Raising funds	1,721	-	152	1,873
Charitable activities:				
Research	1,085	5,079	46	6,210
Patient support	1,706	-	74	1,780
Campaigning and raising awareness	675	-	87	762
Total expenditure on charitable activities	3,466	5,079	207	8,752
Total expenditure	5,187	5,079	359	10,625

	Direct Costs £'000	Grants £'000	Support Costs £'000	2021 Total £'000
Raising funds	1,579	-	165	1,744
Charitable activities:				
Research	1,167	5,446	31	6,644
Patient support	2,019	-	76	2,095
Campaigning and raising awareness	769	-	80	849
Total expenditure on charitable activities	3,955	5,446	187	9,588
Total expenditure	5,534	5,446	352	11,332

5. Research grant cost analysis

	2022 £'000	2021 £'000
Research programmes	3,640	4,406
Research projects	1,145	831
Clinical trials	299	155
Fellowships	-	54
Conferences	(5)	-
	5,079	5,446

A breakdown of research costs by individual award is provided in note 22.

6. Support costs by activity

	Finance and human resources £'000	Central facilities £'000	Information technology £'000	Central management £'000	Governance £'000	Total £'000
Raising funds	44	25	44	11	28	152
Charitable activities:						
Research	13	7	14	4	8	46
Patient support	21	12	22	6	13	74
Campaigning and raising awareness	25	14	25	7	16	87
2022 Total	103	58	105	28	65	359

	Finance and human resources £'000	Central facilities £'000	Information technology £'000	Central management £'000	Governance £'000	Total £'000
Raising funds	54	19	37	17	38	165
Charitable activities:						
Research	10	4	7	3	7	31
Patient support	25	9	17	8	17	76
Campaigning and raising awareness	26	9	19	8	18	80
2021 Total	115	41	80	36	80	352

7. Governance costs

	2022 £'000	2021 £'000
Auditor's remuneration	15	20
Legal and professional fees	-	3
Staff	50	57
	65	80

In addition to Auditor's remuneration for audit shown above, a further £4,500 was paid for accounting and tax advice. Trustees received no remuneration (2021: £nil). Trustees received no reimbursement for travel expenses in the year totalling £nil (2021: one for £26). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2021: £nil).

8. Staff costs

	Group		Company	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Wages and salaries	2,776	3,402	2,776	3,402
Social security costs	223	311	223	311
Payments to defined contribution pension plans	223	296	223	296
	3,222	4,009	3,222	4,009

During the year redundancy payments were made totalling £nil (2021: £29,000). At 31 March 2022 there was £nil provided (2021 £nil).

The average number of employees during the year was 86 (2021: 108).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2022	2021
£60,001 - £70,000	2	1
£70,001 - £80,000	1	1
£80,001 - £90,000	1	1
£90,001-£100,000	-	-

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £453,000 (2021: £572,000).

9. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. Intangible fixed assets

Group and Company

	Computer Software £'000
Cost	
At 1 April 2021	161
Additions	-
At 31 March 2022	161
Depreciation	
At 1 April 2021	128
Charge for the year	18
At 31 March 2022	146
Net book value	
At 31 March 2022	15
At 31 March 2021	34

11. Tangible fixed assets

Group and Company

	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2021	289	168	457
Additions	3	6	9
At 31 March 2022	292	174	466
Depreciation			
At 1 April 2021	14	161	175
Charge for the year	19	4	24
At 31 March 2022	34	165	199
Net book value			
At 31 March 2022	258	9	267
At 31 March 2021	274	7	281

12. Investments

(a) Subsidiary Investment

Equity investment in group undertakings

Cost	£
At 1 April 2021	100
Additions	100
At 31 March 2022	200

On 3 March 2022 The Charity formed a new subsidiary Acquist Data Holding Limited. The Charity owns 100% of the £1 ordinary share capital of Acquist Data Holding Limited, a dormant company incorporated in England and Wales, company number 13951266. Acquist Data Holdings Limited owns 100% of Acquist Data Limited, a dormant company incorporated in England and Wales, company number 13951572

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

At 31 March 2022 the aggregate of the share capital and reserves of TBTC Trading Ltd was £21,000 (2021: £21,000).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2022 £'000	2021 £'000
Turnover	59	49
Cost of sales	(15)	(12)
Gross profit	44	37
Other operating expenses	(3)	(16)
Profit before donation	41	21
Donation	(21)	(4)
Retained profit/ (loss)	20	17

Cost of sales represent cost of stock sold in the year.

At 31 March 2022 the aggregate assets of TBTC Trading Ltd were £45,000 (2021: £24,000), aggregate liabilities £4,000 (2021: £3,000) and shareholder's funds £41,000 (2021: £21,000).

(b) General investments

	2022 £'000	2021 £'000
Group and Company		
At 1 April	14,652	12,033
Additions at cost	635	1,464
Disposals	(533)	(4,541)
Net unrealised (loss) on revaluation	(218)	5,696
At 31 March	14,536	14,652
Historical cost	12,306	12,204
	2022 £'000	2021 £'000
Investments at market value comprised:		
UK equities	3,236	3,775
Overseas equities	3,679	3,539
Absolute return funds	418	442
Property	124	-
Multi asset funds	509	234
Alternative investments	287	578
Fixed income securities	3,421	3,184
Cash held within the investment portfolios	2,862	2,900
Accrued income	-	-
At 31 March	14,536	14,652

During the year income from listed investments was £324,000 (2021: £350,000) and interest on deposits £1,000 (2021: £4,000).

13. Debtors

	Consolidated		Company	
	2022 £'000	2021 £'000	2022 £'000	2021 £'000
Trade debtors	373	74	373	74
Accrued income and prepayments	446	353	446	353
Other debtors	1	26	1	26
Amounts owed by TBTC Trading Ltd	-	-	-	-
	820	453	820	453

14. Creditors

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2022 £191,000 (2021: £297,000) of income was deferred and £357,000 (2021: £97,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Grants payable	12,650	12,293	12,650	12,294
Accruals and deferred income	381	468	378	465
Trade creditors	38	593	38	593
Other creditors	28	28	28	28
Social security and other taxes	77	67	76	67
Amounts owed to TBTC Trading Ltd	-	-	38	9
	<u>13,174</u>	<u>13,449</u>	<u>13,208</u>	<u>13,456</u>

15. Provision for liabilities

	Consolidated		Company	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
At 1 April 2021	100	-	100	-
Additions	-	100	-	100
Disposals	-	-	-	-
At 31 March 2022	<u>100</u>	<u>100</u>	<u>100</u>	<u>100</u>

The provision related to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. Research commitments

At 31 March 2021 The Charity had authorised commitments that were subject to outstanding conditions amounting to £8,254,000 (2021: £13,586,000), these are expected to fall due as follows:

	2022	2021
	£'000	£'000
Within one year	3,712	5,736
Between one and two years	2,768	3,609
Between two and three years	1,361	2,546
Between three and four years	134	1,283
Between four and five years	134	133
Five years and further	145	279
	<u>8,254</u>	<u>13,586</u>

The above commitments will be funded from reserves and future income.

17. Operating lease commitments

The total of future minimum property lease payments on operating leases are as follows:

	Consolidated		Company	
	2022	2021	2022	2021
	£'000	£'000	£'000	£'000
Within one year	301	143	301	143
Between one and five years	<u>1,182</u>	<u>1,242</u>	<u>1,182</u>	<u>1,242</u>
	<u>1,483</u>	<u>1,385</u>	<u>1,483</u>	<u>1,385</u>

Operating lease charges during 2022 were £57,000 for property (2021: £30,000).

18. Analysis of net assets between funds

	Unrestricted Funds	Restricted Funds	Total 2022
	£'000	£'000	£'000
Intangible fixed assets	15	-	15
Tangible fixed assets	267	-	267
Investments	14,536	-	14,536
Other current assets	(887)	6,953	6,066
Current liabilities	<u>(9,577)</u>	<u>(3,697)</u>	<u>(13,274)</u>
	<u>4,354</u>	<u>3,256</u>	<u>7,610</u>

	Unrestricted Funds	Restricted Funds	Total 2021
	£'000	£'000	£'000
Intangible fixed assets	34	-	34
Tangible fixed assets	281	-	281
Investments	14,652	-	14,652
Other current assets	(1,572)	7,011	5,439
Current liabilities	<u>(10,047)</u>	<u>(3,502)</u>	<u>(13,549)</u>
	<u>3,348</u>	<u>3,509</u>	<u>6,857</u>

19. Funds

Consolidated	At 1 April 2021 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2022 £'000
Restricted funds:						
Research funds	2,056	1,637	(1,495)	-	-	2,198
Everest fund	486	191	(677)	-	-	-
Awareness funds	383	2	(3)	-	-	382
Support funds	584	478	(387)	-	-	675
	<u>3,509</u>	<u>2,309</u>	<u>(2,562)</u>	<u>-</u>	<u>-</u>	<u>3,256</u>
Unrestricted funds:						
General reserve	1,752	8,112	(7,105)	-	(97)	2,662
Designated funds	1,596	1,054	(958)	-	-	1,692
	<u>3,348</u>	<u>9,166</u>	<u>(8,063)</u>	<u>-</u>	<u>(97)</u>	<u>4,354</u>
	<u>6,857</u>	<u>11,475</u>	<u>(10,625)</u>	<u>-</u>	<u>(97)</u>	<u>7,610</u>
Company	At 1 April 2021 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2022 £'000
Restricted funds:						
Research funds	2,056	1,637	(1,495)	-	-	2,198
Everest fund	486	191	(677)	-	-	-
Awareness funds	383	2	(3)	-	-	382
Support funds	584	478	(387)	-	-	675
	<u>3,509</u>	<u>2,309</u>	<u>(2,562)</u>	<u>-</u>	<u>-</u>	<u>3,256</u>
Unrestricted funds:						
General reserve	1,731	8,053	(7,087)	21	(97)	2,621
Designated funds	1,596	1,054	(958)	-	-	1,692
	<u>3,327</u>	<u>9,107</u>	<u>(8,046)</u>	<u>21</u>	<u>(97)</u>	<u>4,313</u>
	<u>6,836</u>	<u>11,416</u>	<u>(10,607)</u>	<u>21</u>	<u>(97)</u>	<u>7,569</u>

Consolidated	At 1 April 2020 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2021 £'000
Restricted funds:						
Research funds	684	635	(294)	1,031	-	2,056
Everest fund	1,395	36	(945)	-	-	486
Awareness funds	392	6	(15)	-	-	383
Support funds	520	518	(378)	(77)	-	584
	<u>2,991</u>	<u>1,194</u>	<u>(1,631)</u>	<u>955</u>	<u>-</u>	<u>3,509</u>
Unrestricted funds:						
General reserve	2,499	6,244	(8,693)	(955)	2,656	1,752
Designated funds	1,744	859	(1,007)	-	-	1,596
	<u>4,243</u>	<u>7,103</u>	<u>(9,700)</u>	<u>(955)</u>	<u>2,656</u>	<u>3,348</u>
	<u>7,235</u>	<u>8,297</u>	<u>(11,332)</u>	<u>-</u>	<u>2,656</u>	<u>6,857</u>
Company	At 1 April 2020 £'000	Incoming resources £'000	Resources expended £'000	Fund transfers £'000	Investment gains £'000	At 31 March 2021 £'000
Restricted funds:						
Research funds	684	635	(294)	1,031	-	2,056
Everest fund	1,395	36	(945)	-	-	486
Awareness funds	392	6	(15)	-	-	383
Support funds	520	518	(378)	(77)	-	584
	<u>2,991</u>	<u>1,194</u>	<u>(1,631)</u>	<u>955</u>	<u>-</u>	<u>3,509</u>
Unrestricted funds:						
General reserve	2,495	6,195	(8,665)	(950)	2,656	1,731
Designated funds	1,744	859	(1,007)	-	-	1,596
	<u>4,239</u>	<u>7,054</u>	<u>(9,672)</u>	<u>(950)</u>	<u>2,656</u>	<u>3,327</u>
	<u>7,230</u>	<u>8,248</u>	<u>(11,303)</u>	<u>4</u>	<u>2,656</u>	<u>6,836</u>

PURPOSE OF RESTRICTED FUNDS

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 22.
Everest fund	During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. Related parties

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2022 The Charity owed TBTC Trading Ltd £37,933 (2021: £9,444).

The Charity owns 100 of the issued £1 ordinary shares of Acquist Data Holdings Limited, a company with the same registered address as The Charity. Acquist Data Holdings Limited wholly owns the share capital of Acquist Data Limited. Acquist Data Holdings Limited and Acquist Data Limited were dormant in the financial year. At 31 March 2022 The Charity owed Acquist Data Holdings Limited £100 (2021: £nil).

Trustees, their close family members and entities they control, made donations to The Charity totalling £41,336 during the year (2021: £16,783) and paid contributions totalling £381 (2021: £nil) during a number of our fundraising events.

21. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated to specific areas of activity as follows:

Trust and foundation	£'000	Charitable activity
Albert Gubay Charitable Foundation	141	Restrict fund for Research

22. Research awards

	2022 £'000	2021 £'000
Programme - Chesler - ICR - Medullo super enhancers	308	306
Programme - Pollard - University Edinburgh - Chromatin targets in GBM	-	317
Programme - Jones - DKFZ - Everest Centre	914	945
Programme - Kennedy - University Southampton - PNET5 QoL	45	43
Programme - Wurdinger - VU Amsterdam - WINDOW	-	387
Programme - Zadeh - University Health Network - Clinically aggressive meningiomas	130	300
Programme - Northcott - St Jukes - MERIT	130	291
Programme - Hankinson - University Colorado - Adamantinomous craniopharyngioma	267	216
Programme - Parrinello - UCL - Mapping spatio-temporal heterogeneity	357	339
Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC	299	238
Programme - Carragher - University Edinburgh - Therapeutic combinations in GBM	564	578
Project - Edinburgh - Brenan	-	(73)
Project - Development of a novel tumour-targeting thermogel activated by Matrix Metalloproteinases	-	(7)
Project - Clark - UCL Neurocognitive effects of medullo	-	(73)
Project - Kennedy - University Southampton - PROMOTE	-	(22)
Project - Rooney - University Edinburgh - BT LIFE	-	(28)
Project - Sharp - Newcastle University - Self-supporting management for survivors	111	-
Project - Northcott - St Jukes - Refining medullo in USA clinical trials	100	100
Project - van den Bent - Erasmus Medical Centre - Refining glioma classification in CATNON trial	-	18
Project - Taphoorn - Leiden University Medical Centre - Defining patient reported outcomes	-	43
Project - Hawkins - Uni Birmingham - Combining child and young adult data for better monitoring	18	140
Project - Thomas - Nottingham Childrens' Hospital - AC therapy in young people	82	-
Project - Schuemann - Massachusetts General Hospital - Extreme dose rate proton therapy	-	56
Project - Hegi - Lausanne - MGMT methylation	42	-
Project - Smith - Nottingham - RNA methylation	-	60
Project - Rominiyi - Sheffield - Ex-vivo 3D models	60	-
Clinical Trial - Kearns - University Birmingham - PNET5 CTU	44	44
Clinical Trial - HR-MB - Bailey - Newcastle	109	111
Clinical Trial - ARISTOCRAT - Short - Leeds	146	-
Fellowship - Bihannic - St Jude - Origins of Groups 3 and 4 medullo	-	54
Programme - Quest for Cures 2019 - Chesler ICR	296	338
Programme - Quest for Cures 2019 - Beroukhim - Dana-Farber	329	195
Project - Clinical Biomarkers 2019/2 - Zadeh - UHN	207	96
Project - Clinical Biomarkers 2019/2 - Euskirchen - Charite Hospital	96	101
Project - Expanding Theories 2019/2 - French - Erasmus	60	60
Project - Expanding Theories 2019/2 - Brandner - UCL	58	56
Project - Future Leaders 2019 - Croal - Nottingham	66	36
Project - Future Leaders 2019 - Watson - Lausanne	60	60
Project - Future Leaders 2019 - Miller - Massachusetts	60	60
Project - Future Leaders 2019 - Rendo - Dana-Farber	60	60
Project - Quality of Life 2019 - Byrne - Cardiff	65	88
Conferences and workshops - Kennedy - Southampton	(5)	-
Other	-	(85)
	<u>5,079</u>	<u>5,446</u>

thebraintumourcharity.org

Registered office: Fleet 27, Rye Close,
Fleet, Hampshire, GU51 2UH
© The Brain Tumour Charity 2021.
Registered Charity in England and
Wales (1150054) and Scotland (SC045081).



**THE
BRAIN
TUMOUR
CHARITY**

Accounts

ANNUAL REPORT AND ACCOUNTS 2020-2021



CONTENTS

	Page
1. Report of the Trustees	3
a. Strategic Report	12
b. Statement of the Trustees' responsibilities	40
2. Independent auditor's report	41
3. Statement of financial activities	45
4. Balance sheet	46
5. Cash flow statement	47

N.B. Images throughout taken prior to the Coronavirus pandemic.



CHAIR'S REPORT

In reflecting on the Financial Year 2020/21, it will of course go down in history as being the year of the COVID-19 pandemic – a global crisis which continues to play havoc with countless lives. This crisis has heightened the needs of those with brain tumours, as well as straining NHS brain tumour services further, significantly slowing the pace of research and impacting on our own income and resources.

This year has been about pulling together in response to the pandemic, to support those in need while making sure we're in a strong position to pursue our goals in an altered world once the crisis abates.

My enormous gratitude goes to all those who've stood with us during this time to support those with brain tumours – whether personally affected, fundraisers, volunteers, researchers, clinicians, partner charities, healthcare providers, campaigners or the team at The Charity. Each of you has gone to extraordinary lengths to make a difference in this most challenging of years. Thanks to you, together we've supported thousands during this most isolating and testing of times; we've been able to maintain our commitment to our pioneering research programmes; and have been able to sustain innovative projects that'll accelerate our goals of doubling survival and halving the harm that brain tumours have on quality of life.

In addition to coping with the effects of the pandemic, I'm proud to share some of the progress we've made over the past five years in this report, across all areas of our strategy, 'Defeating Brain Tumours'. As that strategy draws to a close, we used this year to consolidate that progress and renew our plans, in response to the heightened need for support and focussing our reduced resources during the pandemic, while pressing forward with long-term change. Our new transition strategy, 'Leaning In', provides the foundations for building upon our achievements, through what has been one of the most challenging periods in modern history. It aims to accelerate change in three ways: by ensuring the **Best Care Everywhere** through driving up standards; by harnessing the **Power of Data** to tackle inequality and evidence change; and by collaborating with all those who share our vision, hearing, strengthening and adding our voice to those **Voices for Change**, so we can support one another in coping with this devastating disease, raising funds and campaigning for a better future.

At the end of 2020/21, our CEO, Sarah Lindsell left The Charity after 10 years at the helm. Sarah joined The Charity when it was still quite small, although very ambitious, and built it into the formidable organisation it is today. Her passion and determination over the years played a vital part in taking us where we are, for which we thank her and wish her well for the future. I'm also most grateful to Dr. David Jenkinson, our Chief Scientific Officer, for stepping into the Interim CEO role following Sarah's departure and for so ably leading The Charity since then.

In September 2020, Angela Dickson MBE retired as a trustee after 23 years. Angela, with her husband Neil, founded The Samantha Dickson Trust in memory of their dear daughter who passed away from a brain tumour. The trust was one of the key founding charities which merged to become what's now known as The Brain Tumour Charity and, as one of our founders, Angela has worked tirelessly for our cause. I'm delighted that The Charity's relationship with Angela will continue with her becoming our first Emeritus Founder Trustee.

I'm equally delighted that Robert Posner will also be taking on a new role with The Charity as Emeritus Trustee after stepping down from his position as a trustee earlier in the year. Robert also joined The Charity as part of the 2013 merger that created what's now known as The Brain Tumour Charity, having served as a trustee with Brain Tumour UK since March 2008. He has our sincerest thanks for everything that's been achieved with his support.

I would like to also thank and pay tribute to my fellow trustees for their continual support and hard work. Trustees are often the unsung heroes in charities, giving their time freely and generously while having to oversee (particularly in the last year) some very stressful and challenging issues. The Brain Tumour Charity is blessed with having a board of Trustees that are talented, passionate and committed, and I'm deeply grateful for the unwavering support they provide in everything we do.

The achievements of the past and the potential of the future are only possible thanks to your continued support and we remain deeply appreciative of that gift. You've not only underpinned the sustenance and determination necessary over the last year but also provide us with the springboard and direction for the path ahead. I look forward to being a voice for change with you all, as we emerge with purpose from this crisis towards our shared vision of a world where brain tumours are defeated.

Jack Morris CBE

Chair of Trustees, The Brain Tumour Charity





CEO'S REPORT

The 2020-21 year has been one focussed on supporting the community through the pandemic. Not only were people less likely to come forward for a diagnosis, but treatments have been delayed and research halted, as NHS resources were diverted. It's been thanks to the help of amazing volunteers that we've been able to meet the increased demand for support this year, with the boosted team helping over 27,000 individuals directly (up 50%) - and over 1.2 million globally online (up 27% - in coping with their experience and navigating an NHS at full stretch. Sadly, at the same time, we've had to reduce our resources as, despite your inspiring fundraising efforts this year, the lack of big events meant that our income came under pressure. I want to publically recognise the selfless contribution made by those who left us this year to our long-term ability to serve the community.

We'd planned to share our new research strategy prior to the pandemic, based on wide consultation in 2019. Those plans have been postponed, but we're adapting them and will share them shortly, so we can continue to accelerate a cure. We did renew our overall strategy, Defeating Brain Tumours 2015-2020, as planned this year, although in a scaled down way, starting with an Impact Report. I'm delighted to introduce each section of this report with a taste of that impact as context, and links to where you can find out more.

Thanks to your support, the needle is shifting towards our goal of doubling survival: over the past five years, average life expectancy for those with high grade tumours increased by 5 months in the UK - the biggest percentage shift of any significant disease - representing countless celebrations and other precious memories. Momentum is building and our new strategy, 'Leaning In', will accelerate this further, reflecting the changed circumstances and our reduced resources but retaining our pioneering spirit and ambition.

The crisis has not stopped us in making progress aligned to this new strategy: in addition to growing the reach of our support, the community have shaped the development of a 'step-by-step' guide for patients that's now being used as UK best practice standard; we've mobilised a growing network of experts by experience - now over 700 people - whose voices are shaping our future direction; we've recruited a data science team to generate evidence to inform change; we've maintained the funding of our existing research programmes; and worked hard on awareness campaigns that matter the most to you.

As some will be aware, our outstanding CEO of 10 years, Sarah Lindsell, took the decision to move on during this year, once the new strategy was in place. On behalf of The Charity and wider community, we're deeply grateful for her inspirational and dedicated leadership over the past decade. That leadership transformed us into the global force we are today for championing justice, pioneering change, funding research and providing support and hope for those with brain tumours.

So this has been another year of change and challenge and it's only thanks to you that we can continue to represent hope for those most in need. As we close this tumultuous year, I'm deeply grateful for your ambition and passion which - together with the momentum of past years - we'll use to change the future for those with this brutal disease. Thank you for all that you've done and please continue to add your voice to ours so we can go further, together.

A cure can't wait.

Dr David Jenkinson
Interim CEO and Chief Scientific Officer



OUR VISION

Our vision is for a world where brain tumours are defeated.

OUR GOALS

Our two overarching goals are:

1. Double survival.
2. Halve the harm that brain tumours have on quality of life.

OUR VALUES

Our values underpin our culture, the way we do things and what we believe in. We are **PIONEERING, PASSIONATE, COLLABORATIVE** and **SMART**.



FOUNDERS WIN GLOBAL RECOGNITION FOR CHARITY ACHIEVEMENT

Neil and Angela Dickson have been named as the first recipients of a major global award from world leaders in the field.

They both set up the Samantha Dickson Brain Tumour Trust at their home in Dogmersfield following the death of their daughter in October 1996, just a few days before her 17th birthday.

The couple had discovered there was no charity dedicated to offering support for patients and families affected by a brain tumour, while research into the disease was almost non-existent. The Trust went on to become the largest dedicated brain tumour charity in the world. In 2013 it merged with two similar organisations to become what's now The Brain Tumour Charity. In 2014 the couple were both awarded an MBE. So far, we've committed more than £38 million to research into brain tumours - more than any other organisation of its kind in the world. We've supported around 32,000 people affected by the disease.

Now Mr Neil and Angela are to receive the newly-launched Paediatric Neuro-Oncology Community Service Award from the International Society of Paediatric Neuro-Oncologists. The award was presented to them at the virtual ISPNO 2020 annual conference today, the 14th December. Dr Koichi Ichimura, Chair of ISPNO2020, said Mr and Mrs Dickson had been the 'strongest supporters' of research into childhood brain tumours over many years.

"Through their endless dedication and tireless work, they have helped a great many researchers, patients and families across the years. The Chairs of ISPNO over the last 10 years agreed unanimously that Mr and Mrs Dickson deserve to be recognised at the highest level with this prestigious award, and we are tremendously honoured to nominate them."

Neil, said: "Angela and I are immensely proud to accept this award from ISPNO. We could never have dreamt, in those early days after we lost Samantha, that her legacy would reach so far and so wide. When she was diagnosed with a brain tumour at the age of 14, there was absolutely no support mechanism for those diagnosed and research into the disease was almost non-existent. Through The Samantha Dickson Brain Tumour Trust we were able to change all that.

"In the first 10 years, we had two research breakthroughs which led to two new treatments for childhood brain tumours. Our work to raise awareness of childhood brain tumour symptoms culminated in the launch of the HeadSmart campaign, which has won five national awards. Since HeadSmart began, the average time taken to diagnose a childhood brain tumour in the UK has fallen from more than 13 weeks to 6.5 weeks.

"On the support side, we now have a substantial network throughout the UK and globally to help patients and their families. And The Brain Tumour Charity is still growing, investing in research around the world to accelerate progress towards our twin goals of doubling brain tumour survival and halving the harm caused by the disease."

Sarah Lindsell, Former Chief Executive of The Brain Tumour Charity, said: "Since losing Samantha, Neil and Angela have worked ceaselessly towards ensuring that other families facing the shock of a brain tumour diagnosis are not left without help or without hope. This award from ISPNO recognises the very real difference they've made to so many thousands of people in the UK and around the world whose lives have been changed forever by this devastating disease.

"It's richly deserved and all of us at The Brain Tumour Charity are thrilled that their achievements have been marked in this way."

OUR OBJECTIVES AND ACTIVITIES

The objectives of The Charity are to provide public benefit by:

- Relieving sickness and protecting good health by supporting research and publishing useful results of research into the nature, causes, diagnosis and treatment, as well as the social consequences of, tumours of the brain and central nervous system
- Relieving the suffering of people with tumours of the brain and central nervous system, their families and carers, through the provision of information and support
- Advancing the education of the public in all areas relating to tumours of the brain and central nervous system

The Charity's aims to achieve these objectives through the following activities:

- A Cure Can't Wait – This initiative is committed to funding leading research projects and programmes under the guidance of our Scientific Advisory Boards. All projects are reviewed annually to determine how they are performing against their stated objectives.
- Every Patient is a Research Patient – This aims to relieve suffering and support research by enabling all patients to contribute to research and clinical trials. We've created a pioneering app and databank BRIAN (**B**rain tumou**R** **I**nformation and **A**nalysis **N**etwork) and we measure the number of patients who contributed to research.
- Early and Accurate Diagnosis – Working to reduce diagnosis times and improve accuracy which should relieve suffering and harm. This is achieved through different activities that raise awareness and assist early diagnosis. Improvements are measured by reduced diagnosis times and better outcomes.
- Equal Access to the Best Treatment and Care – By ensuring every person with a brain tumour has the same access to high-quality treatment, care and information we will reduce suffering. Activities such as publishing a Patient Guide, performing regular surveys and working with the Tessa Jowell Centres of Excellence will drive up standards of care.
- Improving Life Today – This advances education and relieves suffering by providing information and support to help every person navigate the healthcare systems. We measure our performance by the number of contacts we have and events we hold.
- United in our Battle to Defeat Brain Tumours – Leading and facilitating a community that works collaboratively to achieve all of our objectives by working more effectively together. Success in this area can be measured through mergers with other charities and the number of events held and participants attending.

PUBLIC BENEFIT STATEMENT

The Trustees have considered the Charity Commission's general guidance on public benefit and have taken it into account when reviewing The Charity's aims and objectives and in planning its future activities. The Trustees are satisfied that the aims of The Charity are carried out wholly in pursuit of its charitable aims for the public benefit.



**THE
BRAIN
TUMOUR
CHARITY**

A CURE CAN'T WAIT



STRATEGIC REPORT

A CURE CAN'T WAIT

We'll invest in forward-thinking, outcome-orientated and patient-focused research. We'll bring about global collaboration to speed up the time it takes to turn discoveries into treatments and cures.

This initiative was driven by our 2015 research strategy, 'A Cure Can't Wait'. Since 2015, and under the guidance of our Scientific Advisory Boards, we have committed over £38m to leading research projects and programmes, resulting in a global, collaborative network of brain tumour researchers. You can see our full impact [here](#), but in summary we have:

- Funded the discovery of new brain tumour knowledge, with our research leading to nearly 300 new research papers, tools and databases.
- Translated research into new or improved treatments, resulting in almost 30 new clinical trials, products, interventions and start-up companies focussed on improving outcomes, including pioneering partnerships with industry and the launch of '**BRAIN MATRIX**', a UK-wide platform study designed to accelerate the development and delivery of brain tumour clinical trials.
- Stimulated new research into brain tumours, with our investment of £38m attracting £43m in collaborative funding from other investors and a further £46m in follow-on funding for these pioneering projects.



We maintained funding towards our existing research commitments, spending £6.5m this year (highlights below). This was less than we wanted because of COVID-19 and the fact that researchers were diverted to fighting the pandemic, with many laboratories forced to close or operate at reduced capacity globally. However, we were the only major funder to commit new funds to research into brain tumours this year, awarding 11 new grants worth £4.8m. We've also been planning for the future, in line with our new strategy, by using the **Power of Data**, building our capability to use data from research to provide evidence for change. We'd already consulted widely on an updated research strategy, prior to the pandemic, and will share this shortly as research restarts.



HIGHLIGHTS OF 2020/21

NEW RESEARCH PARTNERSHIP WITH THE OLIVIA HILSDON FOUNDATION

The Foundation was set up to fund research into brain tumours in loving memory of Oli Hilsdon, who lost his battle with glioblastoma (GBM) – an aggressive grade 4 brain tumour – in January 2019, just 10 days before his 27th birthday. The Foundation's promising partnership with The Brain Tumour Charity will accelerate research into GBM in the search for a cure.

“The Oli Hilsdon Foundation believes that exceptional breakthroughs come from exceptional research – and breakthroughs are desperately needed in brain cancer. Our collaboration with The Brain Tumour Charity allows us to invest 100% of our resources in the most effective way, committing to world-class, pioneering projects that offer the best chance of success and will lead to change.

- The Oli Hilsdon Foundation

PROMISING RESEARCH ON LOW GRADE GLIOMA DRUG FOR CHILDREN

Our researchers from The Everest Centre published new results in 2020 that show the drug trametinib can stop tumour growth in some children with low grade brain tumours, and in some cases the tumour was seen to shrink as well. This highlights the need for more prospective trials (analysing information as the treatment is given) to test promising new treatments for these children.



IMPROVED UNDERSTANDING OF CHILDHOOD BRAIN TUMOURS

Our funded researcher Todd Hankinson and his team at Children's Hospital Colorado have studied biological differences between paediatric and adult adamantinomatous craniopharyngiomas (ACP) tumours. They concluded that there were no differences in the presence of these targets between age groups. This exciting news means that in the future, identification of targeted therapies and implementation of these into the clinic may be relevant for both children and adults.

“Research into ACP biology has been overlooked and nearly no novel therapies have been introduced for over 50 years, resulting in patients having the lowest quality of life. This research has massive potential for patient benefit.

- Dr Todd Hankinson, University of Colorado, USA

NEW WAYS TO TEST DRUGS FOR CHILDHOOD BRAIN TUMOURS

Funded researcher Till Milde and his team from the Hopp Children's Cancer Center Heidelberg (KiTZ) have developed a new test system that enables them to rapidly test different combinations of drugs and measure their effect on paediatric low-grade glioma cells grown in the lab. Using this test system, the researchers were able to identify a group of promising candidate substances that inhibit the 'MAPK' signalling pathway, thereby suppressing the growth of the cancer cells. These results are currently being used by the KiTZ Clinical Trial Unit to prepare a phase I/II clinical trial.

PREDICTING RELAPSE AND IMPROVING TREATMENT FOR MEDULLOBLASTOMA

Research led by Professor Steve Clifford from Newcastle University has revealed that experts can now identify the time, nature and outcome of medulloblastoma relapse from the biology of the disease at diagnosis and the initial therapy received. This breakthrough will help doctors to identify which patients are most at risk of continuing problems with the disease, giving them the opportunity to fine-tune treatment and surveillance to improve quality of life after relapse for these children.

IDENTIFYING DIFFERENCES IN GLIOBLASTOMA CELLS

Our funded researchers Drs Stuart Smith and Ruman Rahman at the University of Nottingham Biodiscovery Institute, were able to use a substance called 5-ALA to separate cells found at the core of a glioblastoma (GBM) from the cells found at the edge of the tumour and which infiltrate into the surrounding healthy brain tissue. This enabled them to uncover key differences between the two cell populations. One of the differences the team found was that a gene called SERPINE1 was only expressed in the infiltrating cells but not in the core cells; when these cells were treated with a drug targeting SERPINE1, they lost their infiltrative properties. These exciting findings give hope towards developing treatments that'll target invasive GBM cells.

RESEARCH WEBINARS DURING THE PANDEMIC

Over the year, we've curated and facilitated a series of 60-minute webinars for researchers. The webinars feature experts in the brain tumour field speaking on a wide range of current topics and have helped to keep the research community connected and engaged during the pandemic. So far we've held 10 webinars involving nearly 1,000 researchers. This has resulted in us reaching 904 researchers who are new to us and who'll therefore receive information about our research strategy and funding opportunities.

“This format makes it so much easier to hear, and share, new data and explore new avenues as they arise, which is sure to accelerate progress.

-Dr Lucy Stead, Head of Glioma Genomics, Leeds Institute of Medical Research, UK

CANNABINOID DRUG TRIAL

To enable us to try to continue investing in new, world-class research to improve survival for adults affected by a glioblastoma, we're piloting a new research funding mechanism. There's considerable interest in both the lay and scientific communities relating to the activity of cannabinoids in brain tumours with the view that cannabinoid-based products not only help to relieve the symptoms of a brain tumour but also have a positive impact on survival. In February 2021, we launched an exceptional grant round with a view to funding a phase II/III clinical trial of cannabinoids in the treatment of high grade gliomas in adults later this year. This was approved by our Scientific Advisory Board, and we're now seeking to raise the funds via an urgent fundraising campaign before the trial can begin.





EVERY PATIENT IS A RESEARCH PATIENT

We'll make sure every patient is able to contribute to research and clinical trials, as this gives them faster access to treatments, better care and the opportunity to help defeat this disease.

Since 2015, we've launched our pioneering app and databank, BRIAN (**B**rain tumou**R** Information and **A**nalysis **N**etwork), to harness the power of patient data for those affected and for researchers. We encourage people to participate in research not only through BRIAN but also through our growing Involvement Network (see below), our step-by-step guide to brain tumour diagnosis and treatment, and on social media. Our patient survey found that, in 2020, 42% of people contributed to research or discussed options – such as bio-banking or molecular testing – compared to just 24% in 2016. The clinical trial options for brain tumour patients remain low compared to other cancers, but we're taking steps to address this with the BRAIN MATRIX clinical study platform – see below.

For more information on our impact in this area, see [here](#).

We're building on this progress by developing the BRIAN project, using the **Power of Data** to support those using the app and to accelerate research. We're also funding the BRAIN MATRIX platform study and driving forward best practice in the treatment centres so that more people are offered the chance to participate in research, including routinely having molecular testing of their tumour.

HIGHLIGHTS OF 2020/21

OPENING OF THE BRAIN MATRIX CLINICAL TRIAL PLATFORM

One of the most recent significant developments in research and care for people with a brain tumour is the opening and recruitment of the first patients to the Tessa Jowell BRAIN MATRIX. Set up and funded by The Brain Tumour Charity, BRAIN MATRIX provides a platform to trial precision medicine, using its multi-centre 'portal' protocol to recruit patients and enable enrolment into biomarker-driven trials. All participants in BRAIN MATRIX will have their tumour tested in a lab to uncover its molecular profile. In addition to the information about molecular changes in the tumour, imaging, treatment and other clinical and quality of life data from each participant will be collected and analysed at a central hub. This will allow for more powerful analysis than ever before. By having molecular profiles ready-to-hand, future trials will be a step ahead and people will know, sooner, if new experimental treatments could be appropriate for them. BRAIN MATRIX represents a significant step towards providing the infrastructure to facilitate the opening of glioma clinical trials in the UK as well as ensuring the feasibility of genetic testing in a clinically relevant timeframe.

BRIAN

BRIAN is our ground-breaking app and databank that's revolutionising the way we tackle brain tumours. It's the biggest data collection project in the history of research into this disease, and it's powered by those who are personally affected. BRIAN not only helps people with a brain tumour take more control of their diagnosis but will help shape the future of research into brain tumours.

First, BRIAN supports people by letting them track symptoms, appointments, moods and more, quickly and easily logging their experiences and getting the knowledge they need to make more informed decisions. Then, this anonymised data will go to world-leading scientists, who'll use it to kickstart vital research into brain tumours. Every single experience logged adds hope for the future and accelerates progress towards a cure.

We were thrilled to launch BRIAN as a mobile app in December 2020 – and since then it's gone from strength to strength. As of writing, we now have over 5,000 sign ups, a fantastic stride forward in our drive for better data availability, better care and improved quality of life for people diagnosed with a brain tumour.

“ BRIAN helps you stay on top of your diagnosis and treatment and it actually helps you to learn from other people's experiences, make better informed decisions about your own treatment, and empowers you as a patient or as the carer. And I think that's a really positive thing in the very difficult world that you've found yourself in.

Knowing that Silas's data is now in BRIAN, and might one day hopefully contribute to the advancement of treatments for brain tumours, helps to give his life meaning, which is really comforting. And I think the important thing to remember is that the more data that is in BRIAN, the better BRIAN becomes.

-Sarah Pullen, whose son Silas died from a brain tumour in 2013 at 11 years old



“Working with Lorcan and The Brain Tumour Charity has been such a positive experience. Our members were provided with an evening of informed advice, debate and up-to-date medical knowledge, delivered in an easy-to-understand manner. Our members are already asking when the next event is!

-Sali Davis, Chief Executive of Optometry Wales

EARLY AND ACCURATE DIAGNOSIS

We continue to work to reduce diagnosis times and improve accuracy of diagnosis so that brain tumours are treated earlier, with the best possible treatment at the right time.

Our **key impact** over the past few years has been through our HeadSmart campaign, which has helped to reduce childhood diagnosis times from 13 weeks (prior to the strategy) to 6.5 weeks, making a difference to thousands of children. Another success since 2015 has been the progress made in access to biomarker testing, which is critical to getting appropriate treatment for a tumour. Testing is now available to all children following our pilot scheme, and an increasing number of adults (up from 6% in 2016 to 30% in 2020). Our main challenge has been in adult early diagnosis, which we know from our 'Life with a brain tumour' research, and anecdotally, to be an issue, with a high proportion of diagnoses following an emergency admission.

The Charity commissioned research to understand this better and the results included an improved understanding of, and evidence for, symptoms of brain tumours in adults. This year, we are using this knowledge to develop a symptom awareness campaign due to launch post COVID-19. Our HeadSmart campaign also continues, with a move away from physical HeadSmart cards to digital campaigning by the **Voices for Change** in the community that care deeply about this issue. Also, as we know that many people are diagnosed via their optician, we've been working to raise awareness of brain tumours within that sector (see below).

HIGHLIGHTS OF 2020/21

ADULT EARLY DIAGNOSIS CAMPAIGN

With little to go on but a gut feeling that something is wrong and some disconnected symptoms, our research shows that many adults are unable to make sense of what is happening, sent home multiple times when trying to get help, misdiagnosed and sometimes accused of exaggerating their symptoms by baffled healthcare professionals. This delay – commonly months and often years – causes real anxiety and gives the tumour time to grow so that, when the diagnosis finally comes, the outlook can be poorer and key abilities, like sight, can be put in jeopardy. Our research has identified the common signs and symptoms of a brain tumour and we're prioritising the roll-out of an adult symptom awareness campaign, building on the success of our HeadSmart campaign for children's symptoms, as soon as the impact of the pandemic declines a little.

OPTICAL ENGAGEMENT

We've been hosting a range of virtual events to raise awareness of our work and the vital role optometrists, dispensing opticians and students can play in brain tumour diagnosis. This year, we've trained over 3,600 optical professionals in 41 training webinars ranging from 8 to 400 people, and enabled these professionals to play their part in early diagnosis.



EQUAL ACCESS TO THE BEST TREATMENT AND CARE

We're working to ensure every person with a brain tumour has the same access to high-quality treatment, care and information regardless of postcode, age or tumour type.

Since 2015, we've published a Patient Guide to raise awareness of good practice and carried out numerous campaigns to close the gaps in care. Our regular patient surveys show significant increases since 2015 in access to key services such as a holistic needs assessment (13% increase); biomarker testing (24% increase); and the contact details of a key worker (19% increase). We also campaigned for 5-ALA (the 'pink drink') to be available for all patients undergoing surgery, to improve the accuracy of surgery. For more details see [here](#).

This year, we've strengthened the framework for making sure everyone has access to the best care. Shaped by experts by experience, we've upgraded both our understanding of best practice and the scope of our surveys for people to give feedback on those standards. Our resulting excellence standard now underpins our support offer and the related and comprehensive suite of Improving Brain Tumour Care Surveys gathers feedback and helps us drive standards higher, with thousands starting to share their experience using these surveys this year. We'll use this information and evidence to drive further progress in the future.

HIGHLIGHTS OF 2020/21

IMPROVING STANDARDS OF TREATMENT

During the year we worked to upgrade our Patient Guide into a standard for excellence, shaped by experts by experience. The resulting standard is set out in our step-by-step guide to life with a brain tumour and forms an integral part of the support we provide online and face to face. At the same time, we developed a series of Improving Brain Tumour Care Surveys to get timely feedback on the application of those standards



across the UK and across six areas of care. These surveys have already been completed by thousands of people going through treatment and we've just shared the first findings with the treatment centres as part of our mission to improve care across the UK.

“I found out I had a meningioma eight years ago following a sudden seizure at home. While the initial care provided in my local A&E was exemplary, the subsequent poor communication and inability to speak with any kind of specialist for several days meant I felt completely abandoned and terrified about what was happening to me. It doesn't need be like this for others.

The Brain Tumour Charity uses a series of short, easy-to-complete surveys to gain invaluable data and insights from those who have a tumour diagnosis. This information is then used to help highlight where treatment centres are performing well and also where standards of care can be improved."

-Neil Munn

TESSA JOWELL CENTRES OF EXCELLENCE

Our Excellence Standard now sets the bar for treatment centres applying to become Tessa Jowell Centres of Excellence: a programme run by the Tessa Jowell Brain Cancer Mission, of which we are a founder member. We can confirm that nine treatment centres were designated as Tessa Jowell Centres of Excellence with six more working towards the standard. We continue to work with the Mission, with our Involvement Network and with thousands completing the Improving Brain Tumour Care Surveys to raise standards and identify gaps.



IMPROVING LIFE TODAY

We provide information and support to help every person to navigate the system and improve their quality of life.

Looking back, we commissioned 'Life with a brain tumour' research in 2015 to find out what life was really like for those affected by a brain tumour diagnosis. This was the most comprehensive study of its kind globally and the results were compelling – please refer to the **reports** for the detailed impacts. Our services have grown over the past five years, driven by these findings. We've also made much more information available for self-service via our website, have award-winning information sheets on a wide range of topics from brain tumour types to how to cope after a diagnosis, set up a Benefits and Money Clinic, established a relationship support partnership and are now using BRIAN to take this support further. For more on our impact see **here**.

During 2020 we developed The Excellence Standard (see above) – an evolution of our original Patient Guide – which is now woven into our support. Our service offer now spans: digital support through the website and BRIAN app, with email support journeys and interactive tools; advice line through phone, email, live chat and social media, with a dedicated service for adults, young adults and children and families; specialist partnerships delivering a Relationship Support Service and Benefits and Money Clinic; and peer support through 11 support groups, virtual events and podcasts.

Overall, our support services grew significantly this year in response to the pandemic. 1.2 million people used our website support pages (an increase of 27% from last year); peer support through online groups continued to grow with 20,015 members across 11 support groups (up 50%); and calls to our advice line were up 50% to 3,792 calls with longer, more complex and more emotional support required. To help meet this demand, we turned to the community, who responded amazingly in volunteering their experience and time – fully trained and supported by us – in many ways including monitoring online groups and answering support call lines. Our thanks go to each and every one of them.

We'll build on this going forward, using our combined voices for change to support each other and reach more people in need.



HIGHLIGHTS OF 2020/21

SUPPORT DURING THE PANDEMIC

As the pandemic spread, we coordinated all our support and managed spikes in demand by creating a comprehensive coronavirus (COVID-19) hub on the website. This hub had 40,500 visits and 4,300 video views in its first two months and now 105,000 views over the year. People asked us for help with: understanding and accepting changes to treatment; assessing vulnerability and what isolating measures to take; thinking about treatment choices if infected with coronavirus; and coping practically and psychologically with isolation. We sourced responses from leading experts, uploading over 15 videos on the website, to help answer questions from the community while official communications caught up.

VIRTUAL EVENTS

Out of necessity, our support events went online this year, with over 160 people joining us (for an average of almost four events each), including family events, young adult events, phone support groups, and events for carers and adults. We also ran a number of Facebook Live events for several online support groups. Although this was a significant decline in attendance than for physical events (with over 70% fewer people than last year), virtual events do enable greater accessibility and we will make this option a permanent fixture long term.

“The reason I joined was because my friends don’t understand what I go through, I don’t feel like I can open up to them in a way that I could for someone who understands. People can give me support and advice and I can do the same and it’s just a very nice feeling of community and feeling that you’re not alone; it’s a reassurance that other people know what you go through.

- A teenager who took part in our Online Meet Ups for Teenagers

“It was lovely to meet new people, hear their stories and gauge others’ experiences of scans etc. during and after lockdown.”

- A participant in our Young Adults’ virtual meet ups



OUR YOUNG AMBASSADORS

Our Young Ambassadors are an integral part of The Brain Tumour Charity, helping us raise awareness of brain tumours and passionate about changing the future for those affected. The two-year Young Ambassador programme is for young adults aged 18-25 and we currently have 23 Young Ambassadors along with a team of Young Ambassador Mentors. As well as campaigning and supporting other teenagers and young adults affected by a brain tumour diagnosis, their ideas and input have been vital in shaping our Young Adult Service and developing our resources and we thank them all.

“Through the Young Ambassadors programme I've had support that I never knew I needed. I've met the most wonderful group of people who inspire me every day. For the first time I was able to speak to someone who'd been through the same things I'd been through, and I realised all the feelings I had were OK, they were normal. It was like having a huge weight lifted off my shoulders, and finally, I've come to terms with what happened.

- Georgia

UNITED IN OUR BATTLE TO DEFEAT BRAIN TUMOURS

We will lead and facilitate a community that works collaboratively. We value everyone's contribution.

Over the past five years, we've worked hard to bring an historically fragmented community together to defeat brain tumours. For those personally affected, we've built our advocacy and research network communities – with our amazing Young Ambassadors and the Research Involvement Network as key highlights. Specific events, such as The Twilight Walk and young adult meet-ups as well as our online peer-support communities and media stories, are all established as platforms for bringing people together and demonstrating impact. The development of funding partnerships is now central to our research and fundraising plans and our culture going forward – and have helped attract a further £89m directly from our own £38m of research spend since 2015. Please see [here](#) for more details.

This year, we've leant into the community further to continue, in line with our new strategy, to make an impact with our restricted resources. For example, we've brought all of our volunteer groups together under one Involvement Network; we've developed different ways to help our amazing supporters fundraise in a pandemic; we've welcomed new named funds (Supporter Groups) to The Charity; and we've merged with another UK charity to provide better meningioma support services. We'll build further on mobilising, combining and amplifying these voices for change going forward.

HIGHLIGHTS OF 2020/21

THE TWILIGHT WALK GOES VIRTUAL!

Sadly, The Twilight Walk could not go ahead due to the pandemic but we instead supported our amazing community in doing their own socially distanced walks during October and November 2020. This was a great success, thanks to the inventiveness and persistence of so many, with over 500 supporters taking part, raising over £300k between them.

“2020 had always felt like it would be my year to take part and I wasn't going to let the coronavirus pandemic stop me from doing that. It's been amazing for me to be back outside and to be completing the challenge finally. This is something that I always wanted to do – particularly to help raise awareness of and fund research into more rare brain tumour types like my own to help others like me.

- Sadaf

MERGER WITH MENINGIOMA UK

Meningiomas are the most common form of brain tumour in adults, accounting for around one in three of those diagnosed. The vast majority of meningiomas are low grade (non-cancerous) but they can cause significant health problems and damage to quality of life.

In 2020 we merged with Meningioma UK, consolidating our resources in a drive to improve services and outcomes for everyone affected by a brain tumour. Meningioma UK was founded in 1998 by Ella Pybus and Dr Caroline Rutgers, both of whom had been diagnosed with a meningioma. The charity focused on offering support and information to people affected by a meningioma. Following Dr Caroline Rutgers' death, Ella Pybus remained at the helm of Meningioma UK until the decision to merge with The Brain Tumour Charity.

“Our community was always at the heart of this decision. Together, with unified resource and vision, we'll be able to support more of, and do more for, the thousands of families whose lives are shattered by a meningioma diagnosis. This merger will build on the successes of the two charities and create a stronger, more powerful voice for change in the future.

- Ella Pybus

“This merger is extremely exciting news. Creating larger communities that work together to advance understanding and treatment of rare diseases is critical. The merger will accelerate progress, without doubt; driving new research and improving clinical practice, allowing the voices of many, not a few, to be heard.

- Professor Richard Gilbertson

INVOLVEMENT NETWORK

During the year, we called on members of the community with personal experience of brain tumours to join us, as people who are passionate about improving outcomes for everyone affected. Supported by us, these champions represent the brain tumour community in shaping our work and direction, using their own experiences as well as taking into account the issues and challenges that affect the wider community. To date, over 700 people have joined the Involvement Network as influencers, with 20 taking on a formal volunteering role at The Charity to directly input into the way we do things. We look forward to working together to change the future!

FINANCE REVIEW

The global pandemic, had a severe impact on The Charity's finances and activities throughout the financial year. Income fell 26% (£3.0m) to £8.3m compared to the previous year due to the pandemic and would've fallen further were it not for the generosity of the community.

The fall in income necessitated difficult decisions to control costs, including reducing the size of the team and ceasing or delaying avoidable expenditure. While doing this, priority was given to maintaining our research commitments and supporting the community, many of who needed our help more than ever as they had to cope with the impact of the pandemic both directly in their lives and due to the care they were receiving from health services being under severe pressure.

Where possible The Charity made use of the Coronavirus Job Retention Scheme, furloughing staff rather than losing them.




INCOME

Our funding comes through a diverse portfolio of income streams, with no reliance on any one stream. This provides greater security in funding multi-year research commitments.

The nature of the pandemic, with the main measure to control it being social distancing measures for the duration of the financial year, meant that face-to-face events were most heavily impacted. Mass social gatherings such as marathons, as well as smaller gatherings like cake sales or corporate fundraisers, were postponed or cancelled. Similarly fundraising dependent on travel such as sponsored activities, most notably Everest in the Alps, could not take place. Of the £3.0m fall in income, £2.5m is attributable to the reduction in Events, Community Fundraising, Celebrity Foundations (the Lewis Moody Foundation) and Everest in the Alps. The fact that this fall is not larger is thanks to the generosity and ingenuity of our supporters and fundraisers who switched to virtual events or new forms of giving to continue to raise money.

The Charity achieved an income of £8.3m against a budget of £8.0m which was considered an excellent result in the circumstances. The budget was set taking allowance of the pandemic and was 40% lower than it would otherwise have been.

The Charity made use of the Coronavirus Job Retention Scheme and £329k of grants from the scheme is included in "Other Income".



EXPENDITURE

Expenditure in the year reduced by £1.2m to £11.3m. The reduction was necessitated by the restriction of activities caused by the pandemic as well as a need to reduce expenditure given the fall in income and uncertainty due to the pandemic.

We are a research charity and funding quality research is vital to us achieving our ambitious objectives. In the year we prioritised funding of research projects. For that reason we both committed to 11 new projects at a cost of £4.8m over the coming years, and maintained funding to our existing projects with a total research spend this year of £6,644,000, slightly exceeding last year's £6,567,000.



Other than in research, in other areas spending was down on last year as a response to the pandemic. General overheads were reduced and staff numbers and costs fell. Fundraising spend was down £0.5m to £1.7m as physical events could not take place and had to be deferred or became virtual. Expenditure on patient support reduced £0.6m to £2.1m despite the level of support via calls and on-line increasing. You can read more about this and our other achievements in the year on pages 24 to 26 of this report.

The Charity aims to spend at least 80p of every pound of expenditure on its charitable objectives. In the year to 31 March 2021 we managed to spend 84p as we continued our investment in quality research.

The Charity has one subsidiary, TBTC Trading Limited. The subsidiary, which is wholly owned by The Charity, carried out non-charitable retail trading activities for the benefit of The Charity. During the year, TBTC Trading Ltd made a profit of £21k which is to be donated to The Charity.

INVESTMENTS AND CASH

The COVID-19 pandemic caused considerable volatility in world-wide stock markets. At the end of the previous financial year The Charity's investments were valued £12.0m after booking a loss of £1.8m in that year. In the financial year ended 31 March 2021 The Charity's investments recovered this loss and increased further in value, with a gain of £2.7m in the year, such that they ended the year at a value of £14.7m. This exceeded the budgeted gain of £0.5m. Cash held as at 31 March 2021 was £5.0m.

RESERVES POLICY

COVID-19 has had a significant impact on The Charity's income in the financial year to 31 March 2021 and it will continue to impact the year to 31 March 2022. Before the outbreak of COVID-19 the reserves policy of The Charity was to maintain unrestricted funds of at least six months' operational costs to ensure the long-term sustainability of our services for our beneficiaries and to support our research commitments. The annual operational cost is about £5.9m. The level of total Funds at 31 March 2021 was £6.9m, consisting of unrestricted

general reserves of £1.8m, designated of £1.6m and restricted of £3.5m. After deducting the value of functional fixed assets, Free Reserves available are £1.4m.

The restricted and designated reserves are earmarked for use in the next two financial years. As a result of COVID-19, The Charity's new reserves policy until 31 March 2023 is to have total reserves in excess of six months' operational costs. As at 31 March 2021, the actual cover was 13.9 months.

At 31 March 2021, we had unaccrued but committed research expenditure totalling £13.7m which was subject to the satisfying of our ongoing monitoring requirements and expected to fall due over the next five years. The investments and cash at 31 March 2021 (which are all liquid) were £19.6m.

Our Supporter Groups typically express a preference over how the funds they raise should be spent. These preferences usually include our research or support activities and The Charity has earmarked these funds for future specific projects in the next two financial years. Income raised by these Supporter Groups is designated by the Trustees for the activities identified by each group.

From time to time, The Charity may hold accumulated reserves, which are intended to be utilised to commission further research and to cover existing research commitments. Accumulated funds are invested in accordance with The Charity's investment policy.

The Finance Committee meets at least three times a year to review income, expenditure and all other financial issues, including risk, and reports to the main Board of Trustees.

INVESTMENT POLICY

The investment of funds is controlled by the Trustees who've appointed The Charity's Finance Committee to implement the Trustees' investment decisions. Albert E Sharp and Smith & Williamson have been appointed to manage the investment of any surplus liquidity we may have from time to time.

The mandate agreed with the investment managers is to hold a mixture of good quality cash proxies, government gilts and other fixed income securities, together with some equity exposure, with the objective of generating a balance between capital growth and income generation over the investment cycle. All investments are liquid. In reaching investment decisions, the Trustees consider the cash position of The Charity and our projected short and medium term cash needs. Investment manager performance is measured against established market benchmarks suitable for each investment class.

Overall, investment decisions are designed to produce the best financial return, within an acceptable level of risk, and also to maintain the value of funds in real terms, so far as practical. At the year end, The Charity had a £14.7m portfolio of UK equities, fixed interest securities, mixed funds, alternative investments and cash. In a volatile year for investments due mostly to COVID-19 the portfolio generated income of £355k and a valuation gain of £2,497k.

EMPLOYEES

The Charity operates an equal opportunities recruitment policy. The Remuneration Committee is responsible for overseeing The Charity's pay and reward structures for all staff. The Remuneration Committee is also responsible for setting senior management salaries annually; having taken account of skills and experience, pay levels in similar organisations and the achievement of personal objectives and living The Charity's values.

The long-term success and performance of The Charity is directly linked to the talents, motivation and accomplishments of our employees. We recognise the importance of developing our employees and focus on building organisational capability through first recruiting great people, then building high levels of relevant skills and knowledge through our High Performing Team programme. Staff motivation is fostered by providing an environment where work is stimulating and rewarding and a high level of collaboration across the organisation is encouraged.

The work we do wouldn't be possible without the incredible contribution we receive from our volunteers. We currently have 1028 active volunteers across the UK, which has grown from 818 last year, who support in



different roles within the organisation. Voluntary activities include: supporting community fundraising activity, attending challenge events, campaigning, reviewing information resources for those diagnosed with a brain tumour, sitting on the panel who decide which research we fund and supporting different projects in our head office.

RISK FACTORS

The Trustees have considered the major risks to which The Charity is exposed. They have reviewed those risks and established systems and procedures to manage them such that they are part of the senior leadership's regular management focus. The Finance Committee reviews governance and risk during each year and makes recommendations on best practice to the Trustees. The principal risks and uncertainties facing The Charity, and how we endeavour to mitigate these, are:

- That we fail to secure adequate income. We've developed our detailed fundraising strategy, intended to widen the balance of our portfolio of fundraising activities. We've invested in our people and systems to increase our fundraising capability. We measure fundraising performance against budgets and forecasts. We maintain at least six months of reserves. We have no overreliance on any one income stream and generally 40% of our income for the year is known income at the start of the year. The investment in CRM systems helps optimise stewardship plans.
- That we're not able to commission enough high-quality research projects. We're developing our engagement with the brain tumour research community, and working to build capacity in the sector. We're also looking at alternative research models. In addition, we've extended funding globally and put significant emphasis on building relationships with key researchers.
- That we become affected by damage to our reputation, or by negative sentiment in the charity sector. Entering and winning charity sector awards is a strong mitigation factor in this area. We also manage reputation risk through staff training and effective HR and volunteer policies. We monitor social and traditional media to inform us of factors impacting The Charity and the wider sector. We continue to be transparent and trustworthy in providing effective communications with donors, stakeholders and other key groups.
- That our IT infrastructure is not adequate to support our activities. We continue to invest and develop improved IT platforms and provide suitable training for our staff. Our IT infrastructure is hosted and managed externally by an IT solutions company.
- That we're the victim of cyber-crime. We outsource our IT hosting to a third party who meet the ISO 27001 Standard for datacentres, and ensure that we have leading-edge malware protection and cyber security. Online banking arrangements include double authorisation of all transactions and the use of random number generating security devices. All websites use SSL technology. In addition, we have cyber insurance policy.
- That we're impacted by a global pandemic, just like COVID-19. We have an incident management plan and this was implemented in March 2020, with the priority of helping those most vulnerable in the community to deal with the anxiety and practicalities caused by the pandemic. We've set up The Charity so that everyone can work from home, we've introduced virtual fundraising activities and have been able to furlough staff members if necessary. By having a six months' reserve policy we should be able to ride out any significant adverse financial impact on The Charity.

GOING CONCERN

The Trustees have reviewed The Charity's annual budget and five-year projection, which are updated on an annual basis, as well as the principal financial risks.

The COVID-19 pandemic impacted The Charity's community, finances and activities, as described in various sections of this report, including the Finance Review. It impacted on the daily activities of The Charity as employees had to work remotely. The Charity was able to rapidly adapt to these changes, with systems that facilitated remote working, cost saving measures utilising the Coronavirus Job Retention Scheme and adapting to virtual fundraising events.

The Charity expects income to slowly recover in the following 12 months as the worst effects of the pandemic subside. Trustees are closely monitoring the financial position. The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The Trustees consider that there is a reasonable expectation that The Charity has sufficient resources to continue operating for the foreseeable future. For this reason, they continue to adopt the going-concern basis of accounting in preparing the accounts.

OBJECTIVES FOR 2021-22

During the summer of 2020, it became clear that the COVID-19 crisis would have a significant and enduring impact on the community and on The Charity. We've responded with a scaled down, modified strategy to maximise our impact and support those in need, despite reduced resources, and at the same time start to lever long-term change. Our priority objectives for the year are:

- We'll drive the Best Care Everywhere across the UK, including sharing real-time experience and care during and beyond the pandemic.
- We'll mobilise Voices for Change, sharing evidence and platforms so passion and experience is amplified to support those affected, raise funds and drive progress.
- We'll harness the Power of Data to accelerate research, tackle inequality, empower choices, inform change and maximise our impact.

PLANS FOR THE FUTURE

Our goals remain unchanged, to defeat brain tumours. While the pandemic continues to have a global impact, the situation in the UK and many other countries is stabilising and improving through the vaccine programmes. In this backdrop our immediate plans for 2021-22 are to return The Charity to growth. Growth in income and activities as stated above in the objectives for 2021-22. If circumstances and finances allow, we'll prepare plans for new rounds of research expenditure, either for the second half of 2021-22 or in 2022-23 and for each year thereafter.

We'll return to working on our new strategy, to build on the successes of our last five-year strategy, Defeating Brain Tumours, and this will guide our plans for future years.

We're also planning on developing and extending the reach of the technology underlying our app and databank, BRIAN (**B**rain tumou**R** **I**nformation and **A**nalysis **N**etwork). This would include creating a separate product that could provide commercial opportunities by offering it to other charities.

THANKS

Last year, The Charity continued to fund our existing commitments to highest quality research, raise awareness and support thousands of people affected by a brain tumour. This work is only possible due to the unwavering commitment of our supporters and the companies, charitable trusts and foundations, both in the UK and internationally, which continue to work with us. To everyone involved, we cannot thank you enough for continuing this vital help in the most challenging of years.

In addition to the donors named below, we would like to thank all our anonymous donors.

TRUSTS

BBC Children in Need
DWF Foundation
Garfield Weston Foundation
St James's Place Charitable Foundation
The AOK Trust
The Colin Oliphant Charitable Trust
The Eveson Charitable Trust
The National Lottery Community Fund Coronavirus Community Support Fund
The Peter Stebbings Memorial Charity
The Syncona Foundation
The William Brake Foundation

Lloyds Bank: Mid Corporates Team (Midlands)
Mulberry Marketing Communications
Salesforce
Thunderhead
Underbelly
We Got Tickets

CO-FUNDING PARTNERS

Action Medical Research
Great Ormond Street Hospital Children's Charity
Cancer Research UK
Worldwide Cancer Research
Children with Cancer UK

FAMILY-LED CHARITY PARTNERS

The Brian Cross Memorial Trust
The Katy Holmes Trust
The Oli Hilsdon Foundation
OSCAR's Paediatric Brain Tumour Charity

CORPORATES

Allports Group
Baked In
BECG
Benesys
Box of Hugs London
BlueCube Technology Solutions
Capital Group
CDM London
Childs Farm
Clicky Media
Decanter
DHL Express Americas
DWF Law
Federated Hermes
Future plc
GoodStuff
HSBC
Joelson
Knight Security Group
K&L Gates

HIGH PROFILE SUPPORTERS

Alastair Stewart OBE
Dominic Matteo
Earl Spencer
Ella and Matt Mills (Deliciously Ella)
Guy Opperman MP
Hal Cruttenden
Holly Matthews
Jason Durr
James Jordan
Jess Mills
Jonny Wilkinson CBE
Ian Chillcott
Liam Conlon
Lewis Moody OBE and Annie Moody
Lorraine Kelly OBE
Marc Silk
Matt Allwright
Mel Giedroyc
The Neales
Nick Baines (Peanut – Kaiser Chiefs)
Nicki Chapman
Olivia Colman CBE
Owain Arthur
Philippa Forrester
Russell Watson
Sandy Lyle MBE
Sherrie Hewson



Sian Reese-Williams
Steve Backshall
Tcheky Karyo
Tim Burgess and The Charlatans
Tom Daley

We'd also like to thank the actress and writer Dawn French, one of The Charity's first patrons and friend of Angela and Neil Dickson. Dawn has supported The Charity for over 20 years and continues to offer auction prizes and practical support wherever possible.

TRUSTEES AND GOVERNANCE

Trustees

Jack Morris CBE (Chair)
Neil Dickson MBE (Vice Chair)
Graham Lindsay (Vice Chair)
Dr. Elena Bechberger (appointed 17/09/2020)
Angela Dickson MBE (resigned 17/09/2020)
Dr. Rachel Edgar (appointed 10/12/2020)
Simon Hay
Sean Hird (appointed 10/12/2020)
Justine McIlroy
Philippa Murray
Berendina Norton
Graham Norton
Professor Alan Palmer
Robert Posner (resigned 18/09/2020)
Beth Worrall

President

Professor Sir Colin Blakemore

Chief Executive Officer

Sarah Lindsell (resigned 31/03/2021)
David Jenkinson (Interim CEO appointed 01/04/2021)

Company Secretary

Liam Heffernan

Charity Registration Numbers

England and Wales 1150054
Scotland SC045081

Principal and Registered Office

Fleet 27, Rye Close, Fleet, Hampshire
GU51 2UH

Auditors

Menzies LLP Centrum House, 36 Station Road,
Egham, Surrey TW20 9LF

Bankers

Lloyds Bank Plc, 147 High Street, Guildford
GU1 3AG

Investment Managers

Albert E. Sharpe, 7 Elm Court Arden Street,
Stratford-upon-Avon
Smith and Williamson, 25 Moorgate, London



RESEARCHERS IN OUR COMMUNITY

As well as members of our Scientific Advisory Board (mentioned on page 37), these are just some of the researchers providing an ongoing contribution to our success.

Adam Waldman
Adel Samson
Adrian Bracken
Al Yung
Alex Bullock
Andrew Peet
Anthony Byrne
Anthony Chalmers
Antony Michalski
Barry Pizer
Bob Brown
Catherine McBain
Chris Jones
Colin Kennedy
Colin Watts
Conor Mallucci
Darren Hargrave
David Jones
David Walker

Denise Sheer
Diane Puccetti
Eric Aboagye
Federico Roncaroli
Filomena Maggino
Gelareh Zadeh
Gregor Hutter
Ian Waddell
Jan Schuemann
JP Martinez-Barbera
Katie Bushby
Keyoumars Ashkan
Laure Bihannic
Linda Dirven
Linda Sharp
Louis Chesler
Lucy Stead
Maggie Watson
Marion Smits
Mark Gilbert
Martin Taphoorn
Martin van den Bent
Matt Williams
Michael Hawkins
Michael Jenkinson
Michael Taylor
Michael Vogelbaum

Monika Heki
 Neil Carragher
 Ola Rominiyi
 Olivier Ayrault
 Pamela Kearns
 Paul Brennan
 Paul Northcott
 Paula Croal
 Phedias Diamandis
 Philipp Euskirchen
 Pim French
 Rachel Cox
 Rameen Beroukhim
 Richard Gilbertson
 Roel Verhaak
 Roger Packer
 Russ Hagen
 Sebastian Brandner
 Sebastien Serres
 Siddhartha Mitra
 Simon Bailey
 Simona Parrinello
 Sophie Thomas
 Spencer Watson
 Stefan Pfister
 Steve Pollard
 Steven Clifford
 Stuart Allan
 Stuart Smith
 Susan Picton
 Susan Short
 Terri Armstrong
 Thomas Wurdinger
 Todd Hankinson
 Tyler Miller
 Veronica Rendo
 Victor Levin
 Vincenzo D'Angiolella

BIOMEDICAL SCIENTIFIC ADVISORY BOARD

Name

Professor Richard Gilbertson
 Professor Steve Clifford
 Dr Mark Gilbert
 Dr David Adams
 Dr Susan Chang
 Dr Cynthia Hawkins
 Dr Paul Northcott
 Professor Simona Parrinello
 Professor Colin Watts
 Dr Duane Mitchell
 Professor Rick Livesey
 Dr Marcel Kool
 Dr Lucy Stead

Dr Gerry Thompson
 Professor Nicola Sibson

Institution

The Cambridge Cancer Centre, UK
 The Institute of Child Health, Newcastle University, UK
 National Institutes of Health (NIH), USA
 The Wellcome Trust Sanger Institute, UK
 University of California San Francisco, USA
 The Hospital for Sick Children, Canada
 St Jude Children's Research Hospital, USA
 University College London (UCL), UK
 University of Birmingham, UK
 University of Florida, USA
 University College London (UCL), UK
 German Cancer Research Centre, Germany
 University of Leeds, UK
 University of Edinburgh, UK
 University of Oxford, UK

CANNABINOID CLINICAL TRIAL SAB

Name

Dr Susan Chang
 Dr Annette Molinaro
 Dr Jeffrey Wefel
 Professor Martin van den Bent
 Dr Mark Gilbert

Institution

University of California, San Francisco, USA
 University of California, San Francisco, USA
 The University of Texas MD Anderson Cancer Center, USA
 Erasmus MC Cancer Center, The Netherlands
 National Institutes of Health (NIH), USA

Lay advisors

Ms Christina Brincat
 Mrs Deborah Crossan
 Mrs Rachel Rathbone
 Ms Louise Webber-Edwards
 Mr John Graham

STRUCTURE, GOVERNANCE AND MANAGEMENT

The Brain Tumour Charity is a registered charity, number 1150054, which was incorporated on 24 October 2012 and is governed by its memorandum of association.

When a vacancy occurs on the Board of Trustees, the Board will take the opportunity to review the skills matrix of Trustees, to identify specific skill sets that would strengthen the Board's overall effectiveness. In addition, consideration is given to whether there is a need for any specific community or stakeholder group that needs to be represented by a new Trustee. The Board operates an equal opportunities recruitment policy and Trustees that are recruited are required to have demonstrable experience in the areas identified by the skills review.

Induction information covering the role and responsibilities of Trustees are provided to the Trustees and governance updates are provided as and when appropriate. The Trustees who served during the year are listed above.

The Trustees meet as a full Board four times per year and agree the broad strategy and areas of activity for The Charity including research strategy, approval of research grants, information and support strategy, financial planning, fundraising, investment, reserves and risk management policies and performance. All Trustees give of their time freely and no Trustee remuneration was paid in the year. Details of Trustee expenses are disclosed in Note 7 to the accounts. Trustees are required to disclose all relevant interests and register them with the Chief Executive and, in accordance with The Charity's policy, withdraw from decisions where a conflict of interest arises.

Day-to-day operations and management are delegated to the Chief Executive and Senior Leadership Team who provide regular reports to the Trustees on performance and operations.

The Charity benefits from six committees which have been established to advise on key areas of activity, which are:

- Finance
- Research & Databank
- Information and Support
- Governance and Ethics
- Equality, Diversity and Inclusion
- Remuneration

The Charity has formed two Scientific Advisory Boards (SABs) to ensure that we only fund the highest quality research. Further details of the Biomedical Scientific Advisory Board (Biomed SAB) and the (Cannabionoid Clinical Trail SAB) can be found on page 33, set out under 'Governance'.

EQUALITY, DIVERSITY AND INCLUSION

The Charity is committed to enhancing equality, diversity and inclusion, both within all areas of the organisation and in The Charity's work and objectives, ensuring we represent and help the whole community we serve.

To expand on this long standing goal, in December 2020 the Trustees decided to form a standing committee looking at equality, diversity and inclusion across The Charity. The new committee to comprise of at least two members of the Executive team and two Trustees along with other members as required. The purpose of the committee is to make The Charity more proactive in reducing disparities, enhancing consistency of effort, raising awareness as well as evidencing and reporting on progress.

Progress is being made in numerous areas, with a focus on ensuring we're collecting appropriate and accurate information to measure where things are being done well and where improvements are required. For example patient surveys are being adapted to offer participants the option to complete details of their background from which we may be able to draw better insights on disparities in care.



GRANT-MAKING POLICY

The Charity has established its grant-making policy to achieve its objectives for the public benefit to improve the lives of people diagnosed with a brain tumour, to advance scientific research into the disease and to seek a permanent cure or cures in the future.

The Brain Tumour Charity funding opportunities are based on the key aims of our research strategy 'A Cure Can't Wait' as we aim to double survival and halve the harm caused by brain tumours. We fund research into a wide variety of brain tumour types that affect both adults and children. We issue open calls for applications for project grants, programme grants and clinical trials.

More than 12,000 people are diagnosed with a primary brain tumour each year and over 5,000 lose their lives. Brain tumours are the biggest cancer killer of children and adults under 40.

The beneficiaries of our grant-making programme are ultimately people with brain tumours and their families and carers. We know that only research can make a difference in helping us understand how the disease develops, what causes it and how we might develop new treatments to improve outcomes for people with brain tumours.

The Charity invites applications for research grants from institutions by advertising in specialist publications and through the brain tumour and wider cancer networks. As a member of the Association of Medical Research Charities, we seek to follow best practice in retaining the independence of research funding and ensuring that successful applicants and research institutions abide by best practice in research ethics.

Research grants are funded on an annual basis to undertake an agreed programme of research. Continuation of the grants is subject to annual assessment by our Research Team, supported by our Scientific Advisory Board and Research & Databank Committee. In all cases, continuation of funding is subject to the research undertaken continuing to be in the interests of our beneficiaries and a progress assessment that is satisfactory.

APPROACH TO FUNDRAISING

The Charity is a member of the Fundraising Regulator, who holds the Code of Fundraising Practice for the UK.

Our approach is to ensure that we comply with the standards as set out in the Code across all of our fundraising activity. We did not engage with any third party fundraisers during the year. We comply with the key principles and behaviours of the Code to ensure that any vulnerable persons are treated fairly. All staff go through mandatory training when they join The Charity.

We received no complaints this year relating to fundraising.

There have been no breaches of the code of practice during the year.

STATEMENT OF THE TRUSTEES' RESPONSIBILITIES

The Trustees (who are also directors of The Brain Tumour Charity for the purposes of company law) are responsible for preparing the Trustees' report and the financial statements in accordance with applicable law and United Kingdom Accounting Standards (United Kingdom Generally Accepted Accounting Practice) including FRS 102: The Financial Reporting Standard applicable in the UK and Republic of Ireland.

Company law requires the Trustees to prepare financial statements for each financial year which give a true and fair view of the state of affairs of The Charity and the Group and of the incoming resources and application of resources, including the income and expenditure of the Group for that period. In preparing these financial statements, the Trustees are required to:


- Select suitable accounting policies and then apply them consistently
- Observe the methods and principles in the Charities SORP.
- Make judgements and estimates that are reasonable and prudent.
- State whether applicable UK Accounting standards have been followed, subject to any material departures disclosed and explained in the financial statements.
- Prepare the financial statements on the going-concern basis unless it is inappropriate to presume that The Charity will continue in business.

The Trustees are responsible for keeping adequate accounting records that are sufficient to show and explain The Charity's transactions and disclose with reasonable accuracy at any time the financial position of The Charity and the Group and enable them to ensure that the financial statements comply with the Companies Act 2006. They are also responsible for safeguarding the assets of The Charity and the Group and hence for taking reasonable steps for the prevention and detection of fraud and other irregularities.

In so far as we are aware:

- There is no relevant audit information of which the charitable company's auditor is unaware.
- The Trustees have taken all steps that they ought to have taken to make themselves aware of any relevant audit information and to establish that the auditor is aware of that information.

The Trustees Report (including the Strategic Report) was approved and authorised for issue by the Trustees on 27 September 2021 and signed on their behalf by:

A handwritten signature in black ink, appearing to read 'Jack Morris', with a long horizontal flourish extending to the right.

Jack Morris CBE
Chair of Trustees

INDEPENDENT AUDITORS' REPORT TO THE MEMBERS OF THE BRAIN TUMOUR CHARITY

OPINION

We have audited the financial statements of The Brain Tumour Charity (the 'parent charitable company') and its subsidiaries (the 'group') for the year ended 31 March 2021 which comprise the Consolidated statement of financial activities, the Consolidated balance sheet, the Company balance sheet, the Consolidated statement of cash flows and the related notes, including a summary of significant accounting policies. The financial reporting framework that has been applied in their preparation is applicable law and United Kingdom Accounting Standards, including Financial Reporting Standard 102 'The Financial Reporting Standard applicable in the UK and Republic of Ireland' (United Kingdom Generally Accepted Accounting Practice).

In our opinion the financial statements:

- give a true and fair view of the state of the Group's and of the parent charitable company's affairs as at 31 March 2021 and of the Group's incoming resources and application of resources, including its income and expenditure for the year then ended;
- have been properly prepared in accordance with United Kingdom Generally Accepted Accounting Practice; and
- have been prepared in accordance with the requirements of the Companies Act 2006.

BASIS FOR OPINION

We conducted our audit in accordance with International Standards on Auditing (UK) (ISAs (UK)) and applicable law. Our responsibilities under those standards are further described in the Auditors' responsibilities for the audit of the financial statements section of our report. We are independent of the Group in accordance with the ethical requirements that are relevant to our audit of the financial statements in the United Kingdom, including the Financial Reporting Council's Ethical Standard, and we have fulfilled our other ethical responsibilities in accordance with these requirements. We believe that the audit evidence we have obtained is sufficient and appropriate to provide a basis for our opinion.

CONCLUSIONS RELATING TO GOING CONCERN

In auditing the financial statements, we have concluded that the Trustees' use of the going concern basis of accounting in the preparation of the financial statements is appropriate.

Based on the work we have performed, we have not identified any material uncertainties relating to events or conditions that, individually or collectively, may cast significant doubt on the Group's or the parent charitable company's ability to continue as a going concern for a period of at least twelve months from when the financial statements are authorised for issue.

Our responsibilities and the responsibilities of the Trustees with respect to going concern are described in the relevant sections of this report.

OTHER INFORMATION

The other information comprises the information included in the Annual report other than the financial statements and our Auditors' report thereon. The Trustees are responsible for the other information contained within the Annual report. Our opinion on the financial statements does not cover the other information and, except to the extent otherwise explicitly stated in our report, we do not express any form of assurance conclusion thereon. Our responsibility is to read the other information and, in doing so, consider whether the other information is materially inconsistent with the financial statements or our knowledge obtained in the course of the audit, or otherwise appears to be materially misstated. If we identify such material inconsistencies or apparent material misstatements, we are required to determine whether this gives rise to a material misstatement in the financial statements themselves. If, based on the work we have performed, we conclude that there is a material misstatement of this other information, we are required to report that fact.

We have nothing to report in this regard.

OPINION ON OTHER MATTERS PRESCRIBED BY THE COMPANIES ACT 2006

In our opinion, based on the work undertaken in the course of the audit:

- the information given in the Trustees' Report and Strategic Report for the financial year for which the financial statements are prepared are consistent with the financial statements.
- the Trustees' Report and Strategic Report have been prepared in accordance with applicable legal requirements.

MATTERS ON WHICH WE ARE REQUIRED TO REPORT BY EXCEPTION

In the light of our knowledge and understanding of the charitable company and its environment obtained in the course of the audit, we have not identified material misstatements in the Trustees' Report or Strategic Report.

We have nothing to report in respect of the following matters in relation to which Companies Act 2006 requires us to report to you if, in our opinion:

- the parent charitable company has not kept adequate and sufficient accounting records, or returns adequate for our audit have not been received from branches not visited by us; or
- the parent charitable company financial statements are not in agreement with the accounting records and returns; or
- certain disclosures of Trustees' remuneration specified by law are not made; or
- we have not received all the information and explanations we require for our audit: or

RESPONSIBILITIES OF TRUSTEES

As explained more fully in the Trustees' responsibilities statement, the Trustees (who are also the directors of the charitable company for the purposes of company law) are responsible for the preparation of the financial statements and for being satisfied that they give a true and fair view, and for such internal control as the Trustees determine is necessary to enable the preparation of financial statements that are free from material misstatement, whether due to fraud or error.

In preparing the financial statements, the Trustees are responsible for assessing the Group's and the parent charitable company's ability to continue as a going concern, disclosing, as applicable, matters related to going concern and using the going concern basis of accounting unless the Trustees either intend to liquidate the Group or the parent charitable company or to cease operations, or have no realistic alternative but to do so.

AUDITORS' RESPONSIBILITIES FOR THE AUDIT OF THE FINANCIAL STATEMENTS

Our objectives are to obtain reasonable assurance about whether the financial statements as a whole are free from material misstatement, whether due to fraud or error, and to issue an Auditors' report that includes our opinion. Reasonable assurance is a high level of assurance, but is not a guarantee that an audit conducted in accordance with ISAs (UK) will always detect a material misstatement when it exists. Misstatements can arise from fraud or error and are considered material if, individually or in the aggregate, they could reasonably be expected to influence the economic decisions of users taken on the basis of these financial statements.

Irregularities, including fraud, are instances of non compliance with laws and regulations. We design procedures in line with our responsibilities, outlined above, to detect material misstatements in respect of irregularities, including fraud. The extent to which our procedures are capable of detecting irregularities, including fraud is detailed below:


- The charitable company is subject to laws and regulations that directly affect the financial statements including financial reporting legislation. We determined that the following laws and regulations were most significant including the Companies Act 2006, Charities Act 2011, Employment and Health and Safety legislation, GDPR and the UK Code of Fundraising Practice. We assessed the extent of compliance with these laws and regulations as part of our procedures on the related financial statement items.
- We understood how the charitable company is complying with those legal and regulatory frameworks by, making inquiries to management, those responsible for legal and compliance procedures and the company secretary. We corroborated our inquiries through our review of board minutes.
- The engagement partner assessed whether the engagement team collectively had the appropriate competence and capabilities to identify or recognise non-compliance with laws and regulations. The assessment did not identify any issues in this area.
- We assessed the susceptibility of the charitable company's financial statements to material misstatement, including how fraud might occur. Audit procedures performed by the engagement team included:
 - Identifying and assessing the design effectiveness of controls management has in place to prevent and detect fraud;
 - Understanding how those charged with governance considered and addressed the potential for override of controls or other inappropriate influence over the financial reporting process;
 - Challenging assumptions and judgments made by management in its significant accounting estimates; and
 - Identifying and testing journal entries, in particular any journal entries posted with unusual account combinations.
- As a result of the above procedures, we considered the opportunities and incentives that may exist within the organisation for fraud and identified the greatest potential for fraud in the following areas:
 - Posting of fraudulent journal entries
 - Posting of fraudulent payments and receipts in the accounting software
 - Authorisation, processing, and payment of fraudulent expenses
 - Fictitious employees
 - Timing of revenue recognition

Because of the inherent limitations of an audit, there is a risk that we will not detect all irregularities, including those leading to a material misstatement in the financial statements or non-compliance with regulation. This risk increases the more that compliance with a law or regulation is removed from the events and transactions reflected in the financial statements, as we will be less likely to become aware of instances of non-compliance. The risk is also greater regarding irregularities occurring due to fraud rather than error, as fraud involves intentional concealment, forgery, collusion, omission or misrepresentation.

A further description of our responsibilities for the audit of the financial statements is located on the Financial Reporting Council's website at: www.frc.org.uk/auditorsresponsibilities. This description forms part of our Auditors' report.

USE OF OUR REPORT

This report is made solely to the charitable company's members, as a body, in accordance with Chapter 3 of Part 16 of the Companies Act 2006. Our audit work has been undertaken so that we might state to the charitable company's members those matters we are required to state to them in an Auditors' report and for no other purpose. To the fullest extent permitted by law, we do not accept or assume responsibility to anyone other than the charitable company and its members, as a body, for our audit work, for this report, or for the opinions we have formed.

A handwritten signature in black ink that reads "Janice Matthews". The signature is written in a cursive style and is positioned above a thin horizontal line.

Janice Matthews FCA (Senior statutory auditor)

for and on behalf of

Menzies LLP

Chartered Accountants

Statutory Auditor

Centrum House

36 Station Road

Egham

Surrey

TW20 9LF

Date: 27-09-2021

Consolidated Statement of Financial Activities for the year ended 31 March 2021

	Notes	Unrestricted Funds £'000	Restricted Funds £'000	Total 2021 £'000	Unrestricted Funds £'000	Restricted Funds £'000	Total 2020 £'000
Income and Expenditure							
Income from:							
Donations and Legacies	3	6,577	1,180	7,757	8,025	2,331	10,356
Other Trading		171	15	186	405	149	554
Investments		355	-	355	398	-	398
Total Income		7,103	1,195	8,298	8,828	2,480	11,308
Expenditure on:							
Raising Funds		1,742	2	1,744	2,096	102	2,197
Charitable Activities							
Research		5,405	1,239	6,644	4,342	2,225	6,567
Patient Support		1,724	371	2,095	2,298	352	2,650
Campaigning & Raising Awareness		829	20	849	1,118	27	1,146
Total expenditure on Charitable Activities		7,958	1,630	9,588	7,758	2,604	10,362
Total expenditure	4	9,700	1,632	11,332	9,854	2,706	12,560
Net income before gains and losses on investment assets		(2,597)	(437)	(3,034)	(1,026)	(226)	(1,252)
Realised and Unrealised gains on investment assets		2,656	-	2,656	(1,561)	-	(1,561)
Net income/(expenditure)		59	(437)	(378)	(2,586)	(226)	(2,813)
Transfers		(955)	955	-	-	-	-
Net movement in funds for the year		(896)	518	(378)	(2,586)	(226)	(2,813)
Reconciliation of funds							
Balances at 1 April 2020		4,244	2,991	7,235	6,830	3,217	10,047
Balances at 31 March 2021		3,348	3,509	6,857	4,244	2,991	7,235

The Statement of Financial Activities includes all gains and losses recognised in the year. All incoming resources and resources expended derive from continuing activities.

The notes on pages 48-63 form part of these financial statements.

Consolidated Balance Sheet at 31 March 2021

Company number: 08266522

		Consolidated		Company	
	Notes	2021	2020	2021	2020
		£'000	£'000	£'000	£'000
Fixed Assets					
Intangible Assets	10	34	57	34	57
Tangible Assets	11	281	14	281	14
Investment in Subsidiary	12	-	-	-	-
Investments	12	14,652	12,033	14,652	12,033
Current Assets					
Stock		9	11	-	-
Debtors	13	452	720	453	727
Cash at Bank		4,978	7,306	4,972	7,306
		<u>5,439</u>	<u>8,037</u>	<u>5,425</u>	<u>8,033</u>
Creditors					
Amounts falling due within one year	14	(13,449)	(12,907)	(13,456)	(12,907)
Provision for liabilities	15	(100)	-	(100)	-
Net Current (Liabilities)/Assets		<u>(8,110)</u>	<u>(4,870)</u>	<u>(8,132)</u>	<u>(4,875)</u>
Total Assets less Current Liabilities		<u>6,857</u>	<u>7,235</u>	<u>6,836</u>	<u>7,230</u>
Funds					
General Reserve		1,752	2,500	1,731	2,495
Designated funds		<u>1,596</u>	<u>1,744</u>	<u>1,596</u>	<u>1,744</u>
Unrestricted funds		3,348	4,244	3,327	4,239
Restricted Funds		<u>3,509</u>	<u>2,991</u>	<u>3,509</u>	<u>2,991</u>
		<u>6,857</u>	<u>7,235</u>	<u>6,836</u>	<u>7,230</u>

The financial statements were approved by the trustees on 27th September 2021 and signed on their behalf by:



.....
Jack Morris CBE
Chair of Trustees



.....
Neil Dickson MBE
Vice-Chair of Trustees

The notes on pages 48-63 form part of these financial statements.

Consolidated Cash Flow for the year ended 31 March 2021

	2021 £'000	2020 £'000	
<u>Reconciliation of net income to net cash flow from operating activities</u>			
Net income for the year	(378)	(2,813)	
Adjustments for:			
Depreciation	50	49	
Losses/ (Gains) on investments	(2,619)	1,611	
Income from Investments	(355)	(398)	
Provision for liabilities	100	-	
Loss/ (profit) on sale of fixed assets	2	-	
(Increase)/ decrease in stocks	2	(2)	
Decrease/ (increase) in Debtors	268	21	
Increase / (decrease) in Creditors	541	6	
Net cash (used in)/ provided by operating activities	(2,388)	(1,526)	
	2021 £'000	2020 £'000	
<u>Statement of cash flows</u>			
Cash flows from operating activities			
Net cash (used in)/ provided by operating activities	(2,388)	(1,526)	
Cash flows from investing activities:			
Dividends, interest and rents from investments	355	389	
Purchase of computer software	-	(10)	
Purchase of PP&E	(296)	(1)	
Sale/(purchase) of investments	-	2,000	
Net cash provided by/ (used in) investing activities	59	2,378	
Change in cash and cash equivalents in the year	(2,328)	852	
Balances at 1 April 2020	7,306	6,454	
Balances at 31 March 2021	4,978	7,306	
<u>Analysis of cash and cash equivalents</u>	2021 £'000	2020 £'000	
Cash in hand	2,944	2,275	
Notice deposits (less than 3 months)	2,034	5,031	
Total cash and cash equivalents	4,978	7,306	
	At 1 April 2020	Other Cash flows	At 31 March 2021
<u>Analysis of changes in net debt</u>			
Cash	2,275	669	2,944
Cash equivalents	5,031	(2,997)	2,034
Net debt	7,306	(2,328)	4,978

Notes to the Financial Statements

1. Statement of compliance

These financial statements have been prepared in compliance with Accounting and Reporting by Charities: Statement of Recommended Practice applicable to charities preparing their accounts in accordance with the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) (effective 1 January 2016) – (Charities SORP (FRS 102)), the Financial Reporting Standard applicable in the UK and the Republic of Ireland (FRS 102) and the Companies Act 2006.

The Brain Tumour Charity is a private company limited by guarantee registered in England and Wales under the Companies Act. The address of the registered office and company number are given on page 35. The principal activity of the company and the nature of its operations are set out in the trustees report starting on page 3.

2. Accounting Policies

(a) **Basis of preparation of financial statements**

The financial statements have been prepared on the historical cost basis, as modified by the revaluation of investments at market value through the statement of financial activities.

The Brain Tumour Charity ("The Charity") constitutes a public benefit entity as defined by FRS 102.

The financial statements are prepared in sterling, which is the functional currency of the entity.

The results and balance sheet of The Charity's subsidiary undertaking, TBTC Trading Ltd has been consolidated on a line by line basis. TBTC Trading Ltd prepares its accounts to 31 March.

In accordance with s408 of the Companies Act 2006, The Charity has not presented its unconsolidated statement of financial activities. The net outgoing resources for The Charity in the year were £394,000 (2020: £2,801,000).

The financial statements have been prepared under the historical cost convention.

Judgements and key sources of estimation uncertainty

The preparation of the financial statements requires management to make judgements, estimates and assumptions that affect the amounts reported. These estimates and judgements are continually reviewed and are based on experience and other factors, including expectations of future events that are believed to be reasonable under the circumstances.

Significant judgements

The judgements (apart from those involving estimations) that management has made in the process of applying the entity's accounting policies and that have the most significant effect on the amounts recognised in the financial statements are as follows:

Income recognition

In the recognition of income in accordance with the accounting policy the management consider the detailed criteria for the income recognition from its activities and, in particular, whether The Charity had entitlement to the funds.

Key sources of estimation uncertainty

Accounting estimates and assumptions are made concerning the future and, by their nature, will rarely equal the related actual outcome. The key assumptions and other sources of estimation uncertainty that have a significant risk of causing a material adjustment to the carrying amounts of assets and liabilities within the next financial year are as follows:

Full payment of our research grants is contingent upon the successful outcome of periodic reviews. Research expense is recognised in advance of each phase of individual projects and the outcome and final cost of projects can vary, depending on a number of uncertain factors.

Some of our legacy income is dependent on the outcome of future events, for example the sale of property. Where the value of a legacy can be estimated reliably at the balance sheet date, the value is recognised as income in the year. In addition we occasionally benefit from donated services, which we would otherwise have to purchase, these donations are valued and included as income and cost at the estimated price we would pay in the open market.

(b) **Company status**

The company was incorporated on 24 October 2012 as a company limited by guarantee. The members of the company are the trustees named on page 35. In the event of the company being wound up, the liability in respect of the guarantee is limited to £1 per member of the company.

(c) **Income**

All income is included in the Statement of Financial Activities when The Charity is legally entitled to the income and the amount can be quantified with reasonable accuracy.

Donations and fundraising events from private individuals and sponsors are taken into account on the basis of cash receipts. Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. Income tax recoverable is accounted for on the same basis as the income to which it relates. Bank interest and investment income is accounted for on an accruals basis.

Government grants received as a result of the Coronavirus Job Retention scheme are recognised as income when the charity is entitled to the money.

Income which is material either because of its size or nature, or which is non-recurring, is treated as exceptional. Exceptional income is excluded in our underlying income.

(d) **Expenditure**

All expenditure is accounted for on an accruals basis and has been included under expense categories that aggregate all costs for allocation to activities. Where costs cannot be directly attributed to particular activities they have been allocated on a basis consistent with the use of the resources.

Grants payable are charged in the year when the offer is conveyed to the recipient except in those cases where the offer is conditional, such grants being recognised as expenditure when the conditions attaching are fulfilled. Grants offered subject to conditions which have not been met at the year-end are noted as a commitment, but not accrued as expenditure.

Direct costs, including directly attributable salaries, are allocated on an actual basis to the key strategic areas of activity. Overheads and other salaries are allocated between the expense headings on the basis of time spent. Termination payments are accounted for when notice has been given to the employees concerned.

Support costs are those costs incurred directly in support of expenditure in the objects of The Charity and are allocated to activities on a consistent basis.

Governance costs are those incurred in connection with enabling The Charity to comply with external regulation, constitutional and statutory requirements and in providing support to the trustees in the discharge of their statutory duties.

Employee Termination Benefits are accounted for when notice is given to the employee concerned.

(e) **Stocks**

Stock is measured at the lower of cost and net realisable value.

(f) **Fund accounting**

General funds are unrestricted funds which are available for use at the discretion of the trustees in furtherance of the general objectives of The Charity and which have not been designated for other purposes.

Restricted funds are funds which are to be used in accordance with specific restrictions imposed by donors which have been raised by The Charity for particular purposes. The aim and use of each restricted fund is set out in the notes to the financial statements.

Investment income, gains and losses are allocated to unrestricted funds unless they are generated from investing a specific endowment.

(g) **Fixed assets**

Intangible fixed assets comprise computer software purchased from third parties as well as related external development costs. Computer software costs are amortised on a straight-line basis over the estimated useful lives of the software, from the date the software is available for use.

Tangible fixed assets are shown at purchased cost, together with incidental expenses of acquisition. Tangible fixed assets under £1,000 are not capitalised. Fixed assets are depreciated on a straight-line basis over their estimated useful lives.

(h) **Estimated useful lives**

The estimated useful lives of fixed assets are as follows:

Computer equipment	3 years
Office equipment	5 years
Leasehold improvements	the lease term
Computer software	5 years

(i) **Investments**

Investments are revalued at fair value at the balance sheet date and any unrealised gain or loss is taken to the Statement of Financial Activities. Investments are intended to be available for use by The Charity in its charitable activities.

(j) **Donated Assets and Services**

Where services or assets are provided to The Charity as a donation that would normally be purchased from suppliers, this contribution is included in the financial statements at an estimate based on the value of the contribution to The Charity.

(k) **Operating lease**

The Charity classifies the lease of Fleet 27 as an operating lease. Rental charges are provided over the term of the lease (15 years).

(l) **Pensions**

The charitable company operates a defined contributions pension scheme. The scheme is funded partly by contributions from the employees and from The Charity. Such contributions are held and administered completely independent of the charitable company's finances. The contributions are made by The Charity and are accounted for on an accruals basis.

(m) **Financial instruments**

A financial asset or a financial liability is recognised only when the entity becomes a party to the contractual provisions of the instrument.

Basic financial instruments are initially recognised at the transaction price, unless the arrangement constitutes a financing transaction, where it is recognised at the present value of the future payments discounted at a market rate of interest for a similar debt instrument.

Financial assets that are measured at cost or amortised cost are reviewed for objective evidence of impairment at the end of each reporting date. If there is objective evidence of impairment, an impairment loss is recognised in profit or loss immediately.

(n) **Going concern**

No material uncertainties that may cast significant doubt about the ability of The Charity to continue as a going concern have been identified by management or the trustees.

The COVID-19 pandemic began to impact in March 2020 and continued to affect the entire financial year, having an impact on the Charity's income through fundraising from mass participation events such as sponsorship of marathon participants or holding of physical fundraising events. It impacted on the daily activities of the Charity as employees had to work remotely. It also created volatility in the book value of financial investments. The Charity was able to rapidly adapt to these changes, with systems that facilitated remote working, cost saving measures utilising the Coronavirus Job Retention Scheme and reducing headcount as well as adapting to virtual fundraising events. The Charity expects income will return to growth in the following twelve months, as the benefits of the vaccination programme reduce the effects of the pandemic. The Charity has sufficient cash and investments to cover current liabilities and research grant commitments.

The financial statements are accordingly prepared on the Going Concern basis.

3. Donations and legacies

	Unrestricted £'000	Restricted £'000	2021 Total £'000	Unrestricted £'000	Restricted £'000	2020 Total £'000
Ordinary activities:						
Regular Giving	258	41	299	221	14	235
Donations, appeals and fundraising	5,352	1,120	6,472	6,437	2,270	8,707
Gift Aid	483	18	501	576	46	622
Legacies	155	-	155	791	1	792
Government Grants	329	-	329	-	-	-
	<u>6,577</u>	<u>1,180</u>	<u>7,757</u>	<u>8,025</u>	<u>2,331</u>	<u>10,356</u>

Government Grants consist of amounts received under the Government Coronavirus Job Retention Scheme.

4. Analysis of resources expended

	Direct Costs £'000	Grants £'000	Support Costs £'000	2021 Total £'000
Raising funds	1,579	-	165	1,744
Charitable activities:				
Research	1,167	5,446	31	6,644
Patient Support	2,019	-	76	2,095
Campaigning and raising awareness	769	-	80	849
Total expenditure on charitable activities	3,955	5,446	187	9,588
Total expenditure	5,534	5,446	353	11,332

	Direct Costs £'000	Grants £'000	Support Costs £'000	2020 Total £'000
Raising funds	2,083	-	114	2,197
Charitable activities:				
Research	1,711	4,820	36	6,567
Patient Support	2,573	-	77	2,650
Campaigning and raising awareness	955	-	191	1,146
Total expenditure on charitable activities	5,238	4,820	305	10,362
Total expenditure	7,321	4,820	419	12,560

5. Research grant cost analysis

	2021 £'000	2020 £'000
Research programmes	4,406	2,967
Research projects	831	1,333
Clinical trials	155	444
Fellowships	54	66
Conferences	-	10
	5,446	4,820

A breakdown of research costs by individual award is provided in note 22.

6. Support costs by activity

	Finance and Human resources £'000	Central facilities £'000	Information technology £'000	Central management £'000	Governance £'000	Total £'000
Raising funds	53	19	38	17	38	165
Charitable activities:						
Research	10	4	7	3	7	31
Patient Support	25	9	17	8	17	76
Campaigning and raising awareness	26	9	19	8	18	80
2021 Total	114	41	81	36	80	353

	Finance and Human resources £'000	Central facilities £'000	Information technology £'000	Central management £'000	Governance £'000	Total £'000
Raising funds	32	16	32	9	25	114
Charitable activities:						
Research	10	5	10	3	8	36
Patient Support	22	11	22	6	17	77
Campaigning and raising awareness	54	26	54	15	41	191
2020 Total	<u>119</u>	<u>58</u>	<u>117</u>	<u>34</u>	<u>91</u>	<u>419</u>

7. Governance costs

	2021 £'000	2020 £'000
Auditor's remuneration	20	15
Trustee meetings	-	2
Legal and professional fees	3	2
Staff	57	72
	<u>80</u>	<u>91</u>

Trustees received no remuneration (2020: £nil). One trustee was reimbursed for travel expenses in the year totalling £26 (2020: one for £325). The premium in respect of professional liability insurance covering trustee indemnity was £nil (2020: £nil).

8. Staff costs

	2021 £'000	2020 £'000
Wages and salaries	3,402	3,704
Social security costs	311	338
Pension	296	228
	<u>4,009</u>	<u>4,272</u>

	Group		Company	
	2021 £'000	2020 £'000	2021 £'000	2020 £'000
Wages and salaries	3,402	3,704	3,402	3,704
Social security costs	311	338	311	338
Payments to defined contribution pension plans	296	228	296	228
	<u>4,009</u>	<u>4,272</u>	<u>4,009</u>	<u>4,272</u>

During the year redundancy payments were made totalling £29,000 (2020: £6,000). At 31 December 2021 there was £nil provided (2020 £nil).

The average number of employees during the year was 108 (2020: 118).

The number of employees whose total employee benefits (excluding employer pension costs) amounted to over £60,000 in the year were as follows:

	2021	2020
£60,001 - £70,000	1	2
£70,001 - £80,000	1	1
£80,001 - £90,000	1	1
£90,001-£100,000	-	1

Total employment costs of the Senior Leadership Team who are considered to be the key management personnel of The Charity was £572,000 (2020: £759,000).

9. Taxation

The Brain Tumour Charity is a registered charity and all of its activities fall within the exemptions afforded to charities under taxation legislation. TBTC Trading Ltd donates its net trading profit to The Brain Tumour Charity and accordingly has no taxable income. No charge to taxation therefore arises.

10. Intangible fixed assets

Group and Company

	Computer Software £'000
Cost	
At 1 April 2020	162
Additions	-
At 31 March 2021	162
Depreciation	
At 1 April 2020	104
Charge for the year	24
At 31 March 2021	128
Net book value	
At 31 March 2021	34
At 31 March 2020	57

11. Tangible fixed assets

Group and Company

	Leasehold Improvements £'000	Computers and Office Equipment £'000	Total £'000
Cost			
At 1 April 2020	63	161	223
Additions	289	7	296
Disposals	(63)	-	(63)
At 31 March 2021	289	168	456
Depreciation			
At 1 April 2020	59	151	210
Charge for the year	17	10	27
Disposals	(61)	-	(61)
At 31 March 2021	14	161	175
Net book value			
At 31 March 2021	274	7	281
At 31 March 2020	4	10	14

12. Investments

(a) Subsidiary Investment

	£
Cost at 1 April 2020 and 31 March 2021	100

The Charity owns 100% of the £1 ordinary share capital of TBTC Trading Ltd, a company incorporated in England and Wales, company number 08855559. The business activity of TBTC Trading Ltd is retailing.

At 31 March 2021 the aggregate of the share capital and reserves of TBTC Trading Ltd was £21,000 (2020: £4,000).

The net profit of TBTC Trading Ltd consolidated in to these accounts, as set out below, will be donated to The Brain Tumour Charity.

	2021 £'000	2020 £'000
Turnover	49	53
Cost of sales	(12)	(16)
Gross profit	37	37
Other operating expenses	(16)	(33)
Profit before donation	21	4
Donation	(4)	(16)
Retained profit/ (loss)	17	(12)

Cost of sales represent cost of stock sold in the year.

At 31 March 2021 the aggregate assets of TBTC Trading Ltd were £24,000 (2020: £20,000), aggregate liabilities £3,000 (2020: £16,000) and shareholder's funds £21,000 (2020: £4,000).

(b) General Investments

	2021	2020
Group and Company	£'000	£'000
At 1 April	12,033	15,635
Additions at cost	1,464	1,030
Disposals	(4,541)	(2,830)
Net unrealised (loss) on revaluation	5,696	(1,802)
At 31 March	14,652	12,033
Historical Cost	12,204	14,258

	2021	2020
Investments at market value comprised:	£'000	£'000
UK Equities	3,775	2,662
Overseas Equities	3,539	2,418
Absolute return funds	442	404
Multi asset funds	234	241
Alternative investments	578	791
Fixed income securities	3,184	5,410
Cash held within the investment portfolios	2,900	99
Accrued income	-	9
At 31 March 2021	14,652	12,033

During the year income from listed investments was £350,000 (2020: £371,000) and interest on deposits £4,000 (2020: £27,000).

13. Debtors

	Consolidated		Company	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Trade debtors	74	181	74	181
Accrued income and prepayments	353	381	353	374
Other debtors	26	158	26	158
Amounts owed by TBTC Trading Ltd	-	-	-	14
	453	720	453	727

14. Creditors

Donations received in respect of challenge events, which could become refundable if the event were cancelled, are deferred and recognised at the time of the event. In the year to 31 March 2021 £297,000 (2020: £243,000) of income was deferred and £97,000 (2020: £331,000), brought forward from previous periods, was released.

	Consolidated		Company	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Grants payable	12,293	11,647	12,294	11,647
Accruals and deferred income	468	307	465	305
Trade Creditors	593	815	593	816
Other creditors	28	42	28	42
Social Security and other taxes	67	96	67	97
Amounts owed to TBTC Trading Ltd	-	-	9	-
	<u>13,449</u>	<u>12,907</u>	<u>13,456</u>	<u>12,907</u>

15. Provision for liabilities

	Consolidated		Company	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
At 1 April 2020	-	-	-	-
Additions	100	-	100	-
Disposals	-	-	-	-
At 31 March 2021	<u>100</u>	<u>-</u>	<u>100</u>	<u>-</u>

The provision related to the future cost of obligations under the terms of a property operating lease at Fleet 27.

16. Research commitments

At 31 March 2021 The Charity had authorised commitments that were subject to outstanding conditions amounting to £13,586,000 (2020: £14,802,000), these are expected to fall due as follows:

	2021	2020
	£'000	£'000
Within one year	5,736	5,762
Between one and two years	3,609	4,278
Between two and three years	2,546	2,598
Between three and four years	1,283	1,833
Between four and five years	133	85
Five years and further	279	246
	<u>13,586</u>	<u>14,802</u>

17. Operating lease commitments

The total of future minimum property lease payments on operating leases are as follows:

	Consolidated		Company	
	2021	2020	2021	2020
	£'000	£'000	£'000	£'000
Within one year	143	6	143	4
Between one and five years	1,242	-	1,242	-
	<u>1,385</u>	<u>6</u>	<u>1,385</u>	<u>4</u>

Operating lease charges during 2021 were £30,000 for property (2020: £102,000).

18. Analysis of net assets between funds

	Unrestricted Funds	Restricted Funds	Total 2021
	£'000	£'000	£'000
Intangible fixed assets	34	-	34
Tangible fixed assets	281	-	281
Investments	14,652	-	14,652
Other current assets	(1,572)	7,011	5,439
Current liabilities	<u>(10,047)</u>	<u>(3,503)</u>	<u>(13,549)</u>
	<u>3,348</u>	<u>3,509</u>	<u>6,857</u>

	Unrestricted Funds	Restricted Funds	Total 2020
	£'000	£'000	£'000
Intangible fixed assets	57	-	57
Tangible fixed assets	14	-	14
Investments	12,033	-	12,033
Other current assets	2,240	5,798	8,037
Current liabilities	<u>(10,101)</u>	<u>(2,807)</u>	<u>(12,907)</u>
	<u>4,243</u>	<u>2,991</u>	<u>7,235</u>

19. Funds

Consolidated	At 1 April 2020 £'000	Incoming Resources £'000	Resources Expended £'000	Fund Transfers £'000	Investment Gains £'000	At 31 March 2021 £'000
Restricted funds:						
Research funds	684	635	(294)	1,031	-	2,056
Everest Fund	1,395	36	(945)	-	-	486
Awareness funds	392	6	(15)	-	-	383
Support funds	520	518	(378)	(77)	-	584
	<u>2,991</u>	<u>1,194</u>	<u>(1,631)</u>	<u>955</u>	<u>-</u>	<u>3,509</u>
Unrestricted funds:						
General reserve	2,499	6,244	(8,693)	(955)	2,656	1,752
Designated funds	1,744	859	(1,007)	-	-	1,596
	<u>4,243</u>	<u>7,103</u>	<u>(9,700)</u>	<u>(955)</u>	<u>2,656</u>	<u>3,348</u>
	<u>7,235</u>	<u>8,298</u>	<u>(11,332)</u>	<u>-</u>	<u>2,656</u>	<u>6,857</u>
Company	At 1 April 2020 £'000	Incoming Resources £'000	Resources Expended £'000	Fund Transfers £'000	Investment Gains £'000	At 31 March 2021 £'000
Restricted funds:						
Research funds	684	635	(294)	1,031	-	2,056
Everest Fund	1,395	36	(945)	-	-	486
Awareness funds	392	6	(15)	-	-	383
Support funds	520	518	(378)	(77)	-	584
	<u>2,991</u>	<u>1,194</u>	<u>(1,631)</u>	<u>955</u>	<u>-</u>	<u>3,509</u>
Unrestricted funds:						
General reserve	2,495	6,195	(8,665)	(950)	2,656	1,731
Designated funds	1,744	859	(1,007)	-	-	1,596
	<u>4,239</u>	<u>7,054</u>	<u>(9,672)</u>	<u>(950)</u>	<u>2,656</u>	<u>3,327</u>
	<u>7,230</u>	<u>8,248</u>	<u>(11,303)</u>	<u>4</u>	<u>2,656</u>	<u>6,836</u>

Consolidated	At 1 April 2019 £'000	Incoming Resources £'000	Resources Expended £'000	Fund Transfers £'000	Investment Gains £'000	At 31 March 2020 £'000
Restricted funds:						
Research funds	321	1,273	(1,261)	350	-	684
Everest Fund	2,214	167	(986)	-	-	1,395
Awareness funds	371	50	(29)	-	-	392
Support funds	311	989	(430)	(350)	-	520
	<u>3,217</u>	<u>2,480</u>	<u>(2,706)</u>	<u>-</u>	<u>-</u>	<u>2,991</u>
Unrestricted funds:						
General reserve	5,552	7,804	(9,282)	(13)	(1,561)	2,499
Designated funds	1,278	1,024	(571)	13	-	1,744
	<u>6,830</u>	<u>8,828</u>	<u>(9,854)</u>	<u>-</u>	<u>(1,561)</u>	<u>4,243</u>
	<u>10,047</u>	<u>11,307</u>	<u>(12,560)</u>	<u>-</u>	<u>(1,561)</u>	<u>7,235</u>

Company	At 1 April 2019 £'000	Incoming Resources £'000	Resources Expended £'000	Fund Transfers £'000	Investment Gains £'000	At 31 March 2020 £'000
Restricted funds:						
Research funds	321	1,273	(1,261)	350	-	684
Everest Fund	2,214	167	(986)	-	-	1,395
Awareness funds	371	50	(29)	-	-	392
Support funds	311	989	(430)	(350)	-	520
	<u>3,217</u>	<u>2,480</u>	<u>(2,706)</u>	<u>-</u>	<u>-</u>	<u>2,991</u>
Unrestricted funds:						
General reserve	5,535	7,751	(9,234)	3	(1,561)	2,495
Designated funds	1,278	1,024	(571)	13	-	1,744
	<u>6,814</u>	<u>8,775</u>	<u>(9,805)</u>	<u>16</u>	<u>(1,561)</u>	<u>4,239</u>
	<u>10,031</u>	<u>11,254</u>	<u>(12,511)</u>	<u>16</u>	<u>(1,561)</u>	<u>7,230</u>

Purpose of restricted funds

Research funds	Research funds comprise income which is restricted to expenditure on research, an analysis of research expenditure by award is provided in note 22.
Everest fund	During 2015/16 we received exceptional income of £2,889,949 which is restricted to funding research into paediatric low grade brain tumours. During 2016/17 we launched our investment in The Everest Centre for Research into Paediatric Low Grade Brain Tumours.
Awareness funds	Awareness funds comprise income which is restricted to raising awareness of brain tumours across the UK. Our current campaign is HeadSmart: be brain tumour aware.
Support funds	Support funds comprise funds raised and used to provide support to individuals and families affected by brain tumours through the operation of a helpline, support groups and networks, responding to email enquiries and any other activities that may be beneficial to those affected.

Designated Funds represent accumulated net income raised by our Supporter Groups where they have expressed a preference over how the funds they raise should be spent. Supporter Group preferences typically include our research and support activities. In addition, approved funding of a Chair position at a UK university has also been classed as designated funds.

Fund transfers represent transfers between funds to apply income raised to specific causes for the Lewis Moody Foundation or to reallocate expenses that had been over-allocated to restricted funds back to unrestricted funds.

20. Related parties

The Charity owns 100 of the issued £1 ordinary shares of TBTC Trading Ltd, a company with the same registered address as The Charity. TBTC Trading Ltd acts as a sales agent on behalf of The Charity. At 31 March 2021 The Charity owed TBTC Trading Ltd £9,444 (2020: TBTC Trading owed The Charity £14,058).

Trustees, their close family members and entities they control, made donations to The Charity totalling £16,783 during the year (2020: £771,205) and paid contributions totalling £nil (2020: £595) during a number of our fundraising events.

21. Grants receivable

During the year The Charity received support from the following trusts and foundations, where donations were restricted or designated to specific areas of activity as follows:

Trust and foundation	£'000	Charitable activity
Peter Stebbings Memorial Charity	8	ET 2019/2 - Brandner - UCL
Garfield Weston Foundation	75	BRIAN Databank
The National Lottery Community Fund		Coronavirus Community
Coronavirus Community Support Fund	89	Support Fund

22. Research awards

	2021 £'000	2020 £'000
Programme - Hochhauser - UCL - SDBC	-	15
Programme - Chesler - ICR - Medullo Super enhancers	306	325
Programme - Pollard - University Edinburgh - Chromatin targets in GBM	317	306
Programme - Jones - DKFZ - Everest Centre	945	964
Programme - Kennedy - University Southampton - PNET5 QoL	43	44
Programme - Wurdinger - VU Amsterdam - WINDOW	387	375
Programme - Zadeh - University Health Network - Clinically Aggressive Meningiomas	300	390
Programme - Northcott - St Jukes - MERIT	291	328
Programme - Hankinson - University Colorado - Adamantinoma Craniopharyngioma	216	219
Programme - Parrinello - UCL - Mapping Spatio-temporal heterogeneity	339	-
Programme - Gilbertson - CRUK Cambridge Cancer Institute- ST-EP-RELA and CPC	238	-
Programme - Carragher - University Edinburgh - Therapeutic Combinations in GBM	578	-
Project - Brennan - University Edinburgh - LG to HG transformation	-	(12)
Project - Edinburgh - Brennan	(73)	-
Development of a Novel Tumour-Targeting Thermogel activated by Matrix Metalloproteinases	(7)	-
Project - Clark - UCL Neurocognitive effects of medullo	(73)	-
Project - Kennedy - University Southampton - PROMOTE	(22)	-
Clinical Trial - Mallucci - Alder Hey - NORDIC	-	51
Project - Jones - ICR - Gene editing for DIPG - Billie Butterfly Fund	-	86
Project - Rooney - University Edinburgh - BT LIFE	(28)	-
Project - Sharp - Newcastle University - Self-supporting management for survivors	-	98
Project - Bracken - Trinity College - EZH2 in DIPG	-	34
Project - Stead - University Leeds - GBM Nanobiopsy	-	23
Project - Smits - Erasmus Medical Centre - Mapping biomarkers with MRI	-	65
Project - Serres - University Nottingham - STAT3 and hypoxia in GBM	-	72
Project - Johns - Telethon Kids Institute - Ion channel drugs	-	66
Project - Diamandis - University Health Network - AI to classify tumours	-	58
Project - Hutter - University Basel - Microglial drug response in GBM bioreactors	-	59
Project - D'Angiolella - University Oxford - Blocking MTAP in GBM	-	61
Project - Northcott - St Jukes - Refining medullo in USA clinical trials	100	99
Project - van den Bent - Erasmus Medical Centre - Refining glioma classification in CATNON trial	18	160
Project - Taphoorn - Leiden University Medical Centre - Defining Patient Reported Outcomes	43	-
Project - Hawkins - Uni Birmingham - Combining child and YA data for better monitoring	140	-
Project - Verhaak - Jackson Laboratory - ecDNA isolation and targeting in GBM	-	60
Project - Schuemann - Massachusetts General Hospital - Extreme dose rate proton therapy	56	-
Research awards sub-total carried forward	4,114	3,946

	2021 £'000	2020 £'000
Research awards sub-total brought forward	4,114	3,946
Project - Hegi - Lausanne - MGMT methylation	-	92
Project - Smith - Nottingham - RNA Methylation	60	60
Project - Rominiyi - Sheffield - Ex-vivo 3D models	-	60
Project - Cambridge - Hart	-	(11)
Project - Bullock - SGC Oxford - ALK2/ACVR1 Kinase Inhibitors for DIPG Therapy	-	190
Clinical Trial - Hargrave - University Birmingham - BIOMEDE	-	19
Clinical Trial - Chalmers - University Glasgow - PARADIGM 2	-	2
Clinical Trial - Short - University Leeds - ReoGlio	-	16
Clinical Trial - Kearns - University Birmingham - PNET5 CTU	44	44
Clinical Trial - Walker - INTREPID Nottingham	-	10
Clinical Trial - Michalski - Birmingham (9/120)	-	(17)
Clinical Trial - HR-MB - Bailey - Newcastle	111	371
Fellowship - Bihannic - St Jude - Origins of Groups 3 and 4 medullo	54	66
QfCs 2019 - Chesler ICR	338	-
QfCs 2019 - Beroukhim - Dana-Farber	195	-
CB 2019/2 - Zadeh - UHN	96	-
CB 2019/2 - Euskirchen - Charite Hospital	101	-
ET 2019/2 - French -Erasmus	60	-
ET 2019/2 - Brandner - UCL	56	-
FL 2019 - Croal - Nottingham	36	-
FL 2019 - Watson - Lausanne	60	-
FL 2019 - Miller - Massachusetts	60	-
FL 2019 - Rendo - Dana-Farber	60	-
QoL 2019 - Byrne - Cardiff	88	-
Conferences and workshops - Kennedy - Southampton	-	5
Conferences and workshops - ReMission Summit	-	5
Other	(85)	(37)
	<u>5,446</u>	<u>4,820</u>

23. Business Combination

During the year, the activities of Meningioma UK, a charity registered with The Scottish Charity Regulator were merged with those of The Brain Tumour Charity to improve services and outcomes for those affected by brain tumours. Assets totalling £5,375 were taken over by The Brain Tumour Charity and this combination is not accounted for as a formal merger.

**WE'RE GOING
FURTHER,
FASTER FOR A CURE!**

thebraintumourcharity.org

Registered office: Fleet 27, Rye Close, Fleet, Hampshire, GU51 2UH

© The Brain Tumour Charity 2021. Registered Charity in
England and Wales (1150054) and Scotland (SC045081).